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Gastric cancer (GC) is a leading cause of cancer deaths. However, analysis of its molecular
and clinical characteristics has been complicated by histological and etiological heterogeneity.
Adenocarcinoma can be subdivided into histological Lauren and World Health Organization (WHO)
classifications, however, this information has not led to the development of histologic subtype-specific
treatment options. One way to potentially improve treatment for GCs is to better understand the
molecular pathogenesis of the disease as well as the contribution of Helicobacter pylori infection and
host immune responses leading to the development of an integrated histological and molecular
classification schemes for GC.
Over the last several years, two major and comprehensive studies have been published focusing
on a molecular classification of GC, the Cancer Genome Atlas (TCGA) and the Asian Cancer Research
Group (ACRG) networks. Both Alessandrini [1] and Tirino [2], assessed the most common molecular
GC classifications reported over the last years and found the main targetable molecular drivers
highlighted by these studies. Indeed, only trastuzumab (anti-HER2 monoclonal antibody) and
ramucirumab (anti-VEGFR monoclonal antibody) have proven to be successful in treating advanced or
metastatic GC and they are currently used as a standard of care, but new drugs, e.g., nivolumab
(PD-1 immune check-point inhibitor) showed activity against MSH-high locally advanced GC.
Although the patient’s condition improved by using these drugs, clinically, the practical use of the
results remain is limited. Thus, GC remains one the most lethal diseases in the world with systemic
chemotherapy still necessary to support its advanced stages. The hope is that combining histological
and molecular classification will help identify more specific and limited in number biomarkers
that consent to categorized patients who will really benefit from such therapies. With this aim
Machlowska et al. [3], highlights the current status of prognostic molecular biomarkers that can be used
in GC with a particular attention to those impacting on peritoneal spreading and neo-vascularization of
the tumor, two of the most important mechanism by which tumors become more aggressive. In respect
of the discovery of predictive tumor response markers in specific GC subset, Caggiari et al. [4], report
that the characterization of a CDH1 haplotype is associated with improved survival in metastatic
GC targeted by HER2 therapy. Indeed, the positivity for the HER2 status (by IHC or by fluorescence
in situ hybridization) is a prerequisite for trastuzumab (anti-HER2 monoclonal antibody), which is
the treatment currently used as a standard of care in advanced and metastatic GC. However, due to
the heterogeneity of the tumor, the identification of the targeted HER2 molecules the treatment is
not sufficient to predict drug response. In the present study, the authors also proposed a functional
role of E-cadherin, the protein codified by the CDH1 gene in the HER2 pathway, which may be
involved in better response to treatment. Although, the role of the CDH1 mutations in this context
requires elucidation through further studies, the study is of interest for its novelty and for its potential
utility in selecting patients who may benefit from new anti-HER2 agents. Hyperfibrinogenemia
is also an important risk factor known to influence GC development and outcome, but the exact
fragment of fibrinogens preferentially produced in the tumor environment is less known. A study
reported by Repetto et al. [5], provides evidence of an increase in region D of the fibrinogen B chain
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fragments, as well as the entire fibrinogen chain production, in the tumor biopsies of patients with
GC compared to the equivalent biopsies at least 5 cm from the tumor lesion of the same patients.
Furthermore, they found a relationship between the increase in the load of fibrinogen fragments in
tumor mass with an increase of the platelets number with a higher GC stage and the stomach corpus
localization. Their results, thus, sustain the potential role of fibrinogen and platelets in the progression
of tumor cell growth and aggressiveness of the tumor. Their data support the usefulness of plasma
fibrinogen/fibrinolysis evaluation and platelet count in GC to evaluate the treatment response and
patients’ prognosis. Data have also helped to further characterize the interconnections between GC
and platelet/coagulation pathways.
Part of the issue was focused on the characterization of specific GC subtypes to reinforce
the TCGA classification. In this context Gullo et al. [6], investigate the transcriptomic landscape
showed by EBV+ and the MSI-High subtypes identified in the TCGA classification. Their results
strengthen the value for molecular segregation of these two subtypes and underline their relation
with difference in clinical presentation. In particular, they confirm the importance of immunogenicity
of EBV+ tumors and the mitotic signature of MSHI-high+ tumors, and reinforce the robustness of
the Nanostring CodeSet proposed by TCGA classification. Notably, they highlighted a difference in
the distribution of important checkpoint molecules, e.g., PD-1/PD-L1 molecules between EBV+ and
MSHI-High subtypes, underling the best predictive value of protein expression rather than PD-L1
expression by immunohistochemistry to select GC patients eligible for anti-PD-1 immunotherapy. Their
study offers a biological rationale to explain the unexpected positive response observed in patients
harboring PD-L1-negative tumors, treated with anti-PD-1 therapy and a reasonable use of multiple
immune targeted therapies in the specific EBV+ GC subtype, although further studies are necessary
to sustain this proposal. The review reported by Dolcetti et al. [7], highlighted the observations
of more recent advances in immunotherapeutic approaches overall of the GC subtypes. Indeed,
immunotherapeutic approaches are still in the early phases but rapidly evolving in clinic. They discuss
more important clinical trials reported by scientific communities, highlighting salient critical factors
and possible solutions when they can be hypothesized. They also bring attention to the developments
of more promising immunotherapies using adoptive cell and/or engineered cell; immune checkpoint
inhibitors, immune modulator pathways, agonistic antibodies for co-stimulatory receptors, and cancer
vaccines, thereby highlighting that for good clinical trials, the evaluation are also required to predict
which patients will be responsive to particular treatments. Aldinucci et al. [8], focus on a particular
immune axis: The interactions of chemokine CCL5, also known as RANTES, with its receptor CCR5,
which regulates the immune and inflammatory responses by inducing lymphocytes and monocytes
migration. Some researchers have demonstrated that cancer cells subvert the normal chemokine role,
transforming them into a fundamental constituent of the immunosuppressive tumor microenvironment
with tumor-promoting effects. The authors discuss the potential role of CCL5 leading to GC cell
proliferation and metastasis and its proangiogenic effect in GC, although the exact functions of CCL5
in GC biology are not completely know. Moreover, CCR5 is not only a chemokine but also a co-receptor
for HIV cell entry and a target of several drug researches, including GC treatment in pre-clinical and
clinical trials as discussed by the authors. Notably, H. pylori increases the CCL5 secretion and interfere
with the interaction between tumor cells and tumor microenvironment. Moreover, it was demonstrated
that an increase in the CCL5 serum level and/or immunohistochemical staining is associated with
more advanced GC stages and risk for peritoneal metastatization. Different algorithms include a CCL5
factor in order to predict treatment response, prognosis, and survival outcomes in GC. Thus, based on
current knowledge, the CCL5/CCR5 axis may be considered a therapeutic target in GC.
Other landmark approaches to analytically photograph GC at molecular level are the modern
mass spectrometry molecular imaging (MALDI-MSI) and flow cytometry. By using the first technique
some pathologically significant molecules have already showed promise in the study of GC, providing
greater insights into the molecular aspects of the disease and aiding in the identification of candidate
biomarkers. Smith et al. [9] provided an overview of the MALDI-MSI innovative methodologies
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and summarize how the technique has been used to advance GC research for biomarker detection
and for monitoring treatment response. Examples of MALDI-MSI applications in GC are the fasudil
drug and its metabolites and inhibitors of the ROCK protein kinases, that can reach cancer cells in
mice non-selectively. The proteomic differences may highlight a phenotypic tumor heterogeneity,
which cannot be uncovered by using traditional histology; the identification is then successfully
validated by immunohistochemistry of prognostic factors able to distinguish patients between stage I
GC from those at the other stages; the identification of a protein profile predicting the HER+ GC tumor
status with an accuracy of about 88–90%; the importance of difference in the distribution of lipids,
metabolites and glicosilated fragments between the tumoral lesion and the non-neoplastic mucosa of
a same patient. The second approach, the flow cytometry, has been used by Bockerstett [10], to analyze
individually viable epithelial cells from gastric mucosa, which usually is limited due to difficulties in
tissue processing. They develop and herein report an effective method for processing stomach tissue by
enzymatic digestion and then analyze, via flow cytometry gastric epithelial cell, changes at single cell
level from a large cell number of viable gastric cells in a model of inflammation induced gastric atrophy
in mice. This approach results particularly useful for studying the inflammatory changes in surface
markers on gastric epithelial cells during chronic disease. Their method confirms the up-regulation of
MHC-II molecules on the epithelial cells caused by H-pylori-mediated inflammation. It is also possible
that in the near future, a similar flow cytometric non-invasive diagnostic approach will be used to
identify specific GC biomarker subtypes in circulating tumor cells.
The second part is in relation to environments and genetic factors that are known to increase the
risk for GC development and how these factors may be useful to identify particular subjects that could
be included in specific GC subtypes or at high risk for GC development.
H. pylori is the most abundant bacterium in the gastric epithelium and its presence was clearly
associated with the risk of developing GC. In the last 100 years, infections have gradually declined
due to new technologies, although other bacteria have been now identified in the stomach. Li and
Perez. [11] discussed the potential role of the human gastric microbiota change in the presence or
absence of H. pylori and moreover, they discuss which factors contribute to the increasing risk of GC.
In particular, they confirm that the increased risk for GC is associated with the presence of highly
virulent H. pylori strains (e.g., CagA+ and VacA+), and simultaneously by host genetic polymorphisms
in the pro-inflammatory cytokine genes. However, it is now evident that during the progression of
disease from H. pylori infection to GC, the stomach increases its pH thereby reducing the presence
of H. pylori. In the same way, other bacteria increase with the possibility that the phenomena could
be at patch trough the overall the stomach and with a different clinical outcome. Indeed, the change
in the microbiota composition may also change the chronic inflammatory status in the stomach and
a “point of no return” was reported in the cascade of events that lead to GC, which is associated with
patients having intestinal metaplasia and dysplasia and is independent of H. pylori status. An elegant
model to sustain gastric microbiota in the development of GC was in fact shown using the transgenic
insulin-gastrin mouse model, but this could not be sufficient to demonstrate a direct role of microbiota
in carcinogenesis. Nonetheless, the authors emphasize that in some regions, despite the decline of
H. pylori infections, an increased incidence of GC was especially found in young adults (<40 years),
GC diffuse type, and with no difference in the sex frequency. For the authors these new epidemiological
data are particularly important since they could imply that changes in the gastric microbiota associated
with new standards of living may be implicated in the specific increase in the GC development showed.
On the other hand, the increase of GC incidence may be associated with the increase of another
disease, like autoimmune gastritis that was found similarly to GC increase in the same population.
Thus, a direct role for microbiota in GC development need further studies before being clearly accepted
as a model of GC carcinogenesis. Kidane [12], discusses current molecular mechanisms that lead
to DNA single and double-strand breaks and that reduce the capacity of DNA repair caused by
H. pylori infection. The model discussed highlights the necessity for H. pylori-gastric cell contact and
the infiltration of immune cells into the tumor microenvironment. The production of RONS, reactive
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oxygen species and nitrogen species, which cause DNA base damage and activation of the NF-κB
factors that induces the cleavage of promoter gene regions and double strand breaks are the major
consequence of H. pylori infection, although H. pylori itself may result directly from mechanisms not yet
fully known through epigenetic alterations and overall a host genome instability. Excision DNA repair
are complex and may be resumed in three major pathways that use different enzymes and recognition
process: The base excision repair (BER) that use specific glycosylases and preferentially recognize small
damages, the nucleotide excision repair (NER) involved also in bulky DNA reparation, and the DNA
mismatch repair (MMR). BER, repairs during the cell cycle the majority of break damages resulting
from oxidation and alkylation and it is the primary repair pathway occurring during H. pylori infection.
Authors discuss how H. pylori is involved in BER and NER processes and the effect known today in
enzyme alterations involved in these processes, including gene mutations occurring in the host and
associated with the process of DNA repair. Authors also evidence that H. pylori infection enhances the
transcription factor NF-κB pathway in immune and epithelial cells, thus resulting of the modulation
of many DNA repair genes and the production of the inducible inflammatory mediator nitric oxide
synthase (iNOS), which through the production of nitric oxide, contribute to enhanced inactivation
of DNA repair enzymes and DNA double strand breaks. Thus, we can conclude that host genetic
variants involved in DNA repair could modify the process of carcinogenesis in H. pylori infected hosts
in any way, but that specific association among them require further studies. Indeed, the molecular
mechanisms of DNA break formation, how these breaks are repaired and the interference of H. pylori
in these processes remain largely to be clarified. Reprimo is a family of gene downstream effectors
of p53-induced cell cycle arrest at G2/M checkpoint. Epigenetic silencing of RPRM, mainly by DNA
methylation of its promoter region or P53 pathway, occurs at early stages and is a common event in GC.
Amigo et al. [13], emphasize the role of this poorly studied gene in GC carcinogenesis. Of particular
interest, previously authors demonstrated that methylation of the reprimo promoter region was
associated with the infection of H. pylori and in particular with the more virulent cytotoxin-associated
gene A (CagA) positive strains and that DNA methylation of reprimo may predict the progression of
gastric lesions with a high sensitivity and specificity. Authors propose that reprimo methylation of
cell-free DNA could be a marker for non-invasive discovery of GC in the next future.
While intestinal GC is more associated to H. pylori infection, the diffuse type composed by
non-cohesive cells is more observable in a hereditary form. Ansari et al. [14], focus their review on
the pathogenicity of this specific diffuse-GC type and report the most current understanding of the
host factors, as well as the bacterial H. pylori factors that have been specifically involved. Although
the pathogenicity of DGC has not yet been clarified in detail, authors indicate the central role of
E-cadherin and cell-signaling pathways in the maintenance of cell integrity and function in particular
in this subtype of GC. Melo et al. [15], highlight the state of art regarding the best methodologies,
including the evaluation of migration dynamics of cells carrying E-cadherin variants in a transgene
drosophila melanogaster model, to categorize the missense mutations in the CDH1, the gene codifying
for the E-cadherin protein. Indeed, in the hereditary form of GC 155 different mutations have been
reported to date but in about 17% of these cases the mutation remains with a function not predictable.
The definition of how these alterations could perturb the expression and function of E-cadherin,
as well as related signaling and cellular mechanisms, are fundamental to help clinicians and genetic
counsellors in the management of the patients with GC and their familiars. Moreover, some mutations
in the CDH1 gene may result in a slight down regulation rather than a complete abolition/function of
the E-cadherin, and these alterations may be present also in other than hereditary form of GC. In that
context, Melo and Seruca’s group is considered a worldwide reference center to study the predictable
function of CDH1 mutations. Their studies are also relevant to gain further understanding of the GC
pathogenesis. In that context, the study of Caggiari et al. [4], highlight the possibility that CDH1 gene
mutations can also be used as a potential prognostic factor for GC survival.
Bizzaro [16] noted that autoimmune diseases may also predispose individuals to malignancies.
A link between chronic autoimmune gastritis and GC development has been known from some
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time. Bizzaro et al. describes autoimmune gastritis and review its association with GC, in particular
of the intestinal type and type I gastric carcinoid. The show particular attention to autoantibodies
produced during autoimmune gastritis as markers for monitoring patient’s response to treatment
and during follow-up. The low sensitivity of autoantibodies has limited their application in clinical
practice for an early detection of patient at risk for GC, but in the next future, the availability of new
multiplex technology for the simultaneous detection of many autoantibodies could to overcome
these limitations. Another important autoimmune disease associated with the development of
GC and lymphoproliferative disorders is the common variable immunodeficiency disorder (CVID),
a hypogammaglobulinemia, highly variable and heterogeneous in clinical manifestations, although
frequently expresses severe, recurrent, and chronic bacterial infections of the respiratory and
gastrointestinal tracts. The exact molecular pathways underlying the relationships between CVID
and GC remain poorly understood. Leone et al. [17] assessed the most frequent genetic abnormalities
resulting in CIVD discovered today, although they account for less than 15% of the overall cases.
They also provided a hypothetical mechanism of GC development based on the peculiar features of
the tumor occurring in these patients. Accordingly, they propose a protocol to screening patients with
CVID at risk for GC by using three easy and non-invasive tests based on the evidence of a megaloblastic
or macrocytic anemia, a deficiency in serum vitamin B12 and iron, and a positive urea breath test
for H. pylori infection. Another hereditable predisposition for GC is the Lynch syndrome (LS) and
familial adenomatous polyposis (FAP), two autosomal dominant genetic conditions leading to the
development of colorectal cancer, but also to other tumors. Fornasig et al. [18] reported detailed
clinical and molecular features of GC occurring in these patients since characteristics of GC associated
with these diseases are still not well known. There information’s added an important contribution to
the recognition of patients at higher risk for GC development, which could be direct for the endoscopic
surveillance. Family history of GC is a generic but a well-recognized risk factor for developing
GC. Serum metabolic profiles including 188 serum metabolites were used by Corona et al. [19],
to differentiate GC patients from first-degree relatives of patients with GC in two separate and
independent series. The best discriminators they found belonged to phospholipids and acylcarnitines
classes, and the discrimination increased in power when the C16 and M(OH)22:1 metabolites were
integrated with serum pepsinogen-II value and with the age of the individual tested. The results
of the study also provided new insights into the metabolism of GC. The increased acylcarnitines
probably reflects alterations in the mitochondrial respiratory complex activities arising in GC that
further increase H. pylori infection and the major age of patient with GC; while the decrease of some
phosphatidylcholine lipid derivatives may be a consequence of a predisposition of tumor cells for
a phospholipid storage. Authors propose that the effect of this storage may alter the cell lipid raft
known to be involved in several tumor processes and at the same it may reflect the increase in tumor
nerve growth observed in GC.
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Abstract: Gastric cancer (GC) is a common malignant neoplasm worldwide and one of the main
cause of cancer-related deaths. Despite some advances in therapies, long-term survival of patients
with advanced disease remains poor. Different types of classification have been used to stratify
patients with GC for shaping prognosis and treatment planning. Based on new knowledge of
molecular pathways associated with different aspect of GC, new pathogenetic classifications for GC
have been and continue to be proposed. These novel classifications create a new paradigm in the
definition of cancer biology and allow the identification of relevant GC genomic subsets by using
different techniques such as genomic screenings, functional studies and molecular or epigenetic
characterization. An improved prognostic classification for GC is essential for the development
of a proper therapy for a proper patient population. The aim of this review is to discuss the
state-of-the-art on combining histological and molecular classifications of GC to give an overview of
the emerging therapeutic possibilities connected to the latest discoveries regarding GC.
Keywords: gastric cancer; gene expression profile; gene mutation; molecular gastric cancer subtype;
EBV infection; microsatellite; preclinical models; miRNA
1. Introduction
Gastric cancer (GC) is the fifth malignant neoplasm worldwide and the third cause of
cancer-related deaths [1]. Despite some advances in therapies for GC, long-term survival of patients
with advanced disease is poor. GC is a multifactorial disease in which both genetic and environmental
factors are involved. Historically, different types of classification have been used to shape prognosis
and plan treatment [2–6]. Proposed in 1965, the Laurén system was widely used in GC classification
for half a century, which was very useful in evaluating the natural history of GC carcinogenesis. Based
on pathological morphology, the Laurén system divides GC into intestinal (G-INT), diffuse (G-DIF)
and mixed GC (G-Mix). An improved prognostic classification for GC is essential for the development
of a proper therapy for patients. Therefore, based on new knowledge of molecular pathways, new
pathogenetic classifications for GC have been proposed. The aim of this review is to update molecular
classifications of GC to give an overview of the emerging therapeutic possibilities
2. Histological and Molecular Classifications of GC
Based on the gene expression profile for GC cell lines and patients’ tissue, Tan et al. [7] classified
GC into two intrinsic genomic subtypes that overlapped with the histological Lauren’s classification.
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The G-INT subtype and the G-DIF are related to intestinal and diffuse histology, respectively. The two
intrinsic subtypes have distinct patterns of gene expression.
In the G-INT subtype, genes associated with the carbohydrate and protein metabolism (FUT2)
and cell adhesion (LGALS4, CDH17) are upregulated. The FUT2 gene codes for the galactoside
2-alpha-L-fucosyltransferase 2 enzyme affecting the Lewis blood group involved in Helicobacter pylori
(H. pylori) infection; the LGALS4 gene codes the galectin 4 implicated in the modulation of the
interaction between cell-cell and cell-matrix and the peptide transporter cadherin-17 coded by the
CDH17 gene.
Instead, in the G-DIF subtype, genes related to cell proliferation (AURKB) and fatty acid
metabolism (ELOVL5) are upregulated. The AURKB gene codes for the Aurora B kinase that functions
in the attachment of the mitotic spindle to the centromere, and the ELOVL5 gene encodes the elongation
of the very long chain fatty acids protein. The prognosis of G-DIF tumour type is poor, and the response
to chemotherapy is reduced compared to those of the G-INT type. In vitro, G-INT cell lines are more
sensitive to 5-FU and oxaliplatin than G-DIF lines, which result in being more sensitive to cisplatin [7,8].
There were many more other molecular studies based on the Laurén classification [9–12].
A molecular classification for GC, independent of the histological Laurent classification, was made
in 2013 by Singapore Researchers. They categorized GC into three main types: [13] a proliferative profile
associated with a high genomic instability and TP53 gene mutation, a metabolic profile associated
with a higher anaerobic glycolysis and resulting in tumour cells more sensitive to 5-FU therapy and
a mesenchymal stem cell profile with a high capacity for self-renewal, immunomodulation and tissue
regeneration showing a sensitivity to PIK3CA-mTOR pathway inhibitors.
Soon after, The Cancer Genome Atlas (TCGA) research group categorized GC into four main
groups by introducing new technologies of large-scale genome sequencing analyses [14]: Epstein-Barr
virus (EBV)-positive cancers (9% of all GC) characterized by DNA hypermethylation, a high frequency
of PIK3CA mutations and PDL1/PDL2 overexpression, microsatellite instable (MSI, 22%) tumours,
showing a very high number of mutations and DNA methylation sites and chromosome instable
tumours (CIN, 50%) mainly coding for alteration in tyrosine kinase receptors and genome stable
tumours (GS, 20%).
In 2015, by using similar multi-platform molecular approaches, the Asian Cancer Research
Group (ACRG) developed a novel molecular classification for GC based on a pre-defined set
of genetic pathways relevant to the biology of GC, including epithelial-mesenchymal transition
(EMT), microsatellite instability, cytokine signaling and P53 activity [15]. The ACRG classification
included four subtypes [16]: an MSI subtype (22.7%), a mesenchymal group microsatellite stable
(MSS)/EMT (15.3%) based on the evidence of epithelial-to-mesenchymal transition, a microsatellite
stable TP53-positive subtype MSS/TP53+ (26.3%) and a microsatellite stable TP53-negative subtype
MSS/TP53− (35.7%), according to the presence/absence of P53 mutations. By using this approach,
the MSI subtype had the best prognosis, while the MSS/EMT subtype had the worst one. The former
occurred predominantly at an early stage in the distal part of the stomach and showed mainly
an intestinal histology (according to Lauren’s classification); the latter occurred at an advanced stage,
at a younger age and with a diffuse histology (>80%) including a large set of signet ring cell carcinomas
seeding in the peritonea with malignant ascites (64.1% vs. 15–24% in the other subtypes) and showed
loss of CDH1 expression. Given the earlier stage of diagnosis, MSI and MSS/TP53− patients also had
the best overall survival and when recurrence occurs, this was generally limited to liver metastasis
(about 20%). EBV infection was more frequent in the MSS/TP53 active group.
In ACRG, the correlation between molecular classification and prognosis was validated using the
TCGA [14] and the Gastric Cancer Project ′08 Singapore datasets [16]. As shown in Table 1, the ACRG
subtypes show a significant overlap with the TCGA subtypes, and this confirms the association
between better survival and the MSI subtype [17]. However, the overlap is only partial and probably
due to the differences in the patient population (Korea in ACRG and USA and Western Europe in
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TCGA), tumour sampling and technical platforms used. Nonetheless, these novel classifications
created a new paradigm in the definition of GC, although some limitations persist:
i. these classifications are based on a highly complex methodology, which is not always available
in every laboratory;
ii. they lack a prospective validation on a large scale;
iii. they have striking differences in epidemiology, underlying molecular mechanisms and prognosis;
iv. their prognostic power is decreased by limited follow-up of patients;
v. none of them takes into account the active, non-malignant stromal cells
Table 1. Key characteristics of The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group
(ACRG) molecular classifications of gastric cancer (GC). MSI, microsatellite instable; CIN, chromosome
instable; GS, genome stable; EGJ, esophagogastric junction; MSS, microsatellite stable.
TCGA EBV MSI CIN GS
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3. Integrated Molecular Signatures to Discriminate Intestinal and Diffuse Histological GC Subtypes
Previous findings indicated that diffuse and intestinal GC might be two distinct diseases with
different molecular bases, aetiologies, epidemiologies and, thus, response to therapies. A recent study
based on a population of 300 GC identified 40 genes specifically expressed in diffuse or intestinal
GC [12] and three genes associated with the patients’ prognosis, namely EFEMP1 and FRZB in
G-DIF and KRT23 in G-INT. The products of the former are an extracellular matrix glycoprotein
and a secreted protein regulating bone development and influencing the Wnt/beta-catenin pathway.
The latter encodes for a member of the keratin family, which regulates epithelial cell structures.
In the last year, a nine-gene signature, including two negative impact factors (NR1I2 and LGALSL)
and seven positive ones (C1ORF198, CST2, LAMP5, FOXS1, CES1P1, MMP7 and COL8A1), was
proposed to predict the outcome of GC, and the model was able to predict patients’ outcome in terms
of survival and recurrence, clustering GC cases into low-risk and high-risk groups [18].
Although molecular characterizations have identified the gene signature for prognosis in GC,
today, signatures are still inadequate for accurate patient therapy. Identifying new tumour markers or
constructing gene models is still the focus of many research works and studies.
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4. TCGA Classification of GC and Related Signaling Pathways
4.1. EBV-Related GC
EBV-positive GC is one of the four subtypes of GC, as defined by TCGA, found in 9% of GC and
characterised by high EBV burden [13]. EBV-positive tumours were more frequent in men (81% of the
cases) and mainly occurred in the upper part of the stomach. In addition, EBV-positive GC was more
prevalent in younger patients compared to older subjects (Figure 1). The histology of EBV-related GC
is moderately- to poorly-differentiated adenocarcinoma, often accompanied by dense lymphocytic
infiltration [19–22]. In this subtype were identified pathways related to the elevated expression
of programmed death ligands 1 and 2 (PD-L1 and PD-L2), phosphatidylinositol-4,5-bisphosphate
3-kinase, the catalytic subunit α (PIK3CA) mutation and Janus kinase 2 (JAK2) amplification.
 
Figure 1. The most relevant clinic-pathological and molecular features of TCGA subtypes.
PD-L1 helps neoplastic cells to escape from antitumoral immune response, by binding to PD-1,
which is expressed on cytotoxic T-cells [23–25]. In the literature PD-L1, expressed on cancer cells
or tumour infiltrating immune cells, has emerged as a prognostic factor in GC, but its specific
role in EBV-related GC has not yet been described [26–30]. In a recent study [31] focusing on
EBV-related GC, the expression of PD-1/PDL-1 on immune and neoplastic cells, respectively, was
directly related to diffuse histology (according to Lauren’s classification) and depth of tumour invasion.
Therefore, targeted immune therapy against the PD-L1/PD-1 axis could be effective in this subtype.
Pembrolizumab, a highly specific monoclonal antibody targeting the PD-1 receptor, showed an overall
response rate of 22% in a cohort of patients previously treated with chemotherapy [32]. Subsequently,
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PD-L1 expression in at least 1% of neoplastic cells from paraffin-embedded tissue was significantly
related to response to this drug [33]. Another anti-immune strategy, already employed in melanoma,
targeting both the PD-1/PD-L1 and the CTLA/B7 axis, is under evaluation in several clinical trials [34].
The PI3K family of intracellular kinases is involved in cell survival, proliferation, differentiation
and migration [35]. In GC, the PI3K/AKT/mTOR pathway is frequently activated and associated
with nodal metastasis: in 35–80% of GC cases, PI3KCA is overexpressed [27–29], and in 40–82% of
GC cases, phosphorylation of AKT is described [36–40]. The EBV and MSI molecular subtypes of
GC show alterations in PIK3CA, in 80% and 42% of cases, respectively [14]. However, molecular
mechanisms responsible for sensitivity to PI3K inhibitors are not clearly defined, and the potential
use of this drug category in advanced GC is still in the preclinical stage. [41]. In GC, the PIK3CA
mutation could be predictive of response to everolimus and AKT inhibitors [42,43]. It is hypothesised
that AKT affects the BCL2 protein and the NF-κB pathway. PI3K may also induce upregulation of
the chemo-resistance proteins, MDR1/Pgp, BCL2 and XIAP, and downregulation of the expression
of BAX and caspase 3. In vitro, in tumour tissues of GC patients, AKT activation and PTEN loss
were associated with increased resistance to multiple chemotherapeutic agents (5-FU, doxorubicin,
mitomycin C and cisplatin) [44]. Similarly, in GC cell lines, a combination of PI3K and AKT inhibitors
with chemotherapy agents has successfully attenuated chemotherapeutic resistance [45,46].
The JAK/STAT signaling pathway has been identified in several types of tumours, including
GC, and especially in the EBV-subtype [47,48]. The phosphorylation and subsequent activation of
JAK2 lead to STAT activation by phosphorylation and activation of downstream gene expression
involved in cell proliferation and apoptosis arrest [49]. Therefore, JAK2 inhibitors may also represent
a potential therapeutic treatment for solid tumours, such as GC, despite them being primarily
studied in inflammatory and myeloproliferative disorders [50]. Ruxolitinib, a JAK1 and JAK2
inhibitor, in combination with capecitabine has demonstrated preliminary efficacy in pancreatic
cancer and, in combination with regorafenib, and is currently under evaluation in colorectal cancer
(ClinicalTrials.gov identifier: NCI02119676) [51]. However, there are no trials ongoing in GC.
4.2. GC with MSI
Microsatellite instability (MSI) is the hallmark of the MSI subtype according to TGCA classification.
MSI represents 15–30% of all GCs, is more frequently associated with intestinal histology and usually
arises in the mucosa of the antrum, mainly in females at an older age [14,52,53] (Figure 1). MSI is
a change that occurs in the DNA of certain cells (such as tumour cells) in which the number of repeats
of microsatellites (short, repeated sequences of DNA) is different than the number of repeats in the
DNA when it was inherited. The cause of MSI may be a defect in the ability to repair mistakes made
when DNA is copied in the cell, determined by mutations in one of several different DNA mismatch
repair genes (i.e., MLH1 or MSH2) [54]. The principal mechanism causing MMR deficiency in this GC
subtype relies on different MMR genes probably involved in MSI-high (MSI-H) sporadic GC without
MLH1 hypermethylation [55,56]. Zhu et al. in a meta-analysis showed a significant reduction of
mortality in patients with MSI-H compared with MSI-L (low) or microsatellite stable (MSS) cases [57].
In the MRC MAGIC trial, the relationship between MMRd, MSI and survival in patients with resectable
GC randomised to surgery alone or perioperative chemotherapy has been examined. MSI status and
MLH1 deficiency had a positive prognostic role in patients treated with surgery alone, while a negative
prognostic effect was established in patients treated with chemotherapy [55]. In contrast to MSI in
colorectal cancer, in MSI GC, alterations in PIK3CA, ERBB3, ERB22 and EGFR genes, along with major
histocompatibility complex I are known [14,53], whereas BRAF V600E mutations have never been
found [14]. In MSI-positive colorectal cancer, pembrolizumab has shown objective response and
progression-free survival rates of 40% and 78%, respectively [58]. Both MSI and EBV subtypes have
been associated with a more favourable prognosis and are, therefore, detected in lower percentage in
the metastatic setting, with subsequent difficult case finding in clinical trial design [59,60].
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4.3. GC with CIN
The largest group, CIN subtype, accounts for approximately 50% of GCs, and its most frequent
location is in the esophagogastric junction (EGJ)/cardia, as established by the TCGA study [14]
(Figure 1). CIN GC with an intestinal type histology is associated with copy number gains of
chromosomes 8q, 17q and 20q, whereas gains at 12q and 13q are more related to diffuse histology [61,62].
The effect of these alterations is the loss or gain of function of oncogenes and tumour suppressor
genes [63]. In the CIN subtype, some specific mutations are frequently found, i.e., in the TP53 gene
and receptor tyrosine kinases (RTKs), as well as amplifications of cell cycle genes (cyclin E1, cyclin D1
and cyclin-dependent kinase 6) and of the gene that encodes the ligand vascular endothelial growth
factor A (VEGFA) [14,64]. Furthermore, HER2, BRAF, epidermal growth factor (EGFR), MET, FGFR2
and RAS mutations have been discovered in the CIN subtype [14,65] (Figure 2).
The most frequent genetic alteration of this subtype, along with their respective targeted drugs,
is detailed in Table 2.
 
Figure 2. The most relevant targetable pathways in GC.
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4.4. Genomic Stable (GS) GC
The GS subgroup included all tumours that did not fulfil appropriate criteria for inclusion in one
of the other groups [14]. Patients included in this subgroup represent nearly 20% of all GC, usually
show diffuse histology, have a diagnosis at an earlier age (median 59 years), distal localization and
occurring equally in males and females (Figure 1). Several subtype-specific molecular changes have
been described for GS tumours. The principal somatic genomic alterations observed in GS gastric
tumours involve CDH1, ARID1A and RHOA and are described in Table 2. Moreover, an additional
translocation (between CLDN18 and ARHGAP26) involved in cell motility was later identified [14].
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4.5. Patient-Derived Preclinical Models of GC
The lack of effective preclinical models of human tumours, reflecting the complexity and
heterogeneity of cancer, has consistently limited the development of targeted drugs. In vitro and
in vivo models are available: cancer cell lines; cell line xenograft mouse models (PDX), created
transplanting human neoplastic fresh tissue into immunodeficient mice and organoids, which are
three-dimensionally cultured tissues, mimicking human tissues [110–122]. Their advantages and
disadvantages are summarised in Table 3.
Stem cell-derived gastric organoids have proven to be effective models of gastric cancer
pathogenesis: H. pylori-activated c-Met by its virulence factor cytotoxin-associated gene A and induced
a two-fold increase in epithelial cell proliferation [123]. Furthermore, epithelial dysplasia was found
in gastric organoids, and adenocarcinoma quickly developed in mice having mutations in KRAS or
P53 [124]. Murine epithelial-mesenchymal organoids were used also to successfully replicate hereditary
GC, with short hairpin RNA knockdown of TGFBR2 [125]. The fundamental role of RHOA function in
mediating anoikis in diffuse-type GC was demonstrated also in mouse organoids [126].




- no tumour-microenvironment interaction
- loss of architecture
- genetic modifications
- rapid analysis of drug response
- immortal cell lines allow unlimited source
of material
- low cost, low complexity
PDX models
- limited source of material
- high failure rate of engraftment
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- includes microenvironment
- can predict response to drugs
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- high level of architectural and physiological
similarity to native tissue
- intermediate cost, easy to handle
- large-scale drug screening
4.6. Role of microRNAs in Signaling Pathways of GC
MicroRNAs (miRNAs) are short, approximately 22 nucleotides in length that play key roles in the
regulation of gene expression [127]. Accumulating evidence indicates that miRNAs play an important
role in regulating cancer-related genes. They contribute to GC as oncogenes or tumour suppressors
by inhibiting either directly or indirectly the expression of target genes, some of which are involved
in signaling pathways [128]. Phosphatase and tensin homologue (PTEN) functions as a tumour
suppressor by counteracting PI3K signaling [129]. miRNA-221/222 has been found to be a modulator
of PTEN: by antisense or overexpression strategies, it directly affects PTEN expression [130]. PTEN is
also a target gene of miRNA-21 that increases the proliferation and invasion of GC cells. A similar
effect is displayed by miRNA-214 [131].
miRNA-375 is one of the most downregulated miRNAs in GC, by directly targeting PDK1,
a kinase that phosphorylates Akt. Ectopic expression of miRNA-375 reduces cell viability by inducing
the caspase-dependent apoptotic pathway [132]. Instead, miRNA-143 regulates the function of
GC cells in the PI3K/Akt pathway because its gene target is Akt itself [133]. Down-expression
of miR-181c stimulates KRAS expression and may have an important role in GC [134]. It was
found that miRNA-29s could influence the Ras/Raf/MEK/ERK pathway, which acts on cell cycle
progression by induction of cell cycle regulatory proteins such as CDKs and cyclins. miRNA-29c
inhibits protein expression/phosphorylation of Cdc42 [135,136]. Feng et al. demonstrated that
CDK6 is regulated by miRNA-107 [137]. Its expression is significantly decreased in GC, and its
re-expression significantly decreases proliferation. In GC, miRNA-206 modulates downstream target
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cyclin D2, involved in proliferation [138]. miRNA-106b and miRNA-93 could be upregulated
in GC and be downstream targets of the oncogenic transcription factor E2F1, which make the
tumour-suppressive function of transforming growth factor-β less effective [139]. E2F1 is a gene
target of miRNA-331-3p and miRNA-106a, modulating the G1/s transition [140,141]. miRNA-331-3p
is a tumour suppressor, whereas miRNA-106a promotes tumour growth. A group of researchers
demonstrated that the p21 family of CDK inhibitors was suppressed by miRNA-106b-93-25 and
miRNA-222-221 clusters. In particular, miRNA-25 targets p57 through the 3′-untranslated region;
miRNA-106b and miRNA-93 control p21, whereas p27 and p57 are downregulated by miRNA-222 and
miRNA-221 [142]. miRNA-148a has as direct target, p27, so by suppressing p27 expression, it may
promote gastric cell proliferation [143]. miRNA-196a, when highly expressed, is associated with
clinic-pathological parameters, such as tumour size, poor pT stage, pN stage and patients’ overall
survival times. In vitro and in vivo, a downregulation of miRNA-196a suppresses gastric cancer
proliferation by targeting p27kip [144]. Previous research has shown that miRNA-375, by targeting the
JAK2 oncogene, may act as a tumour suppressor and regulate GC cell proliferation [139]. Moreover,
miRNA-135 by targeting JAK2 may repress p-STAT3 activation, reduce cyclin D1 Bcl-xL expression
and inhibit cell proliferation [47].
4.7. Clinical Implications of Tissue miRNAs in GC
Tissue-based GC-related miRNA biomarkers are listed in Table 4, focusing particularly on their
application as diagnostic and prognostic indicators [145–159]. Dysregulated expression of miRNA
can play an oncogenic or tumour-suppressor role. In fact, they can regulate different signal pathways,
targeting genes involved in cell migration, angiogenesis and cell proliferation. Table 5 summarises
specific miRNA targeting pathways described above [160–167].
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5. Conclusions
The recent molecular research on GC has generated large amounts of data that are currently not
integrated into clinical practice.
However, they may be of help in the design of future clinical trials aiming to personalise treatment
in several ways: (i) by identifying the driving pathways of tumour growth; (ii) by discovering potential
drugs targeting such pathways; (iii) by finding predictable mechanisms of resistance and strategies to
overcome them.
It must be emphasised that each targetable molecular alteration/pathway is not specific to
a distinct subtype of GC; therefore, molecular subgroups alone are not sufficient to assign a patient
to a clinical trial. On the contrary, molecular characterization of patients is useful to select a small
population to be screened for protocol-eligible molecular aberrations. The implementation of GC
research and the molecular classification of patients in clinical trials may be important to select the
most appropriate therapies in GC. The hope is that combining histological and molecular classification
will be supportive of GC therapeutics and prognosis, but also in the near future for new non-invasive
diagnostic approaches such as to identify specific GC biomarker subtypes from circulating nucleic acid
or tumour cells.
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Abstract: Despite some remarkable innovations and the advent of novel molecular classifications
the prognosis of patients with advanced gastric cancer (GC) remains overall poor and current
clinical application of new advances is disappointing. During the last years only Trastuzumab
and Ramucirumab have been approved and currently used as standard of care targeted therapies,
but the systemic management of advanced disease did not radically change in contrast with the
high number of molecular drivers identified. The Cancer Genome Atlas (TCGA) and Asian Cancer
Research Group (ACRG) classifications paved the way, also for GC, to that more contemporary
therapeutic approach called “precision medicine” even if tumor heterogeneity and a complex genetic
landscape still represent a strong barrier. The identification of specific cancer subgroups is also
making possible a better selection of patients that are most likely to respond to immunotherapy.
This review aims to critically overview the available molecular classifications summarizing the main
druggable molecular drivers and their possible therapeutic implications also taking advantage of
new technologies and acquisitions.
Keywords: gastric cancer; molecular classifications; targeted therapy; immunotherapy
1. Introduction
During the last years, “precision medicine” has deeply changed the therapeutic landscape of
several malignancies. The customization of healthcare led to a global and significant improvement
in cancer management and has faded the “one size fit-all” era. However, in contrast to the steady
increase in survival observed for most cancer types, advances have been slow and difficult for gastric
cancer (GC).
In fact, despite some remarkable innovations there is still an urgent need for a deeper understanding
of the genetic and molecular background of this cancer and for novel treatment approaches.
Several therapeutic strategies have been already investigated and new molecular classifications
have been proposed, nevertheless the prognosis of patients with advanced disease remains overall
poor with a median overall survival (OS) of about 11 months and disappointing five-year survival
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rate of approximately 25–30% [1,2], even if a correct “continuum of care” is making longer survivals
less anecdotical.
Only trastuzumab (anti-HER2 monoclonal antibody) and ramucirumab (anti-VEGFR monoclonal
antibody) have proven to be successful weapons among all of the several molecular drivers identified,
but currently still lacking of any clinical utility; for these reasons, the standard systemic chemotherapy
still represents a “forced” mainstay of the treatment of advanced disease.
All of these efforts led to a fundamental acquisition: gastric cancer should be considered to be a
collection of different molecular entities, rather than a single homogeneous disease.
As a matter of fact, in contrast with the overall declining trends for the four major malignancies,
gastric cancer has still one of the highest estimated mortality rate, representing the third leading cause
of cancer-related death (8.8%) with alarming statistics that make it one of the most lethal disease in the
world (723,000 estimated deaths out of almost one-million new cases per year worldwide) [3].
Even if its incidence significantly fell over the last decades it still represents the fifth most common
cancer (6.8% of all) with 10,800 new diagnoses still expected in 2018 only in the United States (US) [4].
These numbers require the biggest effort and attention on this cancer in order to investigate its
heterogeneity and to maximize treatment outcomes.
The biggest challenge for the next future will be to understand which cancer subgroup deserves a
specific targeted agent, also reconsidering drugs that have failed at an early research stage through
the definition of more precise molecular drivers by using new technologies, such as patient-derived
xenograft (PDX) and tumor organoids or an integrated genomic analysis, and consequently to minimize
the amount of patients who receive a same treatment without any molecular selection.
This review aims to critically overview the available molecular classifications and the latest
findings for GC and to outline the possible future scenarios and implications of these acquisitions.
2. Where It All Began: The “Old Dear” Histology
Gastric cancer of epithelial origin (GC) is today recognized as an extremely heterogeneous
disease both in the clinical presentation modes as well as histological appearances and molecular
basis. A first attempt to define GC heterogeneity was to look at it by microscope as performed
by Lauren P. [5], who identified two main types of GC on histological bases: the first one called
“intestinal”, as it displayed features characteristic of intestinal mucosa (and it was thought to arise
from intestinal metaplasia of the stomach), and the other one called “diffuse” because the cancer
cells, often poorly cohesive, diffusely infiltrated the gastric wall. The World Health Organization
(WHO) classification of tumors of digestive system [6], on the other hand, classifies GCs, according
to their histological appearance, in “tubular adenocarcinomas” (that contain dilatated and branching
tubules, with cytological atipia varying from low to high-grade), “papillary adenocarcinomas”
(typically well-differentiated exophytic carcinomas with elongated finger-like processes), “mucinous
adenocarcinomas” (>50% of the tumor contains extracellular mucinous pool), and “signet-ring cell
adenocarcinomas” (more than 50% of the tumor consists of isolated or small groups of malignant
cells, highly infiltrative, containing intracytoplasmatic mucin), the latter one resembling those that are
classified as “diffuse type” in the “Lauren classification”.
3. Two Steps Towards Precision Medicine: Molecular Classifications
This histological heterogeneity is only the tip of the iceberg if we think about the GC underlying
molecular complexity, and, as a matter of fact, many molecular classifications have succeeded over the
years (immunohistochemistry based, genomic based, proteomic based, etc.): in this section, we have
tried to report the most significant, also in relation to novel therapeutic possibilities.
The first molecular attempt to classify comprehensively GC at molecular level was made by
Patrick Tan’s group in Singapore [7]: they analyzed 60 GC samples (from 60 patients) by expression
microarrays and comparative genomic hybridization and identified three molecular GC subgroups:
“tumorigenic”, “reactive”, and “gastric-like”.
28
Int. J. Mol. Sci. 2018, 19, 2659
Each subtype was associated to a different biological function; for example, “reactive” group
highly expresses endothelial growth factors and appears more sensitive to anti-angiogenic strategies.
However, no associations were found between each subtype and Lauren’s histology or tumor grading,
but, when survival analysis was performed, “gastric-like” tumor emerged as the most favorable
subtype in a statistically significant way.
In 2011, the same Singapore group proposed another classification of GCs in G-INT (genomic
intestinal) and G-DIF (genomic diffuse) [8]. Differently from others, the authors did not start their
research characterizing primary human tissue, but they used a panel of 37 GC cell lines: in that
way, they identified a “gene expression signature” of 171 genes that are able to distinguish these two
intrinsic GC subtypes, the first one called “G-INT” because more related to Lauren’s intestinal subtype
and the other one “G-DIF” more related to diffuse subtype. Moreover, this classification was also
validated on a clinical cohort of 270 GC patients, with important prognostic informations: G-DIF
tumors showed a statistically significant worse overall survival when compared to G-INT tumors,
while Lauren’s histologies were not prognostic. Furthermore, predictive informations came out from
in vitro experiments on 28 cell lines, with possibly relevant implications for patient’s care: G-INT
cell lines were more sensitive to 5-fluorouralcil and oxaliplatin, while G-DIF resulted in being more
sensitive to cisplatin. On that basis, authors designed a prospective “genomic-guided” chemotherapy
trial (NCT01100801) [9], in which GC patients were allocated to “oxaliplatin arm” or “cisplatin
arm” based on their intrinsic subtype; indeed, trial data were recently published [10], with some
disappointing results since, although G-INT GC patients allocated to Oxaliplatin arm showed a deeper
level of response, overall survival was better in G-INT patients that were allocated to cisplatin arm,
leaving the authors a little bit confused, as well as the readers.
In the same years, Manish Shah proposed a new GC classification that is based on epidemiological
and topographic tools [11], recognizing three subtypes: diffuse, proximal non-diffuse, and distal
non-diffuse GC. Proximal non-diffuse GC arises in the cardia and it is preceded by precursor glandular
dysplasia in the setting of chronic inflammation, but, differently from distal non-diffuse GC where
inflammation is more related to H. Pylori infection, in proximal tumors, phlogosis is caused by
gastric acid reflux [12]. To note, many tyrosine kinase receptors, like HER-2 (Human epitelial growth
factor receptor 2) [13,14], EGFR (Epidermal growth factor receptor) [15], and c-MET (Mesenchymal
epithelial transition factor receptor) [16] are more frequently expressed or amplified in proximal
tumors when compared with distal tumors. Moreover, glycolysis and gluconeogenesis pathways
are also upregulated in this subtype [10]. Distal non-diffuse gastric cancers arise instead between
the gastric body and pylorus, often preceded by chronic inflammation with aspects of intestinal
metaplasia, both consequences of chronic H. Pylori infection. These tumors frequently display an
intestinal histological appearance (according to Lauren) and upregulate vascular endothelial growth
factor and many other angiogenic pathways [17]. Finally, diffuse GC is characterized by diffuse pattern
of infiltration: the complete loss of adherence properties by the cancer cells generate the so called
“signet ring cells” histology, which is often due to CDH1 (Cadherin 1) tumor suppressor loss at genetic
level. Other molecular aberrations in diffuse GC include FGF-R2 (Fibroblast growth factor receptor 2)
tyrosine kinase receptor overexpression [18], PI3K (Phosphoinositide 3-kinase) signaling activity [19]
and HER3 receptor overexpression [20]. Finally, expression of some Matrix Metallo-Proteases (MMP) is
more frequent in diffuse versus intestinal cancers and it could contribute to tumor aggressiveness [21].
In 2013, Patrick Tan’s group again published a new attempt to molecularly classify GCs [22]: this
time the authors performed a “consensus hierarchical clustering” of 248 GC samples and identified
three major subtypes (“mesenchymal”, “proliferative”, and “metabolic”). The “mesenchymal”
subgroup was so called because of the high activity of EMT (epithelial-to-mesenchymal transition)
pathway: indeed, this subtype has very high levels of CDH2 (N-cadherin) transcripts and low levels of
CDH1 (E-cadherin), typical of mesenchymal cells. However, many other pathways characterize this
GC subtype:
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(1) Cancer Stem Cells (CSCs) pathway: very high levels of CD44 (a marker of CSC) are described,
with a more frequent poor differentiated histology (a surrogated marker of CSC).
(2) p53 pathway.
(3) Transforming Growth factor Beta (TGF-B) pathway.
(4) Vascular endothelial growth factor (VEGF) pathway.
(5) mTOR pathway (similarly to Shah’s “diffuse subtype”).
(6) Sonic Hedgehog (SHH) pathway: a very well defined pathway active in stem cells.
To note, mesenchymal subtype is more associated to Lauren’s diffuse dubtype than the other two
(60% of tumors in this category are diffuse type), as well as the G-DIF (92%).
The “proliferative” subtype shows the high expression of a large set of genes correlated to
cell cycle (E2F, MYC, RAS, etc.). These tumors are frequently correlated to Lauren’s intestinal
type (74%) and G-INT subgroup (71%) with very high levels of p53 mutations and copy number
amplifications (in CCNE1 locus, MYC locus, KRAS locus, to name a few). Lastly, the “metabolic”
subtype highly expresses metabolic-related genes and digestive-related genes, the latter ones being
typical also of normal gastric mucosa. Therefore the authors hypothesized that this subtype
is closer to the normal gastric mucosa than the other two, even in terms of gene expression
profile. An intermediate step between the normal mucosa and this cancer subgroup could be the
SPEM (spasmolytic-polypeptide-expressing metaplasia), whose genes are highly expressed by the
metabolic subtype.
Although these subtypes are molecularly very distinct, no differences in terms of survival were
identified. However, metabolic subtype seems to be more sensitive to 5-fluorouracil than the other two,
perhaps in relation to low levels of thymidylate synthetase, while the mesenchymal subtype (probably
due to “oncogenic addiction” to PI3K-AKT-mTOR pathway, as we discuss above) seems to be sensitive
to several drugs that block PI3K or mTOR, opening the way for a more precise therapy for GC.
In 2014 Leung et al. [23] demonstrated the multidimensional genomic landscape and the molecular
complexity of gastric adenocarcinomas performing an integrative genomic analysis on a dataset of
100 diffuse and intestinal GC samples (tumor and normal tissue paired). Using four different platforms
(whole-genome sequencing, DNA copy number, gene expression, and methylation profiling), they
identified the main aberrant pathways and subtype-specific genetic and epigenetic perturbations.
In addition to the known mutated driver genes (TP53 frequent in both subtypes, ARID1A in Epstain
Barr Virus-related (EBV) or microsatellite instability-related cancers and CDH1 in diffuse-type),
authors have been able to describe new highly recurrent significant mutations (i.e., MUC6, CTNNA2,
GLI3, RNF4) and particularly the high prevalence of RHOA (Ras homolog gene family, member A)
mutations in diffuse-type tumors (14.3% vs. 0% in the intestinal-type, p < 0.001). These mutations
determines defective RHOA pathway leading to aberrations in the adhesion functionality and escape
from programmed cell death that occours when anchorage-dependent normal cells detach from the
extracellular matrix, also demonstrating the possible tumor suppressive role of RHOA in this subtype.
The study was one of the first to prove the deep molecular differences and to highlight the specific
genetic perturbations covered below different histological features.
Few months later, the Cancer Genome Atlas (TCGA) investigators published the most important
and comprehensive study that we have to date on molecular GC classification [24].
The authors characterized 295 GC tumor samples using six different molecular platforms
(copy number alterations, whole exoms sequencing, mRNA sequencing, miRNA sequencing,
DNA methylation analysis, and phosphoproteomic analysis) and identified four molecular subtypes:
EBV-related, MSI-H (Microsatellite instability-high), Genomically Stable (GS), and Chromosomal
Instability (CIN). The first one (9% of cases) is called “EBV-related”, because it is characterized
by Epstein Barr virus infection in the cancer cells: these tumors are mainly located in the gastric
fundus or body and show extensive DNA promoter hypermethylation (a marker of “gene silencing”).
Moreover, they have the highest frequency of PIK3CA (encoding for the catalytic alfa subunit of
PI3K kinase) mutations (80%), as well as amplifications of JAK2 (Janus kinase 2) or PD-L1/L2 genes,
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making this subtype “ideally” the most sensitive to PI3K or PD1/PDL1 inhibition (as we will see
later). The second group (22% of cases) was called “MSI” because it was characterized by genomic
instability, due to a deficient DNA mismatch repair system, and lacked targetable amplifications. This
subtype shows hypermethylation of MLH1 promoter region (leading to MLH1 silencing)—the cause
of MSI status—and a very high mutation rate with hotspot mutations involving several genes like
HER2 (5%), EGF-R (5%), HER3 (14%), JAK2 (11%), FGFR2 (2%), MET (3%), and PIK3CA (42%). To note,
the BRAFV600E mutation commonly seen in MSI-H colorectal cancer was universally absent. Finally,
gastric MSI tumors have a very high rate of PD-L1 expression that, when associated with the high
number of mutation-associated neoantigens, could make them very sensitive to checkpoint inhibitors.
The third group is called “Genomically Stable” (GC) and it accounts for 20% of TCGA dataset:
it lacked somatic copy number aberrations and was more related to Lauren’s diffuse histology than the
other ones. A pathway frequently destroyed in this subtype is that related to “cell adhesion”, with the
most relevant genes mutated CDH1 (26%), RHOA (15%), and chromosomal translocation involving
CLDN18 and ARHGAP (15%). The last group is characterized by chromosomal instability (50% of
cases), and it thus called “CIN”. Gene amplifications are very frequent, with involvement of different
tyrosine kinase receptors or related pathways: HER2 (24%), EGF-R (10%), HER3 (8%), JAK2 (5%),
FGFR2 (8%), MET (8%), PIK3CA (10%), and KRAS/NRAS (18%).
After all, if we move to clinical significance of this classification, not reported in the original paper,
Sohn et al. [25], while using gene expression data from one of the TCGA cohort (n = 262), developed
a robust subtype-based prediction model with the EBV subtype resulting as the one associated with
the best prognosis and the “GS” subtype with the worst. Moreover, MSI and CIN subtypes had an
intermediate prognosis, with a poorer overall survival than those with EBV+ but better than those
with GS subtype. The authors also found important predictive informations, as the CIN subgroup
experienced the biggest benefit from adjuvant chemotherapy, while the GS subtype the smallest.
One year later, the Asian Cancer research group (ACRG), analyzing 300 gastric tumor samples
by two molecular platforms, provided a new GC classification, and identified four subtype [26]:
“MSI”, “MSS/EMT”, “MSS/p53+” (p53 active), and “MSS/p53−” (p53 inactive). One of the strengths
of ACRG classification is to precisely correlate each molecular subtype with clinical information,
like prognosis, recurrence frequency (after surgery), and pattern of recurrence (i.e., peritoneal versus
hepatic).
The MSI subtype (23% of cases), as in the TCGA cohort, was found to be hypermutated due to the
frequent loss of MLH1. These tumors occur mainly in gastric antrum (75%), they are preferentially of
intestinal subtype (>60%) and >50% of subjects are diagnosed at an early stage (I/II). Genes frequently
affected by mutations are KRAS (23%), ALK (16%), ARID1A (44%), and those related to PI3K pathway
(42%). To note, this group is associated with the best overall prognosis and the lowest frequency
of recurrence (22%) of the four subtypes. The MSS/EMT (epithelial to mesenchymal transition)
group (15% of cases) occurs at significantly younger age and shows mainly diffuse histology. It is
characterized by a very low mutation rate when compared with other MSS groups (p < 0.001), but with
the frequent loss of CDH1 expression, especially in a large set of signet ring cells adenocarcinomas.
More importantly, the majority of subjects (>80%) in this subtype are diagnosed at stage III/IV: therefore
the MSS/EMT has the worst prognosis, with the highest chance of recurrence (63%), mainly at the
peritoneal site.
MSS/p53+ tumors (26% of cases) show frequent EBV positivity (with some overlap with the
“EBV-related” subtype of TCGA) and a preserved activity of p53 tumor suppressor gene. Frequent
mutations hit APC, ARID1A, KRAS, PIK3CA, and SMAD4. This subtype is also associated with the
best overall prognosis after MSI subtype.
MSS/p53− tumors (36% of cases) present overlap with the CIN group from TCGA, showing the
highest prevalence of p53 mutations and recurrent focal amplifications of tyrosine kinase receptors,
like ERBB2 or cell-cycle modulators, like CCNE1 or CCND1.
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4. Comparison of TCGA and ACRG Data
The TCGA and ACRG classifications are partially overlapping and complementary models:
they both identified an MSI group of tumors characterized by high mutation frequency and
best prognosis. While CIN and GS subtypes are present across all the ACRG groups, it is
noteworthy that TCGA EBV+, GS, and CIN subtypes are enriched in ACRG MSS/p53+, MSS/EMT,
and MSS/p53− respectively.
However, while CDH1 and RHOA mutations are highly prevalent in the TCGA GS subtype,
in ACRG MSS/EMT, these mutations are extremely rare, making these two subtypes absolutely not
equivalent or synonyms.
Possible reasons for this partial overlap between these classifications include differences related
to the patient population (Korea in ACRG versus USA and Western Europe in TCGA), tumor sampling
(mainly diffuse in ACRG), and technological platforms (six different molecular platform in TCGA
(exome sequencing, copy number analysis, mRNA-miRNA-methylation analysis), versus only mRNA
expression and targeted gene sequencing in ACRG).
Although their limitations these two classifications represent today the most important
groundwork for the development of targeted therapies inspired to a concept of “biologically-guided
tumor treatment”, as well as patients stratification for clinical trials and improved prognostication.
5. Clinical Implications of Molecular Classifications
How can we use this enormous amount of information for a clinical application? Unfortunately,
neither the TCGA nor AACR classifications can be currently used for patients’ stratification and
selection, as for many of the identified mutated genes the functional relevance of mutation is not
known and, more importantly, they are not yet druggable.
In this section, we individually consider the most relevant molecular targets that are identified in
gastric cancer and we discuss their potential therapeutic implications (Table 1).
Table 1. Major target-oriented phase II/III trials in gastric and esophagogastric adenocarcinomas.
Trial Phase Setting Target Arms N Patients Primary
Endpoint
Result
ToGA III 1st line HER2+ CF/CX ± Trastuzumab 594 OS Positive
JACOB III 1st line HER2+ CF/CX+ Trastuzumab ±Pertuzumab 780 OS Negative
GATSBY II/III 2nd line HER2+ Taxanes ± TDM-1 345 OS Negative
LOGIC III 1st line HER2+ CapeOX ± Lapatinib 545 OS Negative
TyTAN III 2nd line HER2+ Paclitaxel ± Lapatinib 261 OS Negative
EXPAND III 1st line EGFR (unselected) CX ± Cetuximab 894 PFS Negative
REAL-3 III 1st line EGFR (unselected) EOC ± Panitumumab 553 OS Negative
METGastric III 1st line MET+ Folfox ± Onartuzumab 562 OS Negative
RILOMET-1 III 1st line MET+ ECX ± Rilotumumab 609 OS Negative
SHINE II 2nd line FGFGR2+ Paclitaxel ± AZD4546 71 PFS Negative
FAST IIb 1st line CLDN18.2+ EOX ± Claudiximab 161 PFS Positive
AVAGAST III 1st line VEGF CX ± Bevacizumab 774 OS Negative
AVATAR III 1st line VEGF CX ± Bevacizumab 202 OS Negative
REGARD III 2nd line VEGFR2 Ramucirumab vs. Placebo 355 OS Positive
RAINBOW III 2nd line VEGFR2 Paclitaxel ± Ramucirumab 665 OS Positive
5.1. HER2
HER2 (Human Epidermal Growth Factor Receptor II) or ERBB2 (Avian erythroblastosis oncogene
B), encoded at chromosome 17q21, is a well-defined tyrosine kinase receptor often acting as
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proto-oncogene in many human cancers. Oncogenic mechanisms that hit HER2 are represented
by gene amplification (determining protein over-expression) or less commonly activating mutations.
HER2 lacks of a known exogenous ligand and it is transactivated by the interaction with other
HER family members (EGFR or HER3 overall) or other tyrosine kinase receptors. Its activation leads
to a complex cascade of transduction events within the cytoplasm, that converge on two fundamental
signaling pathways: the RAS-MAP (mitogen activated protein) kinase pathway and the PI3K-AKT
pathway, both determining cell survival, proliferation and migration.
In GC HER2 overexpression is mainly due to gene amplification: it occurs more frequently in
proximal tumors (more than 30% of cases), than in distal cancers (less than 20%), mainly arising from
the gastric body. Furthermore, Lauren intestinal subtype shows a higher expression of HER2 (up to
34%) than diffuse subtype (6%), while, concerning to TCGA classification, CIN tumors more often
express HER2 as consequence of gene amplification (as mentioned above).
Different strategies to target HER2 were developed over the years: monoclonal antibodies
(like trastuzumab) that bind to the extracellular domain of the receptor, determining receptor
down-regulation or antibody-dependent-cytotoxicity (ADCC), and TKIs (tyrosine kinase inhibitors),
that inhibit signaling cascade through the blockade of receptor kinase activity.
The pivotal phase III ToGA (Trastuzumab for Gastric cancer) trial [27] showed that, in HER2
positive GCs, the addition of trastuzumab to standard platinum-based first line treatment was effective,
with a median overall survival (mOS) of about 13.8 months in the experimental arm versus 11.1 in
the standard one (HR: 0.74; p = 0.0046). This OS still represents the highest ever reached in a phase
III trial recruiting GC patients. The greatest benefit was observed in high HER2 expressing patients
(IHC3+ or IHC2+/FISH+), with a mOS of 16 months versus 11.8 in low HER2 expressing patients
(IHC0-1+/FISH+). Therefore, this trial led to the approval of trastuzumab in HER2 positive GC, in the
first line setting for patients with IHC3+ or IHC2+/FISH+.
Based on the extraordinary results of the Cleopatra Trial in HER2 positive breast cancer [28], it has
been speculated that also in GC the addition of pertuzumab (another monoclonal antibody targeting a
different HER2 domain than trastuzumab) to trastuzumab itself and platinum-based chemotherapy
could improve the ToGA survival rates, leading to JACOB Trial design. Unfortunately, this study
was almost negative [29] because the mOS was 17.5 months in experimental arm versus 14.2 in the
standard (HR: 0.84; p = 0.0565), a difference that did not find statistical significance.
Trastuzumab-emtansine (TDM-1) is an antibody-drug conjugate that is widely used in second
line setting for metastatic HER2 positive breast cancer [30]. This drug was also studied in second line
therapy of HER2 positive GC (previously treated with trastuzumab) within the GATSBY phase III
trial [31]: unfortunately, TDM-1 therapy was not superior to standard taxanes (mOS 7.9 months versus
8.6 respectively, HR: 1.15, p = 0.86), although with lower incidence of adverse events.
Another strategy to target HER2 consists of the inhibition of kinase activity with small molecules
TKIs, like Lapatinib (a multi-kinase inhibitor with a strong activity against EGFR and HER2).
This molecule was tested in two randomized phase III trials enrolling GC patients with advanced
disease: the LOGIC and TYTAN trials.
The LOGIC trial [32] tested lapatinib in combination with capecitabine plus oxaliplatin versus
chemotherapy alone in the first line setting of HER2 positive GC patient. The trial results were negative,
because mOS (the study primary endpoint) was 12.2 months in experimental arm versus 10.5 in the
standard (HR: 0.91, p = 0.349), a statistically not significant difference, although secondary endpoints
like ORR or PFS were in favor of Lapatinib arm.
Furthermore, lapatinib has been tested in second line setting within the TYTAN phase III trial [33],
in wich 261 previously treated Asian GC patients were enrolled to receive lapatinib plus paclitaxel
or paclitaxel alone (to note only 15 patients [6%] had previously received trastuzumab in first line).
Once again, the results were negative, with insignificant differences between the two arms for OS
and PFS.
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Due to the disappointing results of these trials (JACOB, GATSBY, TYTAN, LOGIC),
many researchers began to study mechanisms of targeted therapy resistance in GC, when considering
that also patients who achieved a significant response to first line trastuzumab-based treatment can
develop resistance within a few months [34].
In effect, one main bias of the second-line trials, especially the GATSBY trial, seems to be the
absence of tumor rebiopsy (for example at metastatic site) at screening, taking for granted that the
tumor was still HER2 positive on the basis of the basal diagnostic biopsy.
An Italian study [35] clearly showed that the acquired resistance mechanism to trastuzumab-based
first line treatment could be the loss of HER2 receptor, especially for patients with dubious
immunohistochemistry (IHC2+/FISH+), speculating that HER2 negative clones are positively selected
by the first line anti-HER2 therapy and could subsequently expand. In that way, the negative results
of the GATSBY study could be related to the fact that, in a significant proportion of cases, they have
treated with TDM-1 patients who were de facto HER2 negative at the beginning of the second line.
Another possible mechanism of acquired resistance to trastuzumab is likely due to co-existing
molecular alterations within the HER2 positive tumor clones, as clearly showed by Pietrantonio et
al. [36]: mutations of EGFR/MET/KRAS/PIK3CA/PTEN or the amplifications of EGFR/MET/KRAS
can co-occur in HER2 positive cells and could explain the lack of trastuzumab efficacy and/or the
appearance of resistance.
In any case, to date, no standard anti-HER2 treatment is available in trastuzumab refractory
HER2+ patients, and standard chemotherapy with taxanes (mainly the combination of Paclitaxel plus
ramucirumab) or irinotecan is recommended.
5.2. EGFR
Epidermal Growth Factor Receptor (EGFR) or ERBB1 is a transmembrane tyrosine kinase receptor,
expressed approximately in 30% of GC [37], especially those with chromosomal instability (“CIN”
subtype of TCGA). This molecule represents the second most important receptor (after HER2) in GC
pathogenesis: its overexpression is associated with poorly differentiated histology, vascular invasion,
and potentially shorter survival [38].
Several studies evaluated the safety and efficacy of different anti-EGFR drugs, on the basis of
preclinical works [39]: anti-EGFR therapies include—as we just discussed for HER2—monoclonal
antibodies (like cetuximab or panitumumab) and TKIs (gefitinib, erlotinib).
Initial phase II trials combining these agents with cytotoxic chemotherapy in unselected patient
population identified high response rates for the first line setting (from 41 to 65%) [40,41]. Unfortunately,
all of the phase III trials investigating the role of anti-EGFR therapy in GC were negative.
The EXPAND study [42] randomized GC patients in first line setting between cetuximab plus
capecitabine-cisplatin versus chemotherapy alone, showing no advantage for cetuximab arm (mPFS
4.4 months versus 5.6 months, p = 0.32). The patient recruitment was unselected for EGFR positivity,
although in a post-hoc analysis the highest survival benefit was observed in a small subset of patients
with high EGFR expression (representing probably EGFR amplified tumors).
The REAL-3 trial [43] demonstrates that adding panitumumab to epirubicin-oxaliplatin-
capecitabine was even detrimental, as the mOS for the experimental arm was 8.8 months versus
11.3 months for the standard one (HR: 1.37, p = 0.013).
The deep failure of anti-EGFR drugs in gastric cancer can be explained mainly with the lack of a
proper patient selection. In fact, a recent work by Catenacci et al. [44] showed that EGF-R amplified
tumors (5% in Chicago casuistry), some of which were treated with anti-EGFR drugs, seems very
prone to respond to cetuximab or ABT-806 (an investigational anti-EGFR drug), with an ORR of 58%,
a DCR of 100%, and a mPFS of about 10 months. Thanks to next generation sequencing (NGS) and
circulating tumor DNA (ctDNA) studies, the authors also showed the mechanisms of resistance to
anti-EGFR drugs, such as the presence of EGF-R negative tumor clones, KRAS mutation/amplifications,
PTEN deletion, and NRAS/HER2/MYC amplifications.
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This study definitively demonstrates that EGF-R amplification is able to predict response to
anti-EGFR therapies, despite the negative results in prior unselected phase III trials (EXPAND and
REAL-III), but also that mechanisms of resistance exist and could be detected by novel technologies,
like NGS and ctDNA.
5.3. C-MET
MET (Mesenchymal-Epithelial Transition) oncogene, also called Hepatocyte Growth Factor
Receptor (HGF), is a receptor tyrosine kinase that appears to be deregulated in many human
cancers [45], such as breast, colorectal, lung, pancreatic, hepatic and—not least—gastric cancer.
Its activation requires binding to HGF (the soluble ligand of MET), the so-called “canonical
activation”, but can also occur without HGF, through a cross-talk with other receptors (the “non
canonical” pathway) [46]. MET signaling in GC is related to worse prognosis [47], because HGF/MET
activity is involved in cancer growth, invasion, angiogenesis, and epithelial-to-mesenchymal transition.
The main known mechanism of MET overexpression in GC is gene amplification, which occurs
in about 6% of the TCGA dataset (especially in CIN tumors). However, even tumors without gene
amplification can express (or overexpress) MET, although it is not clear whether these tumors really
depend on MET for survival and malignant properties.
Two monoclonal antibodies, Rilotumumab (an anti-HGF antibody) and Onartuzumab
(an anti-MET antibody) were tested in clinical trials in GC: early reports [48,49] suggested that MET
expression could serve as a predictive biomarker for anti-MET directed therapies, but in both phase III
clinical trials evaluating Onartuzumab and Rilotumumab, the results were negative.
The METGastric phase III trial [50] evaluated the addition of onartuzumab to a chemotherapy
backbone (mFOLFOX6), and enrolled 562 GC patients with HER2 negative/MET positive tumors
(defined as score 1+, 2+, and 3+ by immunohistochemistry). The enrollment was stopped early due
to sponsor decision, for a lack of efficacy in a phase II trial also assessing contemporary the role of
onartuzumab in MET positive GC [51]. Unluckily, the addition of onartuzumab to mFOLFOX6 did not
result in an improvement of OS (11 months in the experimental arm versus 11.3 in standard, HR: 0.82,
p = 0.24) and PFS (6.7 versus 6.8 months, respectively, HR: 0.90, p = 0.43).
Negative results were obtained also with rilotumumab within the RILOMET-1 phase III trial [52],
which used a different chemotherapy backbone (Epirubicin plus Cisplatin and Capecitabine). In that
case, not only results were clearly negative with a detrimental effect (mOS was 8.8 in experimental
arm versus 10.7 in the placebo group, HR: 1.34, p = 0.003), but study treatment was also stopped early,
because an independent data monitoring found a higher number of deaths in the rilotumumab group
than the placebo group.
There is a great discordance between the phase II rilotumumab study [48] and the RILOMET-1
results, because the MET+ patients treated with rilotumumab within the phase II (n = 41) had a
mOS of 10.6 months when compared with 5.7 months of patients receiving placebo. Noteworthy,
despite the cutoff to define MET positivity with immunohistochemistry was the same between phase
II and III (expression ≥1+ in ≥25% of tumor cells), there was a relevant difference in the number of
patients screened who were considered MET positive in phase II (64%) and phase III (81%) trial, for
not known reasons.
Probably the main limit of RILOMET and METGastric trials is to have included mostly patients in
whom MET was not a clear “driver” of the disease, since the highest expressing tumors (MET gene
amplification) are under-represented, which can explain the negative results.
5.4. FGF
FGFR2 belongs to FGFR receptor family, which includes four different receptors and almost
23 different ligands, making it an extraordinary complex system [53]. The ligand-receptor interaction
leads to initiation of a signaling cascade that lead, as for the majority of RTKs, to MAPK and PI3K-AKT
pathways activation.
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In GC, the first evidence of FGFR2 amplification has been described in 1990 [54], analyzing KATO
III cell line. Moreover in the TCGA dataset almost 9% of patients within the CIN subtype presented
FGFR2 gene amplification, which convinced researchers to test the FGFR inhibitors in FGFR2
amplified GC.
One molecule tested is AZD4547, a selective FGFR1,2,3 TKI with powerful preclinical activity
in FGFR2 amplified GCs [55]. This drug was evaluated in the SHINE trial [56], in which GC
patients displaying FGFR2 amplification or polysomy were randomized in second line setting between
AZD4547 or paclitaxel. Trial results were negative, with a median PFS of 1.8 months in experimental
arm versus 3.5 in the chemotherapy one. These very disappointing results have been mainly due
to great intratumor heterogeneity for FGFR2 amplification—the FGFR2 status evaluated on archival
tumor tissue may not reflect the molecular status of metastatic tumor at study screening—and to poor
concordance between gene amplification and receptor expression. Therefore, an alternative predictive
biomarker testing for FGFR2 is urgently needed, when considering that FGFR2-amplified tumors with
FGFR2 overexpression, although at very low prevalence, exist and should be appropriately treated.
5.5. CLAUDIN18.2
Claudins are a well-known family of proteins that shape the fundamental part of tight cell
junctions [57]. Within the normal gastric mucosa the isoform 2 of the Claudin18 (claudin 18.2 or
CLDN18.2) is highly expressed, especially in differentiated epithelial cells, while it is quite absent in
the gastric stem cell zone.
Claudin18.2 is retained in malignant transformation and is expressed in a significant proportion
in primary tumors and their metastasis [58]. This molecule seems to be a good target especially in
TCGA “GS” tumors that in a significant proportion (15% of cases) show a chromosomal translocation
involving CLDN18 and ARHGAP.
In a phase IIb study (the FAST trial) [59], the role of Claudiximab (a chimeric monoclonal antibody
against CLDN18.2 also known as Zolbetuximab-IMAB362) has been evaluated in combination with
chemotherapy (epirubicin, oxaliplatin, and capecitabine [EOX]) versus chemotherapy alone in the
first line setting (n = 161). This trial met its primary endpoint, because claudiximab significantly
improved mPFS (7.9 months versus 4.8, HR: 0.47, p = 0.0001) and mOS (13.3 months versus 8.4, HR:
0.51, p < 0.001) as compared to EOX alone. A more pronounced benefit was observed in patients with
very high CLDN18.2 expression (≥2+ intensity in ≥70% of tumor cells), making this combination a
very appealing strategy for HER2 negative GC.
A notable point in the FAST study is that the outcomes in the EOX only arm were not similar to
the corresponding landmark trial REAL 2 study (OS of 11.2 (REAL 2) vs. 8.7 (FAST), which could be
due to patient selection.
Other trials are under development for CLDN18.2 positive gastric cancers such as the phase II
trial with Zolbetuximab (NCT03505320—“ILUSTRO” trial) and a phase III trial with claudiximab is
scheduled and expected.
Overall, the major limitation seems be the availability of the testing for CLDN18.2 and the finding
of the ideal cut-off point for the CLDN18.2 levels, with the suggestion of studies comparing outcomes
between low CLDN18.2 levels versus higher levels. The anti-claudin research is one of the best
examples of how targeted therapy is clearly the future also of gastric cancer treatments.
5.6. VEGF/VEGFR
In the TCGA “CIN” subtype, vascular endothelial growth factor (VEGF), a crucial mediator of
normal and pathogenic angiogenesis, is frequently amplified up to 7% of cases. Although initial studies
with bevacizumab (a monoclonal antibody targeting VEGF-A) were negative, such as the AVAGAST
trial [60] and the Asiatic AVATAR trial [61], in which bevacizumab was combined with platinum-based
chemotherapy in first line setting, other antiangiogenic strategies continued to be investigated.
36
Int. J. Mol. Sci. 2018, 19, 2659
Ramucirumab, a fully human monoclonal antibody directed against VEGFR2 (Vascular
endothelial growth factor receptor 2), which is the main receptor of the VEGF system implicated
in oncogenic angiogenesis, has been used in the second line setting alone [62] or in combination with
weekly paclitaxel [63].
Both studies were positive, with the REGARD trial showing a significant improvement in OS with
ramucirumab alone versus BSC (mOS 5.2 months versus 3.8, respectively, HR: 0.776, p = 0.047) and the
RAINBOW trial showing a significant superiority of combination arm (ramucirumab plus paclitaxel)
versus paclitaxel alone (mOS 9.63 months versus 7.36 months, respectively, HR: 0.807, p = 0.017).
On that positive basis, ramucirumab has been tested in first line setting in combination with
cisplatin-based standard chemotherapy within the RAINFALL trial [64]: although the study formally
met its primary endpoint, with an improvement in mPFS from 5.4 months (placebo arm) to 5.7 months
(ramucirumab arm) (HR: 0.75, p = 0.011), there was no survival benefit for patients treated with RAM +
Capecitabin/Cisplatin versus placebo + Capecitabin/Cisplatin (mOS 11.2 months versus 10.7 months,
HR: 0.96, p = 0.68), making the results negative de facto and not significant for clinical practice.
Therefore, the role of antiangiogenic agents seems to be essential in second line setting, but in the
first line, like the AVAGAST and AVATAR trial, showed for bevacizumab, probably we need to better
understand who are the patients that really benefit from this strategy.
5.7. PI3K Pathway
The PI3K/AKT/mTOR pathway is a fundamental promoter of cell growth, metabolism, survival,
and cell migration: it is mainly activated by cell surface tyrosine kinase receptors, but in human cancer,
many component of this pathway could be affected by activating mutation (PIK3CA) or inactivating
genetic events (PTEN), like gene deletion.
Approximately, 80% of PIK3CA mutations occur at three recurrent hotspots: E545K and E542K in
the exon 9, and H1047R in the exon 20 [65].
In gastric adenocarcinomas, PIK3CA is one of the most frequent mutated genes especially in
EBV-related GC (almost 80% of cases are mutated) and “MSI” subtype (42% of cases), as shown by
TCGA, making this molecule an appealing target to pharmacological inhibition.
One of the first study evaluating the block of PI3K-AKT-mTOR pathway in GC is the GRANITE-1
Trial [66], a phase III study in which 656 GC patients who progressed after previous one or two lines
of systemic chemotherapy were randomized between everolimus (a mTOR inhibitor) or placebo.
Results were almost negative, because the mOS (primary endpoint of the study) resulted 5.4 months
with everolimus versus 4.3 with placebo (HR: 0.90, p = 0.124) and mPFS was 1.7 months versus 1.4,
respectively (HR: 0.66, p < 0.001). The modest (and statistically significant) improvement in PFS
suggested a potential benefit in selected patients: for example, PIK3CA/PTEN mutations could be
predictive of mTOR inhibition, as suggested by Meric-Bernstam et al. [67].
Other studies with drugs that inhibit directly PI3K or AKT are in early phase clinical trials and to
date no data are available.
6. Gastric Cancer in the Immunotherapy Era: A Hope for the Future
Immunotherapy deeply changed the therapeutic landscape for several malignancies (advanced
melanoma, lung, urothelial, kidney cancer, etc.) determining a global outcome improvement
completely unexpected until a few years ago by boosting the body’s natural defenses to fight cancer [68].
Gastric cancer is still late when compared to these others cancer types, even if some relevant results
have been lately scored leading to a more confident vision for the future [69].
As already reported comprehensive molecular characterization performed by the TGCA group
showed a relatively high mutational load (up to 10–15 mutations per megabase) in about 34% of gastric
adenocarcinomas analyzed and a subset of tumors with microsatellite instability-high (MSI-H, 22%) or
with an ideally favorable immune-environment (the “EBV-related” subgroup that shows molecular
hallmarks of sensitivity to immunotherapy, such as intra- or peritumoral immune cell infiltration and
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PD-L-1/PD-L-2 expression), suggesting that also gastric cancer could be a promising “fertile soil” for
immunotherapy, especially based on immune checkpoint inhibitors.
These checkpoints play critical roles for physiological homeostasis and for balanced immune
responses and they are heavily involved in the immune escape mechanisms of GC as well.
Also, other previous preclinical evidence supports the idea that immunotherapy can be a
successful anti-GC strategy, particularly regarding the T cell-based treatment protocols: cytotoxic T
lymphocytes (CTL) and tumor infiltrating lymphocytes (TIL) [70,71].
Induced CTL cell culture technology (using specific peptides) led to the clinical tests based on
adoptive transfer of CTLs in patients. The induced CTLs showed specific activity against tumor cells
in vitro and against primary cell culture isolated from GC patients, suggesting that this strategy could
be a kind of “vaccine” and adoptive immunogenic therapy as already preliminarily demonstrated in
melanoma patients (up to 40% of antitumor immune responses in phase 2 trial) [72]. As a matter of
fact CTLs from GC patients are able to identify specific tumor-associated antigens and to attack the
autologous neoplastic cells triggering the immune responses against gastric cancer [73].
Furthermore, Kim et al. [74] also demonstrated the anti-gastric cancer activity of cytokine-induced
killer cells (CIK) that are mainly T CD80+ cells isolated from human peripheral blood mononuclear
cells cultured with IL-2 and anti-CD3 antibody. The CIK cells were capable of destroying human
gastric cancer cells in vitro and to inhibit tumor growth in mouse model, indicating a potential role of
CIK cells as adoptive immunotherapy for GC as well.
The transfer therapy with TILs requires first of all the T cell isolation from neoplastic tissue, then
the in vitro expansion and finally the selection of tumor-specific T cells. The application of these
protocols in GC patients is more difficult compared to melanoma because of an hardest surgical
availability of adequate tumor tissue (only 30–40% of biopsies usually acceptable for the procedure)
but this strategy seems particularly promising, as shown by the positive correlation between the
presence of TILs and survival in ovarian, colorectal and pancreatic cancer [75–77] and it should be still
encouraged and enforced. It is important to underline that in some cases TILs can even promote cancer
development depending on the functional features of lymphocytic infiltrate [78]. These techniques
and others (such as dendritic cell-based vaccination [79]) need to be deepened and optimized also for
gastric cancer and they appear as a complex universe yet to be entirely discovered.
With regards to checkpoint inhibitors, we can find the strongest evidence that is currently available
to support the approval for use of immunotherapy in GC with first promising results.
The KEYNOTE-012 trial [80] demonstrated in an early-phase the potential application of anti-PD1
therapy with pembrolizumab (humanized IgG4-k monoclonal anybody selective to bind PD1, currently
approved by FDA in the US) in 39 patients that were affected by PD-L1 positive refractory advanced
gastric cancer with promising overall response (22%, 95% CI 10–39). In the single arm phase 2 trial
KEYNOTE-059 [81] this activity has been confirmed in an unselected population of patients with
metastatic GC (cohort 1, n = 259) previously treated with two or more systemic lines of therapy.
Objective response rate (ORR) was 11.6% but it reached 15.5% in patients who were PD-L1 positive
(57.1% of all, cut-off of PDL-1 ≥1%) versus 6.4% in PD-L1 negative. The outcomes were significantly
better when treatment were used in an early setting (third line ORR = 16.4% versus 6.4% in the fourth
line), supporting the rationale to use immunotherapy as soon as possible in the natural history of the
disease when the immune response is not compromised, and when population has been stratified
according to MSI status (ORR = 57.1% in MSI-H; ORR = 9.0% in MSS), although only seven patients
(4%) resulted with a microsatellite instability-high status. With a median OS of 5.6 months (secondary
endpoint) a promising survival rate of 23.4% at 12 months has been described.
These results suggest the need for an accurate selection of patients in order to maximize the
outcome of immunotherapy and to identify the subset of patients who respond favorably.
For this purpose, Kim et al. [82] designed an open label phase 2 trial with integrated genomic
analysis of all baseline tumor tissue samples and genomic profiling of circulating tumor DNA (ctDNA)
in order to classify the disease characteristics of responders and non-responders to immunotherapy.
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61 Asian patients with metastatic or recurrent gastric cancer refractory to standard chemotherapy
were enrolled and treated with Pembrolizumab, the population included six EBV-positive diseases
and seven MSI-H. An ORR of 24.6% was observed but EBV-positive and MSI-H patients obtained
dramatic responses to pembrolizumab (ORR, respectively, of 85.7% and 100%), furthermore activity
was significantly higher in PDL-1 positive cancer (cut-off ≥ 1) when compared to PDL-1 negative (ORR
of 50.0% versus 0.0%, p ≤ 0.001). In addition, other cancer subtypes such as genome stable, CIN and
mesenchymal (defined by positive EMT signature) demonstrated poor responses to pembrolizumab,
and particularly, the EMT subtype has been demonstrated to be a negative predictor of response to
immunotherapy determining a poor survival.
Investigators additionally demonstrated a strong correlation between ctDNA mutational load
and tumor mutational burden (TMB) and that decreasing ctDNA levels during the treatment are a
powerful predictor of prolonged PFS and good response, opening the way to the use of ctDNA to
identify patients that are likely to respond to pembrolizumab.
It is important also to outline that Pembrolizumab did not improve survival as second line
treatment for PDL-1 positive advanced GCs according to findings from phase 3 KEYNOTE-061 trial
recently published [83], even if the approved FDA indication for patients who have received at least
two previous lines of treatment remains unchanged at current time. These negative findings added
interpretative complexity to the knowledge about immunotherapy in GC.
Another anti-PD-1 drug that was successfully tested in the treatment of GC has been
Nivolumab (fully human IgG4 monoclonal antibody). In the large randomized Asian phase 3 trial
ATTRACTION-2 [84] Nivolumab showed a significant survival benefit in heavily pretreated patients
(≥2 previous lines of treatment) with advanced gastric or gastro-esophageal junction cancer reaching
an overall survival of 5.26 months as compared to 4.14 months in the placebo group (HR: 0.63–95% CI
0.51–0.78; p < 0.0001) and with an ORR of 11.2% (0% in the placebo arm). Interestingly remarkable
survival rates were described at 12 months (26.2%) and at 18 months (16.2%) in the immunotherapy
group, when considering the advanced setting of treatment. We could infer that there is a definite
subset of patients that strongly benefits from the treatment and has durable responses.
A potential limit of this trial could be considered the lacking of molecular analysis and patients
selection (the cohort was unselected according to PDL-1 status and tumor tissue samples was not
mandatory at the screening). For the 26 patients for whom PDL-1 positivity assessment was available
(cut-off ≥1%) OS did not change when compared to the overall unselected population (5.22 months
in the Nivolumab group) and the activity of immunotherapy in PDL-1 negative patients was fully
superimposable with an OS of 6.05 months in the Nivolumab arm. At the moment no further data
are available about other biomarkers (i.e., MSI status) but it is absolutely noteworthy that this is the
first positive randomized phase 3 study of an immune checkpoint inhibitor in patients with advanced
gastric cancer.
Anyhow ATTRACTION-2 is a fully Asian trial and a possible debate could arise about whether
its data could be transferred or not to the western population. GC patients from Asia and
from western countries are known to have different clinical outcomes [85,86], these differences
have been conventionally attributed to different clinical management and disease stage. Instead,
recent evidences suggest that gene expression differences exist among Asian and non-Asian gastric
adenocarcinomas and different molecular signatures influence clinical outcome, especially concerning
tumor immunity [87].
However, we should consider that Pembrolizumab has been successfully used also in the western
population (KEYNOTE-059) and even Nivolumab has been tested in a non-Asian population. As a
matter of fact in the gastric cohort of phase 1/2 trial CheckMate-032 [88] a favorable and promising
activity of Nivolumab +/− Ipilimumab (a fully human monoclonal IgG1-k against CTL antigen 4) has
been described in a fully Western population (160 heavily pretreated patients). Even in the Nivolumab
single agent arm (quite similar to Attraction-2 experimental arm), ORR was 12% in the unselected
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population and 19% in PDL-1 positive patients, although outcomes have been worse than in the
combination arms, and a survival rate of 39% has been observed at one year.
Tan et al. [89] published a large retrospective investigation of more than 1600 gastric cancers
from six Asian and three non-Asian cohorts demonstrating that tumor immunity signatures differ
significantly between Asian and non-Asian cancers. These different tumor immunity signatures,
especially related to T cell function, might explain the geographical differences in clinical outcome
always observed and might condition different responses to immunotherapy.
In particular Non-Asian gastric cancer seemed to be associated with enrichment of tumor
infiltrating T-cells as well as T-cell gene expression signatures, including CTLA-4 signaling, while Asian
gastric cancers had a significantly higher numbers of cells positive for neutrophil markers.
Asian and Caucasian GCs had distinct immune-related components, intratumoral immune,
and inflammation cells populations.
Investigators also analyzed whether these differences might be due to different EBV and MRR
status, both conditions notoriously related to high load of infiltrating lymphocytes [90], but no
significantly differences have been demonstrated between the two cohorts.
Due to the retrospective nature of this study, results need to be further validated but we
should consider that western population seems to have an “immune-environment” more favorable
to immunotherapy and a stronger immune-signature, even if, as already reported, the biggest
immune-oncology phase 3 trial currently available (ATTRACTION-2) has been conducted only on a
entirely Asian population.
Results of ongoing immune-oncology trials [91,92] on western populations are hopefully awaited,
but the design of future gastric cancer trials should consider an accurate patient selection and tumor
immunity differences in patients from different geographic regions.
7. Conclusions
Clinical application of new advances and recent molecular classifications is still disappointing.
Tumor heterogeneity and the still imperfect understanding of the complex tumor biology represent a
brake to the definitive overcoming of the “one size fit-all” era also for gastric cancer.
With the exception of first accelerated anti-PD-1 drugs approval, at current time, as mentioned
above, only two target therapies have been approved and are currently used as a standard of care:
Trastuzumab and Ramucirumab.
When compared to the big amount of molecular drivers identified and tested for GC, these
advances represent still a small step to that more contemporary and comprehensive clinical approach,
called “precision medicine”, to which genomic heterogeneity is a stubborn barrier.
New treatments are urgently needed in order to give patients more benefits from new drugs and
new technologies available. What molecular classifications can already teach us is that in the next
future it will not be possible to give patients a same treatment in an unselective manner and that a
more rigorous selection of patients will be mandatory.
For example evidence clearly identified two subgroups of GC, as characterized by MSI-H and
EBV-positive status, which may benefit from immunotherapy and for whom front-line anti-PD1
drugs could be pursued, in addition to other hallmarks (PD1 status, TMB) that will drive therapeutic
approaches and future research.
On the other side it is also possible to identify another subset of GCs (GS, MMT/EMT) poorly
responsive to immunotherapy and in which for example the development of inhibitors of cMET
pathway, Rho-kinase, PI3K/mTOR pathway should be encouraged as demonstrated by the anti-claudin
line of research, which seems particularly promising in the selected population.
Another challenge is represented by the development of predictive biomarkers of response also
using the ctDNA technology, a procedure that will need to be validated and studied in deep but
that could help identifying patients with a high risk for progressive disease early and their possible
resistance mechanisms.
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The analysis of ctDNA might also help detecting genomic alterations not detected in primary
tumors at baseline, considered the evidence of a possible significant discrepancy within a same primary
tumor and between primary tumors and metastatic sites genomic alterations, a discrepancy potentially
determining the targeted therapies failure [93].
As already tested in other cancer types [94], also the use of patient-derived xenograft (PDX)
models could help in the search of these predictors. Analyzing non-responder PDXs, for example,
we could identify those mechanisms that determine resistance to the tested therapy facilitating the
ideation of dedicated prospective trials. As a matter of fact gastric PDX platforms are already available
and first studies have been conducted [55,95].
A complementary interesting possibility could be represented by the use of “tumor organoids” [96]
utilized as an alternative model for the research in order to verify ex vivo the sensitivity of tumor cells
to targeted therapies. Furthermore PDXs and organoids can help in understanding why in different
tumor contexts effective targeted agents are poorly active in different cancer types (i.e., anti-HER2
therapy in colorectal and gastric cancer).
GC is a collection of different molecular entities and its landscape is enormously complex,
but recent efforts and knowledge laid the foundations for the development of more modern and
solid therapeutic approaches and clinical trials, also taking advantage of new preclinical models to
revalue promising drugs that failed in the past years.
Molecular classifications, especially TGCA and ACRG, opened the doors wide on the complete
comprehension of the complex genetic landscape of gastric cancer and on the way to the full application
of precision medicine also for this malignancy, even if at current time they still appear as separated
and isolated systems, while a standardization and a “common strategy” approach would be desirable.
The biggest challenge for the next future will be to understand which cancer subgroup deserves a
specific targeted agent and to design clinical trials tailored on these subgroups, in order to transfer the
molecular classifications acquisitions into the clinical practice and to minimize the numbers of patients
who receive a systemic treatment without any molecular selection.
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Abstract: Gastric cancer is one of the most common malignancies worldwide and it is a fourth
leading cause of cancer-related death. Carcinogenesis is a multistage disease process specified
by the gradual procurement of mutations and epigenetic alterations in the expression of different
genes, which finally lead to the occurrence of a malignancy. These genes have diversified roles
regarding cancer development. Intracellular pathways are assigned to the expression of different
genes, signal transduction, cell-cycle supervision, genomic stability, DNA repair, and cell-fate
destination, like apoptosis, senescence. Extracellular pathways embrace tumour invasion, metastasis,
angiogenesis. Altered expression patterns, leading the different clinical responses. This review
highlights the list of molecular biomarkers that can be used for prognostic purposes and provide
information on the likely outcome of the cancer disease in an untreated individual.
Keywords: gastric cancer; HER2; cell cycle regulators; microsatellite instability; apoptosis; mucins;
multidrug resistance proteins; invasiveness; peritoneal spreading; neovascularization
1. Introduction
Gastric cancer (GC) is an aggressive disease that is still a global health problem with its
heterogeneous nature. In the last several decades, the decrease of gastric cancer incidence has been
noted, however it is still the fourth leading cause of cancer-related death worldwide [1]. Alternative
prevention, as food preservation, earlier diagnosis, and therefore, prior treatments cause abatement
of recorded incidents, although the prognosis is still bad. The standard therapies include surgical
resection with chemotherapy, and in suitable cases, chemoradiation [2]. To treat advanced gastric
cancers and metastasis, it is still a huge barrier to be overlapped; however, little progress has been
reported [3]. Gastric cancer is a heterogeneous disease; therefore, new investigation and approaches
need to be considered including prevention, early detection, as well as innovative and effective
therapeutic efforts.
Neoadjuvant therapy as the dosing of therapeutic agents before a major treatment of cancer,
became more popular in recent studies on gastric cancer combating. The first approach in this field
was reported in 1989, concerning gastric cancer patients, where cisplatin (EAP) was confirmed as
an effective agent in locally advanced gastric cancer, and therefore it was a chance for surgery in
patients with poor prognosis [4]. Nowadays, the importance of neoadjuvant therapy is an interesting
investigation for many researchers for extension of survival time in advanced GC cases. The
randomized controlled trials have been implemented; nevertheless, the final outcomes are still not
consistent [5,6]. The study that was conducted by Songun et al., 1999 [7] showed that more active
regimens than methotrexate (FAMTX) are required for future randomized trials.
Gastric cancer immunotherapy is another powerful approach due to better understanding of
immunological networks and molecular mechanisms of immunosuppression in the cancer environment.
Vaccination strategies based on protein and peptide vaccines, which can be identified by cytotoxic
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T and helper T lymphocytes. Currently, there are several immunotherapy-based approaches like
adoptive cell therapy, where various cell types can be implemented, like lymphokine-activated killer
cells [8], tumor infiltration lymphocytes (TILs) [9], and anti-CD3 monoclonal antibody-induced killer
cells [10]. Dendritic cells incubated with mRNA can show the encoded antigen, which making them
another vaccine type based on mRNA gene transfer [11]. Both protein and peptide targets are useful
tool for stimulation of immune response, HER2/neu-derived peptide [12] and MAGE [13] which are
related to MHC class I and induce cytotoxic T cells against GC cancers.
Discovering the pattern of signatures could be used as a biomarker to guide targeted therapy
for gastric cancer. This heading will individualize the cancer therapy relay on integrated and global
recognition of dysfunctional signalling pathways. The presented review pays attention on the currently
available biomarkers for prognosis of gastric cancer. Nowadays, there are many different signatures
that can provide the division of gastric carcinoma by taking in consideration age, histopathological
type, Helicobacter pylori infection, microsatellite instability, module of HER2 expression, molecular
markers of cell cycle regulators, factors that regulate apoptosis, multidrug resistance proteins, agents
that influence cell membrane properties, and agents with an impact on the progression of gastric cancer
and peritoneal metastasis. Radical patient selection, appropriate combinations of targeted therapies,
and deployment of emerging immunotherapeutic investigations will for sure hone the treatment of
this global disease.
2. Screening for Epstein–Barr viruses
Infection with Epstein-Barr virus (EBV) is associated with a wide spectrum of malignant diseases,
like Hodgkin and non-Hodgkin lymphomas, post-transplant lymphoproliferative disorder (PTLD),
and gastric cancer [14]. It must be clarified that EBV infects basically all humans by the time that
they reach adulthood and the viral genome is detained in a low number of B lymphocytes. To assess
EBV as a marker for cancer development, it is strongly advised to quantify the number of infected
cells and to indicate their types. Upon primary infection, it transiently runs a short lytic program and
after predominantly establishes latent infection [15]. Serological tests are commonly used to confirm
the primary infection and report remote infection [16]. One of the most popular serological assays is
heterophile antibody test. Cancer related to EBV infection is correlated with high titers against Early
Antigen (EA) and IgG Viral Capsid Antigen Antibody (VCA) with low EBV Nuclear Antigen Antibody
(EBNA) titer. Unfortunately, analogous patterns are probable in autoimmune disease and this test is
not decisive when the immune system is defective, for instance, acquired immunodeficiency syndrome
(AIDS) or allogeneic transplant patients.
EBER in Situ Hybridization Assay is a gold standard for localization of EBV in biopsied
tumor [17]. EBER1 and EBER2 are non-polyadenylated viral transcripts, which are conjointly called
Epstein–Barr virus-encoded small RNA (EBER), which are expressed at a very high level in infected
cells. They have been labelled as a natural marker for latent type of infection. DNA of EBV is
evidential within malignant epithelial cells in 10% of gastric adenocarcinomas, mostly in those arising
in the stump after surgical gastrectomy and in undifferentiated with abundant tumor-infiltrating
lymphocytes [18]. EBV positive gastric cancer patients have specific genetic mutations and epigenetic
patterns profile, which is assigned to the clinical phenotype of the malignancy. It was postulated that
some genes, like BcLF1, BHRF1, BARF0, BARF1, BZLF1, EBNA1, BLLF1, and BRLF1 are overexpressed
in GC cases with positive EBV infection [19–21]. EBV occurs as episomes in nuclei of host cell and
averagely 205 host cell genes are altered in patients with EBV-positive GCs, embracing TGFBR1,
AKT2, MAP3K4, and CCNA1 [21]. Epigenetic alterations are also connected to the EBV positive
gastric carcinoma. Zhao et al., 2013 [21] showed that 216 genes were hypermethylated and were
transcriptionally down-regulated, and 46 were demethylated and transcriptionally up-regulated in the
study that was conducted on cultured EBV positive GC cells. The hypermethylation status of the IHH,
ACSS1, TRABD, and FAM3B genes was also found among analysed tumor samples. Targeted therapies
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in advanced GC with Epstein-Barr virus positive patients, can be applied to the PIK3CA/Akt pathway,
JAK2 and PD-1/PD-L1, and PD-L2 pathway [22].
3. HER2 Status in Gastric Cancer
The HER2 receptor is a member of the Epidermal Growth Factor Receptor (EGFR) family.
Its activation is going through its spontaneous homo/heterodimerization with the other EGFR family
receptors [23]. Many studies have been investigated on HER2 amplification and high expression
in gastric cancer, applying a different method, showing the range of positive cases between 6%
and 30% [24–26]. GC very often displays heterogeneity of the HER2 genotype and phenotype,
which can have impact on testing inaccuracy [27]. The EMEA (European Medicines Agency)
recommended the IHC immunohistochemistry method (IHC) as a first screening, adding the scoring
criteria, with 3+ samples to be positive and 2+ only positive, when approved by Fluorescence in situ
hybridization (FISH). When considering the increased frequency of overexpression/amplification of
HER2 among GC cases, preclinical and early phase clinical studies have been conducted to assess the
therapeutic value for targeted approaches [28,29]. Tanner et al., 2005 [29] investigated the occurrence
and the clinical importance of HER-2/neu amplification in gastric carcinoma. The frequency of
HER2/neu amplification was, respectively, 12.2% of the gastric and 24.0% of the gastroesophageal
adenocarcinomas. HER-2/neu amplification was higher in the intestinal histologic type of gastric cancer
(21.5%) in comparison to the diffuse (2%), it was not associated with age and gender, but with the
poor survival of GC patients. Trastuzumab antibody that was targeting HER-2/neu inhibited the
growth of a p185 (HER-2/neu) overexpressing gastric. Accuracy of trastuzumab was tested as a
single dose or in combination with other chemotherapeutic agents in human gastric cancer xenograft
models with high HER2 expression [28]. Trastuzumab, while added as a single drug, inhibited the
tumor expansion in HER2-overexpressing models, but not in the HER2-negative. Trastuzumab with
combinations of any other agents, like docetaxel, paclitaxel, capecitabine, irinotecan, and cisplatin,
displayed higher anticancer action than being administrated separately. Other molecular agents
targeting HER2 have been analyzed, such as pertuzumab, lapatinib, and the antibody-drug conjugate
trastuzumab-emtansine (TDM-1) [28,30,31]. Unfortunately, the final effect of them has been displayed
to be poor in comparison to trastuzumab, which is the first agent of targeted therapy confirmed as a
standard treatment in gastric cancer.
4. Gastric Cancers with Microsatellite Instability
Microsatellite instability (MSI) is an important indication of the DNA mismatch repair deficiency,
and therefore it is perceived as a factor in the expeditive collection of genetic changes in the gastric
carcinogenesis process [32]. Hang et al., 2018 [33] presented the molecular mechanisms of of
microsatellite instability (MSI) and its importance in GC prognosis. Next generation sequencing data
of the whole transcriptome were investigated from The Cancer Genome Atlas (TCGA), covering 64
high-level MSI (MSI-H) gastric cancer samples, 44 low-level MSI (MSI-L) and 187 stable microsatellite
(MSI-S) gastric cancer samples [33]. The results showed that MSI status might have impact on the
prognosis of GC patients, partially through the inflammatory bowel disease, antigen processing and
presentation, measles, toxoplasmosis, and herpes simplex infection pathways. HLA-DRA, HLA-DRB5,
JAK2, HLA-DQA1, HLA-DMA, CASP8, and Fas could be predictive factors for gastric cancer prognosis.
Although MSI cases in general are deprived of targeted alterations, mutations in PIK3CA, EGFR,
ERBB3, and ERBB2 were detected [22]. Additionally, MSI tumors alteration status of genes showed
common mutations in major histocompatibility complex class I genes, including B2M and HLA-B.
To reveal a precise association between human mutL homolog 1 (hMLH1) promoter methylation
and gastric cancer, a meta-analysis study was investigated by Ye et al., 2018 [34]. It was postulated
that hMLH1 promoter methylation had significant correlation with not only microsatellite instability,
but also with lymph node metastasis and the low expression of hMLH1 protein. Polom K et al., 2018 [35]
investigated the analysis of MSI status among cases with marginal involvement after gastrectomy, and
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the establishment of an association between MSI, margin status, and survival rate They displayed that
patients with MSI-H gastric cancer might possess long-term survival despite positive resection margin
(RM+) status. This might be important step towards surgical treatments that are based on to clinical
and pathological factors [35].
5. CDX2 Expression in the Intestinal Type of Gastric Epithelial Dysplasia and Its Correlation
with CD10
CDX2 is a Drosophila caudal-related homeobox transcription factor, and it is a member of the
caudal-related homeobox gene family. It is perceived as an important factor in mammalian early
intestinal development and the regulation of intestine-characteristic gene transcription [36]. The role
of CDX2 in gastric cancer has been reported as responsible for the proliferation and differentiation of
intestinal type of epithelial cells by controlling transcriptional activation of intestine specific proteins,
like sucrase-isomaltase, carbonic anhydrase I, or Mucin 2 (MUC2) [37]. It also acts through the
inhibition of growth by the activation of WAF1 (cyclin-dependent kinase inhibitor) [38]. In the study
that was conducted by Park et al., 2010 [39], CDX2 is expressed mostly among adenomatous-type
gastric epithelial dysplasia in comparison to the hybrid or foveolar types. CDX2 expression level
is the lowest in the advanced gastric cancers, and it is also very decreased in the early onset of
gastric cancers, indicating the possibility to act as a tumor suppressor. The study also showed that an
increasing expression of CDX2 is correlated with an increased expression of CD10, which is cell surface
zinc-dependent metalloprotease, also called as endopeptidase (NEP) (EC 3.4.24.11), enkephalinase,
or acute lymphoblastic leukemia antigen, which in this case is promoting intestinal metaplasia of gastric
epithelium. The study that was performed by Huang et al., 2005 [40] reported that CD10 expression
by stromal cells was meaningfully increased in the primary gastric carcinomas in comparison to
normal mucosas. CD10 expression was detected more frequently in differentiated carcinomas and
it seems to cause the promotion of invasion and lymph node metastasis processes of differentiated
gastric carcinoma.
6. Abnormalities in Cell Cycle Regulators
Genetic alterations in several regulators of the cell cycle have a significant impact on the gastric
carcinogenesis process. Cyclin D1 and retinoblastoma protein (pRb) are important factors in the
progression from G1 phase to S phase, which is crucial in the cell cycle [41]. In general, cyclins are
positive regulators of the cell cycle process and their overexpression is linked to uncontrolled cell
growth and cancer development. The main targets of cyclin D1-Cdk complexes are the retinoblastoma
family of protein Rb [42]. The study that was conducted by Arici et al., 2009 [43] intimated the
higher expression of Rb and cyclin D1 among nonneoplastic mucosa comprising dysplasia, intestinal
metaplasia, atrophy, and gastritis to carcinoma, which indicates that the expression of pRb and
cyclin D1 can occur in early stages of gastric carcinogenesis. Cyclin D1 is expressed among genetic
alterations in gastric carcinomas, including advanced gastric carcinomas and early stage, using
immunohistochemistry as a good standard method for the detection of early stage gastric cancers and
their differentiation from hyperplastic polyp patients [44].
Another very important cell cycle regulatory protein is p16, which is cyclin-dependent kinase
inhibitor (CDKI) [45]. The p16 gene acts as a tumor suppressor gene and negatively regulates cell
growth and proliferation. The relation between the inactivation of p16 and the evolution of gastric
cancer has been reported by several study groups. Deletion of p16 gene exon 2 is related to the
carcinogenesis process and progression of gastric carcinoma, which was reported by Hayashi et al.,
1997 [46]. Wu et al., 1998 [47] showed that deletion of p16 gene was oftentimes present in intestinal
type of gastric cancer in comparison to the diffuse type. Hypermethylation of the p16 locus, which
causes functional inactivation, plays a relevant role in the pathogenesis of sporadic gastric cancer [48].
Cyclin-dependent kinase inhibitor 1B, called p27Kip1, is referred to play a role as a cell cycle
inhibitor protein with the main function to slow down or even stop the cell division cycle [49].
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Nitti et al., 2002 [50] showed that low p27Kip1 protein expression in gastric adenocarcinoma relates to
advanced tumours, it is significantly higher in weakly differentiated cases and is perceived as a negative
prognostic agent for patient’s survival. Zheng et al., 2005 [51] first reported that p27Kip1 expression,
cell cycle arrest, and apoptosis are strongly correlated in the SGC7901 cell line. Overexpression of
p27KIP1 was associated with the induction of apoptosis and the extension of cell cycle in G1 phase of
SGC7901 cells.
p21Cip1, also known as cyclin-dependent kinase (CDK) inhibitor 1, which can inhibit all
cyclin/CDK complexes and it is a main target of p53 operations [52]. p21 protein expression progressive
decreases from normal gastric mucosa, chronic superficial gastritis, and precancerous gastric lesions to
gastric cancer was reported by Luo et al., 2014 [53]. They also suggested that the loss of p21 expression
was very closely correlated with stadium of tumour differentiation, area of invasion, vascular invasion,
Lauren classification, and metastasis to lymph node. It seems that p21 occurs in a role of tumour
suppressor in the development and expansion of gastric cancer.
7. Factors that Regulate Apoptosis Process
Many studies have been investigated on p53 genetic alterations in gastric carcinomas. It became
clear that p53 mutational changes show up in early stages of cancer development and their frequency
is much higher with the cancer development process [54]. P53 mutations are detected in 0–77% of
gastric cancer cases [55] and they are significantly more frequent in proximal lesions than in distal.
They mostly occur in exons 4–11, and they have several hot spots at codons 175, 245, 248, 273, 282,
and 213. G:C > A:T transitions at CpG sites and are therefore are very popular types of alterations
in GC patients [56]. P53 immunoreactivity is observed in 17–90.7% of invasive gastric cancer cases.
Nuclear staining of p53 is not similar between diffuse and intestinal gastric carcinomas, with distinctly
higher appearance in intestinal types [57]. Molecular analysis of gastric cancer that was performed by
Cristescu et al., 2015 [58] showed the different gastric cancer subtypes are assigned to the different
clinical outcomes and the TP53 is also a part of division of molecular gastric cancer. The group revealed
that the tumor protein 53 active and TP53-inactive subtypes incorporate patients with intermediate
prognosis and recurrence rates, however TP53-active group displays more promising prognosis.
The cell surface receptor programmed death-1 (PD1) and its ligand (PDL1) have been described
in gastric tumours as markers assigned to poor prognosis of the patient [59]. Screening of clinical
importance of PD1 and its ligands’ expression, as well as T cell infiltration might be a future perspective
for using this as biomarkers in GC immunotherapy [60]. Correlation with clinical features showed that
PDL1 membranous expression was in around 38% of tumour cells among the analysed cases, as well
as 75% of infiltrating immune cells. The expression of PDL1 was visibly higher in a group of patients
without metastasis, with PCNA and C-met expression, as well as EBV positive group. The study
that was conducted by Böger et al., 2016 [61] displayed that PD-L1 expression was importantly
dominated among men with GC, Her2/neu positive, Epstein Barr virus positive, microsatellite instable,
PIK3CA-mutated, GCs of the proximal stomach, unclassified, and papillary. The significantly
better patient’s outcome was correlated with the high PD-L1/PD-1 expression was associated with
a significantly better patient outcome. The connection of PD-L1/PD-1 expression with various
clinico-pathological characteristics might supply as a surrogate marker of PD-L1-positive gastric
carcinomas, as well as can allow for improving the immune checkpoint treatment possibilities [61].
The p73 gene encodes for a protein with high similarity to this displayed by p53. Kang et al.,
2000 [62] described the expression of p73 in gastric carcinoma tissues. Importantly, low levels of p73
expression were detected in noncancerous gastric tissues and analysed cell lines, whereas p73 was
detected in 94.9% of carcinoma tissues. The study demonstrated that p73 is not an aim of genetic
modifications in gastric carcinogenesis. Wild-type p73 is very often overexpressed in gastric cancer
tissues by the activation of a silent allele or transcriptional induction of an active allele.
Murine double minute gene 2 (mdm2) is a newly described oncogene that is placed at chromosome
12q13-14 [63]. Studies on the expression of mdm2 revealed that it is increasing in gastric cancer [64].
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Moreover, expression level of the MDM2 protein is significantly higher in intestinal metaplasia in
comparison to chronic gastritis [65]. Subtypes of intestinal metaplasia show different patterns of
expression of the mdm2 and p53 protein [66]. Their expression is increased in atypical intestinal
metaplasia (AIM) and gastric carcinomas in comparison to simple intestinal metaplasia (SIM). AIM may
display the precancerous nature of gastric carcinoma more largely than SIM or the conventional IM
subtypes. Moreover, AIM may be concerned as a preneoplastic lesion and be a significant indicator in
the clinical follow-up of GC patients.
B-cell lymphoma 2 (Bcl-2) expression and increased risk of gastric carcinoma recurrence was
studied by Wu et al., 2014 [67]. There is still a lack of predictive indicators for GC recurrence, therefore,
the determination of such factors, like it was performed for bcl-2 expression, might be applicable after
curative resection in patients with gastric cancer. In fact, the researchers displayed that peritoneal
recurrence occurred as the mostly observed type after curative gastrectomy. Moreover Wu et al.,
2014 [67] showed that lymph node metastases, depth of invasion, as well as negative expression of
bcl-2 were correlated with a higher probability of recurrence action.
8. Multidrug Resistance Related Proteins
DNA repair protein complementing XP-A cells is a protein that in humans is encoded by the XPA
gene [68]. XPA A23G and XPC exon 8 Val499Ala polymorphisms were explored to be effective markers
for the recognition of individuals at risk of developing gastric cardiac adenocarcinoma (GCA) [69].
D’Errico et al., 2006 [70] have displayed that mutation in the XPC gene are responsible for accumulation
of oxidative damage in human cells. ‘A’ allele of XPA-23G > A has been correlated with increased levels
of places tender to formamidopyrimidine DNA glycosylase that shows oxidative DNA damage in the
lymphocytes of carriers [71]. Polymorphisms in both genes can impact on destroying the capability to
look for bulky adducts and oxidative DNA damage. This might promote the accumulation of DNA
lesions, and therefore increased gastric cancer risk.
Expression of multidrug resistance-associated protein 2 (MRP2) was detected in several
carcinomas, which was reported by Sandusky et al., 2002 [72]. High expression of MRP2 is important
in the in initial absence of reaction to chemotherapy treatment of tumor, and therefore, it might
be a significant biomarker for chemotherapy response. Immunohistochemistry was conducted on
zinc formalin-fixed tissue. Immunostaining was detected in neoplastic cells on the cell membrane
with M2-lll-6 antibody against MRP2 and cell membrane and cytoplasm with EAG5 against MRP2.
Among examined cancers MPR2 was localized in eight of 13 gastric carcinomas and the expression
was increased in well differentiated tumours. MRP2 is associated with irinotecan and anthracyclines
transport, therefore the clinical applications of pharmacogenetics might allow for accurately defining
the appropriate drug and dose for individual treatment [73].
The multidrug resistance 1 gene (MDR1) is very important candidate gene in developing gastric
cancer susceptibility [74]. A total 365 gastric cancer patients and 367 controls were genotyped using the
designed restriction site-polymerase chain reaction method to look for single genetic polymorphisms
(SNPs) of the MDR1 gene. The outcome showed the allele and genotype frequencies of c.159G > T and
c.1564A > T to be statistically different among both analysed groups in the Chinese Han population.
Detected variants could play a role as molecular markers in early gastric cancer diagnosis. Zhu et al.,
2013 [75] reported that MDR1 has a significant impact on drug resistance answer, and the knockdown
of MDR1 might reverse this phenotype among gastric cancer cells. To present the exact role of MDR1,
the group performed knockdown of MDR1 expression using shRNA in gastric cancer cells that are
resistant to drugs. The results were reviewed to assess Adriamycin (ADR) accumulation and drug
sensitivity. Using two shRNAs it was possible to inhibit the expression of mRNA and protein of
MDR1 in SGC7901-MDR1 cells. In final observation the group concluded MDR1 knockdown to cause
decreasing of ADR collection in cells and increment of susceptibility to ADR treatment.
The expression of Glutathione S-transferases Pi (GST-P), also known as GST-π, is readily higher in
tumours chemically induced. In response to the tumor creation, GST-π is expressed as a resistance
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mechanism by which cells can survive [76]. The expression of GST-π in patients with gastric carcinoma
was increased in comparison to normal mucosa (51.3% versus 23.2%), which was reported by Yu et
al., 2014 [77]. The correlation of GST-π expression was observed with sex (male versus female, 59.7%
versus 35.7%, p < 0.05) and differentiation (well, moderately, and poorly, 40.5%, 41.9%, and 64.7%,
respectively, p <0.05). Moreover, high expression of GST-π was connected to the tumor invasion,
recurrence, as well as poor prognosis.
9. Mucins with Impact on Cell Membrane Properties
Mucins are a family of extracellular large molecular weight, heavily glycosylated proteins
(glycoconjugates). Both membrane bound mucins and secreted mucin possess many shared
features [78]. Their important properties have related to capability to form gels, with main functions
regarding lubrication, cell signalling, and the creation of chemical barriers. Mucins are frequently
engaged in an inhibitory role [79]. Overexpression of mucin proteins, MUC1, MUC2, MUC5AC,
and MUC6 have been reported in to be present in the gastric carcinogenesis process [80]. The correlation
between the expression of several mucins and clinicopathologic profiles and patient’s survival are
presented in Table 1.
Table 1. Mucins and their impact on patient’s survival with gastric cancer.
MUC Type Function Expression Patterns in Gastric Cancer Authors
MUC1
Protective role by binding to pathogens,
functions in a cell signalling capacity,
presented in the nucleus regulation the
activity of transcription factor complexes,
which take part in tumor-induced changes of
host immunity system
MUC1 positive cases highly
overexpressed in intestinal-type
carcinomas, increased rate of vascular
invasion and lymph node metastasis,




The major intestinal mucin, expressed by
goblet cells of the small intestine and colon,
important role in organizing the intestinal
mucus layers at the epithelial surface;
forming trimers that crosslink with TFF3 and
Fcγbp, allow to highly viscous
extracellular layer
Strongly correlated with the intestinal
histological type, the correlation
between MUC2 and HER2 expression is
possible to demonstrate the connection
between the intestinal differentiation of




Glycoprotein of gastric and respiratory tract
epithelium guards the mucosa from infection
and chemical damage, thanks to binding to
inhaled microorganisms and particles, which
are later removed by the mucociliary system
Decreased Muc5AC expression was
importantly correlated with poor
overall survival, additionally, decreased
Muc5AC expression was also
meaningfully reported to the tumour





Might deliver a mechanism for modulation of
the composition of the protective mucus layer
connected to acid secretion or the presence of
bacteria and noxious agents in the lumen,
involvement in the cytoprotection of
epithelial surfaces
MUC6 is a marker of gastric foveolar
cells and antral/cardiac mucous




10. Factors that Influence High Progression of Gastric Cancer and Peritoneal Metastasis
In metastatic gastric cancer, expansion into the peritoneal cavity is present in more than 55–60%
of patients [85]. Peritoneal dissemination is an important clinical indication, resulting in poor
prognosis [86]. Recently, Cristescu et al., 2015 [58] investigated a gene expression dataset of 300
primary gastric tumors to sectionalize four molecular subtypes of GC, which were connected with
different patterns of molecular alteration, prognosis of GC patients, progression, and cancer prognosis,
which encompass MSS/TP53+ subtype, MSS/TP53− subtype, MSI subtype, and MSS/EMT subtype.
The MSS/EMT subtype includes diffuse tumors type of GC with very poor prognosis, with the
disposition to come up in young age and the highest recurrence frequency (63%) of the four classified
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subtypes is present [58]. An insightful view of the molecular occurrence of each step of peritoneal
dissemination is shown in Figure 1, indicating markers of prognosis that are described in the next
four sections. Described molecules may contribute to the multiple steps; we tried to highlight
their impact on each process while taking into consideration their putative primary involvement
to peritoneal dissemination.
Figure 1. Peritoneal dissemination steps and molecular markers.
10.1. Gastric Cancer Cells Invasiveness
Epithelial cellular adhesion molecule (EpCAM) is a factor that is involved in physical homophilic
interaction between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the
mucosal epithelium, and it is involved in first line of defence against mucosal infection [87].
The EpCAM expression has been investigated in GC patients with peritoneal metastasis (PM) [88].
They reported that the expression of EpCAM was visibly higher in the PM lesions when compared
to the primary lesions. Therefore, the intraperitoneally dosed EpCAM antibody may possibly play a
role to contribute to the anti-cancer outcome in PM lesions of GC. In conclusion, the authors gave the
suggestion that only GC cells with an increased level of EpCAM have a potential to metastasize to
the peritoneum.
E-cadherin (epithelial-cadherin), which was encoded by the CDH1 gene, is a transmembrane
glycoprotein that takes part mainly in cell-cell adhesion maintenance. Its role is regarded to
the signalling pathways, which controls cell proliferation, migration, survival, and invasion [89].
Dysregulation of E-cadherin allows for gastric carcinoma development by disturbing gastric epithelial
cells [90]. E-cadherin is a tumor suppressor that has been described to be downregulated in
gastric cancer [22]. They highlighted the abnormal E-cadherin expression and some connections
with tumor stage, grade, depth of invasion, and therefore it might be useful as a predictor for
tumor invasiveness in gastric cancer patients. Moreover, genetic alterations in the CDH1 gene and
epigenetic factors, such as DNA hypermethylation, are significant factors to decrease E-cadherin in
GC development [91]. The authors observed high correlation of promoter hypermethylation of CDH1
with gastric cancer, which shows that epigenetics and CDH1 are important to GC ethology. The group
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also mentioned that genetic variant C-160A in CDH1 was associated with cardia, intestinal and diffuse
GC. The association between H. pylori infection and promoter methylation of CDH1 gene were studied
by Perri et al., 2007 [92] and CDH1 methylation was categorized as an early event in H. pylori gastritis.
The environmental effect of H. pylori infection on methylation status was assigned to the H. pylori
eradication therapy in reversal methylation profile among patients with chronic gastritis [93]. In 1998,
the linkage between germline mutation in CDH1 gene and the genetic cause of hereditary diffuse GC
(HDGC) was revealed [94]. Germline CDH1 mutations are connected to the increased lifetime risk of
occurring diffuse gastric (DGC). Intestinal-type GC cases do not belong to the HDGC type, and among
these families there is no evidence to analyze the CDH1 mutation [95].
Annexin A1 (AnxA1) is well described glucocorticoid-regulated anti-inflammatory protein.
The exogenous and endogenous form of annexin A1 counter-regulate the actions of inborn immune
cells, specifically extravasation and the formation of proinflammatory mediators, which control the
appropriate level of activation to be reached but not overstepped [96]. The role of AnxA1 in GC
survival was described by Cheng et al., 2012 [97]. High expression of AnxA1 was correlated with
peritoneal metastasis and serosal invasion. Additionally, AnxA1 expression was certainly associated
with invasiveness of human gastric cancer cells both in vitro and in vivo studies. The regulation of cell
invasion by AnxA1 was also observed in this study, by the formyl peptide receptor (FPR)/extracellular
signal-regulated kinase/integrin beta-1-binding protein pathway, in which all three FPRs (FPR1-FPR3)
were committed in this regulation process.
Neurotrophin receptor-interacting melanoma antigen-encoding gene homolog (NRAGE) induces
cell apoptosis and suppresses cell metastasis [98]. To understand the role and the clinical importance
of NRAGE in GC, Kanda et al., 2016 [99] reported the expression levels of NRAGE and its putative
interacting genes. Their studies showed the correlation between a higher level of NRAGE mRNA
expression in GC patients in comparison to normal tissues. Both NRAGE mRNA and protein levels
were strictly correlated. Increased NRAGE expression in GCs was connected to the disease-free
survival and described as an autonomous marker for GC prognosis. Additionally, expression of
NRAGE mRNA was observed to be correlated with that of apoptosis antagonizing transcription factor
(AATF), as well as NRAGE knockdown importantly reduced the proliferation, migration, and invasion
actions of GC cells.
10.2. Expansion of Peritoneal Dissemination
Peritoneal dissemination very often shows in late-stage GC and it is perceived as a crucial problem
that shortens the survival time of patients with gastric carcinoma [100]. Peritoneal milky spots (PMSs)
are omentum-associated lymphoid tissues that have been described as the area of origin of immature
PMS macrophages [101]. The hypoxic microenvironment is engaged in supervising the tumor stem cell
phenotype and is connected to the patient’s prognosis through hypoxia-inducible factor-1α (HIF-1α),
which is a major transcriptional factor that corresponds to hypoxic stimuli. While the peritoneal
dissemination is expanding, the gastric cancer stem/progenitor cells (GCSPCs) are eligible to come
into PMSs, in which the hypoxia is maintained. Miao et al., 2014 [102] displayed the correlation of the
higher expression of HIF-1α and gastric cancer peritoneal dissemination (GCPD) among GC cases.
The GCSPC population expanded in primary gastric cancer cells when hypoxia was present in vitro,
also hypoxic GCSPCs displayed intensified self-renewal action, but decreased differentiation ability,
which was interceded by HIF-1α. The authors concluded the results to PMSs role, which is assigned to
serve a hypoxic niche and favour GCSPCs peritoneal dissemination through HIF-1α.
The tumor suppressor gene phosphatase and tensin homolog (PTEN) is one of the major factors in
decreasing tumor growth, expansion, and metastasis [103]. Zhang et al., 2014 [104] revealed a unique
action by which PTEN can prohibit the growth and invasion of gastric carcinoma. This mechanism is
regarding the downregulation of focal adhesion kinase (FAK) expression and highlights that exploiting
PTEN/PI3K/NF-κB/FAK axis is an auspicious direction to treat gastric cancer metastasis. The results of
this investigation showed that the high expression of PTEN or knockdown in GC cells in consequence
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provoked the downregulation or the upregulation of FAK, and lowered or raised cell invasion,
appropriately. Additionally, FAK increased expression might redeem the inhibition of cell invasion by
PTEN. PTEN can inhibit PI3K/NF-κB pathway and reduce the DNA binding of NF-κB on the FAK
promoter. Ma et al., 2017 [105] have been reported that low expression of PTEN was detected in a large
part of GC tissues, which displayed important associations with differentiation grade in GC patients.
PTEN knockdown encouraged the expansion and invasion of cells and could lead to an expected
increase in p-AKT, p-GSK-3β, β-catenin, E-cadherin, MMP-7, MMP-2, and MMP-9 in GC cells.
Cancer-associated fibroblasts (CAFs) are apparently responsible for the invasion process and
metastatic actions in some cancers, among them gastric cancer is titled, through the activation of
CXCL12/CXCR4 signalling [106]. The group investigated increased CXCL12 expression levels, which
correlated with grater tumor size, higher tumor depth, lymphatic invasion, and poor prognosis in GC.
Stimulation CXCL12/CXCR4 by CAFs interceded integrin β1 clustering at the cell surface increases
invasiveness of GC cells. Yasumoto et al., 2006 [107] visibly showed the CXCR4/CXC12 axis actions in
the development of peritoneal carcinomatosis from gastric carcinoma. They conducted the calculation
of CXCR4 mRNA expression levels among NUGC4 cells, and it was increased, also the cells displayed
sprightly migratory actions, answering to its ligand CXCL12. The CXCL12 intensified proliferation
and fast escalations in the phosphorylation of protein kinase B/Akt and extracellular signal-regulated
kinase of NUGC4 cells. Analysis showed that 67% primary tumours of the stomach with peritoneal
metastasis were positive for CXCR4 expression, in comparison to 25% with another distant metastasis
were positive. Explicitly, 85% of CXCR4-expressing primary tumours raised peritoneal metastases.
CXCR4 positivity of primary gastric carcinomas meaningfully was associated with the evolution of
peritoneal carcinomatosis.
Yasumoto et al., 2011 [108] were interested in whether epidermal growth factor receptor (EGFR)
ligands play any role in the expansion of peritoneal spread from gastric cancer. According to their
observations, an increased concentration of the EGFR ligands amphiregulin, heparin-binding EGF-like
growth factor (HB-EGF) and CXCL12, occurred in malignant ascites. High expression levels of EGFR
and CXCR4 mRNA and protein were observed among primary tumours and human gastric cancer
cell lines, with an upraised possibility to evoke peritoneal carcinomatosis. Amphiregulin AREG
and HB-EGF were provoking factors of intensified proliferation, migration, and functional CXCR4
expression in gastric cancer NUGC4 cells, with the overexpression of CXCR4. These observations drew
attention to the EGFR ligands amphiregulin and HB-EGF as important factors, interacting with the
CXCL12/CXCR4 axis, in the development of peritoneal spread from gastric cancer.
10.3. Adhesion of Gastric Carcinoma Cells to the Peritoneum
The connection between peritoneal lining and GC cells is a major move in peritoneal dissemination.
Takatsuki H et al., 2004 [109] showed that, the peritoneal implantation of NUGC-4 human gastric
carcinoma cells in athymic mice, dosing of the cells with anti-alpha2 or anti-alpha3 integrin antibody
decreased the number of disseminated nodules. Moreover, suppression by the anti-alpha3 integrin
antibody was more powerful than that by the anti-α2 integrin antibody. The cDNAs to human α2 and
α3 integrins (ITGAs) were applied into K562 leukemic cells. Those cells displayed a positive occurrence
of the integrin beta1 subunit and negative of the α2 or α3 subunit. The α3 integrin-transfected cells
were adhered to the monolayer of peritoneal mesothelial cells intensely in comparison to others.
Reverse transcription-PCR was applied to detect the expression of laminin-5 and laminin-10/11, which
were both high-affinity ligands for alpha3beta1 integrin. mRNA for these isoforms was observed in
mesothelial cells from the diaphragm and parietal peritoneum. To conclude, α3β1 integrin is important
factor in activation the first steps in attachment of cancer cells to the peritoneum, and therefore allowing
for the creation of peritoneal metastasis.
Maternal embryonic leucine zipper kinase (MELK) is a serine/threonine-protein kinase that is
engaged in multiple processes, including cell cycle regulation, self-renewal of stem cells, apoptosis and
splicing regulation. It has a significant impact on cell proliferation and carcinogenesis [110]. Du et al.,
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2014 [111] described the expression of mRNA and protein level of MELK in gastric cancer. Reduction
the proliferation, migration, and invasion actions of GC cells were observed after the knockdown
of MELK activity, as well as lower number of cells in the G1/G0 phase and higher those in the
G2/M and S phases. Further knocking down of the MELK expression was assigned to the decreased
quantity of actin stress fibers and inhibited RhoA operations. At the end, the scientists reported
that the knockdown of MELK reduced the phosphorylation of the FAK and paxillin, and prevented
gastrin-stimulated FAK/paxillin phosphorylation. To summarize the MELK importance, it is an
essential factor for causing cell migration and invasion via the FAK/Paxillin pathway, and therefore,
it is crucial in GC development.
Matrix metalloproteinase-7 (MMP-7) is an enzyme that plays a role in matrix degrading and
impacts on the occurring of invasion and metastasis in gastric cancer patients [112]. Yonemura et al.,
2000 [113] investigated experiments to check the machinery creation of peritoneal dissemination among
GC cases. The MMP-7 protein level and mRNA expression were studied in primary gastric cancers
and peritoneal dissemination. The obtained results revealed the overexpression of MMP-7 mRNA in
53% of cases regarding primary gastric tumours, whereas in the normal gastric mucosa, fibroblasts,
and mesothelial cells, there was negative expression of this marker. Immunohistochemistry analysis
displayed the MMP-7 immunoreactivity on the cell membrane and the cytoplasm of GC cancerous
cells. The higher MMP-7 protein level was observed among 53% of primary cancers and MMP-7
tissue status had a statistically relevant correlation with lymph node metastasis, weak differentiation,
and peritoneal dissemination. Examined GC cases with MMP-7 expression had a worse survival
rate and an increased risk of death of peritoneal recurrence. The 100% of investigated peritoneal
disseminations expressed MMP-7 mRNA and 93% revealed immunoreactivity to anti-human MMP-7
monoclonal antibody. The results suggested the substantial role of MMP-7 in the creation of peritoneal
dissemination in gastric cancer.
Connective tissue growth factor (CTGF) has been reported to be involved in peritoneal metastasis
and gastric cancer progression [114]. High expression of CTGF, as well as treatment with the
recombinant protein considerably reduced cell adhesion [115]. CTGF enduring transfectants displayed
a lower number and size of tumor nodules in the mesentery, during in vivo peritoneal metastasis.
Overexpression of CTGF among GC patients was significantly correlated with the earlier TNM staging
and an increased survival rate after the surgery. Coimmunoprecipitation analysis showed that CTGF
binds to integrin α3. These results demonstrated that the mediation of GC peritoneal metastasis is
occurring through integrin α3β1 attaching to laminin, and CTGF efficiently stops the cooperation by
binding to integrin α3β1.
10.4. Peritoneal Spreading and Neovascularization
High expression of IRX1 gene, which codes iroquois-class homeodomain protein IRX1,
was strongly connected with the growth arrest in GC cases. Additionally, the overexpression of
IRX1 gene suppresses peritoneal expansion and spread the tumor metastasis [116]. Human umbilical
vein endothelial cells (HUVECs) and chick embryo and SGC-7901 gastric cancer cells were operated
for angiogenesis and vasculogenic mimicry (VM) tests. For detecting the function of the downstream
target gene of IRX1, the bradykinin receptor B2 (BDKRB2), small interfering RNA was applied.
Results showed the suppression of peritoneal spreading with the reduction of angiogenesis as well
as VM creation. The supernatant from SGC-7901/IRX1 cells, revealed a strong inhibiting effect
on angiogenesis both in vitro and in chick embryo.Reduction of tube formation, cell proliferation,
and migration, as well as invasion in vitro, were reported by gene-specific RNA interference for
BDKRB2, or its effector PAK1, which codes serine/threonine-protein kinase PAK1. It is now proved that
enforcing IRX1 expression, importantly suppresses peritoneal expansion and pulmonary metastasis
via anti-angiogenesis and anti-VM mechanisms.
The important role of angiogenesis in cancer and the cloning of vascular endothelial growth
factor (VEGF) in 1989 focused the research studies on this issue and allowed for the important clinical
58
Int. J. Mol. Sci. 2018, 19, 1658
translation of VEGF—directed therapies to the clinic [117]. VEGFR2 receptor expression is limited
to vasculature and it is a very significant factor in angiogenesis. Its activation in consequences
allow for actuation a complex cascade of downstream signalling pathways that are caused by VEGF
receptors, which further results in neovascularization, vasodilation, higher vascular permeability,
and migration of bone marrow endothelial cells [118]. VEGF blockade inhibits these pathways and
effects tumor survival, migration, and invasion. Advanced gastric cancer is still a huge challenge
to find an effective treatment. Monoclonal antibody Ramucirumab can block VEGFR2 activation
by binding to it. Randomized phase III trial, called REGARD, was using ramucirumab treatment
in comparison to the placebo for patients with advanced, pre-treated gastric cancer, which achieves
its initial endpoint of increased total survival [119]. Another RAINBOW trial of paclitaxel with
ramucirumab versus paclitaxel with placebo for advanced pre-treated gastric cancer approved the
increased survival benefit of ramucirumab, as an antiangiogenic cure among GC patients. Therefore,
ramucirumab is the first FDA approved treatment for advanced gastric cancer after previously applied
chemotherapy. Recently Roviello et al., 2017 [120] performed a meta-analysis to check the efficacy and
the safety of the novel VEGFR-2 inhibitors among cases with metastatic gastric and gastroesophageal
junction cancer. A meta-analysis that is based on the literature of randomized controlled trials (RCTs)
was investigated. A significant impact of overall survival, which was increased, was detected. This
study confirmed the anti-VEGFR-2 inhibitors, like apatinib and ramucirumab positive action [120].
Cyclooxygenase-2 (COX-2) expression is connected to the angiogenesis and Helicobacter pylori
infection among gastric cancer patients [121]. Immunohistochemical stain against cyclooxygenase
1 and 2 has been investigated among samples that were resected from patients with GC. Among
the 72 analysed patients, cases with cyclooxygenase 2-positive staining were tightly correlated
with vascular invasion and H. pylori infection, as well as poorer prognosis. On the other hand,
multivariate analysis displayed that vascular invasion, serosal invasion, and lymph node metastasis
were autonomous prognostic factors for patients with gastric cancer, but cyclooxygenase 2 expression
was not.
Knowing the apoptotic and proliferative levels among gastric cancer patients may be helpful to
find better treatment options and prevention of developing GC. The importance of Ki-67, caspase-3,
and p53 expression levels were demonstrated by Xiao et al., 2013 [122], and were correlated with clinical
data among patients with GC. The Ki-67 and p53 expression was correlated with tumor-node-metastasis
staging. Detection of increased caspase-3 and p53 expression were assigned to the intestinal-type of
GC. Correlation between three tested agents: Ki-67, caspase-3, and p53 was statistically significant.
Positive correlation among caspase-3 expression and adverse prognosis of GC patients was displayed
by the Kaplan-Meier analysis. Additionally, the Cox’s proportional hazards model was used to
show that several clinical data, such as: age, gender, depth of invasion, lymphatic invasion, lymph
node metastasis, TNM staging, Lauren’s classification, and caspase-3 expression were autonomous
prognostic agents for gastric cancer patients. In conclusion, expression of Ki-67, caspase-3, and p53 can
be perceived as factors that influence the differentiation and progression of GC.
11. Conclusions
Gastric cancer is a highly heterogeneous disease. Advantageous studies of the molecular
biomarkers of gastric cancer have been deeply investigated, in outcome provided a wide spectrum of
signatures in this area. This review summarized the recognition patterns of gastric cancer, including
cell cycle regulators, factors that regulates apoptosis, microsatellite instability, multidrug resistance
proteins, factors that influence cell membrane properties, module of HER2 expression, and agents with
impact on the progression of gastric cancer and peritoneal metastasis. Novel investigation must be
done to display specific signatures for the early diagnosis of gastric cancer and for the prediction of
chemo/radiotherapy. Nowadays, is it possible to apply high throughput technologies, such as whole
genome and exome sequencing, to find various biomarkers with prognostic and diagnosis potential.
It is a promising tool to obtain auspicious outcomes to further clinical applications.
59
Int. J. Mol. Sci. 2018, 19, 1658
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Zhang, X.; Zhang, P. Gastric cancer: Somatic genetics as a guide to therapy. J. Med. Genet. 2017, 54, 305–312.
[CrossRef] [PubMed]
2. Franz, J.L.; Cruz, A.B., Jr. The treatment of gastric cancer with combined surgical resection and chemotherapy.
J. Surg. Oncol. 1977, 9, 131–137. [CrossRef] [PubMed]
3. Coburn, N.; Cosby, R.; Klein, L.; Knight, G.; Malthaner, R.; Mamazza, J.; Mercer, C.D.; Ringash, J. Staging and
surgical approaches in gastric cancer: A systematic review. Cancer Treat. Rev. 2018, 63, 104–115. [CrossRef]
[PubMed]
4. Wilke, H.; Preusser, P.; Fink, U.; Gunzer, U.; Meyer, H.J.; Meyer, J.; Siewert, J.R.; Achterrath, W.; Lenaz, L.;
Knipp, H. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: A phase II study
with etoposide, doxorubicin, and cisplatin. J. Clin. Oncol. 1989, 7, 1318–1326. [CrossRef] [PubMed]
5. Kelsen, D.; Karpeh, M.; Schwartz, G.; Gerdes, H.; Lightdale, C.; Botet, J.; Lauers, G.; Klimstra, D.; Huang, Y.;
Saltz, L.; et al. Neoadjuvant therapy of high-risk gastric cancer: A phase II trial of preoperative FAMTX and
postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J. Clin. Oncol. 1996, 14,
1818–1828. [CrossRef] [PubMed]
6. Newman, E.; Marcus, S.G.; Potmesil, M.; Sewak, S.; Yee, H.; Sorich, J.; Hayek, M.; Muggia, F.; Hochster, H.
Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer.
J. Gastrointest. Surg. 2002, 6, 212–223. [CrossRef]
7. Songun, I.; Keizer, H.J.; Hermans, J.; Klementschitsch, P.; de Vries, J.E.; Wils, J.A.; van der Bijl, J.;
van Krieken, J.H.; van de Velde, C.J. Chemotherapy for operable gastric cancer: Results of the Dutch
randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur. J. Cancer 1999, 35, 558–562.
[CrossRef]
8. Rosenberg, S. Lymphokine-activated killer cells: A new approach to immunotherapy of cancer. J. Natl.
Cancer Inst. 1985, 75, 595–603. [PubMed]
9. Rosenberg, S.A.; Spiess, P.; Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with
tumor-infiltrating lymphocytes. Science 1986, 233, 1318–1321. [CrossRef] [PubMed]
10. Yun, Y.S.; Hargrove, M.E.; Ting, C.C. In vivo antitumor activity of anti-CD3-induced activated killer cells.
Cancer Res. 1989, 49, 4770–4774. [PubMed]
11. Kyte, J.A.; Gaudernack, G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells.
Cancer Immunol. Immunother. 2006, 55, 1432–1442. [CrossRef] [PubMed]
12. Kono, K.; Rongcun, Y.; Charo, J.; Ichihara, F.; Celis, E.; Sette, A.; Appella, E.; Sekikawa, T.; Matsumoto, Y.;
Kiessling, R. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific
cytotoxic T lymphocytes. Int. J. Cancer 1998, 78, 202–208. [CrossRef]
13. Traversari, C.; van der Bruggen, P.; Luescher, I.F.; Lurquin, C.; Chomez, P.; Van Pel, A.; de Plaen, E.;
Amar-Costesec, A.; Boon, T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by
cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 1992, 176, 1453–1457. [CrossRef]
[PubMed]
14. Gulley, M.L.; Tang, W. Laboratory assays for Epstein–Barr virus-related disease. J. Mol. Diagn. 2008, 10,
279–292. [CrossRef] [PubMed]
15. Tsurumi, T.; Fujita, M.; Kudoh, A. Latent and lytic Epstein-Barr virus replication strategies. Rev. Med. Virol.
2005, 15, 3–15. [CrossRef] [PubMed]
16. Klutts, J.S.; Ford, B.A.; Perez, N.R.; Gronowski, A.M. Evidence-Based Approach for Interpretation of
Epstein-Barr virus Serological Patterns. J. Clin. Microbiol. 2009, 47, 3204–3210. [CrossRef] [PubMed]
17. Weiss, L.M.; Chen, Y.Y. EBER in situ hybridization for Epstein-Barr virus. Methods Mol. Biol. 2013, 999,
223–230. [PubMed]
18. Zur Hausen, A.; van Rees, B.P.; van Beek, J.; Craanen, M.E.; Bloemena, E.; Offerhaus, G.J.; Meijer, C.J.;
van den Brule, A.J. Epstein-Barr virus in gastric carcinomas and gastric stump carcinomas: A late event in
gastric carcinogenesis. J. Clin. Pathol. 2004, 57, 487–491. [CrossRef] [PubMed]
60
Int. J. Mol. Sci. 2018, 19, 1658
19. Kim, J.; Lee, H.S.; Bae, S.I.; Lee, Y.M.; Kim, W.H. Silencing and CpG island methylation of GSTP1 is rare in
ordinary gastric carcinomas but common in Epstein-Barr virus-associated gastric carcinomas. Anticancer Res.
2005, 25, 4013–4019. [PubMed]
20. Sudo, M.; Chong, J.M.; Sakuma, K.; Ushiku, T.; Uozaki, H.; Nagai, H.; Funata, N.; Matsumoto, Y.;
Fukayama, M. Promoter hypermethylation of E-cadherin and its abnormal expression in Epstein-Barr
virus-associated gastric carcinoma. Int. J. Cancer 2004, 109, 194–199. [CrossRef] [PubMed]
21. Zhao, J.; Liang, Q.; Cheung, K.F.; Kang, W.; Lung, R.W.; Tong, J.H.; To, K.F.; Sung, J.J.; Yu, J. Genome-wide
identification of Epstein-Barr virus-driven promoter methylation profiles of human genes in gastric cancer
cells. Cancer 2013, 119, 304–312. [CrossRef] [PubMed]
22. Bass, A.J.; Thorsson, V.; Shmulevich, I.; Reynolds, S.M.; Miller, M.; Bernard, B.; Hinoue, T.; Laird, P.W.;
Curtis, C.; Shen, H.; et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature
2014, 513, 202–209. [CrossRef] [PubMed]
23. Akiyama, T.; Sudo, C.; Ogawara, H.; Toyoshima, K.; Yamamoto, T. The product of the human c-erbB-2
gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986, 232, 1644–1646. [CrossRef]
[PubMed]
24. Kim, M.A.; Jung, E.J.; Lee, H.S.; Lee, H.E.; Jeon, Y.K.; Yang, H.K.; Kim, W.H. Evaluation of HER-2 gene
status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time
quantitative polymerase chain reaction. Hum. Pathol. 2007, 38, 1386–1393. [CrossRef] [PubMed]
25. Takehana, T.; Kunitomo, K.; Kono, K.; Kitahara, F.; Iizuka, H.; Matsumoto, Y.; Fujino, M.A.; Ooi, A. Status
of c-erbB-2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in
situ hybridization and enzyme-linked immuno-sorbent assay. Int. J. Cancer 2002, 98, 833–837. [CrossRef]
[PubMed]
26. Tsapralis, D.; Panayiotides, I.; Peros, G.; Liakakos, T.; Karamitopoulou, E. Human epidermal growth factor
receptor-2 gene amplification in gastric cancer using tissue microarray technology. World J. Gastroenterol.
2012, 18, 150–155. [CrossRef] [PubMed]
27. Hofmann, M.; Stoss, O.; Shi, D.; Büttner, R.; van de Vijver, M.; Kim, W.; Ochiai, A.; Rüschoff, J.; Henkel, T.
Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology
2008, 52, 797–805. [CrossRef] [PubMed]
28. Fujimoto-Ouchi, K.; Sekiguchi, F.; Yasuno, H.; Moriya, Y.; Mori, K.; Tanaka, Y. Antitumor activity
of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
Cancer Chemother. Pharmacol. 2007, 59, 795–805. [CrossRef] [PubMed]
29. Tanner, M.; Hollmén, M.; Junttila, T.T.; Kapanen, A.I.; Tommola, S.; Soini, Y.; Helin, H.; Salo, J.;
Joensuu, H.; Sihvo, E. Amplification of HER-2 in gastric carcinoma: Association with Topoisomerase
IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 2005, 16,
273–278. [CrossRef] [PubMed]
30. Kasprzyk, P.G.; Song, S.U.; Di Fiore, P.P.; King, C.R. Therapy of an animal model of human gastric cancer
using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res. 1992, 52, 2771–2776. [PubMed]
31. Nicholas, G.; Cripps, C.; Au, H.J.; et al. Early results of a trial of trastuzumab, cisplatin and docetaxel (TCD)
for the treatment of metastatic gastric cancer overexpressing HER2. Ann. Oncol. 2006, 17, 316.
32. Yuza, K.; Nagahashi, M.; Watanabe, S.; Takabe, K.; Wakai, T. Hypermutation and microsatellite instability in
gastrointestinal cancers. Oncotarget 2017, 8, 112103–112115. [CrossRef] [PubMed]
33. Hang, X.; Li, D.; Wang, J.; Wang, G. Prognostic significance of microsatellite instability-associated pathways
and genes in gastric cancer. Int. J. Mol. Med. 2018, 42, 149–160. [CrossRef] [PubMed]
34. Ye, P.; Shi, Y.; Li, A. Association between hMLH1 Promoter Methylation and Risk of Gastric Cancer:
A Meta-Analysis. Front. Physiol. 2018, 9, 368. [CrossRef] [PubMed]
35. Polom, K.; Marrelli, D.; Smyth, E.C.; Voglino, C.; Roviello, G.; Pascale, V.; Varas, J.; Vindigni, C.; Roviello, F.
The Role of Microsatellite Instability in Positive Margin Gastric Cancer Patients. Surg. Innov. 2018, 25, 99–104.
[CrossRef] [PubMed]
36. Beck, F.; Chawengsaksophak, K.; Waring, P.; Playford, R.J.; Furness, J.B. Reprogramming of intestinal
differentiation and intercalary regeneration in Cdx2 mutant mice. Proc. Natl. Acad. Sci. USA 1999, 96,
7318–7323. [CrossRef] [PubMed]
37. Freund, J.N.; Domon-Dell, C.; Kedinger, M.; Duluc, I. The Cdx-1 and Cdx-2 homeobox genes in the intestine.
Biochem. Cell Biol. 1998, 76, 957–969. [CrossRef] [PubMed]
61
Int. J. Mol. Sci. 2018, 19, 1658
38. Bai, Y.Q.; Miyake, S.; Iwai, T.; Yuasa, Y. CDX2, a homeobox transcription factor, upregulates transcription of
the p21/WAF1/CIP1 gene. Oncogene 2003, 22, 7942–7949. [CrossRef] [PubMed]
39. Park, D.Y.; Srivastava, A.; Kim, G.H.; Mino-Kenudson, M.; Deshpande, V.; Zukerberg, L.R.; Song, G.A.;
Lauwers, G.Y. CDX2 expression in the intestinal-type gastric epithelial neoplasia: Frequency and significance.
Mod. Pathol. 2010, 23, 54–61. [CrossRef] [PubMed]
40. Huang, W.B.; Zhou, X.J.; Chen, J.Y.; Zhang, L.H.; Meng, K.; Ma, H.H.; Lu, Z.F. CD10-positive stromal cells in
gastric carcinoma: Correlation with invasion and metastasis. Jpn. J. Clin. Oncol. 2005, 35, 245–250. [CrossRef]
[PubMed]
41. You, J.; Bird, R.C. Selective induction of cell cycle regulatory genes cdk1 (p34cdc2), cyclins A/B, and the tumor
suppressor gene Rb in transformed cells by okadaic acid. J. Cell. Physiol. 1995, 164, 424–433. [CrossRef]
[PubMed]
42. Rafferty, M.A.; Fenton, J.E.; Jones, A.S. An overview of the role and inter-relationship of epidermal growth
factor receptor, cyclin D and retinoblastoma protein on the carcinogenesis of squamous cell carcinoma of the
larynx. Clin. Otolaryngol. Allied Sci. 2001, 26, 317–320. [CrossRef] [PubMed]
43. Arici, D.S.; Tuncer, E.; Ozer, H.; Simek, G.; Koyuncu, A. Expression of retinoblastoma and cyclin D1 in gastric
carcinoma. Neoplasma 2009, 56, 63–67. [CrossRef] [PubMed]
44. Gao, P.; Zhou, G.Y.; Liu, Y.; Li, J.S.; Zhen, J.H.; Yuan, Y.P. Alteration of cyclin D1 in gastric carcinoma and its
clinicopathologic significance. World J. Gastroenterol. 2004, 10, 2936–2939. [CrossRef] [PubMed]
45. Serrano, M.; Hannon, G.J.; Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition
of cyclin D/CDK4. Nature 1993, 366, 704–707. [CrossRef] [PubMed]
46. Hayashi, K.; Metzger, R.; Salonga, D.; Danenberg, K.; Leichman, L.P.; Fink, U.; Sendler, A.; Kelsen, D.;
Schwartz, G.K.; Groshen, S.; et al. High frequency of simultaneous loss of p16 and p16beta gene expression
in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach.
Oncogene 1997, 15, 1481–1488. [CrossRef] [PubMed]
47. Wu, M.S.; Shun, C.T.; Sheu, J.C.; Wang, H.P.; Wang, J.T.; Lee, W.J.; Chen, C.J.; Wang, T.H.; Lin, J.T.
Overexpression of mutant p53 and c-erbB-2 proteins and mutations of the p15 and p16 genes in human
gastric carcinoma: With respect to histological subtypes and stages. J. Gastroenterol. Hepatol. 1998, 13, 305–310.
[CrossRef] [PubMed]
48. Ficorella, C.; Cannita, K.; Ricevuto, E.; Toniato, E.; Fusco, C.; Sinopoli, N.T.; De Galitiis, F.; Di Rocco, Z.C.;
Porzio, G.; Frati, L.; et al. P16 hypermethylation contributes to the characterization of gene inactivation
profiles in primary gastric cancer. Oncol. Rep. 2003, 10, 169–173. [CrossRef] [PubMed]
49. Cuesta, R.; Martinez-Sanchez, A.; Gebauer, F. miR-181a regulates cap-dependent translation of p27(kip1)
mRNA in myeloid cells. Mol. Cell. Biol. 2009, 29, 2841–2851. [CrossRef] [PubMed]
50. Nitti, D.; Belluco, C.; Mammano, E.; Marchet, A.; Ambrosi, A.; Mencarelli, R.; Segato, P.; Lise, M. Low level
of p27(Kip1) protein expression in gastric adenocarcinoma is associated with disease progression and poor
outcome. J. Surg. Oncol. 2002, 81, 167–175. [CrossRef] [PubMed]
51. Zheng, J.Y.; Wang, W.Z.; Li, K.Z.; Guan, W.X.; Yan, W. Effect of p27(KIP1) on cell cycle and apoptosis in
gastric cancer cells. World J. Gastroenterol. 2005, 11, 7072–7077. [CrossRef] [PubMed]
52. Tsai, L.H.; Harlow, E.; Meyerson, M. Isolation of the human cdk2 gene that encodes the cyclin A- and
adenovirus E1A-associated p33 kinase. Nature 1991, 353, 174–177. [CrossRef] [PubMed]
53. Luo, D.H.; Zhou, Q.; Hu, S.K.; Xia, Y.Q.; Xu, C.C.; Lin, T.S.; Pan, Y.T.; Wu, J.S.; Jin, R. Differential expression
of Notch1 intracellular domain and p21 proteins, and their clinical significance in gastric cancer. Oncol. Lett.
2014, 7, 471–478. [CrossRef] [PubMed]
54. Gonçalves, A.R.; Carneiro, A.J.; Martins, I.; de Faria, P.A.; Ferreira, M.A.; de Mello, E.L.; Fogaça, H.S.;
Elia, C.C.; de Souza, H.S. Prognostic significance of p53 protein expression in early gastric cancer.
Pathol. Oncol. Res. 2011, 17, 349–355. [CrossRef] [PubMed]
55. Gomyo, Y.; Osaki, M.; Kaibara, N.; Ito, H. Numerical aberration and point mutation of p53 gene in human
gastric intestinal metaplasia and well-differentiated adenocarcinoma: Analysis by fluorescence in situ
hybridization (FISH) and PCR-SSCP. Int. J. Cancer 1996, 66, 594–599. [CrossRef]
56. Hongyo, T.; Buzard, G.S.; Palli, D.; Weghorst, C.M.; Amorosi, A.; Galli, M.; Caporaso, N.E.; Fraumeni, J.F., Jr.;
Rice, J.M. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region
around Florence, Italy. Cancer Res. 1995, 55, 2665–2672. [PubMed]
62
Int. J. Mol. Sci. 2018, 19, 1658
57. Kushima, R.; Müller, W.; Stolte, M.; Borchard, F. Differential p53 protein expression in stomach adenomas
of gastric and intestinal phenotypes: Possible sequences of p53 alteration in stomach carcinogenesis.
Virchows Arch. 1996, 428, 223–227. [CrossRef] [PubMed]
58. Cristescu, R.; Lee, J.; Nebozhyn, M.; Kim, K.M.; Ting, J.C.; Wong, S.S.; Liu, J.; Yue, Y.G.; Wang, J.; Yu, K.; et al.
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med.
2015, 21, 449–456. [CrossRef] [PubMed]
59. Tamura, T.; Ohira, M.; Tanaka, H.; Muguruma, K.; Toyokawa, T.; Kubo, N.; Sakurai, K.; Amano, R.; Kimura, K.;
Shibutani, M.; et al. Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of
Patients with Stage II/III Gastric Cancer. Anticancer Res. 2015, 35, 5369–5376. [PubMed]
60. Xing, X.; Guo, J.; Wen, X.; Ding, G.; Li, B.; Dong, B.; Feng, Q.; Li, S.; Zhang, J.; Cheng, X.; et al. Analysis of
PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. Oncoimmunology 2017, 7,
e1356144. [CrossRef] [PubMed]
61. Böger, C.; Behrens, H.M.; Mathiak, M.; Krüger, S.; Kalthoff, H.; Röcken, C. PD-L1 is an independent
prognostic predictor in gastric cancer of Western patients. Oncotarget 2016, 7, 24269–24283. [CrossRef]
[PubMed]
62. Kang, M.J.; Park, B.J.; Byun, D.S.; Park, J.I.; Kim, H.J.; Park, J.H.; Chi, S.G. Loss of imprinting and elevated
expression of wild-type p73 in human gastric adenocarcinoma. Clin. Cancer Res. 2000, 1767–1771.
63. Oliner, J.D.; Kinzler, K.W.; Meltzer, P.S.; George, D.L.; Vogelstein, B. Amplification of a gene encoding a
p53-associated protein in human sarcomas. Nature 1992, 358, 80–83. [CrossRef] [PubMed]
64. Günther, T.; Schneider-Stock, R.; Häckel, C.; Kasper, H.U.; Pross, M.; Hackelsberger, A.; Lippert, H.;
Roessner, A. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein
and p53 alterations. Mod. Pathol. 2000, 13, 621–626. [CrossRef] [PubMed]
65. Nakajima, N.; Ito, Y.; Yokoyama, K.; Uno, A.; Kinukawa, N.; Nemoto, N.; Moriyama, M. The expression of
murine double minute 2 (MDM2) on helicobacter pylori-infected intestinal metaplasia and gastric cancer.
J. Clin. Biochem. Nutr. 2009, 44, 196–202. [CrossRef] [PubMed]
66. Wang, L.; Zhang, X.Y.; Xu, L.; Liu, W.J.; Zhang, J.; Zhang, J.P. Expression and significance of p53 and mdm2
in atypical intestinal metaplasia and gastric carcinoma. Oncol. Lett. 2011, 2, 707–712. [CrossRef] [PubMed]
67. Wu, J.; Liu, X.; Cai, H.; Wang, Y. Prediction of tumor recurrence after curative resection in gastric carcinoma
based on bcl-2 expression. World J. Surg. Oncol. 2014, 12, 40. [CrossRef] [PubMed]
68. Sugitani, N.; Sivley, R.M.; Perry, K.E.; Capra, J.A.; Chazin, W.J. XPA: A key scaffold for human nucleotide
excision repair. DNA Repair 2016, 44, 123–135. [CrossRef] [PubMed]
69. Dong, Z.; Guo, W.; Zhou, R.; Wan, L.; Li, Y.; Wang, N.; Kuang, G.; Wang, S. Polymorphisms of the DNA repair
gene XPA and XPC and its correlation with gastric cardiac adenocarcinoma in a high incidence population
in North China. J. Clin. Gastroenterol. 2008, 42, 910–915. [CrossRef] [PubMed]
70. D’Errico, M.; Parlanti, E.; Teson, M.; de Jesus, B.M.; Degan, P.; Calcagnile, A.; Jaruga, P.; Bjørås, M.;
Crescenzi, M.; Pedrini, A.M.; et al. New functions of XPC in the protection of human skin cells from
oxidative damage. EMBO J. 2006, 25, 4305–4315. [CrossRef] [PubMed]
71. Dusinská, M.; Dzupinková, Z.; Wsólová, L.; Harrington, V.; Collins, A.R. Possible involvement of XPA
in repair of oxidative DNA damage deduced from analysis of damage, repair and genotype in a human
population study. Mutagenesis 2006, 21, 205–211. [CrossRef] [PubMed]
72. Sandusky, G.E.; Mintze, K.S.; Pratt, S.E.; Dantzig, A.H. Expression of multidrug resistance-associated protein
2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 2002, 41, 65–74.
[CrossRef] [PubMed]
73. Toffoli, G.; Cecchin, E. Pharmacogenetics of stomach cancer. Suppl. Tumori 2003, 2, S19–S22. [PubMed]
74. Qiao, W.; Wang, T.; Zhang, L.; Tang, Q.; Wang, D.; Sun, H. Association between single genetic polymorphisms
of MDR1 gene and gastric cancer susceptibility in Chinese. Med. Oncol. 2013, 30, 643. [CrossRef] [PubMed]
75. Zhu, C.Y.; Lv, Y.P.; Yan, D.F.; Gao, F.L. Knockdown of MDR1 increases the sensitivity to adriamycin in drug
resistant gastric cancer cells. Asian Pac. J. Cancer Prev. 2013, 14, 6757–6760. [CrossRef] [PubMed]
76. Hayes, P.C.; Bouchier, I.A.; Beckett, G.J. Glutathione S-transferase in humans in health and disease. Gut 1991,
32, 813–818. [CrossRef] [PubMed]
77. Yu, P.; Du, Y.; Cheng, X.; Yu, Q.; Huang, L.; Dong, R. Expression of multidrug resistance-associated proteins
and their relation to postoperative individualized chemotherapy in gastric cancer. World J. Surg. Oncol. 2014,
12, 307. [CrossRef] [PubMed]
63
Int. J. Mol. Sci. 2018, 19, 1658
78. Dekker, J.; Rossen, J.W.; Büller, H.A.; Einerhand, A.W. The MUC family: An obituary. Trends Biochem. Sci.
2002, 27, 126–131. [CrossRef]
79. Marin, F.; Luquet, G.; Marie, B.; Medakovic, D. Molluscan shell proteins: Primary structure, origin, and
evolution. Curr. Top. Dev. Biol. 2008, 80, 209–276. [PubMed]
80. Lee, H.S.; Lee, H.K.; Kim, H.S.; Yang, H.K.; Kim, Y.I.; Kim, W.H. MUC1, MUC2, MUC5AC, and MUC6
expressions in gastric carcinomas: Their roles as prognostic indicators. Cancer 2001, 92, 1427–1434. [CrossRef]
81. Wang, X.T.; Kong, F.B.; Mai, W.; Li, L.; Pang, L.M. MUC1 Immunohistochemical Expression as a Prognostic
Factor in Gastric Cancer: Meta-Analysis. Dis. Mark. 2016, 2016, 9421571. [CrossRef] [PubMed]
82. Park, K.K.; Yang, S.I.; Seo, K.W.; Yoon, K.Y.; Lee, S.H.; Jang, H.K.; Shin, Y.M. Correlations of Human Epithelial
Growth Factor Receptor 2 Overexpression with MUC2, MUC5AC, MUC6, p53, and Clinicopathological
Characteristics in Gastric Cancer Patients with Curative Resection. Gastroenterol. Res. Pract. 2015, 2015,
946359. [CrossRef] [PubMed]
83. Zhang, C.T.; He, K.C.; Pan, F.; Li, Y.; Wu, J. Prognostic value of Muc5AC in gastric cancer: A meta-analysis.
World J. Gastroenterol. 2015, 21, 10453–10460. [CrossRef] [PubMed]
84. Kim, D.H.; Shin, N.; Kim, G.H.; Song, G.A.; Jeon, T.Y.; Kim, D.H.; Lauwers, G.Y.; Park, D.Y. Mucin expression
in gastric cancer: Reappraisal of its clinicopathologic and prognostic significance. Arch. Pathol. Lab. Med.
2013, 137, 1047–1053. [CrossRef] [PubMed]
85. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62, 10–29. [CrossRef]
[PubMed]
86. Shen, L.; Shan, Y.S.; Hu, H.M.; Price, T.J.; Sirohi, B.; Yeh, K.H.; Yang, Y.H.; Sano, T.; Yang, H.K.; Zhang, X.;
et al. Management of gastric cancer in Asia: Resource-stratified guidelines. Lancet Oncol. 2013, 14, e535–e547.
[CrossRef]
87. Trzpis, M.; McLaughlin, P.M.; de Leij, L.M.; Harmsen, M.C. Epithelial cell adhesion molecule: More than a
carcinoma marker and adhesion molecule. Am. J. Pathol. 2007, 171, 386–395. [CrossRef] [PubMed]
88. Imano, M.; Itoh, T.; Satou, T.; Yasuda, A.; Nishiki, K.; Kato, H.; Shiraishi, O.; Peng, Y.F.; Shinkai, M.;
Tsubaki, M.; et al. High expression of epithelial cellular adhesion molecule in peritoneal metastasis of gastric
cancer. Target. Oncol. 2013, 8, 231–235. [CrossRef] [PubMed]
89. Van Roy, F.; Berx, G. The cell-cell adhesion molecule E-cadherin. Cell. Mol. Life Sci. 2008, 65, 3756–3788.
[CrossRef] [PubMed]
90. Till, J.E.; Yoon, S.S.; Ryeom, S. E-cadherin and K-ras: Implications of a newly developed model of gastric
cancer. Oncoscience 2017, 4, 162–163. [PubMed]
91. Lee, H.S.; Choi, S.I.; Lee, H.K.; Kim, H.S.; Yang, H.K.; Kang, G.H.; Kim, Y.I.; Lee, B.L.; Kim, W.H. Distinct
clinical features and outcomes of gastric cancers with microsatellite instability. Mod. Pathol. 2002, 15, 632–640.
[CrossRef] [PubMed]
92. Perri, F.; Cotugno, R.; Piepoli, A.; Merla, A.; Quitadamo, M.; Gentile, A.; Pilotto, A.; Annese, V.; Andriulli, A.
Aberrant DNA methylation in non-neoplastic gastric mucosa of H. Pylori infected patients and effect of
eradication. Am. J. Gastroenterol. 2007, 102, 1361–1371. [CrossRef] [PubMed]
93. Chan, A.O.; Peng, J.Z.; Lam, S.K.; Lai, K.C.; Yuen, M.F.; Cheung, H.K.; Kwong, Y.L.; Rashid, A.; Chan, C.K.;
Wong, B.C. Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation.
Gut 2006, 55, 463–468. [CrossRef] [PubMed]
94. Guilford, P.; Hopkins, J.; Harraway, J.; McLeod, M.; McLeod, N.; Harawira, P.; Taite, H.; Scoular, R.; Miller, A.;
Reeve, A.E. E-cadherin germline mutations in familial gastric cancer. Nature 1998, 392, 402–405. [CrossRef]
[PubMed]
95. Van der Post, R.S.; Vogelaar, I.P.; Carneiro, F.; Guilford, P.; Huntsman, D.; Hoogerbrugge, N.; Caldas, C.;
Schreiber, K.E.; Hardwick, R.H.; Ausems, M.G.; et al. Hereditary diffuse gastric cancer: Updated clinical
guidelines with an emphasis on germline CDH1 mutation carriers. J. Med. Genet. 2015, 52, 361–374.
[CrossRef] [PubMed]
96. Perretti, M.; D’Acquisto, F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation.
Nat. Rev. Immunol. 2009, 9, 62–70. [CrossRef] [PubMed]
97. Cheng, T.Y.; Wu, M.S.; Lin, J.T.; Lin, M.T.; Shun, C.T.; Huang, H.Y.; Hua, K.T.; Kuo, M.L. Annexin A1 is
associated with gastric cancer survival and promotes gastric cancer cell invasiveness through the formyl
peptide receptor/extracellular signal-regulated kinase/integrin beta-1-binding protein 1 pathway. Cancer
2012, 118, 5757–5767. [PubMed]
64
Int. J. Mol. Sci. 2018, 19, 1658
98. Zhang, G.; Zhou, H.; Xue, X. Complex roles of NRAGE on tumor. Tumour Biol. 2016, 37, 11535–11540.
[CrossRef] [PubMed]
99. Kanda, M.; Shimizu, D.; Fujii, T.; Tanaka, H.; Tanaka, Y.; Ezaka, K.; Shibata, M.; Takami, H.; Hashimoto, R.;
Sueoka, S.; et al. Neurotrophin Receptor-Interacting Melanoma Antigen-Encoding Gene Homolog is
Associated with Malignant Phenotype of Gastric Cancer. Ann. Surg. Oncol. 2016, 23 (Suppl. S4), 532–539.
[CrossRef] [PubMed]
100. Yan, T.D.; Black, D.; Sugarbaker, P.H.; Zhu, J.; Yonemura, Y.; Petrou, G.; Morris, D.L. A systematic review and
meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable
gastric cancer. Ann. Surg. Oncol. 2007, 14, 2702–2713. [CrossRef] [PubMed]
101. Mebius, R.E. Lymphoid organs for peritoneal cavity immune response: Milky spots. Immunity 2009, 30,
670–672. [CrossRef] [PubMed]
102. Miao, Z.F.; Wang, Z.N.; Zhao, T.T.; Xu, Y.Y.; Gao, J.; Miao, F.; Xu, H.M. Peritoneal milky spots serve as a
hypoxic niche and favor gastric cancer stem/progenitor cell peritoneal dissemination through hypoxia-
inducible factor 1α. Stem Cells 2014, 32, 3062–3074. [CrossRef] [PubMed]
103. Chu, E.C.; Tarnawski, A.S. PTEN regulatory functions in tumor suppression and cell biology. Med. Sci. Monit.
2004, 10, RA235–RA241. [PubMed]
104. Zhang, L.L.; Liu, J.; Lei, S.; Zhang, J.; Zhou, W.; Yu, H.G. PTEN inhibits the invasion and metastasis of gastric
cancer via downregulation of FAK expression. Cell Signal. 2014, 26, 1011–1020. [CrossRef] [PubMed]
105. Ma, J.; Guo, X.; Zhang, J.; Wu, D.; Hu, X.; Li, J.; Lan, Q.; Liu, Y.; Dong, W. PTEN Gene Induces Cell
Invasion and Migration via Regulating AKT/GSK-3β/β-Catenin Signaling Pathway in Human Gastric
Cancer. Dig. Dis. Sci. 2017, 62, 3415–3425. [CrossRef] [PubMed]
106. Izumi, D.; Ishimoto, T.; Miyake, K.; Sugihara, H.; Eto, K.; Sawayama, H.; Yasuda, T.; Kiyozumi, Y.; Kaida, T.;
Kurashige, J.; et al. CXCL12/CXCR4 activation by cancer-associated fibroblasts promotes integrin β1
clustering and invasiveness in gastric cancer. Int. J. Cancer 2016, 138, 1207–1219. [CrossRef] [PubMed]
107. Yasumoto, K.; Koizumi, K.; Kawashima, A.; Saitoh, Y.; Arita, Y.; Shinohara, K.; Minami, T.; Nakayama, T.;
Sakurai, H.; Takahashi, Y.; et al. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric
cancer. Cancer Res. 2006, 66, 2181–2187. [CrossRef] [PubMed]
108. Yasumoto, K.; Yamada, T.; Kawashima, A.; Wang, W.; Li, Q.; Donev, I.S.; Tacheuchi, S.; Mouri, H.;
Yamashita, K.; Ohtsubo, K.; et al. The EGFR ligands amphiregulin and heparin-binding egf-like growth
factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer. Clin. Cancer Res. 2011, 17,
3619–3630. [CrossRef] [PubMed]
109. Takatsuki, H.; Komatsu, S.; Sano, R.; Takada, Y.; Tsuji, T. Adhesion of gastric carcinoma cells to peritoneum
mediated by alpha3beta1 integrin (VLA-3). Cancer Res. 2004, 64, 6065–6070. [CrossRef] [PubMed]
110. Nakano, I.; Paucar, A.A.; Bajpai, R.; Dougherty, J.D.; Zewail, A.; Kelly, T.K.; Kim, K.J.; Ou, J.; Groszer, M.;
Imura, T.; et al. Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor
proliferation. J. Cell Biol. 2005, 170, 413–427. [CrossRef] [PubMed]
111. Du, T.; Qu, Y.; Li, J.; Li, H.; Su, L.; Zhou, Q.; Yan, M.; Li, C.; Zhu, Z.; Liu, B. Maternal embryonic leucine
zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway. Mol. Cancer 2014, 13, 100.
[CrossRef] [PubMed]
112. Kitoh, T.; Yanai, H.; Saitoh, Y.; Nakamura, Y.; Matsubara, Y.; Kitoh, H.; Yoshida, T.; Okita, K. Increased
expression of matrix metalloproteinase-7 in invasive early gastric cancer. J. Gastroenterol. 2004, 39, 434–440.
[CrossRef] [PubMed]
113. Yonemura, Y.; Endou, Y.; Fujita, H.; Fushida, S.; Bandou, E.; Taniguchi, K.; Miwa, K.; Sugiyama, K.; Sasaki, T.
Role of MMP-7 in the formation of peritoneal dissemination in gastric cancer. Gastric Cancer 2000, 3, 63–70.
[CrossRef] [PubMed]
114. Jiang, C.G.; Lv, L.; Liu, F.R.; Wang, Z.N.; Liu, F.N.; Li, Y.S.; Wang, C.Y.; Zhang, H.Y.; Sun, Z.; Xu, H.M.
Downregulation of connective tissue growth factor inhibits the growth and invasion of gastric cancer cells
and attenuates peritoneal dissemination. Mol. Cancer 2011, 10, 122. [CrossRef] [PubMed]
115. Chen, C.N.; Chang, C.C.; Lai, H.S.; Jeng, Y.M.; Chen, C.I.; Chang, K.J.; Lee, P.H.; Lee, H. Connective tissue
growth factor inhibits gastric cancer peritoneal metastasis by blocking integrin α3β1-dependent adhesion.
Gastric Cancer 2015, 18, 504–515. [CrossRef] [PubMed]
65
Int. J. Mol. Sci. 2018, 19, 1658
116. Jiang, J.; Liu, W.; Guo, X.; Zhang, R.; Zhi, Q.; Ji, J.; Zhang, J.; Chen, X.; Li, J.; Zhang, J.; et al. IRX1 influences
peritoneal spreading and metastasis via inhibiting BDKRB2-dependent neovascularization on gastric cancer.
Oncogene 2011, 30, 4498–4508. [CrossRef] [PubMed]
117. Leung, D.W.; Cachianes, G.; Kuang, W.J.; Goeddel, D.V.; Ferrara, N. Vascular endothelial growth factor is a
secreted angiogenic mitogen. Science 1989, 246, 1306–1309. [CrossRef] [PubMed]
118. Kowanetz, M.; Ferrara, N. Vascular endothelial growth factor signaling pathways: Therapeutic perspective.
Clin. Cancer Res. 2006, 12, 5018–5022. [CrossRef] [PubMed]
119. Javle, M.; Smyth, E.C.; Chau, I. Ramucirumab: Successfully targeting angiogenesis in gastric cancer.
Clin. Cancer Res. 2014, 20, 5875–5881. [CrossRef] [PubMed]
120. Roviello, G.; Polom, K.; Roviello, F.; Marrelli, D.; Multari, A.G.; Paganini, G.; Pacifico, C.; Generali, D.
Targeting VEGFR-2 in Metastatic Gastric Cancer: Results from a Literature-Based Meta-Analysis.
Cancer Investig. 2017, 35, 187–194. [CrossRef] [PubMed]
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Abstract: The CDH1 gene, coding for the E-cadherin protein, is linked to gastric cancer (GC)
susceptibility and tumor invasion. The human epidermal growth factor receptor 2 (HER2) is amplified
and overexpressed in a portion of GC. HER2 is an established therapeutic target in metastatic GC
(mGC). Trastuzumab, in combination with various chemotherapeutic agents, is a standard treatment
for these tumors leading to outcome improvement. Unfortunately, the survival benefit is limited to a
fraction of patients. The aim of this study was to improve knowledge of the HER2 and the E-cadherin
alterations in the context of GC to characterize subtypes of patients that could better benefit from
targeted therapy. An association between the P7-CDH1 haplotype, including two polymorphisms
(rs16260A-rs1801552T) and a subset of HER2-positive mGC with better prognosis was observed.
Results indicated the potential evaluation of CDH1 haplotypes in mGC to stratify patients that will
benefit from trastuzumab-based treatments. Moreover, data may have implications to understanding
the HER2 and the E-cadherin interactions in vivo and in response to treatments.
Keywords: E-cadherin; CDH1; HER2; metastatic gastric cancer; rs16260; rs1801552
1. Introduction
Gastric cancer (GC) is a serious health problem worldwide. This year 28,000 new cases, with
approximately 10,960 related deaths, are expected in the United States [1]. Even though surgery is
the primary treatment option for early stage GC, diagnosis is often late in Western countries. This is
probably due to the lack of proper screening programs and a lack of symptoms for a long time. About
35% of patients present with “de novo” metastatic GC (mGC) and approximately 70% that underwent
Int. J. Mol. Sci. 2018, 19, 47; doi:10.3390/ijms19010047 www.mdpi.com/journal/ijms67
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surgery for the primary tumor will have disease recurrence or develop distant metastases, with a
median survival of about one year, despite palliative chemotherapy [2–4].
In selected small tumors (i.e., stage Tis or T1) endoscopic resection may be performed, mainly
in experienced centers. However, complete tumor resection with adequate margins and lymph
node dissection remains the only potentially curative therapy for patients with non-metastatic GC.
Furthermore, perioperative chemotherapy can improve survival outcomes for patients with operable
disease [5].
In metastatic or recurrent disease, chemotherapy is the standard treatment, although it is not
curative. However, despite the introduction in clinical practice of new drugs and chemotherapeutic
schedules, only little progress has been made in recent years. The most important advance came
from the international (24 countries) phase 3 randomized “ToGA” study (NCT01041404) [6]. In this
trial, the addition of the trastuzumab, a monoclonal antibody, to the chemotherapy with cisplatin
and capecitabine was compared to the same chemotherapy combination alone, in a population of
HER2-positive metastatic gastric or gastro-esophageal junction cancers. The HER2 is a transmembrane
protein with tyrosine kinase activity implicated by its interaction with epidermal growth factor (EGF)
family in cell growth and differentiation (Figure 1). In the ToGA study the median overall survival
(OS) was found to be higher in patients who received trastuzumab plus chemotherapy compared
with those who received the only chemotherapy (13.8 vs. 11.1 months). Immunohistochemical (IHC)
scoring evaluates both the HER2 membranous staining (absent, weak or detected in only one part
of the membrane, moderate/weak complete or basolateral membranous staining and strong) and
the percentage of the tumor cells staining (<10% or ≥ 10% of cells). A greater survival benefit was
detected in patients whose tumors were IHC-positive (score 3+) or IHC-equivocal (score 2+), but in situ
hybridization-positive (16 vs. 11.8 months; hazard ratio (HR) = 0.65). In addition, it was seen that the
addition of the trastuzumab to chemotherapy did not compromise patient quality of life. Unfortunately,
in a substantial proportion of mGC patient who progress after initial response to chemotherapy the
death occurs in a few months [4]. Furthermore, the prognostic significance of the HER2 expression in
GC remains to be elucidated.
Breakthroughs in the GC biology are currently changing the landscape of GC. More specifically,
the understanding of molecular mechanisms underlying the different pathological features has led to
new GC classifications [7,8]. Originally GC was categorized according to anatomical presentation [9,10],
and to histological classes (WHO classification and Lauren classification) [11,12]. More recently, the
characterization of GC includes the HER2 status and the HER-positive disease is reported in about
18% (range 4.4% to 53.4%) of patients [13].
In 2014, the Cancer Genome Atlas (TGCA) project [14] subdivided GC according to different
molecular biology tests in four subgroups: EBV-positive (about 8% of all GC), Microsatellite
Instable (MSI, about 22%), Chromosomal Instable (CIN, about 50%), and Genomically Stable
(GS, about 20%) cancers. Additionally, in 2015 the Asian Cancer Research Group (ACRG) [15]
proposed an alternative molecular classification due to the different biological characteristics of
Asian patients. This classification divided GC in four subgroups represented by: Microsatellite
Stable/epithelial-to-mesenchymal transition (MSS/EMT), Microsatellite Stable TP53-positive
(MSS/TP53+, somehow overlapping with EBV type of TCGA classification), Microsatellite Stable
TP53-negative (MSS/TP53−, similar to CIN by TCGA), and Microsatellite Instable (MSI).
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Figure 1. Schematic diagram of E-cadherin-HER2 interaction. The E-cadherin present three different
domains: the conserved cytoplasmic domain, a transmembrane domain, and an extracellular
domain. The E-cadherin cytoplasmic tail presents two regions: the catenin-binding domain and
the juxtamembrane domain. β-catenin binds to the E-cadherin domain and this complex via α-catenin
connects and regulates E-cad interaction with the actin cytoskeleton. p120-catenin binds the CDH1
juxtamembrane domain and stabilizes E-cad expression at the cell surface. (A) Activation of the HER2
by inducing the phosphorylation of β-catenin directs the dissociation of β-catenin from the E-cad
complex, thus leading to a decrease of E-cad-mediated cell adhesion, facilitate epithelial-mesenchymal
transition (EMT), and the translocation of β-catenin to the nucleus where it acts as a transcriptional
regulator of genes involved in cell growth and the EMT process; (B) HER2 activation increases
metalloproteinase (MP) activity, which leads to an increased production of soluble E-cadherin (sE-cad)
through the cleavage of E-cad. Metalloproteinase also cleaves HER2 into a cytoplasmic tail domain,
p95HER2, and a shaded soluble HER2 fragment. The p95HER2 fragment maintains the phosphokinase
activity, thus favoring the dissociation of the β-catenin/E-cad complex leading to GC progression and
metastasis. The production of the sE-cad causes a reduction in cell adhesion and, by its diffusion into the
microenvironment, acts as a paracrine/autocrine signaling molecule that regulates numerous signaling
pathways implicated in tumor progression, including a key role in the HER2 interaction/activation
and phosphorylation of β-catenin.
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In the present study, our attention is focused on tumors with CDH1 mutation, which could be
included in the GS subtype of TCGA classification, mostly represented by GC of diffused histotype
widely distributed to all the anatomical sites of the stomach and tending to a metastatic process linked
to EMT [14]. CDH1 encodes the E-cadherin (E-cad), a transmembrane glycoprotein especially abundant
in epithelial tissues that mediate calcium-dependent adhesion between epithelial cells. Several CDH1
mutations with a reduced activity/expression of the E-cad [16], as well as the HER2 overexpression [17],
have been associated with shorter GC patient survival. More recent evidence points to β-catenin as
a common link between the HER2 overexpression and the E-cad repression in influencing EMT, the
metastatic process, and outcome [18].
A deep understanding of molecular characterization of patients with mGC focusing on both the
HER2-positive and the CDH1 polymorphisms could provide the scientific background to develop
modern clinical trial protocols in order to maximize the benefit of novel biological agents in a proper
patient population [7]. The present study was designed to characterize CDH1 in mGC subtypes
according to the HER2-expression and to evaluate the association between the CDH1 and the prognosis.
2. Results
2.1. Patient Characteristics
Fifty-nine consecutive patients with mGC were enrolled in this study; patients meeting the criteria
for hereditary diffuse GC have been excluded. In total, 44 patients were males and 15 were females,
and the mean age at diagnosis was 60 years (range, 40–76 years). Twelve cases (20.3%; (N = 10 males,
median age 56.5 years) were classified at diagnosis as HER2-positive by an IHC score of 2+/neu
amplification or by an IHC score of 3. All mGC patients received the same chemotherapeutic regimen
with the addition of trastuzumab in mGC HER2-positive tumors (mGC-HER2).
At a median follow-up time of two years, a trend for a better OS was showed in the mGC-HER2
positive group of patients although due to the limited number of cases the difference did not reach
a statistical significance (468 days, standard deviation (SD) 389 vs. 584 days, SD 336; p = 0.20)




Figure 2. Cox regression for overall survival (OS) analysis for the mGC patient subgroup based on the
HER2-expression.
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2.2. CDH1 Mutations
A summary of CDH1 mutations found in the promoter/5′UTR region and in all 16 exons and
their surrounding sequences, are reported in Table 1, stratified on the basis of the HER2 status.
Mutations resulted in: (i) missense variant in three cases (mGC-HER2 P296, mGC P310, P623); (ii) a
frameshift variant in one case resulting in a truncating protein (mGC-HER2 P586) [20]; (iii) synonymous
mutations in seven cases, including a new mutation (GeneBank accession number: KT820428.1)
(mGC-HER2 P586, mGC P310, P295, P311, P476, P368, P490); and (iv) eight in the non-coding region
(i.e., promoter/5′UTR/surrounding regions) (mGC-HER2 P586, mGC P377, P304, P294, P376, P479,
P368, P490). Six among these mutations resulted in a polymorphic site (≥5% allele frequency) (Table 1)
(rs5030625 c.-472delA, rs16260 c.-285C>A, rs3743674 c.48+6C>T, rs2276330 c.1937-13T>C, rs1801552
c.2076T>C and rs33964119 c.2253C>T). Allele and genotype frequencies of the six polymorphic variants
are reported in Table 2 stratified based on the mGC-HER2 expression. A significant association was
found between the rs16260 c.-285 A-allele and HER2-positive mGC (p = 0.0009).
2.3. Association between CDH1 P7-Haplotype and mGC-HER2
We investigated the association between mGC stratified by HER2 expression and the CDH1
haplotype resulting from the six polymorphic sites dispersed over the entire CDH1 gene. A total of
11 different CDH1 haplotypes were identified and their frequencies reported in Table 3. Haplotype
P7 was exclusively present in six mGC-HER2 patients, one of them showing a P7 haplotype in
homozygous cases (Table 4). Linkage disequilibrium (LD) analysis in mGC patients showed a tight
association between rs16260 and rs1801552 (D′ = 1.0000, R2 = 0.1731, χ2 = 16.2759, p = 0.0001), which
was not present in mGC-HER2 (D′ = 0.3555, R2 = 0.0721, χ2 = 1.7311, p = 0.1883). The contemporary
presence of the rs16260-A allele and rs1801552-T-allele, both included in the P7 haplotype, was strictly
associated with mGC-HER2 disease (Table 3).
2.4. Association between the CDH1 P7 Haplotype and the Survival of mGC-HER2 Patients
The relationship between the P7 haplotype and OS was statistically analyzed by using Cox
regression curves. The P5, P6, and P8–P11 haplotypes with less than two cases in mGC-HER2 (Table 3)
were combined in a unique group, and designed them as haplotype “matched”. Figure 3A shows the
OS of all GC cases (independent of the HER2-expression) stratified on haplotype-based approaches.
The haplotype P7 was associated with better outcome (median OS: 1037 days) compared to the other
haplotypes (median OS: 312 to 448 days). Notably, a significantly worse prognosis was observed with
the “matched” haplotype (median OS: 312 days; HR 2.79, 95% CI 1.032–7.548) and the haplotype
P1 (median OS: 419 days; HR 2.54, 95% CI 1.049–6.169). The haplotype P7 was present only in the
mGC-HER2 group where it distinguished patients with better survival compared to those with the
“matched” haplotype and haplotype P1 (HR 4.33, 95% CI 1.033–7.548; HR 2.58, 95% CI 0.328–20.275,
respectively). The “matched” haplotype and haplotype P1 were also associated with poorer prognosis
in mGC group when compared to haplotype P3 (HR 1.412, 95% CI 0.717–2.779). Figure 3B indicates
the OS distribution according to the restricted GC haplotype (i.e., rs16260 and rs1801552), specifically
associated with the mGC-HER2 patients as reported above. Data confirmed the better outcome was
associated with the restricted AT haplotype (median OS: 1037 days, 95% CI 371–1037) which, in our
series, is supported by the observation of a statistically significant difference in the OS compared to the
CC haplotype (median OS: 420 days, 95% CI 312–500; HR 2.374, 95% CI 1.077–5.229).
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Allele/Genotype mGC-HER2 Frequency mGC Frequency p OR (95% CI)
rs5030625
Allele
G 23 0.96 84 0.89
0.33 2.738 (0.33–22.51)A 1 0.04 10 0.11
Genotype
G/G 11 0.92 37 0.79
G/A 1 0.08 10 0.21
A/A 0 0.00 0 0.00
Dominant model GG/AA+AG 11/1 0.92/0.08 37/10 0.79/0.21 0.30 2.973 (0.34–25.86)
Recessive model AA/AG+GG 0/12 0.00/1.00 0/47 0.00/1.00 nv
rs16260
Allele
A 14 0.58 22 0.23 ≤0.001 4.582 (1.79–11.75)
C 10 0.42 72 0.77
Genotype
A/A 4 0.33 3 0.06
A/C 6 0.50 16 0.34
C/C 2 0.17 28 0.60
Recessive model CC/AA+AC 2/10 0.17/0.83 28/19 0.60/0.40 ≤0.01 7.368 (1.45–37.46)
Dominant model AA/AC+CC 4/8 0.33/0.67 3/44 0.06/0.94 0.01 7.333 (1.37–39.18)
rs3743674
Allele
T 22 0.92 83 0.88
0.64 1.457 (0.30–7.07)C 2 0.08 11 0.12
Genotype
T/T 11 0.92 37 0.79
T/C 0 0.00 9 0.19
C/C 1 0.08 1 0.02
Recessive model CC/CT+TT 1/11 0.08/0.92 1/46 0.02/0.98 0.29 4.182 (0.24–72.21)
Dominant model TT/CC+CT 11/1 0.92/0.08 37/10 0.79/0.21 0.30 2.973 (0.34–25.86)
rs2276330
Allele
T 22 0.92 84 0.90
0.74 1.309 (0.27–6.42)C 2 0.08 10 0.11
Genotype
T/T 10 0.83 37 0.79
T/C 2 0.17 10 0.21
C/C 0 0.00 0 0.00
Dominant model TT/CT+CC 10/2 0.83/0.17 37/10 0.79/0.21 0.72 1.351 (0.25–7.19)
Recessive model CC/TT+CT 0/12 0.00/1.00 0/47 0.00/1.00 nv
rs1801552
Allele
C 13 0.54 60 0.64
0.39 0.670 (0.27–1.66)T 11 0.46 34 0.36
C/C 4 0.33 18 0.38
Genotype T/C 5 0.42 24 0.51
T/T 3 0.25 5 0.11
Recessive model TT/CC+CT 3/9 0.25/0.75 5/42 0.11/0.89 0.19 2.800 (0.56–13.90)
Dominant model CC/CT+TT 4/8 0.33/0.67 18/29 0.38/0.62 0.75 1.241 (0.33–4.72)
rs33964119
C 23 0.96 92 0.98 0.58 0.500 (0.04–5.76)
Allele T 1 0.04 2 0.02
C/C 11 0.92 45 0.96
Genotype T/C 1 0.08 2 0.04
T/T 0 0.00 0 0.00
Recessive model CC/CT+TT 11/1 0.92/0.08 45/2 0.96/0.04 0.57 2.045 (0.17–24.66)
Dominant model TT/CC+CT 0/12 0.00/1.00 0/47 0.00/1.00 nv
Abbreviations: HER2, the human epidermal growth factor receptor 2; OR, odds ratio; is the relative measure
of the number of an allele or a genotype in the mGC-HER2 group relative to the comparison of the number of
allele/genotype in the mGC, by considering as the reference the most frequent allele in the mGC-HER2. If the
OR is >1 the allele or genotype having the greatest frequency in the mGC-HER2 is higher than that found in the
mGC group. 95% CI (confidence interval) is the probability that the confidence interval contains the true odds ratio.
Statistically significant p values are reported in bold type.
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Figure 3. Cox regression for overall survival analysis according to the CDH1 haplotypes (A) and the
restricted CDH1 haplotype model (B). (A) Overall survival curves of all patients with mGC (n = 59)
based on their different CDH1 haplotype; (B) Overall survival curves of all patients with mGC (n = 59)
according to coupled rs16260 and rs1801552 polymorphisms. * indicates a significant difference
compared to the P7 haplotype (panel A) and coupled AT polymorphism (panel B).
3. Discussion
Targeted HER2 therapy for mGC works differently due to the heterogeneity of the tumor. Positivity
for the HER2 status (by IHC or by fluorescence in situ hybridization) is a prerequisite for the HER2
targeted therapy, but it is not sufficient to predict the treatment response. In the present study,
we found an association between specific CDH1 polymorphisms with a subset of HER2-positive
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mGC that, in turn, are associated with distinct prognosis behavior (Figure 3A). The association
between the haplotype P7 with the better OS is not due to the presence of additional mutations to
the P7-related CDH1 mutations since, among the HER2 patients carrying haplotype P7, only one
had an additional non-polymorphic CDH1 mutation (i.e., pt P296 with a missense variant); of note,
this patient experienced a poor prognosis (median OS: 164 days). Notably, analysis of LD in mGC
showed a specific association with two polymorphisms (i.e., CDH1 rs16260 and rs1801552) that were
not found in the HER2-positive mGC. In fact, these polymorphisms showed minor allele frequency
(MAF) variants in mGC-HER2: rs16260-A and rs1801552-T alleles. By using these two polymorphisms
(i.e., rs16260/rs1801552) Cox regression analysis was simplified from 11 to four haplotypes and
confirmed the association of haplotype P7, including the rs16260-A and the rs1801552-T alleles, with
the mGC-HER2 subtype with the best OS (Figure 3B). Functionally, the rs16260-A polymorphism
located in the CDH1 promoter region had been associated with an alteration in the CDH1 transcriptional
efficiency. In vitro testing using luciferase reporter gene revealed that the rs16260-A allele decreased
CDH1 transcriptional activity by 68% compared to the C-allele. However, the effect of rs16260-A variant
on CDH1 expression in vivo is still unknown [21] and a significant decrease of CDH1 production in
the peripheral blood cells of mutation carrier patients compared to that produced in the control-cohort
was not found [22]. Additionally, the potential contribution of rs16260-A allele to GC risk remains
controversial [23,24], while the potential prognostic value of this variant in breast cancer and in
metastatic colon cancer did not reach statistical significance [25,26].
With regard to the second polymorphism, the rs1801552-T, a protective association between this
variant in homozygous and non-syndromic cleft lip has been reported [27]. Recent studies indicated
that patients with cleft lip had a higher incidence of tumors than the general population [28,29] and,
moreover, family members with pathogenetic CDH1 mutation showed a higher incidence of cleft
lip/palate than the general population (6–7% versus about 0.1%) [28,30,31]. In addition, a previous
study by using rs1801552 heterozygous individuals with GC compared to controls demonstrated a
CDH1 allelic expression imbalance in hereditary GC family members with an increase of the ratio of the
CDH1 RNA rs1801552 T-allele/C-allele that was not found in cancer-free individuals [32]. Results had
suggested, for some unknown reason, the reduction of CDH1 C-allele-specific expression in patients at
risk for GC.
In our series we found relationship between the CDH1 variants and patient survival in the setting
of mGC, particularly in the HER2-positive disease. Previous studies supported a functional interaction
between the HER2 and the E-cad. Briefly, the β-catenin binds the C-terminal cytoplasmic domain
of the E-cad and this complex via the α-catenin connects and regulates the E-cad interaction with
the actin cytoskeleton, while association of the p120-catenin with the juxtamembrane domain of
the E-cad stabilizes the E-cad expression at the cell surface (Figure 1). Activation of the HER2 by
inducing the phosphorylation of the β-catenin directs the dissociation of β-catenin from the E-cad
complex, thus leading to a decrease of the E-cad-mediated cell adhesion facilitating tumor cells
invasion and migration. In addition, the dissociation of the β-catenin from the E-cad complex causes
the translocation of the β-catenin to the nucleus which drives the transcription of various target genes
associated with cell survival, proliferation and metastasis. E-cad can also be solubilized (sE-cad)
by membrane E-cad cleavage and be released into the extracellular environment [33] (Figure 1).
The production of sE-cad not only undermines adherence junctions, but, by its diffusion into the
micro environment, it regulates numerous signals implicated in tumor progression, including a key
role in HER2 interaction/activation and phosphorylation of the β-catenin [18]. Furthermore, HER2
activation was known to increase metalloproteinase activity and, thus, it further leads to high increased
production of the sE-cad by the cleavage of the E-cad. Through the specific cleavage of its cytoplasmic
tail domain into the p95HER2 fragment, it maintains the phosphokinase activity of the HER2 favoring
the dissociation of the β-catenin/E-cad complex that, overall, both promote GC progression and
metastasis (Figure 1).
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Overall, these findings support a possible functional role of the E-cad in response to the
anti-HER2 treatment in mGC-HER2 subtype. However, the role of the CDH1 mutations in this context
requires elucidation through further studies. Interestingly, in human transfected breast epithelial cell
lines over-expressing the HER2 receptor resulted in inhibition of E-cad expression [34]. Lapatinib
resistance in HER2-positive breast cancer cells was also associated with a EMT and the EMT-related
down-regulation of E-cad [35]. Moreover, treatment with the HER2-specific tyrosine kinase inhibitors
(AG285 and HER2 siRNA) was found to produce a down-regulation of the E-cad in ovarian cancer
cells [36]. Overall, these studies demonstrate the important connection between HER2 and E-cad in
human cancers.
The determination of the HER2 status in patients with advanced GC is crucial in order to select
patients who may benefit from the new anti-HER2 agents; the results of this study, if confirmed in a
prospective larger series, could improve the understanding of molecular interactions between HER2
and E-cad and define their role as predictive factors for targeted therapy.
4. Materials and Methods
4.1. Study Population
For the present study, between 2011 and 2017 we enrolled 59 consecutive patients with
confirmatory of metastatic GC. Forty-four were males and 15 were females, and the mean age
at diagnosis was 60 years (range, 40–76 years). Patients were grouped according to confirmed
HER2-status at diagnosis. Patients agreed to participate to the study and provided informed consent
(CRO-2011-2012 Code EUDRACT: 2011-001720-37).
4.2. Genotyping Analysis
Genomic DNA was extracted from each subject’s peripheral blood lymphocytes using an EZ1
DNA blood kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions.
Screening for mutations of CDH1 exons and neighboring intronic sequences was performed
using the polymerase chain reaction (PCR) with previously-described primers and the reaction
conditions [37]. In short, 15 individual PCR reactions were performed on each sample for a full
mutational screen of all 15 exons and splice junctions of the CDH1 gene. Amplified PCR products were
sequenced on an Applied Biosystems 3130 automated sequencer (Applied Biosystems, Foster City, CA,
USA) using the Big Dye v3.1 Terminator Cycle Sequencing Kit (Life Technologies, Monza, Italy) and
sequence data were aligned and analyzed using CodonCode Aligner software.
The promoter, 5′UTR and the exon 1 polymorphisms were genotyped by PCR method.
A 581-bp fragment containing this region was amplified with the following primers: the
forward CDH1FPRO 5′-TCCCAGGTCTTAGTGAGCCA-3′ and the reverse CDH1Exon1REV
5′-TGACGACGGGAGAGGAAG-3′. The amplification was performed in a programmable thermal
cycler as follows: touchdown (hold (94 ◦C 4 min) eight cycles (94 ◦C 45 s; 58 ◦C 50 s; 72 ◦C 1 min;
reducing the annealing temperature by 1 ◦C each cycle)), three cycles (94 ◦C 45 s; 53 ◦C 50 s; 72 ◦C
1 min), and a final cycle of 72 ◦C for 10 min. After amplification the PCR product was sequenced using
the primer CDH1FPRO.
We screened each of the above samples for the c.-472delA CDH1 polymorphism using a new
PCR method in place of current genotyping analysis by the PCR-RFLP method. DNA fragments
containing the promoter region of interest were amplified with two distinct PCR reaction using the
following primers: 1◦ reaction (forward, CDH1G347proFor 5′-CAGCTTGGGTGAAAGAGTGAGC-3′;
reverse ECad347Rev 5′-GGCCACAGCCAATCAGCA-3′); 2◦ reaction (forward, CDH1GA347proFor
5′-CAGCTTGGGTGAAAGAGTGAGA-3′; reverse ECad347Rev 5′-GGCCACAGCCAATCAGCA-3′).
The PCR conditions were set as follows: initial denaturation at 94 ◦C for 4 min; 10 cycles at 94 ◦C
for 30 s, 65 ◦C for 1 min, 20 cycles at 94 ◦C for 30 s, 62 ◦C for 30 s and 72 ◦C for 1 min; and a final
extension at 72 ◦C for 8 min, in a Veriti Thermal Cycler (Life Technologies). PCR products were
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analyzed on a 2.5% agarose gel stained with ethidium bromide and photographed under UV light.
G/G homozygous cases were represented by DNA bands in the 1◦ reaction, GA/GA homozygous
cases were represented by DNA bands in the 2◦ reaction. G/GA heterozygous cases display a
combination of both bands. To validate this new PCR method the promoter region of same samples
was amplified using the following primers: forward, 5′-GCCCCGACTTGTCTCTCTAC-3′; reverse,
5′-GGCCACAGCCAATCAGCA-3′ and PCR products were sequenced.
4.3. Immunohistochemistry
A formalin-fixed, paraffin-embedded tumor block was cut into 4-μm-thick sections for H and
E and immunostaining. Immunohistochemistry was performed by using the rabbit monoclonal
antibodies against HER 2 (clone 4B5, Ventana Medical System, Tucson, AZ, USA).
4.4. Statistical Analysis
The frequencies of allele and genotype were compared between mGC-HER2 and mGC patients
by means of chi-squared test (VassarStats, http://faculty.vassar.edu/lowry/VassarStats.html).
The haplotype frequencies were analyzed with the SNPator [38] and Arlequin software [39].
Survival analysis was performed at the time of the first treatment by using Cox regression analysis.
5. Conclusions
In conclusion, the evaluation of a restricted CDH1 haplotype in mGC could help to select the
patients that gain greater benefit from the anti-HER2 treatments. Furthermore, since a high level of the
sE-cadherin may modulate sensitivity to RTK inhibitors, the evaluation of its serum concentration in
different phases of treatment could have a role in monitoring the therapeutic response overtime.
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Abstract: Elevated plasma fibrinogen levels and tumor progression in patients with gastric cancer
(GC) have been largely reported. However, distinct fibrinogen chains and domains have different
effects on coagulation, inflammation, and angiogenesis. The aim of this study was to characterize
fibrinogen β chain (FGB) in GC tissues. Retrospectively we analyzed the data of matched pairs
of normal (N) and malignant tissues (T) of 28 consecutive patients with GC at diagnosis by
combining one- and two-dimensional electrophoresis (1DE and 2DE) with immunoblotting and mass
spectrometry together with two-dimensional difference in gel electrophoresis (2D-DIGE). 1DE showed
bands of the intact FGB at 50 kDa and the cleaved forms containing the fragment D at ~37–40 kDa,
which corresponded to 19 spots in 2DE. In particular, spot 402 at ~50 kDa and spots 526 and 548 at
~37 kDa were of interest by showing an increased expression in tumor tissues. A higher content of
spot 402 was associated with stomach antrum, while spots 526 and 548 amounts correlated with
corpus and high platelet count (>208 × 109/L). The quantification of FGB and cleaved products may
help to further characterize the interconnections between GC and platelet/coagulation pathways.
Keywords: DIGE; comparative proteomics; gastric cancer; fibrinogen β chain; FGB; coagulation;
platelets; biomarker
1. Introduction
Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer
death in the world [1]. Therefore, there is a great interest in deciphering the molecular pathways
associated with its progression and prognosis. Environment and lifestyles are general risk factors
for GC, but interaction of diet with multiple genetic and epigenetic alterations also occur during GC
development [2–5]. Proteomics provided consistent information in revealing proteome alterations
associated with GC, dissected some of the mechanisms underlying gastric cancerogenesis, and enabled
the identification of several diagnostic, prognostic, and predictive biomarkers [6–9].
Hemostasis systemic perturbations are well known to occur in GC [10]. In particular,
venous thromboembolism (VTE) has been implicated in GC progression and metastasis [11–14].
Clinically relevant VTE in GC patients shows an incidence of >5% at 1 year post diagnosis and 12–17%
at 2 years, increasing to 24.4% in metastatic advanced GC [15–17].
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Most recently, by using a two-dimensional difference in gel electrophoresis (2D-DIGE)-based
comparative proteomic approach on human tissues we identified the fragment D of fibrinogen ß chain
(FGB) as marker of preoperative response to neoadjuvant chemo-radiotherapy in rectal cancer [18].
FGB protein is linked to α and γ chains by numerous disulfide bonds to form fibrinogen, a key
molecular player of both coagulation and inflammation [10,19,20]. The mean pre-treatment plasma
fibrinogen level has been correlated with a hyper-coagulable status, tumor progression and prognosis
of several types of malignancies (ovarian [21], biliary [22], esophageal [23], pancreatic [24]), including
GC [10–14].
At present, the complex molecular interplay between fibrinogen and cancer has not been fully
analyzed locally within the tumor tissue.
In the present study, we investigated differential FGB protein expression levels in biopsies of
non-metastatic GC patients, to assess interconnections between GC and platelet/coagulation pathways,
and to propose FGB as molecular marker for GC diagnosis. Correlations among the means of platelet
(PLT) count, white blood cell count (WBC), neutrophil-to-lymphocyte ratio (NLR) and FGB cleaved
products were also analyzed.
2. Results
2.1. Patients and Disease Characteristics
A total of 28 consecutive patients with GC were included in our analysis. Characteristics of both
patients and the disease are reported in Tables 1 and A1. Patients’ tumors were mostly characterized
by corpus location (65%), diffuse histotype (65%), and T3–T4 pathological stages (68%).
Table 1. Clinicopathological characteristics of the 28 patients affected by gastric cancer included in the
study (n.s., statistically not significant for p > 0.05).















uT, endoscopic ultrasound evaluation of tumor depth: uT1, invasion of lamina propria, muscolaris mucosae or
submucosa; uT2, invasion of muscolaris propria; uT3, invasion of subserosa; uT4, penetration of serosa or invasion
of adjacent structures.
The means of plasma routine blood count parameters at diagnosis are reported in Table 2 (detailed
information in Table A2).
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Table 2. Blood count parameters of gastric cancer (GC)-affected patients (WBC, white blood cells; ANC,
absolute neutrophil count; ALC, absolute lymphocyte count; N/R, ANC/ALC ratio; PLT, platelet
count; PT-INR, prothrombin time–international normalized ratio; FIB, fibrinogen level; APTT, activated
partial thromboplastin time). Values at diagnosis refer to 22 patients.
Parameter Mean (±SD)
WBC (×109/L) 6.33 ± 1.96
ANC(×109/L) 3.93 ± 1.54
ALC (×109/L) 1.83 ± 0.74
N/R 2.54 ± 1.71
PLT (×109/L) 258 ± 114.90
PT-INR 1.00 ± 0.05
FIB g/L 2.97 ± 46
APTTs 29 ± 3
2.2. One-Dimension Immunoblotting
The quantitative proteomics workflow adopted is illustrated in Figure A1.
In T versus N tissues of patients belonging to both groups of tumor staging (Group I: T1 and T2;
Group II: T3 and T4), a higher content of a band at ~50 kDa, corresponding to the weight of the entire
FGB (UniProtKB entry: P02675; Figure A2), occurred (Figure 1b). Two additional bands of ~37 and
~40 kDa were detected in T tissues, with a higher content in Group II patients especially for the 37 kDa
band (Figure 1b). One-dimensional electrophoresis revealed that the amount of total protein loading
among samples was homogeneous (Figure 1a).
Figure 1. One-dimensional electrophoresis (1DE) and immunoblotting of fibrinogen ß chain (FGB)
in normal (N) versus tumor-affected (T) gastric tissues belonging to patients divided according to
their tumor stage (Group I: T1–T2; Group II: T3–T4). (a) Image of the 1DE stain-free gel fluorescence
acquired upon excitation with the Chemidoc system before its transfer to nitrocellulose membrane.
Numbers refer to the relative quantity of the band calculated with the Image LabTM software (R,
reference band for which quantity is 1); (b) Chemiluminescence signals of proteins cross-reacting with
the anti-FGB antibody. Circles and asterisks evidence a band at ~40 and 37 kDa, respectively, while
the arrow shows a band at <50 kDa; (c) From the blue-stained 1DE gel in (a), an area of ~37–60 kDa
was excised, and gel portions numbered 1 to 8 submitted to analysis by mass spectrometry for protein
identification. Asterisks confirmed the presence of FGB product(s) in the gel portions.
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2.3. Validation of Fibrinogen β Chain (FGB) by Mass Spectrometry
The presence of FGB in the 1DE portions of the ~37–60 kDa area (Figure 1c) was validated by
mass spectrometry. FGB peptides were identified at ~50 kDa (Figure 1c, gel portions nr 3 and 4),
~40 kDa (Figure 1c, gel portions nr 6), and ~37 kDa (Figure 1c, gel portions nr 7 and 8) (Table A3).
The FGB identified at ~50 kDa was the entire form after release of fibrinopeptide B by thrombin in
44–45, and the identified peptides covered from 45 to 491 (Table A3, Figure A2). The FGB identified at
~37 kDa corresponded to the fragment D, after plasmin cleavage of FGB in 163–164, and the identified
peptides covered from 164 to 491 (Table A3). Fragment D of FGB was also identified in the band at
~40 kDa, and its slightly different molecular weight (MW) may be related to possible post-translational
modifications such as glycosylation, as evidenced after interrogation with iPTMnet bioinformatic
resource (Figure A2).
2.4. Cross-Reaction of FGB on Two-Dimensional Electrophoresis (2DE) Maps of Gastric Tissue
An immunoblotting performed to detect FGB on 2DE proteome map of gastric tissues is illustrated
in Figure 2. The matching between the spots cross-reacting with anti-FGB antibody on the nitrocellulose
membrane and the protein profiles of the 2DE gel, from which the membrane was obtained, was
digitally performed. A total of 19 matched spots were individuated, and their differential patterns
analyzed in a 2D-DIGE project comparing all the 25 gels (Figure 2c; Table A1).
Figure 2. Two-Dimensional Electrophoresis (2DE) and immunoblotting of FGB from proteins pooled
from normal and tumor-affected gastric tissues. (a) After labelling with cyanines, proteins were
resolved by isoelectrofocusing (IEF) over the pI 3–10, followed by 8–16% gradient Sodium Dodecyl
Sulfate—PolyAcrylamide Gel Electrophoresis (SDS-PAGE). The gel image was acquired and added to
a Decyder project before its transfer to a nitrocellulose membrane. The frame corresponds to the gel
area shown in (b); (b) Visualization of spots cross-reacting with the anti-FGB antibody ([1F9], GeneTex)
in the gel area corresponding to the rectangle in (a). The 2DE protein map showed FGB cross-reacting
spots in the same molecular weights (MWs) as those evidenced by immunoblotting on 1DE gel, here
visualized on the left (for more details, see Figure 1b). The frames corresponds to the gel area containing
the FGB cross-reacting spots shown in (c), on which our image analysis focussed; (c) FGB cross-reactive
spots were identified, numbered, and analyzed using the Decyder software for quantitative analysis
and comparison, as described in Methods section.
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Among the 19 spots cross-reacting with the FGB antibody, a part of them was present in the MW
region of ~50 kDa and another one in the MW region of ~37–40 kDa (Figure 2b).
In particular, a total of 10 cross-reacting spots (numbered as spots 392, 393, 396, 397, 398, 100,
402, 403, 404 and 405) were found in the MW of 50 kDa as multiple pI isoforms, coming from
different phosphorylation status, as evidenced after interrogation with iPTMnet bioinformatic resource
(Figure A2). The interrogation of P02675 sequence (UniProtKB) with PhosphoSite Plus evidenced
a total of 43 possible different pI values depending on 43 different phoshorylated residues (results
in: https://www.phosphosite.org/isoelectricCalcAction.action?id=20774&residues=43&x=41&y=3;
accessed on 18 December 2017). The MW/pI position of spots/isoforms corresponding to the entire
FGB form in our 2D map fitted with others’ published findings as well as with the calculated MW/pI
52.314/7.15. While the position of the FGB cleaved spots/isoforms fitted with our previous findings in
rectal tissues [18], as well as with the calculated MW/pI 37.649/5.85.
2.5. Differential Expression of FGB in Gastric Cancer Tissues
Among the 19 spots cross-reacting with the FGB antibody, a total of 13 spots (numbered as spot
383, 393, 396–398, 402–405, 501, 526 and 548) were present in all the gels and, thus, further analyzed.
The results of variation in their abundance between normal and tumor tissues are reported in
Table 3, where significant changes at p < 0.05 are evidenced in bold. Six among these spots (393, 402,
404, 405, 526 and 548) were differentially expressed between N and T tissue in both Group I and
Group II.
Table 3. Comparison of 13 fibrinogen β chain (FGB) spot abundance between tumor-affected (T) and
not-affected (N) gastric tissues of patients grouped into “Group I” or “Group II” according to their uT



















−1.3 −1.2 −1.2 −1.3 1.5 1.2 3.2 1.1 2.8 1.8 1.22 1.82 1.75
Spot variation in abundance is expressed as average spot volume ratio; values >1 refer to an increase, while values
<−1 refer to a decrease. Statistically significant average spot volume ratios <1.5 or >1.5 (One-way Anova; p < 0.05)
are indicated in bold.
In particular, three spots at ~50 kDa (nr. 402, 404 and 405) and two spots at ~37 kDa (nr. 526 and
548) significantly increased in content in T versus N tissues, as well as, if not statistically significantly,
in T of Group II versus T of Group I (Figure 3a,c,e). These spots were, thus, globally associated with
tumor and, particularly, in tumor at advanced stages (i.e., T3–T4).
Regarding tumor anatomical sites, spot 402, similarly to spots 403, 404, 405, 393 and 396, showed a
significantly higher content in T of antrum (Figure 3b), while spots 526 and 548 showed a significantly
higher content in T of corpus (Figure 3d,f).
Regarding tumor histological classification, only the spot 501 showed an association with the
diffuse type (Figure 3g).
There was no significant difference in FGB abundance depending on either age (except for spot
402) or sex gender (except for spot 501), in any of the spots analyzed (Table 4).
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Figure 3. Graphical visualization of abundance distribution of spots 402, 526, 548 and 501 in tumor
non-affected (N) and tumor-affected (T) gastric tissue biopsies, according to their tumor stage (Group
I: T1–T2; Group II: T3–T4), anatomical site (corpus, antrum) or histological type (intestinal, diffuse).
(a) Abundance of Spot 402, similarly to spots 404, 405, 526 (c) and 548 (d), increased in T versus N tissues
both in Group I and II, and more even in T-tissue of Group II. (b) Spot 402 abundance, similarly to spots
403, 404, 405, 393 and 396 was particularly higher in T than N in the antrum location, while spots 526
and 548, showed the highest abundance associated with corpus location. (e) Spot 548, similarly to spots
402 (a) and 526 (c), increased in content in T versus N tissues both in Group I and II, its abundance
being higher in T-tissues of Group II. (f) Spot 548 content was significantly higher in T versus N tissues
in corpus. (g) Spot 501 content was higher in diffuse than intestinal histological type. In each graph,
a single circle represents the Log standardized abundance of the spot calculated for a single gel/patient.
Asterisks indicate a statistically significant difference at paired t-test p < 0.05 or between T tissues of
different groups (b,g) at Student’s t-test p < 0.05. Dotted lines combine N and T samples belonging to
the same patient and co-migrated within the same gel, while arrows indicate a detail of the Decyder
tridimensional 3D view of the graphically visualized spots.
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Table 4. Intergroup comparison of FGB spots abundance in affected tumor-samples.
Groups
Spots
383 397 398 400 393 396 402 403 404 405 501 526 548
•
“Tumor staging”
Group II (nr = 19) versus
Group I (nr = 9)
−1.3 1.0 −1.2 −1.3 1.4 1.2 3.2 1.1 2.8 1.8 1.2 1.8 1.8
•
“Anatomical subsites”
Antrum (nr = 8) versus.
corpus (nr = 18)
−1.0 −1.9 −2.0 1.4 1.7 1.7 3.4 1.9 2.8 2.3 1.9 −1.5 −1.7
•
“Histological subtypes”
Diffuse (nr = 18) versus
intestinal (nr = 7)
−1.1 1.0 −1.3 −1.3 −1.3 −1.1 −2.1 1.0 −2 −1.7 3.0 1.3 −1.1
•
“Age”
>50 years (nr = 19) versus
<50 years (nr = 7)
1.1 1.4 1.2 1.1 1.1 −1.1 3.6 −1.0 1.8 2.0 −1.1 1.1 1.2
•
“Sex”
Female (nr = 15) versus
male (nr = 13)
1.3 2.0 1.8 1.3 −1.0 1.0 −1.0 −1.1 1.2 1.1 −2 −1.3 1.0
Spot variation in abundance is expressed as average spot volume ratio. Statistically significant spot volume ratio
<1.5 or >1.5 (Student’s t-test; p < 0.05) were indicated in bold. Values >1.5 refer to an increase, while values <−1.5
refer to a decrease in the average spot volume ratio.
2.6. Correlation of Blood Count Parameters and FGB Abundance
We first analyzed the differences in blood cell count and coagulation markers with each of the 13
spots of interest. Among these, an inverse correlation between the activated partial thromboplastin
time (APTT-sec) and the spot 548 log abundance was found (p = 0.05, Figure 4). No significant
difference was found between the other blood coagulation markers and FGB spot abundance.
We further analyzed the association between changes in blood cell count and FGB spot abundance.
By focusing on the only tumor stage Group II, there was a significant correlation between PLT count
and spot 526 and 548 log abundances (p = 0.0006 and p = 0.021, Figure 5a,b, respectively).
In a cohort of healthy blood donors (24 females and 22 males), the optimum cut-off value for
PLT count was fixed at 280 × 109/L, estimating the sample mean (208 × 109/L) and two standard
deviations (±70 × 109/L).
Figure 4. Graphical visualization of the correlation between the activated partial thromboplastin time
(APTT) and the log abundance of spot 548 in normal (N, ) together with malignant (T, ) tissues of
patients belonging to T stage Group II (T3–T4). The broken line indicates the low value considered to
be normal. Regression line values were: intercept 28.3 (SE 0.46) and slope −0.55 (SE 0.26).
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Figure 5. Graphical visualization of the correlation between platelet counts (PLT) and the log
abundance of spot 526 in malignant (T, ¡) tissues (a), and spots 548 in normal (N, ) together with
malignant (T, ) tissues of patients (b) belonging to Group II (T3–T4). The optimum PLT cut-off of
280 × 109/L(mean ± 70 × 109/L), calculated in the cohort of healthy individuals, is indicated with a
broken line. Regression line values were: intercept 260.5 (SE 20.6) and slope 45.0 (SE 12.35) (a); intercept
258.4 (SE 15.45) and slope 20.9 (SE 8.85) (b).
In GC-affected patients, we individuated 5 patients with PLT count >280 × 109/L (patients nr. 3,
6, 9, 12, 18 and 20; Table A2). We excluded patient nr. 11 (PLT count = 330 × 109/L) because it was not
possible to separate her low abundant T protein extracts. For both spots, the highest PLT count was
found in patients nr. 3, 12 and 6, who showed the highest spot abundance (Figure 5a,b,e).
A positive trend between the other blood parameters and FGB spot abundance was found but
without statistical significance.
3. Discussion
The present study evidences the differential expression of FGB and its cleaved forms in the
biopsies of not-metastatic GC patients. Higher protein contents of the entire form of FGB (~50 kDa)
and isoforms containing plasmin-cleavage product “fragment D” of FGB (~37–40 kDa) were found in
tumoral gastric tissues compared with non tumoral adjacent tissues, at both early (Group I: T1–T2) and
advanced tumor depth (Group II: T3–T4). Even not statistically significant, these increases in content
were more evident in patients with advanced GC (Group II: T3–T4) compared with patients at early
pathological stages (Group I: T1–T2).
Together with α and β polypeptides, FGB is part of fibrinogen, a disulfide cross-linked homodimer
of 340 kDa composed by two outer D domains connected to a central E one. Fibrinogen is known as a
principal factor in the maintenance of hemostasis through its conversion from a soluble, plasma protein
to an insoluble fibrin gel [18]. During fibrinolysis, both soluble and cross-linked fibrin is enzymatically
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degraded into fragments, among which the D-dimers typically contains two D domains and one E
domain of the original FGB molecule [10].
In malignancies, the presence of fibrin(ogen) is known to affect the progression of tumor cell
growth and their metastasis. Globally, the assessment of fibrinogen content and fibrinolysis products in
plasma is known to help in cancer diagnosis but also to evaluate both therapeutic effects and prognosis.
In the particular case of GC, the preoperative plasma content of fibrinogen is clinically relevant as
predictor of lymphatic and hematogenous metastasis, tumor progression, as well as tumor stage and
survival [10].
Our data evidencing an up-regulation of both FGB and its cleaved fragments in GC tumors
versus the adjacent non-tumoral tissues agree with the 2D results from Wang et al. [25] and the
label-free quantitative proteomics findings of Dai et al. [26] in six pairs of primary and advanced poorly
differentiated gastric adenocarcinoma tissues. On a larger cohort of patients, our study succeeded in
confirming this increase in content and strengthening the hypothesis of an association between the
accumulation of both FGB and its cleaved products and gastric malignancy directly in tumor tissues.
Our work allowed to evidence a differential accumulation of FGB in gastric tissues of GC
patients depending on the anatomical site affected by cancer: the entire FGB was found to be more
abundant in the antrum of the stomach, while its cleaved forms showed a higher content in the corpus.
This different content of FGB in different stomach regions may reflect different roles played by FGB in
tumorigenesis depending on gastric microenvironments and/or their pathogenesis [27]. For instance,
Helicobacter pylori infection, one of the most important risk factor of GC, is associated with GC of
antrum and intestinal type, and it also causes inflammation and gastritis [28], thus it could have an
impact on the production of fibrinogen which is strictly related to the inflammatory response(s).
In the majority of tumor types, abundant fibrinogen, further assembled into fibrin, within
the stroma has been proposed to originate from plasma exudation deposition [29]. In solid tumor
tissues, the so-called microvascular “enhanced permeability” leads to extravasation and tumoritropic
accumulation within the cancer of macromolecules such as plasma proteins, including all those
necessary for clot formation (e.g., fibrinogen) [10]. At the same time, an extra-hepatic synthesis of
fibrinogen is also known to occur, even if there is still a paucity of information regarding both its
structure and function [30–32]. The extra-hepatic fibrinogen synthesis may be important for tissue
repair at local sites of injury, and/or may have a pathogenetic role, but it is not known whether
extra-hepatic synthesis of FGB significantly contributes to the normal plasma fibrinogen concentration.
The deposition of fibrin/ogen into the extracellular matrix may form a provisional matrix on which new
blood vessels extend, and serve as a scaffold to support binding of tumor growth factors influencing
tumor growth, malignant transformation, and migration [33–37].
Interestingly, a study aimed at defining the role of coagulation proteins in tumor progression
by immunohistochemistry highly localized fibrin II and fragment D of FGB in the stroma at tumor
periphery near the host-tumor interface, and co-localized hemostatic proteins with the “vascular
endothelial growth factor” (VEGF), activated by the “tissue factor” (TF) produced by tumor cells [38].
In addition, factors involved in the regulation of fibrin activation/degradation expressed on
cancer cell surfaces may also play a role in tumor invasion, proliferation, and metastasis [39,40]. It may
thus be tempting in the future to localize FGB and its D fragment in situ in gastric tissues of our cohort
of patients, to better understand a possible role played by FGB in cancer progression.
Globally, hyperfibrinogenemia before treatment is increasingly recognized as an important
risk factor influencing the survival of patients with solid tumors [41]. In the particular case of
GC, hyperfibrinogenemia has been analyzed as prognostic factor of lymphatic and hematogenous
metastasis, tumor progression, adjacent organ involvement and survival [42–50]. In our cohort of
patients, there was a positive trend between fibrinogen level in plasma and FGB spot abundance in the
tissues, but this correlation did not reach a statistical significance. Our data are thus insufficient to
provide a clear information about a correlation between plasma fibrinogen level and FGB spot content
in situ in the tumor microenvironment.
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Nonetheless, we found a negative correlation between spot 548 and APTT, and a positive
correlation between spots 526 and 548 and PLT count, with a better correlation between PLTs and spot
526 in the only malignant T tissues. These associations were particularly evident in T tissues of patients
with the highest tumor depth (Group II), this suggesting that by increasing tumor depth the content of
peptides included in spots 526 and 548 also increased. Normal value of APTT ranged between 27 to 40 s,
and measures the time necessary to generate fibrin from initiation of the intrinsic coagulation pathway,
thus short APTT is indicative of an increased risk of hypercoagulability. Several studies indicated
that hypercoagulability affect tumor cell adhesion and migration across endothelial junctions [51].
Thus, in our series, patients with lower APTT and higher spot 548 values could be considered at higher
risk for tumor growth and metastatic dissemination. Of interest, it has been reported that plasma
D-dimer, the smallest product resulting from fibrin degradation by enzymes including plasmin, can
also interfere with cellular signaling systems, cell proliferation and angiogenesis, but can also affect
PLTs and extra-cellular matrix [52–55]. It has been demonstrated that activation of the coagulation
cascade occurring in a cancer such as GC may arise from the direct capacity of tumor cells to express
and release pro-coagulant factors, including TF, and to activate the host hemostatic system [56].
In our series, patients showing the highest content of the two degraded forms of FGB containing
the fragment D have a significant correlation with PLT count >280 × 109/L suggesting a possible
role between the increase in content of cleaved FGB in T tissues and PLT count at plasma level.
Platelet activation and aggregation, in addition to accelerating coagulation, provide a bolus of secreted
proteins, including fibrinogen, and granule contents to the immediate area, all of which help to initiate
and accelerate the inflammatory response(s) by the host. It is interesting to note that soluble fibrin
monomers have been proposed to enhance PLT adhesion to circulating tumor cells and, thus, facilitate
metastatic spread [36,57]. In particular, activated PLTs, similarly to tumor cells, have receptors specific
for binding with fibrinogen and fibrin fibers (GPIIb/IIIa). It cannot be excluded that these interactions
may also occur in our tissues.
Results of the present study added new information regarding the association of blood parameters
and hypercoagulability in GC with the FGB and its cleaved products, which we found differentially
expressed in situ in our samples. The FGB forms we found may thus represent new candidate molecules
for GC diagnosis, which could be further exploited in terms of possible interconnections between
cancer and platelet/coagulation pathways. Recent proposals of many coagulation assays for prognostic
value strengthen the importance of coagulation-related investigations in cancer clinics [42,43,58,59].
4. Materials and Methods
4.1. Patients and Tissues
A total of 28 tumor (T) and corresponding adjacent healthy normal (N) gastric tissue biopsies were
collected at diagnosis from 28 patients enrolled at the CRO-IRCCS, National Cancer Institute of Aviano
(PN), Italy CRO National Cancer institute (Table 1), following the approval by the Institutional Review
Board (IRB) of CRO-IRCCS, National Cancer Institute of Aviano (PN), Italy (IRB number CRO-2014-03,
3 March 2014) and written informed consent of all the participating patients. These paired biopsies
were stored at −80 ◦C until analyses. Clinical and laboratory evaluations of all patients are reported in
Tables 1 and 2, Tables A1 and A2.
Patients were enrolled between April 2014 and December 2016 and stratified dependently on tumor
depth according to the stomach TNM clinical classification [60], evaluated by ultrasound endoscopy.
4.2. Blood Sample Analysis
Venous blood samples in citrated tubes (0.109 M) were collected at diagnosis before the initiation
of the treatments. Test performed were: prothrom-bin time–international normalized ratio (PT-INR),
activated partial thromboplastin time (APTT), fibrinogen by Clauss clotting method (Siemens-Dade
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Behring Healthcare Diagnostics, Marburg, Germany). White blood cells (WBC) and platelet count
were measured in EDTA blood samples with a ADVIA2120 Analyser (Siemens).
We considered the following blood biomarker data: white blood cells (WBC); absolute neutrophil
count (ANC); absolute lymphocyte count (ALC); ANC/ALC ratio (N/R); platelet count (PLT);
prothrombin time (PT-INR); fibrinogen (FIB); activated partial thromboplastin time (APTT).
For 6 patients these analyses were not performed because plasma was not available.
4.3. Sample Preparation and Grouping
Soluble proteins were extracted from the frozen biopsies as previously reported [61]. Briefly, frozen
tissue samples were lysed in 200 μL cold lysis buffer (4% (w/v) CHAPS, 7 M Urea, 2 M Thiourea, 30 mM
Tris, pH 8.5) with a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA), homogenated
with a sample grinding kit (GE Healthcare, Uppsala, Sweden) and prepared for two-dimensional
electrophoresis (2DE) with 2D Clean-Up Kit (GE Healthcare, Uppsala, Sweden). Protein concentrations
were determined with the commercial Bradford reagent (Bio-Rad, Milan, Italy).
Samples were grouped into two groups: “Group I” and “Group II”, including patients with
primary tumors classified as either “T1 or T2”, or “T3 or T4”, respectively. Other comparison groupings
were based on: (i) anatomical subsite (corpus or antrum); (ii) histological type (diffuse or intestinal);
(iii) age (< or >50 years); and (iv) sex (male or female).
4.4. One-Dimensional Electrophoresis (1DE) and Immunoblotting Anti-Fibrinogen β Chain
The presence of FGB and its possible differential abundance were first investigated by
immunoblotting analyses. Within each T group (I and II), proteins extracted from either GC or C tissues
were pooled (3 patients per pool). Ten μg of proteins per pool were fractionated on 12% Criterion TGX
Stain-Free gels and, after gel image acquisition upon fluorescence excitation with the Chemidoc system
(Bio-Rad, Milan, Italy), electrotransferred onto nitrocellulose membranes. Membranes were incubated
with the monoclonal antibody anti-FGB [1F9] (1:500; GeneTex, Irvine, CA, USA). Antibody-bound
proteins were detected by enhanced chemiluminescence using the Chemidoc system after incubation
with ECL HRP-conjugated secondary antibodies (1:10,000 dilution, Santa-Cruz, CA, USA) and reaction
with ClarityTM Western ECL Substrate (Bio-Rad, Milan, Italy). Because of the lack of universal
house-keeping genes to be used as sample loading control in GC [62], image of the stain-free gel
acquired before its transfer was used as control for equal protein loading among samples.
4.5. Validation of the 1DE Bands Cross-Reacting with Fibrinogen β Chain
Pooled protein T extracts (10 μg per lane) were separated by 1DE, and images of blue-stained gel
were acquired with the Chemidoc system. A total of 10 gel portions in the MW range between 75 and
37 kDa containing proteins cross-reacting with the FGB antibody (Figure 2, rectangle and numbered
lanes) were excised, reduced by incubation with 10 mM dithiothreitol (1 h at 57 ◦C), and alkylated with
55 mM iodoacetamide (45 min at room temperature). Samples were further washed with NH4HCO3,
dehydrated, trypsin digested and processed for LC-MS/MS analyses using a LTQ XL-Orbitrap ETD
equipped with a HPLC NanoEasy-PROXEON (Thermo Fisher Scientific, Waltham, MA, USA). Database
searches were done with the MASCOT search engine version 2.3 against SwissProt and NCBInr (Matrix
Science, London, UK), and the presence of FGB was searched among first 15 report hits.
4.6. Two-Dimensional Difference in Gel Electrophoresis (2D-DIGE) and Immunoblotting Anti-Fibrinogen
β Chain
The entire project consisted of 25 gels detailed in Table A1, each gel containing two protein extracts
(25 μg per extract) from both T and N tissues of the same patient, respectively, each labeled with Cy3
or Cy5 with the internal standard (Cy2) representative of the all samples analyzed. In two gels, when
protein tissue concentration was not sufficient (gels 5 and 10, Table A1), only proteins from one type of
biopsy were analyzed per patient, and protein extracts from two different patients were comigrated.
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Cyanine dyes were used for protein labeling (CyDye DIGE Fluor minimal dyes; GE Healthcare,
Uppsala, Sweden). Proteins were separated by isoelectrofocusing (IEF) on 3–10 pH gradient dry strips
(IPG, GE Healthcare, Uppsala, Sweden) and then on 8–16% Criterion TGX precast midi protein gels
(Bio-Rad, Milan, Italy). After 2DE and image gel acquisition (Amersham Typhoon; GE Healthcare,
Uppsala, Sweden), differential analysis (DeCyder software version 6.5, GE Healthcare, Uppsala,
Sweden) was performed.
One 2DE gel containing 50 μL of two protein extracts (N and T) labeled with cyanines was
scanned, its image being loaded to the Decyder project, and immediately after electrotransferred onto a
nitrocellulose membrane, which was then processed for revelation of FGB as described above. The 2DE
spots visualized in the nitrocellulose membrane as cross-reacting with the anti-FGB antibody were
then found in the corresponding Decyder gel, and further image differential gel analyses focused on
these only spots of interest. This immunoblotting analysis was performed in triplicate.
4.7. Database Searches for Fibrinogen β Chain Sequence and Post-Translational Modifications
To better interpret the experimental data about FGB isoforms, we focused FGB amino acid
sequence and its possible enzymatic cleavage available in UniProtKB (http://www.uniprot.org/
uniprot/P02675). Possible post-translational modifications were searched with the iPTMnet integrated
resource ([63]; http://proteininformationresource.org/iPTMnet) and GeneCards® human gene
database (http://www.genecards.org), using FGB as substrate. The profiles of FGB-spots were
compared with those either found after searches in the bibliographic database PubMed (https:
//www.ncbi.nlm.nih.gov/pubmed/) or available on-line on databases of 2D gel reference maps
(DOSAC-COBS-2DPAGE, OGP, REPRODUCTION-2DPAGE, SWISS-2DPAGE, UCD-2DPAGE).
4.8. Image Analysis and Statistics
First, in intragroup comparisons within Groups I and II, we compared the abundances of a selected
set of spots in N versus T tissues of the same patient (Table 3). While in intergroup comparisons, N
tissue proteome profiles of Group I were compared with N ones of Group II (Table 3) and, similarly, T
tissue proteome profiles of Group I were compared with T ones of Group II (Table 4). Secondly, we
focused on the only T gastric tissues, and we compared the expressions of our spots of interest among
patients depending on: (i) anatomical subsites (corpus versus antrum), (ii) histological types (intestinal
versus diffuse) and (iii) age (> versus <50 years old) (Table 4).
Gel image pairs were processed by the Decyder Differential In-gel Analysis (DIA) module to
co-detect and differentially quantify the protein spots in the images; the internal standard sample was
used as a reference to normalize the data, so the rest of the normalized spot maps could be compared
among them. While the Biological variation analysis (BVA) module allowed to perform a gel-to-gel
matching of spots across multiple gels, allowing quantitative comparison of protein expression.
The BVA workspace was imported in the Decyder EDA (Extended Data Analysis) module to
perform univariate statistical analyses of FGB spot expression. Paired t-test was performed to compare
spot expression in normal versus tumor samples collected from the same patient. While Group I
(N and T) to Group II (N and T) comparison of spot differential expression was analyzed using
independent statistical tests based on average spot volume ratio with One-way Anova corrected
with false discovery rate (default setting). Intergroup comparison depending on (i) gender, (ii) age,
(iii) cancer histological type and (iv) location were performed using independent statistical tests with
Student’s t-test, since these factors between Groups I and II were not statistically different. Based on
average spot volume ratio, spots for which relative expression changed at least 1.5-fold (increase
or decrease) at 95% confidence level (p < 0.05) were considered to be significant. Sample size was
calculated considering an intergroup spot fold change of 1.5, a σ value of 50, an α value of 0.05, and a
power of the test of 0.80. The sample size for each group resulted 8, and it was enlarged in the case of
Group II where preliminary analyses showed a higher FGB content.
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4.9. Correlation Analysis of Blood Parameters
Log standard abundance data of spots 402, 526, 548 and 501 in both T and N tissue proteomes of
Group I and II patients were correlated with blood markers.
We focused on the only 5 patients of our cohort having the abundance of FGB spots in their T
tissue proteome maps and PLT count >280 × 109/L (asterisks in Table A2).
We used a PLT cut-off value of 280 × 109/L estimating the sample mean (208 × 109/L) and
two standard deviations (±70 × 109/L) in a cohort of healthy subjects.
5. Conclusions
By a targeted comparative proteomics, we succeeded in revealing an in situ differential expression
of both the entire and the cleaved FGB forms in GC tissues, depending on cancer development, location,
as well as pathological stage. Some of the found FGB forms were associated with blood parameters
linked to hypercoagulability. The FGB-related proteins may thus represent new candidate(s) for GC
diagnosis, which may be further exploited in terms of possible interconnections between cancer and
coagulation pathways.
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Appendix A
Figure A1. A schematic illustration of the proteomic workflow adopted. Proteins have been extracted
from both gastric tumor-affected (T) and normal (N) biopsies of 28 patients. After extraction (1), some
protein pools were separated by one-dimensional electrophoresis (1DE) (2), the presence of fibrinogen β
chain (FGB) was investigated by western blotting (WB) (3), and the presence of FGB in the cross-reacting
1DE bands was validated by mass spectrometry (4,5). Some protein extracts resulted to contain high
levels of FGB were separated by two-dimensional electrophoresis (2DE) (6), and the presence of FGB
was successfully individuated to some spots after 2DE immunoblotting on gels (7, 8). For comparative
analyses by DIGE, all the protein extracts were labelled (9), separated by isoelectric focusing (IEF) and
molecular weight (2DE) (10), images were acquired (11) and targeted image analyses were performed
on the only spots of interest containing FGB (12,13). Details are explained in Methods section.
Figure A2. The complete amino acid sequence of fibrinogen β chain (FGB) immature form (http://
www.uniprot.org/uniprot/P02675), where the peptides identified by mass spectrometry in gel portions
of Figure 1c are evidenced in bold (a). The FGB immature form of 56 kDa is processed into a mature
form of ~52 kDa after signal peptide removal. During the conversion of fibrinogen into fibrin, thrombin
cleaves fibrinopeptide B from β chains and releases FGB forms of ~51 kDa, which can be further
cleaved by plasmin into fibrinogen fragments D of ~37 kDa to break down fibrin clots. These processes
are summarized in (b). All the possible post-translational modifications (phosphorylation, acetylation
and N-glycosilation) are shown as interactive sequence in (c), after interrogation of P02675 as substrate
with iPTMnet bioinformatic resource (http://proteininformationresource.org/iPTMnet).
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Table A1. Clinical details of the gastric cancer (GC)-affected patients and corresponding protein pairs
extracted from both normal (N) and gastric cancer-affected (T) tissues, labelled with either Cy3 or
Cy5 dyes and mixed with the Cy2-labelled internal standard for two-dimensional difference in gel
electrophoresis, as described in ‘Material and methods’ section.









1 54 M 3 N+ diffuse corpus N cy3 1
T cy5
2 50 F 3 N+ diffuse antrum N cy3 2
T cy5
3 44 F 3 N+ diffuse corpus N cy3 3
T cy5
4 39 F 3 N+ diffuse corpus N cy3 4
T cy5
5 68 M 3 N0 diffuse corpus N cy3 5
6 52 M 3 N+ n.a. corpus T cy5
7 55 M 3 N+ diffuse corpus N cy5 6
T cy3
8 81 F 3 N+ intestinal antrum N cy5 7
T cy3
9 74 M 3 N+ diffuse antrum N cy5 8
T cy3
10 65 M 4 N+ diffuse corpus N cy5 9
T cy3
11 71 F 3 N0 diffuse antrum N cy5 10
12 69 M 3 N+ intestinal corpus T cy3
13 60 F 4 n.a. other corpus N cy5 11
T cy3
14 68 F 4 N0 intestinal corpus N cy5 12
T cy3
15 54 M 3 N+ diffuse cardia N cy5 13
T cy3
16 70 F 2 n.a. intestinal antrum N cy5 14
T cy3
17 76 F 1 N0 intestinal antrum N cy3 15
T cy5
18 59 M 1 N0 other cardia N cy3 16
T cy5
19 66 F 1 N0 diffuse corpus N cy5 17
T cy3
20 48 M 2 N0 intestinal corpus N cy5 18
T cy3
21 36 F 1 N0 intestinal corpus N cy5 19
T cy3
22 59 M 1 N+ diffuse corpus N cy5 19
T cy3
23 69 F 3 N0 n.a. corpus N cy3 20
T cy5
24 58 M 3 N+ diffuse corpus N cy3 21
T cy5
25 45 F 3 N+ diffuse corpus N cy5 22
T cy3
26 68 M 1 N0 diffuse antrum N cy5 23
T cy3
27 50 F 1 N0 diffuse antrum N cy5 24
T cy3
28 55 F 3 N+ diffuse corpus N cy5 25
T cy3
a M, male, F, female; b n.a., not available; c N, normal tissue; T, GC-affected tissue.
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Table A2. Blood biomarkers of gastric cancer-affected patients (WBC, white blood cells; ANC, absolute
neutrophil count; ALC, absolute lymphocyte count; N/R, ANC/ALC ratio; PLT, platelet count; PT,
prothrombin time; FIB, fibrinogen level; APTT activated partial thromboplastin time; APTT RATIO, the










N/R PT-INR FIB g/L b APTTs
APTT
RATIO
1 4.65 221 3 1.3 2.31 0.93 2.91 27 0.83
2 1.19 57 0.7 0.4 1.75 0.93 2.76 26 0.86
3 * 5.23 379 4.5 0.7 6.43 1.13 2.76 26 0.88
4 7.9 272 4.2 2.6 1.62 1 3.54 33 1.1
5 7.61 174 4.1 2.9 1.41 0.99 2.20 28 0.93
6 * 8.95 624 5.3 2.7 1.96 0.95 n.a. 27 0.89
7 6.29 182 3.4 2 1.70 0.99 2.95 34 1.14
8 4.74 184 2.6 1.8 1.44 1 2.76 31 1.03
9 * 7.19 283 4.3 2 2.15 0.96 3.34 29 0.95
10 9.61 137 7.8 1.1 7.09 1.03 3.01 24 0.79
11 7.92 330 5.3 2 2.65 0.99 n.a. 32 1.04
12 * 7.57 421 3.9 3.1 1.26 0.95 2.96 31 1.03
13 8.12 231 6.1 1.2 5.08 1.02 3.37 25 0.83
14 5.11 245 2.7 1.9 1.42 0.92 3.57 24 0.79
15 6.74 212 5.1 1.1 4.64 1.04 3.68 32 1.06
16 4.8 234 2.4 2 1.20 1.06 3.03 29 0.95
17 4,1 215 2.4 1.3 1.85 1.03 3.45 30 1.01
18 * 7.72 283 4.1 2.8 1.46 1.03 3.37 32 1.07
19 7.63 233 5.5 1.6 3.44 0.97 2.16 27 0.89
20 * 6.71 345 3.3 2.7 1.22 1.02 2.56 29 0.97
21 5.05 235 3.2 1.6 2.00 0.95 2.56 27 0.91
22 4.51 177 2.6 1.5 1.73 1.01 2.26 28 0.95
a asterisk indicates patients with PLT count upper the cut-off value: 280 × 109/L; b n.a., not available.
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Abstract: Background: Epstein-Barr Virus (EBV) positive and microsatellite unstable (MSI-high)
gastric cancer (GC) are molecular subgroups with distinctive molecular profiles. We explored the
transcriptomic differences between EBV+ and MSI-high GCs, and the expression of current GC
immunotherapy targets such as PD-1, PD-L1, CTLA4 and Dies1/VISTA. Methods: Using Nanostring
Technology and comparative bioinformatics, we analyzed the expression of 499 genes in 46 GCs,
classified either as EBV positive (EBER in situ hybridization) or MSI-high (PCR/fragment analysis).
PD-L1 protein expression was assessed by immunohistochemistry. Results: From the 46 GCs, 27 tested
MSI-high/EBV−, 15 tested MSS/EBV+ and four tested MSS/EBV−. The Nanostring CodeSet could
segregate GCs according to MSI and, to a lesser extent, EBV status. Functional annotation of
differentially expressed genes associated MSI-high/EBV− GCs with mitotic activity and MSS/EBV+
GCs with immune response. PD-L1 protein expression, evaluated in stromal immune cells, was lower
in MSI-high/EBV− GCs. High mRNA expression of PD-1, CTLA4 and Dies1/VISTA and distinctive
PD-1/PD-L1 co-expression patterns (PD-1high/PD-L1low, PD-1high/PDL1high) were associated with
MSS/EBV+ molecular subtype and gastric cancer with lymphoid stroma (GCLS) morphological
features. Conclusions: EBV+ and MSI-high GCs present distinct transcriptomic profiles. GCLS/EBV+
cases frequently present co-expression of multiple immunotherapy targets, a finding with putative
therapeutic implications.
Keywords: gastric cancer; transcriptomic profiling; Epstein-Barr Virus; EBV; microsatellite
instability; MSI
1. Introduction
Gastric Cancer (GC) is a heterogeneous disease at the morphological and molecular levels [1].
Numerous somatic gene mutations, copy-number variations, translocations/inversions, as well as
epigenetic and transcriptional changes have been described so far in this disease [2]. However,
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very few prognostic and predictive biomarkers of therapy response have been introduced into
clinical practice [3], and the “one-size-fits-all” is currently the main approach to treat GC patients.
Understanding GC molecular heterogeneity and deciphering its players is urgently needed to define
more homogenous and targetable biological subtypes.
Recently, several groups [4–6] were able to uncover distinct molecular subtypes with potential clinical
significance and therapeutic implications, through the integrative analysis of large-scale genomic and
proteomic data. The landmark study of GC that attempted to determine a molecular-based stratification
was carried out by The Cancer Genome Atlas (TCGA) research network [4]. By investigating exome
sequences, copy-number alterations, DNA methylation, gene expression and proteomic data, TCGA
classified GC into four subtypes: (1) Epstein-Barr Virus positive (EBV+) GCs, (2) GCs with microsatellite
instability (MSI-high), (3) genomically stable GCs and (4) GCs with chromosomal instability.
The current study focuses on the EBV+ and MSI-high molecular subtypes. The TCGA study has shown
that EBV+ GCs display distinctive molecular characteristics: high genomic-wide hypermethylation
with CDKN2A silencing, amplification of JAK2, CD274, PDCD1LG2, and ERBB2, mutations of PIK3CA,
ARID1A and BCOR, and very rarely TP53 mutations. Most EBV+ GCs were in the proximal stomach
(fundus/body), affecting mainly male patients and had a better prognosis than other subtypes [4,6].
MSI-high GCs are characterized by: a hypermethylation phenotype associated with MLH1 silencing,
and accordingly a hypermutated status often targeting TP53, KRAS, ARID1A, PIK3CA, ERBB3, PTEN
and HLA-B [4]. Patients with MSI-high tumors are generally diagnosed at older age, are mainly females
and display better prognosis than patients with the genomically stable subtype, but worse than EBV+
GC patients [4–7].
Based on gene expression analysis, the TCGA study revealed four clusters of differentially
expressed (DE)-genes, which have to some extent correspondence with specific molecular subtypes [4],
thus demonstrating the robustness of the proposed classification. An mRNA cluster enriched in genes
involved in mitotic pathways was associated with the MSI-high subtype, while for EBV+ GCs an
enrichment in genes associated with immune signaling was observed [4]. In-depth studies based on
TCGA transcriptomic data confirmed that genes related to T-cell cytotoxic function, pro-inflammatory
cytokines signaling and interferon gamma (IFNγ) response were highly expressed in EBV+ GCs and,
to a lesser extent, in MSI-high GCs [2,6,8,9]. Moreover, PD-1/PD-L1 mRNA and protein expression
are frequently present in both EBV+ and MSI-high molecular subtypes [8,9]. Accordingly, EBV+ and
MSI-high GCs are frequently characterized by prominent immune infiltrate and may display the
morphological features of GC with lymphoid stroma (GCLS) [9–13], a rare histological phenotype
characterized by prominent lymphoid infiltration [14].
These molecular data offer a rationale to investigate the value of EBV and MSI molecular status
in predicting the efficacy of immunotherapy in GC. Currently, the only predictive biomarkers used
to select GC patients for targeted immunotherapy, i.e., Pembrolizumab (anti-PD-1 antibody) [15–17]
are MSI-high status and/or the expression of PD-L1 by immunohistochemistry (IHC) in cancer
epithelial cells and/or in immune cells of the tumor microenvironment. However, several clinical trials
have shown that GC patients benefit from PD-1/PD-L1 immune checkpoint inhibitors regardless
of PD-L1 expression [18–20]. Therefore, the investigation of morphological and new molecular
profiles in this context might help optimizing treatment selection. A recent clinical trial with
Pembrolizumab across different cancer types, including GC, demonstrated that tumors with an
expression signature enriched in genes related to cytotoxic effector signaling, pro-inflammatory
cytokines/chemokines and IFNγ response, showed a T-cell inflamed phenotype associated with
better response to targeted immunotherapies [21]. These and other recent evidences suggest that
measuring multiple immunological determinants may be relevant to predict who will respond to
targeted immunotherapies [22]. Therefore, in this context, the presence of EBV positivity and MSI-high
status in GC may serve to select patients for immune checkpoint inhibitor therapy [8,9,13].
Although a growing number of publications have focused on the study of EBV+ and MSI-high
molecular subtypes separately or as a group, an in-depth analysis of the contribution of EBV infection
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and MSI status to the transcriptomic landscape of GC is still lacking. In this study, we performed
an unbiased analysis, aimed at uncovering differences within the gene expression profiles of EBV+
and MSI-high molecular subtypes, and at analyzing the expression profile of current targets for
immunotherapy in GC.
2. Results
We studied 46 GCs characterized for two molecular features: (1) EBV infection and, (2) MSI-high
status (Figure 1). Fifteen out of 46 GC (32.6%) displayed EBV positivity (EBV+) and the remaining
31/46 (67.4%) were negative (EBV−). Concerning MSI status, 27/46 (58.7%) were MSI-high while
19/46 (41.3%) were microsatellite stable (MSS). All EBV+ GC cases were MSS, while most (27/31)




















Figure 1. Cohort characterization for EBV infection and MSI status.
2.1. EBV+ and MSI-High GCs Displayed Distinct Transcriptomic Signatures
We analyzed the transcriptomic landscape of the 46 GC cases, aimed at unveiling differences
between EBV+ and MSI-high GC subtypes. For this, we have used a previously published
Nanostring nCounter CodeSet [23], which comprised 499 genes associated with oncogenic signaling
pathways, GC molecular subtype signatures and immune response. After adequate data analysis
and normalization, the expression of the 499 genes was plotted in a heatmap and non-hierarchical
clustering and principal component analysis (PCA) were performed (Figure 2).
Concerning MSI-high status, we observed that 26/27 MSI-high cases were clustered in clusters
2A and 2B, and 17/19 MSS cases were clustered together in cluster 2C (Figure 2a). Using a PCA,
we observed a clear separation between MSI-high and MSS cases (circles vs. squares, Figure 2b).
Concerning EBV infection, we observed that most EBV+ cases (13/15) were clustered together in
cluster 2C, with the remaining two EBV+ cases found within/close to cluster 2B (Figure 2a). With the
PCA, almost all EBV+ cases were separated from EBV− cases (black vs. gray, Figure 2b).
As we correlated the information from the heatmap and dendrogram and the PCA, we could
observe the clear separation of two MSS/EBV+ cases in the PCA, which likely reflects overall higher
expression in these two cases (black squares with asterisk, Figure 2). Furthermore, we observed
the MSI-high/EBV− case in MSS-rich cluster 2C, however clustered among MSI-high cases in the
PCA, highlighting the differences in the clustering strategies (gray circle with asterisk, Figure 2).
These results suggested that the transcriptomic landscape assessed can clearly distinguish GC cases
with an MSS phenotype from those with MSI-high phenotype, and, to a lesser degree, EBV+ from
EBV− cases.
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Figure 2. Transcription profile of 46 GC cases for 499 genes in the Nanostring CodeSet. Asterisks are
used for cross-reference between the two figures and as links to the main text. (a) Heatmap for the
expression of all genes in all GC cases (log 2 and Z-score scaled). Indicated are three main clusters:
2A–C. (b) PCA for principal components 1 and 2 for the 46 GC samples. Black squares correspond to
MSS/EBV+ cases (n = 15), gray squares to MSS/EBV− cases (n = 4), gray circles to MSI-high/EBV−
cases (n = 27).
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To further reinforce these findings, we used the partitioning method k-means and several values
of k to understand how strongly the gene expression profile followed the classification MSI-high or
EBV+. The best results were observed for a value of k = 3, as the clusters calculated were the most
homogeneous in terms of molecular subtypes, particularly for the MSS/MSI-high status. In fact,
all MSI-high cases fell into cluster I and were perfectly separated from MSS cases that fell into clusters
II and III (Table 1). For EBV− cases, the clustering was more heterogeneous, spreading across two
different clusters (I and III). Of notice, if we disregard the two samples in cluster II, which correspond
to those previously shown to display an abnormally high global expression profile (black squares with
asterisk, Figure 2), homogeneity in cluster III becomes evident.
Table 1. Clustering results using a k-means approach. Represented is the number of MSI-high/MSS
and EBV+/EBV− cases obtained in each cluster for each k value.
MSI Status EBV Infection
Value of k Cluster ID
MSI-High (n = 27) MSS (n = 19) EBV+ (n = 15) EBV− (n = 31)
2
I 25 1 1 26
II 2 18 14 6
3
I 27 0 0 27
II 0 2 2 0
III 0 17 13 4
4
I 13 0 0 13
II 14 0 0 14
III 0 17 13 4
IV 0 2 2 0
5
I 0 12 9 3
II 12 0 0 12
III 0 2 2 0
IV 12 0 0 12
V 3 5 4 4
Our observations show that the gene expression profile assessed with the Nanostring CodeSet
was sufficient to illustrate the molecular separation of MSS and MSI-high molecular subtypes.
This analysis also provides the rationale to derive a smaller specific gene expression signature that
strongly discriminates MSS and MSI-high phenotypes and, to a lesser extent, EBV infection status.
To better understand this, we next studied each molecular subtype independently, aiming at uncovering
the biological meaning of the gene expression profiles associated with each phenotype.
2.2. MSI-High GC Cases Displayed a Mitotic Signature, While MSS GC Cases Showed an Immune
Response Signature
We first compared the transcriptomic landscape of MSS and MSI-high cases and detected 193 genes
DE-genes (False Discovery Rate (FDR) ≤ 0.05 and 1.5 ≤ fold-change ≤ 0.6). By performing a
non-hierarchical clustering using specifically these DE-genes, we observed that all MSS cases (n = 19/19)
and the majority of MSI-high cases (n = 25/27), were clustered together (cluster 3A and cluster 3B,
respectively) (Figure 3a), while two MSI-high outlier cases clustered together with the MSS cases
(cluster 3A, circles with cross, Figure 3a). However, these two cases were clustered closer to the
remaining MSI-high cases than MSS with PCA, with over 50% of data variability considered (Figure 3b).
In fact, PCA exhibited a clear separation of cases according to MSS/MSI-high status.
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Figure 3. Expression profile of the 46 GC cases for 193 DE-genes between MSS and MSI-high cases.
Asterisks and crosses are used for cross-reference between the two figures and as links to the main
text. (a) Heatmap for the expression of the 193 DE-genes (log 2 and Z-score scaled). Indicated are
two main clusters: 3A and 3B. (b) PCA for principal components 1 and 2 for the 46 GC samples.
Squares correspond to MSS cases (n = 19) and circles to MSI-high (n = 27). Circles with cross or squares
with asterisk for correspondence between panels (a) and (b) and described in the main text.
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We next searched for biological annotations among the 193 DE-genes between MSS and MSI-high
cases [24,25]. We observed enrichment in the more generalist terms such as signal peptide and disulfide
bond, as well as in regulation of cell proliferation and chemotaxis (Table 2).
Table 2. FDR-ranked top 10 biological terms significantly enriched in the set of 193 DE-genes when
comparing the expression profile for 499 genes between MSS and MSI-high cases.
Biological Term Count FDR
Signal Peptide 73 1.24 × 10−11
Disulfide bond 64 1.05 × 10−09
Secreted 44 2.67 × 10−7
GO:0042127~regulation of cell proliferation 31 1.77 × 10−6
GO:0006935~chemotaxis 15 3.16 × 10−6
GO:0042330~taxis 15 3.16 × 10−6
IPR001811:Small chemokine, interleukin-8-like 9 8.69 × 10−6
GO:0007626~locomotory behavior 18 1.08 × 10−5
GO:0045321~leukocyte activation 17 1.26 × 10−5
GO:0008009~chemokine activity 9 2.10 × 10−5
Count: number of DE-genes associated with a given biological term; FDR: False Discovery Rate.
From the 193 DE-genes, 55 were upregulated in MSI-high cases and annotated to terms associated
with cell division. The remaining 138 DE-genes, downregulated in MSI-high cases, were related to
chemotaxis and immune response. The 55 upregulated DE-genes in MSI-high cases were significantly
associated with three annotation clusters: cluster 1 associated with cell cycle and cell division;
cluster 2 with cytoskeleton and; cluster 3 associating more specific terms such as ‘mitotic spindle
organization’ (Table 3). For the 138 downregulated DE-genes, eight clusters were significantly enriched
associated with the terms: signal peptide and disulfide bond; chemotaxis; leukocyte and lymphocyte
activation; chemokine activity; response to stimuli; regulation of cell death; cell migration and motility,
and; polysaccharide binding (Table 3). Taken together, these results showed that MSI-high cases likely
present increased cell division and decreased immune response and cell migration.
Table 3. Functional annotation clustering results for DE-genes separated according to the expression
profile in MSS vs. MSI-high cases. Three clusters of associated biological terms were detected for
upregulated DE-genes, while only one was detected for downregulated DE-genes. Notice that some
terms among clusters are not significantly enriched (FDR > 0.05).
Cluster ID Term Count FDR
Upregulated DE-genes in MSI-high vs. MSS cases (n = 55)
Cluster 1:
ES = 9.5
GO:0022402~cell cycle process 17 1.46 × 10−8
GO:0000279~M phase 14 3.24 × 10−8
GO:0000280~nuclear division 12 1.17 × 10−7
GO:0007067~mitosis 12 1.17 × 10−7
GO:0000278~mitotic cell cycle 14 1.40 × 10−7
GO:0000087~M phase of mitotic cell cycle 12 1.43 × 10−7
GO:0048285~organelle fission 12 1.81 × 10−7
GO:0022403~cell cycle phase 14 5.62 × 10−7
mitosis 10 1.09 × 10−6
GO:0007049~cell cycle 17 1.62 × 10−6
cell division 11 1.48 × 10−6
cell cycle 12 2.50 × 10−5
GO:0051301~cell division 11 4.02 × 10−5
Cluster 2:
ES = 4.3
GO:0005819~spindle 9 2.00 × 10−5
GO:0015630~microtubule cytoskeleton 10 5.42 × 10−2
GO:0044430~cytoskeletal part 10 3.05
GO:0005856~cytoskeleton 12 3.72
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Table 3. Cont.
Cluster ID Term Count FDR
Cluster 3:
ES = 3.7
GO:0007052~mitotic spindle organization 4 2.13 × 10−2
GO:0007051~spindle organization 4 6.18 × 10−1
GO:0000226~microtubule cytoskeleton organization 5 1.92
Downregulated DE-genes in MSI-high vs. MSS cases (n = 138)
Cluster 1:
ES = 16.0
disulfide bond 57 1.67 × 10−13
signal peptide 61 1.67 × 10−13
signal 61 1.44 × 10−13
disulfide bond 57 5.66 × 10−13
Cluster 2:
ES = 9.7
GO:0007626~locomotory behavior 17 2.98 × 10−7
GO:0042330~taxis 14 3.03 × 10−7
GO:0006935~chemotaxis 14 3.03 × 10−7
Cluster 3:
ES = 8.2
GO:0046649~lymphocyte activation 14 4.51 × 10−6
GO:0045321~leukocyte activation 15 5.12 × 10−6
GO:0001775~cell activation 15 4.50 × 10−5
Cluster 4:
ES = 5.4
IPR001811: Small chemokine, interleukin-8-like 8 1.75 × 10−5
GO:0008009~chemokine activity 8 5.02 × 10−5
GO:0042379~chemokine receptor binding 8 7.91 × 10−5
SM00199:SCY 8 1.88 × 10−4
cytokine 9 2.47 × 10−2
109.Chemokine_families 8 6.13 × 10−2
GO:0005125~cytokine activity 9 1.18 × 10−1
hsa04062:Chemokine signaling pathway 10 4.13 × 10−1
hsa04060:Cytokine-cytokine receptor interaction 11 1.19
Cluster 5:
ES = 5.1
GO:0009719~response to endogenous stimulus 15 2.99 × 10−3
GO:0009725~response to hormone stimulus 14 5.54 × 10−3
GO:0010033~response to organic substance 17 1.38 × 10−1
Cluster 6:
ES = 4.9
GO:0043067~regulation of programmed cell death 20 1.27 × 10−2
GO:0010941~regulation of cell death 20 1.34 × 10−2
GO:0042981~regulation of apoptosis 19 4.16 × 10−2
Cluster 7:
ES = 4.9
GO:0016477~cell migration 12 1.10 × 10−2
GO:0006928~cell motion 15 1.88 × 10−2
GO:0048870~cell motility 12 2.99 × 10−2
GO:0051674~localization of cell 12 2.99 × 10−2
Cluster 8:
ES = 4.3
GO:0030247~polysaccharide binding 9 2.18 × 10−2
GO:0001871~pattern binding 9 2.18 × 10−2
GO:0005539~glycosaminoglycan binding 8 9.63 × 10−2
GO:0030246~carbohydrate binding 11 3.40 × 10−1
ES: enrichment score per cluster calculated by DAVID. FDR: False Discovery Rate.
2.3. EBV+ GC Cases Were Associated with Immune Response Signature
Next, we compared the transcriptomic landscape of EBV+ and EBV− GC cases. We detected
142 DE-genes and non-hierarchical clustering revealed two major clusters: cluster 4A with 22/31 cases
EBV− and; cluster 4B constituted by all 15 EBV+ cases plus the remaining 9 EBV− cases (Figure 4a).
This separation between EBV+ and EBV− cases was partially recapitulated by PCA: 4/9 EBV− cases
clustered together with EBV+ cases in the non-hierarchical clustering, were similarly grouped with
PCA (gray diamonds with asterisk, Figure 4). This showed an overall less homogenous clustering
according to EBV status, demonstrating that the MSI-high status was a stronger marker in GC.
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Figure 4. Expression profile of the 46 GC cases for 142 DE-genes between EBV positive and negative
cases. (a) Heatmap for the expression of the 142 DE-genes (log 2 and Z-score scaled). Indicated
are two main clusters: A and B. (b) PCA for principal components 1 and 2 for the 46 GC samples.
Black diamonds correspond to EBV+ cases (n = 15) and white diamonds to EBV− cases (n = 31).
Diamonds with asterisk for correspondence between panels (a) and (b) and described in the main text.
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We then performed biological annotation of the 142 DE-genes and observed a significant
enrichment in terms such as chemotaxis and immune response (Table 4).
Table 4. FDR-ranked top 10 biological terms significantly enriched in the set of 142 DE-genes when
comparing the expression profile for 499 genes between EBV+ and EBV− GC cases.
Biological Term Count FDR
signal peptide 54 1.38 × 10−8
IPR001811:Small chemokine, interleukin-8-like 10 1.40 × 10−8
GO:0042330~taxis 15 3.13 × 10−8
GO:0006935~chemotaxis 15 3.13 × 10−8
disulfide bond 49 5.16 × 10−8
GO:0008009~chemokine activity 10 6.98 × 10−8
GO:0042379~chemokine receptor binding 10 1.28 × 10−7
SM00199:SCY 10 1.99 × 10−7
GO:0007626~locomotory behavior 17 4.65 × 10−7
GO:0006955~immune response 25 5.25 × 10−7
Count: number of DE-genes associated with a given biological term; FDR: False Discovery Rate.
From the 142 DE-genes, 105 were upregulated EBV+ cases vs. EBV− cases and belonged to
six enriched clusters: signal peptide and disulfide bond; chemotaxis and motility; leukocyte and
T-cell activation; chemokines and chemokine activity; immune system development; and T-cell
differentiation (Table 5). The 37 genes downregulated in this comparison were enriched in two
clusters: cell division, mitosis, and cell cycle (Table 5).
Table 5. Functional annotation clustering results for the 141 DE-genes upregulated in EBV+ cases.
Six clusters of associated biological terms were detected for upregulated DE-genes and two clusters
for downregulated DE-genes. Notice that some terms among clusters are not significantly enriched
(FDR > 0.05).
Cluster ID Term Count FDR
Upregulated DE-genes in EBV+ vs. EBV− cases (n = 105)
Cluster 1:
ES = 12.2
disulfide bond 44 1.36 × 10−10
disulfide bond 44 3.56 × 10−10
signal 45 2.94 × 10−9
signal peptide 45 4.07 × 10−9
Cluster 2:
ES = 10.3
GO:0042330~taxis 14 5.99 × 10−9
GO:0006935~chemotaxis 14 5.99 × 10−9
GO:0007626~locomotory behavior 16 3.41 × 10−8
GO:0007610~behavior 16 5.57 × 10−5
Cluster 3:
ES = 10
GO:0045321~leukocyte activation 15 8.26 × 10−8
GO:0046649~lymphocyte activation 14 9.54 × 10−8
GO:0042110~T-cell activation 12 1.43 × 10−7
GO:0001775~cell activation 15 7.88 × 10−7
Cluster 4:
ES = 7.4
IPR001811:Small chemokine, interleukin-8-like 9 3.94 × 10−8
GO:0008009~chemokine activity 9 1.52 × 10−7
GO:0042379~chemokine receptor binding 9 2.60 × 10−7
SM00199:SCY 9 4.73 × 10−7
cytokine 10 2.20 × 10−4
GO:0005125~cytokine activity 10 1.39 × 10−3
hsa04062:Chemokine signaling pathway 11 1.09 × 10−2
109.Chemokine_families 9 1.22 × 10−2
hsa04060:Cytokine-cytokine receptor interaction 12 3.67 × 10−2
Cluster 5:
ES = 5.2
GO:0002520~immune system development 11 4.50 × 10−3
GO:0030097~hemopoiesis 10 9.75 × 10−3
GO:0002521~leukocyte differentiation 8 1.28 × 10−2
GO:0048534~hemopoietic or lymphoid organ development 10 2.13 × 10−2
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Table 5. Cont.
Cluster ID Term Count FDR
Cluster 6:
ES = 5.2
GO:0030217~T-cell differentiation 7 2.48 × 10−3
GO:0002521~leukocyte differentiation 8 1.28 × 10−2
GO:0030098~lymphocyte differentiation 7 3.64 × 10−2
Downregulated DE-genes in EBV+ vs. EBV− cases (n = 137)
Cluster 1:
ES = 5.2
GO:0000279~M phase 8 5.32 × 10−3
cell division 7 4.85 × 10−3
GO:0007067~mitosis 7 7.12 × 10−3
GO:0000280~nuclear division 7 7.12 × 10−3
GO:0000087~M phase of mitotic cell cycle 7 7.90 × 10−3
GO:0048285~organelle fission 7 8.97 × 10−3
cell cycle 8 9.93 × 10−3
mitosis 6 1.38 × 10−2
GO:0051301~cell division 7 3.79 × 10−2
Cluster 2:
ES = 5
GO:0022402~cell cycle process 11 1.46 × 10−4
GO:0005819~spindle 7 5.61 × 10−4
GO:0000278~mitotic cell cycle 9 8.25 × 10−4
GO:0022403~cell cycle phase 9 1.93 × 10−3
GO:0007049~cell cycle 11 2.74 × 10−3
GO:0015630~microtubule cytoskeleton 8 1.20 × 10−1
GO:0044430~cytoskeletal part 8 3.21
GO:0005856~cytoskeleton 9 6.62
ES: enrichment score per cluster calculated by DAVID; FDR: False Discovery Rate.
Our results show that EBV infection is not as determinant as MSI-high status. Nevertheless,
the presence of this virus in GC samples was associated with an immune T-cell inflamed phenotype,
in line with current literature [4,6,8].
2.4. MSS/MSI Phenotype Classification Was the Major Molecular Classifier in GC
Given that MSI and EBV status were part of the molecular classification for GC proposed by
TCGA [4], we next assessed the differential expression profile of our GC cases taking into account both
molecular classifications. We detected 166 DE-genes associated with biological annotations such as
interleukin-8-like chemokine, signal peptide and chemotaxis (Table 6).
Table 6. FDR-ranked top 10 biological terms significantly enriched in the set of 166 DE-genes when
comparing the expression profile for 499 genes between MSS vs. MSI-high and EBV+ vs. EBV−
GC cases.
Biological Term Count FDR
IPR001811:Small chemokine, interleukin-8-like 10 6.17 × 10−8
signal peptide 58 1.97 × 10−7
GO:0008009~chemokine activity 10 2.18 × 10−7
GO:0006935~chemotaxis 15 3.16 × 10−7
GO:0042330~taxis 15 3.16 × 10−7
disulfide bond 53 3.22 × 10−7
GO:0042379~chemokine receptor binding 10 3.97 × 10−7
SM00199:SCY 10 8.05 × 10−7
disulfide bond 53 8.56 × 10−7
GO:0045321~leukocyte activation 17 9.73 × 10−7
Count: number of DE-genes associated with a given biological term; FDR: False Discovery Rate.
From the 166 DE-genes, 117 were upregulated and 49 downregulated DE-genes in MSS/EBV+
cases vs. MSI-high/EBV−genes. Next, we plotted the expression of these DE-genes for all 46 GC cases
and observed that, despite adding both molecular classifiers, MSI-high and MSS cases remained well
separated (Figure 5a). As observed before, two MSI-high/EBV− GC cases were clustered together
with MSS cases (cluster 5A, Figure 5a, gray circles with asterisk and cluster 3A, Figure 3a, circles with
cross). Nevertheless, with PCA, the same two cases were clustered closer to MSI-high/EBV− GC cases.
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PCA separated two other MSI-high/EBV− cases, which were already loosely clustered in cluster 5B
(Figure 5, gray circles with cross).
Figure 5. Expression profile of the 46 GC cases for 166 DE-genes between MSS/EBV+ and
MSI-high/EBV− cases. (a) Heatmap for the expression of the 166 DE-genes (log 2 and Z-score scaled).
Indicated are two main clusters: A and B. (b) PCA for principal components 1 and 2 for the 46 GC
samples. Black squares correspond to MSS/EBV+ cases (n = 15), gray squares to MSS/EBV− cases
(n = 4) and gray circles to MSI-high/EBV− cases (n = 27).
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Separate annotation of up- and downregulated DE-genes in MSS/EBV+ cases revealed significant
enrichment for five annotation clusters for upregulated genes: signal peptide and disulfide bond;
chemotaxis and locomotion; leukocyte and T-cell activation; chemokines and chemokine activity, and;
actin fibers (Table 7). Downregulated genes were separated in two clusters: cell cycle and mitosis,
and cytoskeleton.
Table 7. Functional annotation clustering results for the 166 DE-genes derived from the comparison
of MSS/EBV+ cases vs. MSI-high/EBV− cases. Notice that some terms among clusters are not
significantly enriched (FDR > 0.05).
Cluster ID Term Count FDR
Upregulated DE-genes in MSS/EBV+ cases (n = 117)
Cluster 1:
ES = 12.5
disulfide bond 47 1.12 × 10−10
disulfide bond 47 3.06 × 10−10
signal 49 7.15 × 10−10
signal peptide 49 1.03 × 10−9
Cluster 2:
ES = 9.6
GO:0042330~taxis 14 2.32 × 10−8
GO:0006935~chemotaxis 14 2.32 × 10−8
GO:0007626~locomotory behavior 16 1.58 × 10−7
GO:0007610~behavior 16 2.31 × 10−4
Cluster 3:
ES = 8.3
GO:0045321~leukocyte activation 14 4.01 × 10−6
GO:0046649~lymphocyte activation 13 4.72 × 10−6
GO:0042110~T-cell activation 11 7.75 × 10−6
GO:0001775~cell activation 14 3.11 × 10−5
Cluster 4:
ES = 6.8
IPR001811:Small chemokine, interleukin-8-like 9 9.74 × 10−8
GO:0008009~chemokine activity 9 3.30 × 10−7
GO:0042379~chemokine receptor binding 9 5.62 × 10−7
SM00199:SCY 9 1.34 × 10−6
cytokine 9 5.94 × 10−3
109.Chemokine_families 9 4.48 × 10−3
hsa04062:Chemokine signaling pathway 11 1.87 × 10−2
GO:0005125~cytokine activity 9 2.77 × 10−2
hsa04060:Cytokine-cytokine receptor




GO:0001725~stress fiber 5 2.38 × 10−2
GO:0032432~actin filament bundle 5 3.31 × 10−2
GO:0042641~actomyosin 5 3.87 × 10−2
Downregulated DE-genes in MSS/EBV+ cases (n = 49)
Cluster 1:
ES = 9.9
GO:0000278~mitotic cell cycle 14 2.51 × 10−8
GO:0000280~nuclear division 12 2.79 × 10−8
GO:0007067~mitosis 12 2.79 × 10−8
GO:0000087~M phase of mitotic cell cycle 12 3.39 × 10−8
GO:0048285~organelle fission 12 4.30 × 10−8
GO:0022403~cell cycle phase 14 1.02 × 10−7
GO:0000279~M phase 13 1.15 × 10−7
mitosis 10 3.25 × 10−7
cell division 11 3.84 × 10−7
cell cycle 12 5.83 × 10−6
GO:0051301~cell division 11 1.15 × 10−5
Cluster 2:
ES = 3.5
GO:0005819~spindle 7 4.12 × 10−3
GO:0015630~microtubule cytoskeleton 9 1.60 × 10−1
GO:0005856~cytoskeleton 11 5.27
GO:0044430~cytoskeletal part 9 5.64
ES: enrichment score per cluster calculated by DAVID; FDR: False Discovery Rate.
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These results were comparable to those previously observed when considering the molecular
classifiers independently. To understand whether this was due to common set of DE-genes across
analyses, we next compared the DE-genes obtained for each comparison: MSS with MSI-high cases;
EBV+ with EBV− cases and; MSS/EBV+ with MSI-high/EBV− cases.
Most DE-genes were shared by the three analyses (n = 133, Figure 6), thus justifying the similar
biological annotation enrichments obtained. Unlike EBV−-based classification, many DE-genes
derived specifically from the MSI-high/MSS-based classification and became lost when combining
both molecular subtypes (n = 34, Figure 6). Functional enrichment of this particular set of DE-genes,
although without any FDR-significant results, pointed toward enrichment in extracellular matrix terms.
Altogether, our results pinpointed MSI-high/MSS phenotype as the major molecular classifier in our
GC cohort, independently of EBV− tatus classification.
 
Figure 6. Venn diagram for shared (or not) DE-genes across the three analyses performed.
2.5. PD-L1 and PD-1 Displayed Opposite mRNA Expression Patterns and Were Differently Associated with
GC Molecular Subtypes and Morphological Features
In GC, several clinical trials have been targeting immune checkpoint regulators, such as CTLA4,
PD-1, PDL1 and VISTA/Dies1 [26]. Given the observed associations between immune response
terms and MSS/EBV+ cases, we further assessed the mRNA expression of these immune checkpoint
regulators across all cases from the 3 GC groups represented in our series (15 MSS/EBV+, 4 MSS/EBV−
and 27 MSI-high/EBV−, Figure 7). CTLA4, PD-1 and VISTA/Dies1, but not PD-L1 mRNA expression
was significantly enriched in MSS/EBV+ cases (Figure 7a). Therefore, we analyzed PD-L1 protein
expression in cancer cells and in the immune cells infiltrating the tumor microenvironment (TME) to
understand this difference. In cancer epithelial cells, PD-L1 protein expression did not differ between
GC groups (Figure 7b). However, in the immune cells of the TME, MSI-high/EBV− cases often
presented low expression of PD-L1, while MSS/EBV+ showed variable PD-L1 expression across all
categories, from low to high (Figure 7c, Fisher’s Exact Test p-value = 7.71 × 10−3)
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These results prompted us to re-analyze the mRNA expression of the four immune checkpoint
regulators on a case-by-case manner. While CTLA4 and VISTA/Dies1 followed the expression pattern
of PD-1, PD-L1 varied in an inverse manner in a large set of cases: for example, GC cases with highest
expression of PD-L1 displayed the lowest expression of PD-1 (Figure 7d).
To validate this observation, we assessed the number of GC cases for each of the four
PD-L1/PD-1 co-expression scenarios observed: (1) high expression of PD-L1 and low expression
of PD-1 (PD-L1high/PD-1low, n = 12); (2) low expression of PD-L1 and high expression of PD-1
(PD-L1low/PD-1high, n = 12); (3) low expression for both (PD-L1low/PD-1low, n = 14) and; (4) high
expression for both (PD-L1high/PD-1high, n = 8, Figure 7d,e). We observed that most MSS/EBV+ cases
were either PD-L1low/PD-1high or PD-L1high/PD-1high (n = 7 and 6, respectively, Figure 7e), while most
MSI-high/EBV− cases were PD-L1high/PD-1low or PD-L1low/PD-1low (n = 23, Figure 7e) (Fisher’s
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Figure 7. mRNA expression of immune checkpoint regulators CTLA4, PD-1, VISTA/Dies1 and PD-L1
and protein expression of PD-L1. (a) Boxplot for the normalized mRNA expression in log2 scale of
CTLA4, PD-1, VISTA/Dies1 and PD-L1. (b,c) Contingency tables for PD-L1 protein expression evaluated
by in cancer cells (b, absent or detected) and in immune cells of the TME (c, low, intermediate, or high
expression level). (d) Heatmap for the mRNA expression of each of the immune checkpoints assessed
per case. (e,f) Contingency tables for combined PD-L1 and PD-1 mRNA expression for GC cases
separated by MSI status and EBV infection (e) or by morphological characteristics (gastric cancer with
lymphoid stroma, GCLS, or conventional-type adenocarcinoma, CA) (f). Green upward arrows for
higher mRNA expression and red downward arrows for lower mRNA expression, as presented in
the heatmap.
These significant results led us to further characterize our GC cohort for morphological
characteristics by histopathological analysis. As a significant fraction of cases displayed a prominent
lymphoid infiltration in the tumor stroma, showing the morphological features of GCLS, we stratified
the GC series into GCLSs (n = 25) and conventional-type adenocarcinomas (CA), i.e., GC cases
not presenting the morphological features of GCLS (n = 21). While most GCLS cases presented
a PD-L1low/PD-1high or PD-L1high/PD-1high (n = 12 + 7, respectively, Figure 7f), CA cases
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either displayed a PD-L1high/PD-1low or PD-L1low/PD-1low (n = 10 + 10, respectively, Figure 7f).
By combining this morphological characterization with the previously described molecular subtypes
(Table 8), we observed that: (1) 20/21 MSI-high/EBV− CA cases presented a PD-L1high/PD-1low
or a PD-L1low/PD-1low expression pattern; (2) 13/15 MSS/EBV+/GCLS cases presented either a
PD-L1low/PD-1high or a PD-L1high/PD-1high expression pattern; (3) 3/4 MSS/EBV−/GCLS cases
presented a PD-L1low/PD-1high co-expression pattern.
Table 8. Contingency table for the number of MSS/EBV− or MSS/EBV+ or MSI/EBV− cases with
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Fisher’s Exact Test: p = 3.71 × 10−6
The most important observation was that 19/25 GCLS cases displayed high PD-1 mRNA
expression, independently of PD-L1 expression (12/19—low PD-L1; 7/19—high PD-L1). We then
analyzed the expression of the other GC immunotherapy targets in the subset of GCLS: Dies1/VISTA
and CTLA4. From the 12 GCLS cases with high PD-1 and low PD-L1 mRNA expression, 10 displayed
high Dies1/VISTA mRNA expression (n = 7 + 3, Figure 8) and 8 high CTLA4 mRNA expression
(n = 7 + 1, Figure 8). From the remaining seven GCLS cases with high PD-1 and PD-L1 mRNA
expression, all displayed high Dies1/VISTA and/or CTLA4 mRNA expression (Figure 8).
Figure 8. mRNA co-expression patterns for PD-1, PD-L1, Dies1/VISTA and CTLA4 in GCLS cases.
Altogether, this gene-oriented analysis showed that PD-L1 and PD-1 exhibit particular
co-expression patterns in an MSS/MSI-high and EBV infection-dependent manner. Moreover,
our results suggest that the evaluation of the tumor immune infiltrate by histopathological analysis
strengthened the stratification of GC cases and helped identifying more homogenous biological
subgroups in terms of co-expression of immune checkpoint regulators.
3. Discussion
In this study, we explored the transcriptomic profile of EBV+ and MSI-high GC, using a Nanostring
CodeSet with 499 genes involved in oncogenic signaling, immune response and molecular gene
118
Int. J. Mol. Sci. 2018, 19, 2079
expression signatures. This small gene expression panel could segregate GCs of our cohort according
to MSI-high status and, to a lesser extent, EBV infection, and was sufficient to reproduce the taxonomy
developed by TCGA.
EBV infection and MSI-high status represent two alternative pathways of gastric carcinogenesis
and two mutually exclusive GC molecular subtypes [11,12,27]. Herein, we confirmed that all
EBV+ cases showed an MSS phenotype, and vice versa, that all MSI-high cases were negative for
EBV infection.
When we focused on determining clusters of biologically-related annotation terms, underlying
the DE-genes found for the two GC molecular subtypes, we found that MSI-high tumors showed an
enrichment in genes related to DNA replication and mitotic cell cycle, as previously reported [4,5].
MSI-high status leads to the accumulation of numerous frameshift mutations throughout the
genome [28] and may determine the inactivation of key tumor suppressor genes, including those
involved in DNA damage repair, cell cycle control and apoptotic signaling [29]. Accordingly,
as demonstrated in the MSI-high colorectal cancer model [30], mutations providing proliferative
and survival advantage are selected during MSI-high GC initiation and/or progression, conferring
a proliferative state. In contrast, EBV+ tumors showed a downregulation of genes involved in
mitotic pathways.
By functional annotation of genes discriminating EBV+ tumors, we identified a gene signature
involved in immune pathways, confirming the data already reported in the literature [4,6,8,31,32].
The immune signature was enriched for genes related to T-cell differentiation, cytotoxic signaling,
pro-inflammatory cytokines/chemokines, leukocyte migration and genes of the immune checkpoint
inhibitors pathways. These features reflect the immunogenicity of EBV infection and provide evidence
of the biological significance of immune cell infiltration in EBV+ tumors [33]. Accordingly, the DE-genes
downregulated in MSI-high cases, hence upregulated in MSS cases, were also found to be associated
with immune response and cell migration. Therefore, in this study we demonstrated, using unbiased
bioinformatics analyses, that the transcriptomic landscape of GCs with EBV+ and MSI-high phenotypes
is different, associating each molecular entity with enrichment of different biological terms, i.e., mitotic
activity and immune response. In this study, gene expression analysis was performed through the
Nanostring Technology Platform, which has shown excellent robustness and sensitivity for the analysis
of formalin-fixed paraffin-embedded (FFPE) samples [34]. Moreover, several authors have shown the
reproducibility of the results obtained in GC tissues through Nanostring technology, using distinct
molecular platforms [23,34]. Importantly, our results were able to confirm the transcriptomic data
obtained in TCGA study, thus further contributing for the validation of the Nanostring CodeSet.
In future studies, it would be interesting to confirm the enrichment of mitotic pathways in MSI GC
cohorts, by investigating mitotic activity/index through histopathological analysis, as demonstrated
already in the colorectal cancer model [30,35].
We also investigated the expression of molecules involved in immune checkpoint inhibitors
pathways and current targets for immunotherapy in GC [26]. By assessing PD-L1 protein expression
by IHC, the current predictive biomarker used for selecting GC patients eligible for Pembrolizumab
immunotherapy [16], we found that PD-L1 protein expression, evaluated in cancer cells, showed
no significant differences between the two molecular subgroups. However, when we evaluated
PD-L1 expression in immune cells of the TME, most MSI-high/EBV− cases presented low expression,
when compared to MSS/EBV+ tumors. This result shows the value of evaluating protein expression in
tissue sections to improve knowledge of topographic distribution of molecular markers.
We also analyzed PD-1, CTLA4 and Dies1/VISTA mRNA expression and observed that all were
significantly enriched in MSS/EBV+ cases, in comparison with MSI-high/EBV− cases. This result
highlighted the high correlation of PD-1, CTLA4 and Dies1/VISTA increased mRNA expression with
EBV+ cases, but not with EBV− cases. However, as we analyzed PD-L1 mRNA expression, we did not
observe any significant difference between the two molecular subgroups. This result prompted us to
analyze the co-expression of PD-1 and PD-L1 at the mRNA level, the two most promising biomarkers
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for GC immunotherapy. Studies have shown that patients with mRNA co-expression of PD-1/PD-L1
were those with better prognosis [36]. However, few GC cases in our cohort presented expression
of both markers simultaneously and, interestingly, most were GCLS cases positive for EBV infection.
Nevertheless, it has been shown that patients treated with anti-PD-1 therapy respond well even in the
absence of PD-L1 expression [37], a fact that may reflect the different co-expression patterns observed
in our cohort.
Taking all these observations into account, we further explored the pattern of co-expression of
PD-1 with Dies1/VISTA and CTLA4. In fact, combination immunotherapies, targeting simultaneously
PD-1 and Dies1/VISTA or CTLA4 are being explored as new strategies for the treatment of GC [38,39].
We observed that from the 19 PD-1 high-expressing GCLS cases, 18 cases also displayed high
Dies1/VISTA and/or CTLA4 mRNA expression. This observation suggests that the recognition of GCLS
morphological features may contribute, in >70% cases, to the selection of patients who would benefit
from a combination immunotherapy, targeting PD-1 and either Dies1/VISTA or CTLA4 (Figure 8).
The results herein described raise the hypothesis that Dies1/VISTA and CTLA4 may be the silent PD-1
partners in GC, explaining the good response observed in patients harboring PD-L1-negative tumors,
treated with anti-PD-1 therapy [18–20,37]. Overall, our results support that most GCLS patients will
benefit from anti-PD-1 therapy combined with either anti-Dies1/VISTA or anti-CTLA4 (Figure 8).
This novel data is worth further studies. To evaluate, in different GC cohorts, protein expression
of multiple immunotherapy targets, besides PD-L1, would be crucial to integrate gene and protein
expression data, as well to explore the topographic distribution (i.e., cancer cells versus TME immune
cells) of different biomarkers. Of notice, Dies1/VISTA expression has already been assessed in a large
GC series, and its expression was mostly detected in >80% of TME immune cells [26].
Our study also revealed that, beyond MSS/MSI-high and EBV infection, the morphological entity
GCLS was strongly associated with PD-1 high expression. In fact, ~80% of all GCLS presented high
PD-1 mRNA expression (Figure 8).
Altogether, our data demonstrated that a small transcriptomic panel can separate MSI/EBV−
from MSS/EBV+ GC cases, and this may have clinical utility. Also, our analysis demonstrates that
EBV+ GCs with GCLS morphological features is the biological subgroup that would more likely
respond to immunotherapy, as they present higher PD-1 expression, the key immunotherapy target in
GC, together with Dies1/VISTA and CTLA4. These observations support the ongoing GC clinical trials
and highlight GCLS as a useful feature to stratify patients for targeted immunotherapies.
4. Materials and Methods
4.1. Case Series
Tissue samples were obtained retrospectively from 46 patients with GC who had undergone
gastrectomy as primary treatment at Centro Hospitalar São João (Porto, Portugal). For mRNA
extraction, frozen tissue was available from 23 cases, whereas FFPE tissue was used in the remaining
23 cases. The series was enriched with GC cases harboring EBV infection (n = 15) and MSI-high status
(n = 27), whereas the remaining four cases were EBV− and MSS. EBV infection and MSI status were
investigated as described below. Histopathological analysis was performed on H&E sections and the
tumors were classified as GCLS or CA, based on the abundance of the lymphoid infiltrate.
4.2. EBV In Situ Hybridization
The presence of EBV infection was studied by chromogenic in situ hybridization (ISH) for EBV−
encoded RNA (EBER-ISH, INFORM EBER probe, Ventana Medical Systems, Tucson, AZ, USA).
One 3 μm section was processed in the automatic Ventana Benchmark Ultra platform with enzymatic
digestion (ISH protease) and the iViewBlue detection kit.
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4.3. PCR/Fragment Analysis for MSI Status
Genomic DNA was extracted from frozen or FFPE tissues (four sections, each 10 μm thick),
using QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA), in accordance with the manufacturer’s
instructions. DNA purity and quantification were assessed using the NanoDrop 2000 UV-Vis
spectrophotometer (NanoDrop products, Wilmington, DE, USA). Five mononucleotide markers
(BAT-25, BAT-26, NR-24, NR-21 and NR-27) were used as a pentaplex panel to determine MSI status
(Multiplex PCR, Qiagen, Valencia, CA, USA). Tumors with instability involving at least two of the five
loci were classified as MSI.
4.4. Gene Expression Profiling by Nanostring nCounter Assay
Total RNA was extracted from frozen or FFPE tissues (four sections, each 10 μm thick), using
miRNeasy Mini Kit (Qiagen, Valencia, CA, USA), in accordance with the manufacturer’s instructions.
High tumor content of the samples was ensured by morphological evaluation of mirror H&E sections
of frozen samples and by microdissection of tumor areas in sections from FFPE blocks. For Nanostring
nCounter assay, we used a custom-designed panel comprising 474 genes previously published [23]
and additional genes associated with immune response (CCL22, CCR7, CD3D, CD3E, CD3G, CD8A,
CD8B, CD19, CD20, CD45, CD68, CXCL10, CXCL11, FOXP3, GZMA, GZMB, IL4, IL13, PD-1, PD-L1,
TNFA, VISTA/Dies1). Nanostring probe hybridization was performed as a service at Genome Institute
of Singapore. Raw counts obtained for each sample were normalized using nSolver software version
3.0 (NanoString Technologies). We performed: (1) background subtraction using eight negative control
probes included in the Nanostring CodeSet; (2) positive control normalization using six positive
control probes also included in the Nanostring CodeSet; (3) housekeeping normalization using the
standard method in the software and five independent housekeeping genes included in the Nanostring
CodeSet. Normalized log2-scaled counts were used for to construct heatmaps, dendrograms and
to perform PCA described in this study, using the R environment and the packages “ggplot2” and
“ggfortify” [40–43]. Next, each sample was identified concerning its MSS/MSI-high phenotype and/or
EBV infection status to perform comparison analysis using also the nSolver software (NanoString
Technologies). Calculated ratios and FDR was used to define the set of up/downregulated DE-genes
considering the comparison performed: genes with ratio above 1.5 and FDR < 0.05 were classified as
differentially expressed upregulated genes; genes with ratio below 0.67 and FDR < 0.05 were classified
as differentially expressed downregulated genes.
4.5. PD-L1 Immunohistochemistry
Staining for PD-L1 was performed in FFPE 3 μm sections with a rabbit monoclonal antibody
(clone E1L3N, 1:1000; Cell Signaling Technology) on the automatic Ventana Benchmark Ultra platform,
using the OptiView Universal DAB detection kit and the OptiView Amplification kit from the same
manufacturer. PD-L1 immunoexpression was evaluated semi-quantitatively for tumor epithelial
and stromal immune cells, according to the immunoreactivity scoring system (IRS) described by
Boger et al. [44]. PD-L1 expression in tumor epithelial cells was dichotomized as positive (detected)
or negative (absent) by an immunoreactivity score (IRS) of 2. PD-L1 expression in immune cells of
the TME was defined as low (1–5% of positive cells), intermediate (6–20% of positive cells) or high
(>20% of positive cells).
4.6. Functional Annotation and Statistical Analysis
Functional annotation was performed using the online tool DAVID 6.7 [24,25]. In particular,
we have used the option ‘Functional Annotation Clustering’ using always the stringency ‘high’ and
the option ‘Functional Annotation Chart’. Selected clusters and/or biological terms were considered
enriched and reported in this study if presenting an FDR < 0.05. Normalized log2-scaled counts for
the genes CTLA4, PD-1, VISTA/Dies1 and PD-L1 was collected from nSolver software (NanoString
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Technologies), as previously described. Boxplots were plotted using R [40] and represented p-values
derived from a Wilcoxon test (Mann-Whitney) also performed using R and all samples (including
outliers). After building a contingency table for the number of cases in each detailed condition,
a Fisher’s exact test was performed using R. This test was selected rather than the chi-square test,
due to the low number of samples available in our cohort.
5. Conclusions
In this study, we have shown that the expression profile of GC cases for the assessed 499 genes
was strongly correlated with the established molecular subtypes currently used for GC molecular
stratification. Altogether, our results have clearly associated: (1) MSI-high/EBV− GC cases with
mitosis and cell cycle biological terms; (2) MSS/EBV+ GC cases with immune response mediated
by T-cells. Importantly, we have also shown that the MSI status is a much more relevant molecular
classifier than EBV infection. We have also revealed that PD-L1 and PD-1 have opposite mRNA
expression patterns in GC, in correlation with MSI phenotype, EBV status and prominent immune
infiltrate, as revealed by the GCLS morphological feature, a highly relevant finding as both genes are
nowadays actively pursued as targets for immunotherapy in GC. Moreover, our study has shown that
Dies1/VISTA and CTLA4 are highly expressed in the majority of EBV+ and GCLS cases, strengthening
the relevance of clinical trials using antibodies raised against these two proteins in combination with
the promising anti-PD-1 therapy.
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Abstract: Over the last decade, our understanding of the mechanisms underlying immune
modulation has greatly improved, allowing for the development of multiple therapeutic approaches
that are revolutionizing the treatment of cancer. Immunotherapy for gastric cancer (GC) is
still in the early phases but is rapidly evolving. Recently, multi-platform molecular analyses
of GC have proposed a new classification of this heterogeneous group of tumors, highlighting
subset-specific features that may more reliably inform therapeutic choices, including the use of new
immunotherapeutic drugs. The clinical benefit and improved survival observed in GC patients treated
with immunotherapeutic strategies and their combination with conventional therapies highlighted
the importance of the immune environment surrounding the tumor. A thorough investigation
of the tumor microenvironment and the complex and dynamic interaction between immune cells
and tumor cells is a fundamental requirement for the rational design of novel and more effective
immunotherapeutic approaches. This review summarizes the pre-clinical and clinical results obtained
so far with immunomodulatory and immunotherapeutic treatments for GC and discusses the novel
combination strategies that are being investigated to improve the personalization and efficacy of
GC immunotherapy.
Keywords: gastric cancer; immunotherapy; immune checkpoint; chimeric antigen receptor;
cancer vaccine; adoptive immunotherapy; Epstein–Barr virus; microsatellite instability;
tumor microenvironment
1. Introduction
Gastric carcinoma (GC) is the third most common cause of cancer deaths worldwide with a median
overall survival (OS) time for patients diagnosed in a metastatic stage still less than one year [1]. A high
proportion of patients diagnosed with GC (≈65%) present with inoperable or metastatic disease,
and the survival rate of GC patients decreases dramatically as the tumor stage increases (Table 1).
Surgical resection is the primary choice of treatment, with limited resection in stage T1N0; preoperative
chemotherapy and surgery, followed by post-operative adjuvant chemo/radiotherapy in stages >T1N0
(advanced tumor); and palliative chemotherapy (supportive care, double, triple regimens ± targeted
therapy) in metastatic disease (metastatic tumor) (Table 1). Currently, in non-metastatic advanced
GC (>T1N0), the best available systemic therapy combinations only yield a median progression-free
survival (PFS) time of 5 to 7 months and a median OS in the range of 8 to 11 months.
Int. J. Mol. Sci. 2018, 19, 1602; doi:10.3390/ijms19061602 www.mdpi.com/journal/ijms126
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Table 1. Tumor stage and associated survival rate.




1 T1-2, N0-1, M0 69 Surgical resection
2 T1-4a, N0-3a, M0 43 Preoperative chemotherapy and surgery followed bypost-operative adjuvant chemo/radio-therapy
3 T1-4b, N1-3b, M0 28
4 Tx, Nx, M0 9 Palliative chemotherapy ± targeted therapy
TNM Classification of malignant tumors [2]. T: size of the primary tumor; N: lymph node involvement; M: metastasis.
Recently, immunotherapy has emerged as one of the most promising strategies in cancer
treatment, with outstanding results in several tumor types [3–5]. The clinical successes of immune
checkpoint inhibitors have revolutionized cancer treatment, clearly indicating that targeting the
host’s immune system rather than the tumor may be more effective than conventional therapies.
Although encouraging, the results obtained so far in GC patients have, however, still been
unsatisfactory, and the majority of novel immunotherapies in this setting are still in the early
phases of clinical investigation [6,7]. The most promising response rates obtained so far by
this class of immunotherapeutic drugs were induced by pembrolizumab monotherapy, targeting
programmed death 1 (PD-1) cells in pre-treated patients with advanced GC [8]. Now, ongoing
randomized clinical trials are conducted to assess pembrolizumab’s safety and efficacy in earlier lines
of therapy and in combination with chemotherapy for patients with advanced adenocarcinomas of the
gastroesophageal junction (GEJ) [9]. Several complex factors are limiting the development of effective
immunotherapeutic strategies for GC, including the heterogeneous immunogenicity among and within
tumor subtypes and the different and still poorly defined immunosuppressive mechanisms that may
hamper effective control of the tumor by host immune cells. In the recently proposed molecular
Cancer Genome Atlas (TCGA) GC classification, the PD-L1 gene was found to be amplified more
commonly in Epstein–Barr virus (EBV)-positive and microsatellite instable (MSI)-high GC subtypes
with respect to the other subtypes [10,11]. Nonetheless, clinical responses were also observed both in
PD-L1- and EBV-negative patients, again highlighting the complexity of the mechanisms underlying
the responses to immune checkpoint blockade. Thus, at the clinical level, it is not clear why some
patients respond to certain immunotherapies and others do not. Therefore, there are no validated
biomarkers allowing reliable discrimination of responders from non-responders. A deeper genetic and
immunologic characterization of GC is required to guide patient selection and identify those who could
benefit from immune intervention in monotherapy, or more likely, within combination schedules.
2. Immunosurveillance and Immunoescape
The critical role of host immunity in controlling cancer development and progression is now well
recognized [12]. Data accumulated so far are consistent in indicating that our immune system is able
to prevent cancer development through a process termed immune surveillance [12]. This complex
process functions through a mechanism of “immunoediting”, which consists of three sequential phases:
(1) the elimination phase, in which growing tumors are effectively recognized and cleared by the
synergic actions of innate and adaptive immune responses that also recognize remodeling of stroma
and changes in the microenvironment; (2) The equilibrium phase, during which, antigen presenting
cells, tumor cells and CD8+ T cells remain in a state of dynamic balance and the surviving tumor
cells remain quiescent under the pressure of immune cells. In this long phase, the immune system of
the host sculpts the immunogenicity of genetically unstable tumor clones, allowing for the selection
of resistant tumor cells, thus leading to (3) the escape phase, favored by regulatory (Treg) cells and
immunosuppressive cytokines, including transforming growth factor-β (TGF-β), Tumor Necrosis
factor (TNF)-α, and Interleukin (IL)-10 [12].
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Dying cancer cells may express and release tumor-specific and tumor-associated antigens
that can be taken up and processed by tissue resident dendritic cells, which then maturate in
professional antigen-presenting cells in the presence of an appropriate microenvironment, usually
enriched in activator molecules, the so-called danger-associated molecular patterns (DAMPs) [12].
Induction of effective anti-cancer immunity generally requires that mature antigen presenting cells
efficiently present tumor antigens in the form of peptides to CD8+ T lymphocytes through major
histocompatibility complex (MHC) Class I molecules and to CD4+ T lymphocytes through MHC
Class II molecules. The immunogenicity of tumor antigens varies considerably, the strongest tumor
antigens being those provided by non-self or mutated proteins, such as those encoded by viruses or
generated by somatic mutations occurring in expressed genes. These latter antigens, the so-called
neo-antigens, are generally unique for each individual tumor, thus providing the rationale for
personalized immunotherapy. For efficient activation of the CD8+ T cells, three different signals
are required: T-cell receptor signalling activation after recognition of antigenic peptides in the context
of MHC Class I molecules, co-stimulatory molecules, and cytokines provided by professional antigen
presenting cells [12]. After activation, T lymphocytes proliferate, infiltrate the tumor, promote the
recruitment of other immune cells, and directly kill the cancer cells through the release of cytokines,
perforin and granzymes [12]. Incomplete T-cell activation in response to suboptimal amounts of
IL-2 or the absence of co-stimulatory signals usually results in T-cell anergy. Another important
phenomenon negatively affecting the efficacy of antitumor immune responses is the induction of
T-cell exhaustion promoted by the complex network of immunosuppressive cells and cytokines that
characterize the tumor microenvironment [13]. T cell exhaustion is a state of altered functionality of
these cells, which progressively lose their proliferation, cytokine production, and cytotoxic capabilities.
Evidence accumulated so far clearly indicates that exhausted T cells up-regulate the expression of
inhibitory receptors, including programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte
antigen-4 (CTLA-4), lymphocyte activation gene 3 (LAG-3), T cell immunoglobulin and mucin domain
containing-3 (TIM-3), B and T lymphocyte attenuator (BTLA), and T cell immunoreceptor with Ig and
ITIM domains (TIGIT) [13,14].
The tumor microenvironment may also impair anti-tumor immunity by promoting the
polarization of infiltrating immune cells towards less cytotoxic and pro-inflammatory subsets of T cells
(e.g., TH2, TH17 and Treg cells). In GC, the tumor-associated macrophages (TAMs) constitute one
of the most abundant immune cell populations present in the tumor microenvironment. These cells
can exert anti-tumor activities, or have pro-tumorigenic effects supporting cancer initiation and
malignant progression according to differentiation patterns into M1 or M2 subtypes [15]. M1 TAMs
exert anti-tumor effects through the release of pro-inflammatory cytokines (IL-1, IL-6, IL-23, TNF-α),
whereas M2 TAMs may drive local immune suppression by producing IL-10 and TGF-β. Indeed, TAM
infiltration has been shown to functionally inhibit T cells in GC [16,17] and may be a marker of
poor prognosis [18,19]. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population
of immature myeloid cells able to inhibit both innate and adaptive immune responses against
tumors [20]. These cells are characterized by the ability display have unique features according
to the different environments to which they are recruited. The various suppressive properties
and functions displayed by MDSCs include increased arginase-1 (Arg-1) and inducible nitric oxide
synthase activities, elevated production of nitric oxide and reactive oxygen species, and secretion of
various pro-inflammatory cytokines [21]. It has been demonstrated that GC patients have increased
numbers of MDSCs in the blood compared with healthy individuals, and this increase was associated
with poor clinical outcomes [22]. Another major component of the immune suppressive tumor
microenvironment is represented by Treg cells, which may inhibit cytotoxic lymphocytes and/or
helper T-cell activity as well as natural killer (NK) cells. Physiologically, Treg cell function is critical
to maintain immunological tolerance to self-antigens and suppress excessive immune responses that
could potentially be deleterious to the host. Tregs have also been identified as the major regulatory
component of the adaptive immune response in H. pylori-related inflammation, GC and bacterial
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persistence [23] as well as in EBV-related GC [24]. A recent study demonstrated that Foxp3+CD4+ICOS+
effector Tregs (eTregs), which has highly suppressive functions, was more abundant in late stage
GCs [25]. These tumor infiltrating Tregs exhibited the ability to produce IL-10, but not IFN-γ, TNF-α,
or IL-17 and to inhibit the proliferation of responder CD8+ T cells.
The presence of tumor infiltrating lymphocytes (TILs) can be detected in various cancers,
including GC. Nevertheless, the considerable variability in the number, types and spatial distribution
of infiltrates suggests that some tumor types are more immunogenic than others. Indeed, tumors with
a low burden of neo-antigens generated by somatic mutations are considered poorly immunogenic and
usually show limited or a total absence of infiltration by TILs (immune-desert tumors). The absence
of intra-tumoral lymphoid infiltrate may also be due to defects intrinsic to the multi-step T-cell
trafficking and homing cascade, a phenomenon that may significantly contribute to immunotherapy
resistance [26].
Evidence accumulated so far indicates that TILs may have an important role in influencing the
clinical course of various tumors, also including GC [27]. A higher density of both intra-tumoral cytotoxic
CD8+ TILs and regulatory FoxP3+ Treg cells is associated with good prognosis, and this is particularly
true for MSI GC, including those that are H. pylori- or EBV-positive [24,28]. A recent meta-analysis
of 31 observational studies including 4,185 GC patients investigated the significance of the prognostic
role of specific T-cell subsets, focusing on overall survival and disease-free survival [29]. In particular,
the study concluded that the numbers of CD8+, FOXP3+, CD3+, CD57+, CD20+, CD45RO+, Granzyme
B+ and T-bet+ infiltrating lymphocytes were significantly associated with improved survival (p < 0.05).
Notably, the amount of CD3+ TILs in the intra-tumoral compartment was the most significant prognostic
marker (pooled Hazard ratio, HR = 0.52; 95% CI = 0.43–0.63; p < 0.001). B-cell activation may also influence
tumor prognosis, by producing antibodies against tumor antigens and by activating of a specific B-cell
subset (i.e., Breg) that secrete anti-inflammatory mediators (e.g., IL-10) and convert T cells to regulatory
T cells (Treg), thus attenuating anti-tumor immune responses [30]. It has been demonstrated that in vivo
primed and in vitro activated B cells have showed therapeutic efficacy in adoptive immunotherapy
protocols [31,32]. Notably, effector B cells were shown to directly kill tumor cells [32]. On the other hand,
resting B cells can promote the development or malignant progression of cancer [33,34].
3. Immune-Based Therapies
3.1. Adoptive Cell Immunotherapy
The tumor-killing properties of T cells and natural killer (NK) cells provide opportunities to
treat cancer. Tumor infiltrating lymphocytes (TILs) and NK cells may have predictive and prognostic
relevance in GC [35–39]. Adoptive cell therapies may harness this potential with different modalities.
The main strategy involves the isolation of immune cells from a cancer patient, their subsequent
genetic modification or treatment to enhance their activity to specifically recognize and kill tumor cells.
After adequate ex vivo expansion, these immune cell populations are re-infused into the patient [40].
This process is applicable to most of cancer patients who are unable to mount an effective anti-cancer
immunity, and therefore, probably also unable to respond to immune checkpoint inhibitors. There are
several different strategies of adoptive cell therapy being used for cancer treatment, most of them have
been or are being investigated in the clinical setting for their potential efficacy in GC patients.
In this setting, MHC Class I-restricted T cells specifically recognizing GC antigens can be
successfully isolated from primary tumors, metastatic lymph nodes and ascites from GC patients [41].
However, the limited proportion (about 40%) of biopsies yielding satisfactory T cell populations and
the time (about 6 weeks) required to generate adequate numbers of cells for infusion have limited
the applicability of approaches using TIL cells [35]. Alternative modalities to generate tumor-specific
immune cells have been investigated to overcome these limitations, including the use of cytotoxic T-cell
lines generated from the spleen of GC patients [42] or the expansion and re-infusion of T lymphocytes
taken directly from a patient’s blood after they have received a cancer vaccine. Indeed, it has been
129
Int. J. Mol. Sci. 2018, 19, 1602
shown that “priming” rare tumor antigen specific T cells first, with active immunization, is associated
with more effective expansion of tumor-specific T cells, which can be obtained in greater numbers for
therapeutic infusion [35].
The use of in vitro expanded allogeneic NK cells, which have cytotoxic function and the
potential to exert antibody-dependent cellular cytotoxicity (ADCC), appears particularly promising
for cancer immunotherapy. Compared to autologous NK cells, allogeneic NK cells are more suitable
for quality control and large-scale production and have the advantage of not being inhibited by
self-histocompatibility antigens, unlike T cells. To expand ex vivo NK cells (over 1000-fold expansion),
peripheral blood mononuclear cells of healthy donors or patients are co-cultured in the presence of
irradiated K562 leukemia cells that have been modified to express membrane-bound IL-15 and 4-1BB
ligands in the presence of IL-2 and IL-15 cytokines in the culture media [43]. However, clinical-grade
NK cells at sufficiently high numbers represents a great challenge; therefore, alternative methods to
obtain sufficient functional NK cells have been investigated [44–46]. Cytotoxic cell lines have been
also established from patients with clonal NK-cell lymphoma, and one of them, the NK-92 cell line,
has been infused into patients with advanced cancer and showed clinical benefit with minimal side
effects [29]. The use of an established NK cell line offers several advantages compared to the use
of in vitro expanded NK-cells. Notably, a NK-cell line does not cause graft versus host rejection,
and thus can safely be used in allogeneic settings. Based on these considerations, researchers are
now exploring the use of engineered NK cells, including the NK-92 cell line, for the treatment of
various haematological and non-haematological malignancies. The first chimeric antigen receptor
(CAR)-expressing NK-92 cells were generated almost 15 years ago [47]. These cells demonstrated
high efficacy against Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast and ovarian
cancer cells both in vitro and in vivo [48]. The therapeutic efficacy of this HER2-CAR NK-92 cells
has been tested in established mouse models of orthotopic human glioblastoma, renal cell and breast
carcinoma [49]. Results of these studies demonstrated specific homing of the NK cells to the tumor
sites, a reduction in the number of metastases and significant tumor regression, indicating that this
could constitute a promising therapeutic approach for HER2+ GC.
Another adoptive cell therapy approach is based on the exploitation of the immunotherapeutic
properties of a heterogeneous population of immune effector cells: the cytokine-induced killer
cells (CIK). These cells can be obtained by treating peripheral blood lymphocytes with interferon-γ
(IFN-γ), a monoclonal antibody against CD3 and an interleukin (IL)-2 [50]. CIK cells are mainly
expansions of CD3+CD8+CD56− negative cells to terminally differentiated CD56-positive natural killer
(NK) T cells. These cells have the peculiar capacity of recognising tumor cells both in the presence
and in the absence of antibodies and MHC; thus, they can also recognise tumor cells that are missing
MHC molecules on their surfaces. The cytotoxicity of CIKs is mediated by perforin release and is
dependent on the interaction between killer cell lectin like receptor K1 (NKG2D) and NKG2D ligands.
Moreover, in vivo CIK cells can also regulate and increase host cellular immune function through
the secretion of several cytokines and chemokines. Available evidence indicates that combination
therapy with chemotherapy and CIK generally improves the progression-free survival (PFS) and
overall survival (OS) times of patients with cancer, including GC (Table 2). Some chemotherapies
(e.g., doxorubicin, mitoxantrone, oxaliplatin and cyclophosphamide) may add positive immune effects
by fostering CD8+ T-cell infiltration into the tumor and promoting the release of tumor antigens
through the induction of immunogenic death of tumor cells [51]. Two meta-analyses considering
relevant clinical trials concluded that CIK cell therapy significantly increases the 5-year OS rate of
GC patients compared to conventional chemotherapy, thus providing statistical evidence to support
the activation of large-scale clinical trials with CIK cell therapy [52,53]. Interestingly, the percentage
of lymphocyte subsets (CD3+, CD4+ and CD3−CD56+, CD3+CD56+; p < 0.01) and the levels of
IL-12 and IFN-γ, which reflect immune function, were significantly increased (p < 0.05) after the
CIK/DC-CIK therapy [53]. A particularly attractive perspective for the clinical exploitation of CIK
cells is their combination with monoclonal antibodies [54]. Indeed, pre-clinical evidence has been
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provided indicating that CIK cells combined with a monoclonal antibody against epidermal growth
factor receptor (EGFR) enhance the antitumor ability of CIK cells both in vitro and in vivo [55].
In summary, the overall data reported so far indicates that autologous immune cell administration
with adjuvant chemotherapy is associated with better prognosis for patients with GC compared to those
treated with chemotherapy only [34]. Some examples are reported in Table 2. Nevertheless, current
approaches of adoptive cell-based immunotherapy need to be improved to make clinical application
more feasible. In this respect, it has been shown that T/NK cell-mediated anti-tumor activity may
be suppressed by tumor or stromal cells via inhibitory soluble factors/cytokines or through the
engagement of inhibitory immune checkpoint molecules. These findings strongly suggested that
blocking inhibitory regulators of T/NK cells might be an attractive and promising strategy to increase
the efficacy of T/NK cell-based tumor immunotherapy [56].
Table 2. Adoptive cell immunotherapy for gastric carcinoma (GC).




advanced GC (n = 23) 13% CR 21.7% PR [57]
Autologous peripheral blood
lymphocytes activated by
anti-CD3 antibody and interleukin
(IL)-2 + chemotherapy
GC with a life expectancy
>12 weeks (n = 84)
OS in patients that had received
surgery was prolonged after
EAAL immunotherapy
[58]
Ex vivo expanded natural killer
(NK) in co-culture with K562 [43]






metastatic GC (n = 3)
phase I trial, good tolerability [44]




metastatic GC (n = 3)
phase I well tolerated with no
severe adverse events [45]




advanced GC (n = 151)
5-year OS 46.8 vs. 31.4% intestinal
type (p = 0.045), 5-year DFS 28.3
versus 10.4% (p = 0.044)
[59]
Autologous CIK + chemotherapy post-operative locallyadvanced GC (n = 95)
DFS and OS were longer in pts
with higher major
histocompatibility complex
(MHC)-I-related gene A (MICA)
[58]
Autologous CIK + chemotherapy post-operative locallyadvanced GC (n = 156) longer OS [60]
Autologous CIK + chemotherapy GC stage II-III (n = 226) longer DFS and OS [61]
Autologous CIK + oxaliplatin post-operative stage II-IIIGC (n = 167)
higher 5-year OS rate (56.6% vs.
26.8%, p = 0.014) and
progression-free survival (PFS) rate
(49.1% vs. 24.1%, p = 0.026)
[62]
Autologous CIK + FolFox4 post-operative GC (n = 51) reduced GC recurrence rates andenhanced survival rates [63]
EAAL: expanded activated autologous lymphocytes; DFS: Disease-free survival.
3.2. Engineered Cells for Adoptive Immunotherapy
To broaden the applicability and enhance the efficacy of adoptive cell therapy that could
potentially lead to the elimination of the tumor cells, techniques have been recently developed
to introduce antitumor antigen receptors into normal T cells that could be then used for therapy.
The specificity of T cells can be redirected towards tumor cells by the use of viral vectors,
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allowing the expression of CARs specific for tumor antigens [64,65]. The T-cell receptor (TCR)
recognition process requires antigen presentation via the major histocompatibility (MHC) complex.
However, a significant proportion of tumors down-regulate MHC expression to escape immune
surveillance. Engineering T lymphocytes with chimeric antigen receptors (CAR) and combining B cell
receptor-derived and T cell receptor domains, has the advantage of bypassing the need for MHC
interaction and costimulatory molecules. The extracellular portion of CAR-T cells is a ligand-binding
domain composed of a B cell receptor-derived single-chain variable fragment, whereas the signalling
domain is composed of CD3ζ and one or more intracellular costimulatory domains (Figure 1).
The adoptive transfer of CAR-T cells has so far demonstrated promising antitumor effects in
advanced hematologic malignancies, but only limited benefits in patients with solid tumors. This may
be due to the heterogeneous tumor antigen expression, immunosuppressive networks in the tumor
microenvironment, the suboptimal trafficking of T cells into solid tumors and the lack of effective
costimulatory signals required for CAR-T persistence after infusion [64–66]. In pre-clinical models of
GC, treatment with CAR-T cells specific for the HER2 oncoprotein as well as the use of a bifunctional
αHER2(Ag1)/CD3 (Ag2) RNA-engineered CAR-T-like human T cells, induced a marked regression of the
tumor and prolonged the survival of tumor-bearing mice [67,68]. Of note, in addition to classical CAR-T
cells, CAR T-like constructs also able to secrete soluble forms of the CAR receptor were able not only to
directly kill HER2+ GC, but also to transfer this ability to bystander T cells [68]. Another HER2-targeting
CAR-T constructs harboring T-costimulatory molecules (i.e., 4-1BB, CD3ζ exhibited a considerably
enhanced tumor inhibition ability and was able to promote long-term survival and T-cell homing to GC
xenotransplanted mice [69]. CAR-T cells were also shown to eliminate patient-derived GC stem-like cells,
an important effect to search for and implement, to enhance the possibility of eradicating tumor cells [50].
A phase I/II clinical study (NCT02713984) involving patients with several HER2-expressing tumor types,
including GC, and treatment with HER2-targeting CAR-T cells is ongoing. Another therapeutic target
antigen for GC is the Human Carcinoembryonic Antigen (CEA), an oncofetal glycoprotein overexpressed
in gastrointestinal carcinomas. With the aim of enhancing the antitumor activity and in vivo persistence
of CAR-T cells, CAR-T were engineered with a construct, combining CEA with a fusion protein of IL-2.
In comparison with free IL-2, the combination of CAR-T cells with IL-2 significantly enhanced the
antitumor activity against human GC cell line MKN-45 cells [70]. Several phase I studies are investigating
the safety and therapeutic efficacy of CAR T cells redirected towards different GC antigenic targets,
including CEA, MUC1 (mucins lining the apical surface of epithelial cells in GC) and EpCAM (an epithelial
cell adhesion/activating molecule) (Table 3).
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Figure 1. Chimeric antigen receptor (CAR)-T cell therapy T cells are isolated from blood of the patient
or a donor, activated, and genetically engineered to express the CAR construct. Engineered CAR-T cells
are then reinfused into the patient. The extracellular portion of CAR-T cells is a ligand-binding domain
composed of a B cell receptor-derived single-chain variable fragment (VH-VL), whereas the T-cell
receptor molecule signalling domain is composed of CD3 molecules and a ζ-chain (zeta chain) and
one or more intracellular costimulatory domains required for T-cell stimulation (i.e., CD28 and 4-1BB
or CD137). CAR-T cells can also be engineered to recognize two different antigens (dual specificity
CAR-T cells). In addition to classical CAR-T cells, new CAR T-like constructs are also able to secrete
soluble forms of the CAR receptor. The secreted CAR construct was demonstrated to be able not only
to directly kill HER2+ GC, but also to transfer this ability to bystander T cells. More recent approaches
have been based on the use of CAR-T cells genetically modified to express CARs along with a gene
cassette driving the expression of cytokines (red arrow) that enhance T-cell activity.
Despite the efficacy shown by CAR-T-cell therapy in some clinical settings, this novel treatment
strategy may be burdened by unique acute toxicities, which can be severe or even fatal [71].
Cytokine-release syndrome (CRS) is the most frequently observed adverse event, which can range
in severity from low-grade constitutional symptoms to a high-grade syndrome associated with
life-threatening multi-organ dysfunction. Only rarely, severe CRS can evolve into fulminant
haemophagocytic lymphohistiocytosis. Neurotoxicity, defined as CAR-T-cell-related encephalopathy
syndrome, is the second most frequent adverse event, and can occur concurrently with or after CRS.
Considering that antigens on cancer cells may be also expressed on normal cells, on target off-tumor
toxicity can occur upon stimulation of T cells following the binding of CARs to their antigens on the
normal cells/tissues. Life-threatening on target off-tumor toxicity may particularly occur in cases
in which the target antigen is expressed in vital tissues such as the respiratory system. This fatal
occurrence was reported in a patient with metastatic colorectal cancer following the administration
of ERBB2 CAR-Ts where low expression of ERBB2 on respiratory normal epithelial cells led to
acute pulmonary manifestation and the patient’s death 5 days after the injection of CAR-Ts [72].
New strategies such as designing CAR-Ts with limited life-span or “on-switch CARs” are under
investigation to ameliorate the toxicity of CAR-T.
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Table 3. Engineered adoptive T/NK cells—CAR-T cells.
Type of Treatment Setting Type of Study/Trial Reference/Trial No.
CAR T cell therapy targeting
human epidermal growth factor
receptor 2 (HER2)
HER2+ GC pre-clinical studies [67,69]
CAR-T-like T cells targeting HER2 HER2+ GC pre-clinical study [68]
CAR targeting HER2+
HER2-positive solid tumors
(breast cancer, ovarian cancer,
lung cancer, GC, colorectal cancer,
glioma, pancreatic cancer)
ongoing phase I studies NCT02713984
CAR targeting the





Mucin-1 (MUC1) GC MUC1-positive ongoing phase I NCT02617134
CAR targeting the epithelial cell
adhesion molecule (EpCAM) GC EpCAM-positive ongoing phase I studies
NCT02725125
NCT03013712
3.3. Immune Checkpoint Inhibitors/Immune Modulatory Pathways
Immune checkpoint therapy exploits the function of molecules that physiologically regulate and
balance immune responses by inhibiting T-cell activation or, alternatively, by activating stimulatory
pathways with the final result to maintain homeostasis and avoid tissue damages due to excessive
immune activation. In the field of cancer immunotherapy, these treatments are designed to release or
enhance pre-existing anti-cancer immune responses. Indeed, tumor cells may induce T-cell suppressive
signalling to successfully evade immune-mediated tumour eradication, a phenomenon called adaptive
immune resistance. The inhibitory signals suppressing T-cell activation are mediated by a variety
of “immune-checkpoint” molecules (inhibitory ligands and their cognate receptors), including the
CD28/cytotoxic T-lymphocyte antigen 4 (CTLA-4) axis, and PD-L1/PD-1 pathway, which have
emerged as promising targets. Other checkpoint molecules, such as TIM3, B7H3, VISTA, LAG3,
and TIGIT, are currently being evaluated as potential targets for cancer immunotherapy [73] (Figure 2).
Pathways involving these regulatory molecules are crucial for maintaining the tolerance against
self-antigens and modulating the duration and amplitude of immune responses against non-self or
mutated tumor antigens in order to avoid tissue damage. When these negative regulatory proteins are
blocked, the inhibition of immune effectors is released, and these cells regain their ability to become
activated and kill tumour cells. The binding of the PD-1 receptor expressed at the surface of T cells
with its cognate ligands, PD-L1 and PD-L2, results in the inhibition of T-cell effector function and
decreased cytotoxic activity within the tumor bed. This is consistent with the notion that antibodies
targeting the PD-1/PD-L1 axis require the presence of tumor-specific T lymphocytes to be effective.
On the other hand, the ubiquitous CTLA-4 has non-overlapping suppressive effects on antitumor
immunity, being preferentially involved in controlling the earlier phases of the immune response
(priming), primarily in lymphoid organs. These effects occurring at different sites and during different
phases of the immune response support the rationale to combine the CTLA-4 blockade with antibodies
targeting the PD-1/PD-L1 axis.
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Figure 2. Blocking the immune checkpoint restores the ability of tumor-specific T lymphocytes to kill
tumor cells. Antibodies/agents against receptors on T cells (i.e., CTLA-4, PD-1, etc.), and/or their
relative ligands (i.e., B7, PDL-1, etc.) on antigen presenting cells or tumor cells re-activate pre-existing
anti-tumor T cells that can induce tumor cell killing. Recognition of the human leukocyte antigen (HLA)
Class I/peptide antigen complex by the T-cell receptor present on T cells is required to induce tumor
cell killing; (A) Inhibitory receptor/ligand interaction is not blocked and the tumor cell is not killed;
(B) the immune checkpoint receptor is blocked by an inhibitory antibody and the T-cell is re-activated
and is thus able to kill tumor cells. PVR: poliovirus Receptor; MHC: Major Histocompatibility Complex;
VISTA: V-domain Ig suppressor of T cell activation; VISTA-R: VISTA Receptor; Gal-9: Galectin-9;
PtdSer: Phosphatidylserine; HMGB1: High Mobility Group Box 1; CEAcam-1: Carcinoembryonic
antigen-related cell adhesion molecule 1; PD-L1: Programmed death-ligand 1; CTLA-4: Cytotoxic
T-Lymphocyte Antigen 4; PD-1: PD-L1: Programmed death 1; TIM-3: T cell immunoglobulin and
mucin domain 3; LAG-3: Lymphocyte-activation protein 3; TIGIT: T-cell immunoreceptor with Ig and
ITIM domains.
With regard to GC, data collected so far indicate that PD-L1 is expressed in about 65% of GC tissues
and CTLA-4 is expressed in 86% of cases, whereas these molecules are undetectable in normal gastric
mucosa of healthy individuals [74–76]. Notably, positive tumour cell staining for PD-L1 or CTLA-4
has been associated with an inferior OS in GC patients and TILs express PD-1, PD-L1, and CTLA-4
molecules at a significantly higher level compared to the T cells of the peripheral blood [77]. A recent
meta-analysis carried out on 15 studies, including 3291 GC patients, confirmed that the expression
level of PD-L1 in tumour cells significantly correlates with a worse OS. In addition, a subgroup analysis
showed that GC patients with deeper tumor infiltration, positive lymph node metastasis, positive
venous invasion, Epstein–Barr virus (EBV) infection, or GC showing microsatellite instability (MSI)
are more likely to express PD-L1. These findings suggest that GC patients, specifically those with
EBV+ and MSI tumors, may be preferred candidates for PD-1-targeting therapies [78]. A FISH analysis
demonstrated amplification of the gene encoding for PD-L1 in 11% of EBV+ cases, suggesting that
this genetic change may be associated with, or even promote, the clonal evolution and malignant
progression of EBV and GC [79]. The expression of PD-L1 by T/NK lymphocytes infiltrating GC may
be also of potential prognostic relevance. Functional studies carried out in vitro revealed that blocking
PD-1/PD-L1 signalling markedly enhanced cytokine production and cytotoxic activity while inhibiting
NK cell apoptosis. Intriguingly, treatment with a PD-1 blocking antibody significantly inhibited the
growth of xenografts in nude mice, an effect that was completely abrogated by NK depletion [80].
Like the alternative immune checkpoint molecule, VISTA appears particularly attractive as
a potential therapeutic target. VISTA is a type I membrane protein expressed predominantly in
myeloid, granulocytic and T cells. Although the ligands for VISTA are not yet known, available
evidence indicates that VISTA may serve both as a ligand (for antigen presenting cells) and as
a receptor (for T cells), and that VISTA suppresses T-cell activation, a function that could be
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independent of PD-1/PD-L1 signalling [81] an analysis of a cohort of 464 therapy-naive GC samples
and 14 corresponding liver metastases disclosed that VISTA expression in tumor cells was detected
in 41 GCs (8.8%) and two corresponding liver metastases (14.3%), but no significant correlation with
patient outcome was observed [82].
TIM-3 is a member of the TNF family and a negative regulator of CD4+ helper 1 and CD8+
cytotoxic T cells. [83]. It has been reported that the expression of TIM-3 defines a subpopulation of
specific PD-1+ exhausted CD8+ T cells with a low production of IFN-γ, TNF-α and IL-2, thus providing
a rationale for combining immunotherapy targeting both TIM-3 and PD-1 inhibitory molecules [84,85].
The anti-CTLA-4 ipilimumab antibody and the anti-PD-1 antibodies, pembrolizumab and nivolumab,
were first approved by the US Food and Drug Administration (FDA) for the treatment of patients with
metastatic melanomas in 2011 and 2014, respectively. However, data accumulated so far indicates that
while anti CTLA-4 antibodies yielded only partially satisfactory results, PD-1/PD-L1 inhibitors show
more promising results (Table 4). Interestingly, patients with a post-treatment CEA antigen proliferative
response had a median survival time of 17.1 months compared with 4.7 months for non-responders to the
anti-CTLA-4, tremelimumab (p = 0.004), suggesting a rationale for combinations of CTLA-4 blockade with
vaccines targeting GC antigens in the future [86]. Moreover, the efficacy of immunotherapies targeting
the PD-1/PD-L1 in different solid tumours stimulated the activation of combination studies with other
active targeted biologic agents or immune modulating treatments. Indeed, several clinical trials using
new antibodies targeting the PD-1/PD-L1 axis in combination with other immunotherapies are ongoing
(Table 4). The rationale supporting the combination of different immunotherapeutic agents is supported
by several pre-clinical data which indicate that targeting only one of the complex steps required for the
generation of effective anti-tumor immune responses is often insufficient. Moreover, taking into account
the ability of several chemotherapeutic drugs to induce immunogenic cell death, therapeutic approaches
combining immunotherapy and chemotherapy are also being actively investigated (Table 4).
Combination therapies with immune checkpoint inhibitors have also targeted the subset of
HER2-overexpressing tumors which almost invariably become resistant to trastuzumab-containing
regimens and progress. Pre-clinical evidence supports the rationale for combining trastuzumab
and inhibitors of the PD-1/PD-L1 axis. In fact, it has been demonstrated that HER-2 inhibition
can promote T-cell activation and trafficking, enhance IFNγ production by NK cells and boost
antibody-dependent cellular cytotoxicity which may efficiently synergize with inhibition of the
PD-1/PD-L1 pathway [87]. A phase Ib/II, open-label, dose-escalation study is investigating the
novel anti-HER2 mAb, margetuximab, in combination with pembrolizumab in patients with advanced
HER2-amplified GC who are refractory to standard trastuzumab-based combination chemotherapy
(NCT02689284) [88]. A variety of other combinations is being investigated in which, on the backbone
of inhibitors of the PD-1/PD-L1 axis, other drugs target additional nodes in the cancer immunity
cycle [89]. The latter include agents inhibiting other immune checkpoints (TIM3, LAG3), T-cell
costimulatory agonist antibodies (GITR, OX40, 4-1BB), enzymatic inhibitors (IDO-1), as well as
radiation and other cytotoxic drugs. In addition, the combination of nivolumab and GS-5745, a matrix
metalloproteinase 9 inhibitor, is also being investigated in patients with unresectable or recurrent
GC/GEJ adenocarcinoma (NCT02864381). Combination with radiotherapy, although still poorly
explored in the setting of GC, represents another promising therapeutic opportunity. Indeed, single
dose and fractionated radiotherapy has been found to upregulate tumor PD-L1 expression in various
pre-clinical models but also promotes the immunogenicity of tumor cells through the generation of new
antigens or enhanced exposure or release of existing tumor antigens. Therefore, concomitant treatment
with anti-PD1 antibodies may overcome the immune suppression activity mediated by PD-L1 that is
up-regulated by radiotherapy, thus allowing for the generation of more effective anti-tumor immune
responses that may lead to long-term tumor control [90]. Clinical trials involving GC patients are
ongoing, including studies combining pembrolizumab with palliative radiotherapy in the metastatic
setting, as well as with neoadjuvant chemoradiotherapy for GEJ and gastric cardia cancers in earlier
stage resettable disease (NCT02730546) [91].
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3.4. Agonistic Antibodies for Costimulatory Receptors
The generation of therapeutically effective immune responses requires not only relieving the
inhibition of negative regulatory pathways but also promoting T cell activation. T cell costimulation
through receptors, like OX40, 4-1BB or ICOS, provides a potent activation signal that actively promotes
the expansion and proliferation of killer CD8 and helper CD4 T cells [105–107]. Studies carried out in
pre-clinical models have demonstrated that treatment with OX40 agonists, including both anti-OX40
mAb and OX40L-Fc fusion proteins, results in tumor regression [105]. These effects are mainly due
to the ability of OX40 ligands to promote the survival and expansion of CD8 and conventional,
non-regulatory CD4 T cells. On the other hand, it is still unclear whether OX40 activation promotes
or inhibits Treg cell responses, as available data in this respect are not univocal [105]. A murine IgG
monoclonal agonistic antibody against OX40 was investigated in a phase I clinical trial in 30 patients
with metastatic solid malignancies. The treatment was overall tolerable, and six patients achieved
stable disease, whereas no partial response was observed [108]. Several phase I clinical trials are
currently ongoing with agonistic monoclonal antibodies targeting OX40 as a single therapy or in
combination with checkpoint inhibitors [105].
4-1BB (CD137) is an inducible costimulatory receptor expressed by T cells, NK cells,
and antigen presenting cells. Activation of 4-1BB by its ligand stimulates the proliferation and
activation of T and NK cells [106] Considering that activation of NK cells results in enhanced
antibody-dependent cell-mediated cytoxicity (ADCC), treatment with anti-41BB agonists not only
increases immune-mediated antitumor activity but may also enhance the therapeutic efficacy
of monoclonal antibodies, such as rituximab and trastuzumab, that function through ADCC
mechanisms [109]. Gonistic 4-1BB antibodies have demonstrated potent anti-cancer efficacy in
murine models and, on the basis of promising pre-clinical findings [110], several clinical trials have
been initiated using the utomilumab and urelumab antibodies, mainly in patients with advanced
solid tumors.
Inducible costimulator (ICOS) is a T cell costimulatory molecule belonging to the CD28/CTLA-4
family, which promotes the proliferation and cytokine production, mainly of CD4 T lymphocytes [111].
Up-regulation of ICOS is frequently found in activated T lymphocytes, particularly in patients treated
with anti-CTLA4 antibodies, and its expression is regarded as a biomarker that is indicative of the
binding of an anti-CTLA4 antibody to its cognate target [112]. Notably, the combination of ICOS agonist
antibodies with CTLA4 blockade results in strong synergistic effects due to the marked up-regulation
of ICOS expression of ICOS after anti-CTLA4 therapy [111]. JTX-2011, GSK3359609 and MEDI-570 are
ICOS agonistic monoclonal antibodies that are currently being investigated in phase I/II clinical trials
as monotherapies or in combination with checkpoint inhibitors, mainly in patients with advanced
solid malignancies.
3.5. Safety Issues Related to the Use of Checkpoint Inhibitors
Overall, checkpoint inhibitors are generally better tolerated than chemotherapy regimens
administered to patients with GC. Generally, the profiles of side effects that occur with different
anti–PD-1/PD-L1 inhibitors are broadly similar [113]. About 10–20% of GC patients treated with
anti-PD-1/PD-L1 monotherapy have adverse grade ≥3 events, including fatigue, anemia, and elevated
alanine and aspartate aminotransferase levels. Checkpoint inhibitor therapy may also induce
immune-related AEs (irAEs) that may affect rheumatic, gastrointestinal, skin, pulmonary, endocrine,
neurological, hepatic, cardiac, and renal tissues [114]. In patients with GC, pneumonitis and colitis
are the most common grade ≥3 irAEs. Usually, higher rates of treatment-related adverse events are
observed in patients treated with anti–CTLA-4 antibodies and combination regimens as compared with
anti-PD-1/PD-L1 monotherapies [114]. Although these adverse events are clinically manageable in
most cases, long-term sequelae and deaths have been reported in a small proportion of patients [114],
pointing to the need to adequately educate healthcare professionals and patients, perform close
monitoring, and activate multidisciplinary collaborations to effectively manage these adverse events.
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3.6. Cancer Vaccines
The therapeutic potential of cancer vaccines is due to their ability to activate and boost anti-tumor
immune responses. Dendritic cells (DCs), the critical target of all cancer vaccines, are professional
antigen presenting cells that play a pivotal role in orchestrating and coordinating anti-tumor immune
responses, and are able to activate NK cells, B lymphocytes, and naïve and memory T cells by presenting
tumor antigen/MHC complexes. In GC patients, higher numbers of DCs infiltrating the tumor have
been associated with lower lymph node metastases and better patient survival [115]. Several strategies
have been used to load DCs with tumor antigen as a vaccine, such as (i) synthetic peptide pulsed
on DCs, (ii) DCs engineered with plasmid DNA, RNA, or viruses, (iii) tumor cell lysate (e.g. RNA,
whole cell, phagosomes) mixed with immature DCs, (iv) DCs fused with whole tumor cells via PEG or
electroporation. The most widely used vaccines are based on DCs pulsed with MHC-restricted peptides
derived from known tumor-associated antigens, although the use of DCs in the clinical setting is limited
by the short life span of these cells in vivo. The tumor-associated antigens targeted so far by vaccines
for GC patients are melanoma-associated antigen (MAGE) A3 [116,117], HER2(p369) peptide [116],
gastrin-17 diphtheria toxoid (G17DT) [118,119], URLC10 or VEGFR1 epitopes [120] and heat shock
protein gp96 [121]; adjuvant BCG (Bacillus Calmette–Guérin) was also tested with chemotherapy [122]
(Table 5). To personalize the choice of peptides to be used as vaccines in individual GC patients,
pre-vaccination peripheral blood mononuclear cells of each patients were tested for their reactivity
in vitro to the repertoire of each MHC peptide, and only the reactive peptides were administered
in vivo [120]. Delayed-type hypersensitivity (DTH) to the vaccinated peptides was observed in some
patients, whereas increased cellular and humoral immune responses to the vaccinated peptides were
observed in others, with a concomitant prolonged survival [123]. Recently, encouraging clinical results
were obtained using HLA-A24-restricted vascular endothelial growth factor receptor 1 (VEGFR1)-1084
and VEGFR2-169 peptides, combined with S-1 and cisplatin chemotherapy [120]. Most patients (82%)
showed the induction of VEGFR1-specific cytotoxic T lymphocyte responses, twelve patients (55%)
showed partial responses and 10 had stable disease after two cycles of the therapy. Notably, patients
showing VEGFR-specific T-cell responses had a significant higher OS and time to progression (TTP),
indicating that cancer vaccination combined with standard chemotherapy warrants further analysis
as a promising strategy for the treatment of advanced GC [124]. To enhance GC vaccine efficacy,
antigenic formulations targeting multiple antigens are being explored. In this direction, a cocktail
vaccine including multiple peptides (DEPDC1, FOXM1, KIF20, URLC10, and VEGFR1) combined with
S-1 chemotherapy was administered as a post-operative adjuvant therapy in a series of pathologically
stage III advanced GC patients [125,126]. The treatment was well tolerated, and an optimal relative dose
was achieved, paving the way for further studies aiming at assessing the efficacy of this therapeutic
strategy an alternative approach to target multiple antigens is the fusion of DCs with whole tumor
gastric cells to generate DC-tumor hybrids, e.g., by the electrofusion technique. These hybrid cells
have the advantage of combining the potent antigen presenting capacity of DCs with the availability
of the full repertoire of antigens expressed by tumor cells [127,128]. To circumvent the disadvantage
of the limited availability of viable autologous tumor cells for the fusion, allogeneic GC cells may
be used instead of autologous GC cells (cross-priming antigens) Therefore, it is not necessary to
match the HLA haplotype between patients and allogeneic tumor cells used to generate the fusion.
Although DC-tumor hybrids are safe and have induced efficient antitumor immune responses in early
clinical trials, limited positive clinical responses have been reported in GC, with better results occurring
with the use of costimulation with IL-12 [129] and the use of the of combination of TLR2 and TLR4
agonists [130].
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Table 5. Vaccines.
Type of Vaccine Setting Primary End-Point Reference
DC pulsed with melanoma-associated
antigen (MAGE) A3 peptides
MAGE-3-expressing advanced
GC (n = 12)





advanced or recurrent GC
HER2+ (n = 9)
phase I, tumor specific
T-cell response [116]
BCG (Bacillus Calmette–
Guérin) + chemotherapy radically resected stage III/IV GC
prolonged 10-year OS (47.1%)
as compared to
mono-chemotherapy (30%)
or surgery alone (15.2%)
[122]
gastrin-17 diphtheria toxoid
(G17DT) + chemotherapy metastatic GC/GEJ (n = 94)
phase II, longer TTP and OS
in responders [118]
URLC10 or VEGFR1 Epitopes chemotherapy-resistantadvanced GC (n = 14)
phase I, tumor specific
T cell responses [120,124]
heat shock protein
GP96 + oxaliplatinum GC (n = 45) phase II, 81.9% 2-year OS [121]
OTSGC-A24 (5 HLA-A24-restricted
peptides DEPDC1, FOXM1, KIF20,
URLC10, and VEGFR1)
inoperable/unresectable,
metastatic GC, 2 line therapy or
greater (n = 23)
favourable results for safety and
immune reactivity [126]
4. Concluding Remarks and Future Perspectives
Over the last decade, our understanding of the mechanisms underlying immune modulation
has greatly improved, allowing for the development of multiple therapeutic approaches that are
revolutionizing the treatment of cancer. Immunotherapy for GC is still in the early phase but is
rapidly evolving. The challenges moving forward are to put much effort into biologic and immunologic
exploration in GC setting to fine-tune and tailor, more precisely, the various available or emerging
immunotherapeutic approaches. In the near future, it will be necessary to design large prospective
trials to validate reliable predictive factors, allowing for the selection of GC patients with the highest
chance of benefitting from immunotherapy.
Author Contributions: R.D., V.C. and V.D.R. contributed to the writing and editing of this review.
Acknowledgments: This work was supported by 5x1000_2010_MdS. The funder had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Bilici, A. Treatment options in patients with metastatic gastric cancer: Current status and future perspectives.
World J. Gastroenterol. 2014, 20, 3905–3915. [CrossRef] [PubMed]
2. Brierley, J.D.; Gospodarowicz, M.K.; Wittekind, C. TNM Classification of Malignant Tumors, 8th ed.; John Wiley
& Sons, Inc.: Chichester, UK; Hoboken, NJ, USA, 2017.
3. Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Schadendorf, D.;
Dummer, R.; Smylie, M.; Rutkowski, P.; et al. Combined nivolumab and ipilimumab or monotherapy
in untreated melanoma. N. Engl. J. Med. 2015, 373, 23–34. [CrossRef] [PubMed]
4. Motzer, R.J.; Escudier, B.; McDermott, D.F.; George, S.; Hammers, H.J.; Srinivas, S.; Tykodi, S.S.; Sosman, J.A.;
Procopio, G.; Plimack, E.R.; et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl.
J. Med. 2015, 373, 1803–1813. [CrossRef] [PubMed]
5. Reck, M.; Rodriguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csoszi, T.; Fulop, A.; Gottfried, M.; Peled, N.;
Tafreshi, A.; Cuffe, S.; et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell
lung cancer. N. Engl. J. Med. 2016, 375, 1823–1833. [CrossRef] [PubMed]
6. Bonotto, M.; Garattini, S.K.; Basile, D.; Ongaro, E.; Fanotto, V.; Cattaneo, M.; Cortiula, F.; Iacono, D.;
Cardellino, G.G.; Pella, N.; et al. Immunotherapy for gastric cancers: Emerging role and future perspectives.
Expert Rev. Clin. Pharmacol. 2017, 10, 609–619. [CrossRef] [PubMed]
141
Int. J. Mol. Sci. 2018, 19, 1602
7. Procaccio, L.; Schirripa, M.; Fassan, M.; Vecchione, L.; Bergamo, F.; Prete, A.A.; Intini, R.; Manai, C.;
Dadduzio, V.; Boscolo, A.; et al. Immunotherapy in gastrointestinal cancers. Biomed. Res. Int. 2017, 3, 4346576.
[CrossRef] [PubMed]
8. Fuchs, C.S.; Doi, T.; Jang, R.W.; Muro, K.; Satoh, T.; Machado, M.; Sun, W.; Jalal, S.I.; Shah, M.A.; Metges, J.P.;
et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced
gastric and gastroesophageal junction cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018,
4, e180013. [CrossRef] [PubMed]
9. National Institutes of Health. Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and
Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
(MK-3475-062/KEYNOTE-062). Available online: https://clinicaltrials.gov/ct2/show/NCT02494583
(accessed on 10 July 2015).
10. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma.
Nature 2014, 513, 202–209. [CrossRef]
11. Derks, S.; Liao, X.; Chiaravalli, A.M.; Xu, X.; Camargo, M.C.; Solcia, E.; Sessa, F.; Fleitas, T.; Freeman, G.J.;
Rodig, S.J.; et al. Abundant PD-L1 expression in Epstein–Barr Virus-infected gastric cancers. Oncotarget 2016,
7, 32925–32932. [CrossRef] [PubMed]
12. Finn, O.J. A believer’s overview of cancer immunosurveillance and immunotherapy. J. Immunol. 2018, 200,
385–391. [CrossRef] [PubMed]
13. Davoodzadeh, G.M.; Kardar, G.A.; Saeedi, Y.; Heydari, S.; Garssen, J.; Falak, R. Exhaustion of T lymphocytes
in the tumor microenvironment: Significance and effective mechanisms. Cell. Immunol. 2017, 322, 1–14.
[CrossRef] [PubMed]
14. Wherry, E.J. T cell exhaustion. Nat. Immunol. 2011, 12, 492–499. [CrossRef] [PubMed]
15. Murray, P.J.; Allen, J.E.; Biswas, S.K.; Fisher, E.A.; Gilroy, D.W.; Goerdt, S.; Gordon, S.; Hamilton, J.A.;
Ivashkiv, L.B.; Lawrence, T.; et al. Macrophage activation and polarization: Nomenclature and
experimental guidelines. Immunity 2014, 41, 14–20. [CrossRef] [PubMed]
16. Ishigami, S.; Natsugoe, S.; Tokuda, K.; Nakajo, A.; Okumura, H.; Matsumoto, M.; Miyazono, F.; Hokita, S.;
Aikou, T. Tumor-associated macrophage (TAM) infiltration in gastric cancer. Anticancer Res. 2003, 23,
4079–4083. [PubMed]
17. Mitchem, J.B.; Brennan, D.J.; Knolhoff, B.L.; Belt, B.A.; Zhu, Y.; Sanford, D.E.; Belaygorod, L.; Carpenter, D.;
Collins, L.; Piwnica-Worms, D.; et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating
cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013, 73,
1128–1141. [CrossRef] [PubMed]
18. Park, J.Y.; Sung, J.Y.; Lee, J.; Park, Y.K.; Kim, Y.W.; Kim, G.Y.; Won, K.Y.; Lim, S.J. Polarized CD163+
tumor-associated macrophages are associated with increased angiogenesis and CXCL12 expression in
gastric cancer. Clin. Res. Hepatol. Gastroenterol. 2016, 40, 357–365. [CrossRef] [PubMed]
19. Wu, M.H.; Lee, W.J.; Hua, K.T.; Kuo, M.L.; Lin, M.T. Macrophage infiltration induces gastric cancer
invasiveness by activating the β-catenin pathway. PLoS ONE 2015, 10, e0134122. [CrossRef] [PubMed]
20. Bronte, V.; Brandau, S.; Chen, S.H.; Colombo, M.P.; Frey, A.B.; Greten, T.F.; Mandruzzato, S.; Murray, P.J.;
Ochoa, A.; Ostrand-Rosenberg, S.; et al. Recommendations for myeloid-derived suppressor cell nomenclature
and characterization standards. Nat. Commun. 2016, 7, 12150. [CrossRef] [PubMed]
21. Ben-Meir, K.; Twaik, N.; Baniyash, M. Plasticity and biological diversity of myeloid derived suppressor cells.
Curr. Opin. Immunol. 2018, 51, 154–161. [CrossRef] [PubMed]
22. Choi, B.D.; Gedeon, P.C.; Herndon, J.E.; Archer, G.E.; Reap, E.A.; Sanchez-Perez, L.; Mitchell, D.A.;
Bigner, D.D.; Sampson, J.H. Human regulatory T cells kill tumor cells through granzyme-dependent
cytotoxicity upon retargeting with a bispecific antibody. Cancer Immunol. Res. 2013, 1, 163–167. [CrossRef]
[PubMed]
23. Kandulski, A.; Malfertheiner, P.; Wex, T. Role of regulatory T-cells in H. pylori-induced gastritis and
gastric cancer. Anticancer Res. 2010, 30, 1093–1103. [PubMed]
142
Int. J. Mol. Sci. 2018, 19, 1602
24. Kang, B.W.; Seo, A.N.; Yoon, S.; Bae, H.I.; Jeon, S.W.; Kwon, O.K.; Chung, H.Y.; Yu, W.; Kang, H.;
Kim, J.G. Prognostic value of tumor-infiltrating lymphocytes in Epstein–Barr virus-associated gastric cancer.
Ann. Oncol. 2016, 27, 494–501. [CrossRef] [PubMed]
25. Nagase, H.; Takeoka, T.; Urakawa, S.; Morimoto-Okazawa, A.; Kawashima, A.; Iwahori, K.; Takiguchi, S.;
Nishikawa, H.; Sato, E.; Sakaguchi, S.; et al. ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and
effector regulatory T cells associated with Helicobacter pylori. Int. J. Cancer 2017, 140, 686–695. [CrossRef]
[PubMed]
26. Sackstein, R.; Schatton, T.; Barthel, S.R. T-lymphocyte homing: An underappreciated yet critical hurdle for
successful cancer immunotherapy. Lab. Investig. 2017, 97, 669–697. [CrossRef] [PubMed]
27. Badalamenti, G.; Fanale, D.; Incorvaia, L.; Barraco, N.; Listi, A.; Maragliano, R.; Vincenzi, B.; Calo, V.;
Iovanna, J.L.; Bazan, V.; et al. Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop
dig a stone? Cell. Immunol. 2018. [CrossRef] [PubMed]
28. Kim, K.J.; Lee, K.S.; Cho, H.J.; Kim, Y.H.; Yang, H.K.; Kim, W.H.; Kang, G.H. Prognostic implications
of tumor-infiltrating FoxP3+ regulatory T cells and CD8+ cytotoxic T cells in microsatellite-unstable
gastric cancers. Hum. Pathol. 2014, 45, 285–293. [CrossRef] [PubMed]
29. Klingemann, H.; Boissel, L.; Toneguzzo, F. Natural killer cells for immunotherapy—Advantages of the NK-92
cell line over blood NK cells. Front. Immunol. 2016, 7, 91. [CrossRef] [PubMed]
30. Sarvaria, A.; Madrigal, J.A.; Saudemont, A. B cell regulation in cancer and anti-tumor immunity.
Cell. Mol. Immunol. 2017, 14, 662–674. [CrossRef] [PubMed]
31. Li, Q.; Teitz-Tennenbaum, S.; Donald, E.J.; Li, M.; Chang, A.E. In vivo sensitized and in vitro activated B cells
mediate tumor regression in cancer adoptive immunotherapy. J. Immunol. 2009, 183, 3195–3203. [CrossRef]
[PubMed]
32. Li, Q.; Lao, X.; Pan, Q.; Ning, N.; Yet, J.; Xu, Y.; Li, S.; Chang, A.E. Adoptive transfer of tumor reactive
B cells confers host T-cell immunity and tumor regression. Clin. Cancer Res. 2011, 17, 4987–4995. [CrossRef]
[PubMed]
33. Perricone, M.A.; Smith, K.A.; Claussen, K.A.; Plog, M.S.; Hempel, D.M.; Roberts, B.L.; St George, J.A.;
Kaplan, J.M. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J. Immunother. 2004,
27, 273–281. [CrossRef] [PubMed]
34. Shah, S.; Divekar, A.A.; Hilchey, S.P.; Cho, H.M.; Newman, C.L.; Shin, S.U.; Nechustan, H.; Challita-Eid, P.M.;
Segal, B.M.; Yi, K.H.; et al. Increased rejection of primary tumors in mice lacking B cells: Inhibition of
anti-tumor CTL and TH1 cytokine responses by B cells. Int. J. Cancer 2005, 117, 574–586. [CrossRef]
[PubMed]
35. Kang, B.W.; Kim, J.G.; Lee, I.H.; Bae, H.I.; Seo, A.N. Clinical significance of tumor-infiltrating lymphocytes for
gastric cancer in the era of immunology. World J. Gastrointest. Oncol. 2017, 9, 293–299. [CrossRef] [PubMed]
36. Ishigami, S.; Natsugoe, S.; Tokuda, K.; Nakajo, A.; Xiangming, C.; Iwashige, H.; Aridome, K.; Hokita, S.;
Aikou, T. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer.
Cancer Lett. 2000, 159, 103–108. [CrossRef]
37. Malmberg, K.J.; Carlsten, M.; Bjorklund, A.; Sohlberg, E.; Bryceson, Y.T.; Ljunggren, H.G. Natural killer
cell-mediated immunosurveillance of human cancer. Semin. Immunol. 2017, 31, 20–29. [CrossRef] [PubMed]
38. Rosso, D.; Rigueiro, M.P.; Kassab, P.; Ilias, E.J.; Castro, O.A.; Novo, N.F.; Lourenco, L.G. Correlation of natural
killer cells with the prognosis of gastric adenocarcinoma. Arq. Bras. Cir. Dig. 2012, 25, 114–117. [CrossRef]
[PubMed]
39. Saito, H.; Takaya, S.; Osaki, T.; Ikeguchi, M. Increased apoptosis and elevated FAS expression in circulating
natural killer cells in gastric cancer patients. Gastric. Cancer 2013, 16, 473–479. [CrossRef] [PubMed]
40. Yang, J.C.; Rosenberg, S.A. Adoptive T-Cell Therapy for Cancer. Adv. Immunol. 2016, 130, 279–294. [CrossRef]
[PubMed]
41. Kono, K.; Ichihara, F.; Iizuka, H.; Sekikawa, T.; Matsumoto, Y. Differences in the recognition of tumor-specific
CD8+ T cells derived from solid tumor, metastatic lymph nodes and ascites in patients with gastric cancer.
Int. J. Cancer 1997, 71, 978–981. [CrossRef]
42. Fujie, T.; Tanaka, F.; Tahara, K.; Li, J.; Tanaka, S.; Mori, M.; Ueo, H.; Takesako, K.; Akiyoshi, T. Generation of
specific antitumor reactivity by the stimulation of spleen cells from gastric cancer patients with MAGE-3
synthetic peptide. Cancer Immunol. Immunother. 1999, 48, 189–194. [CrossRef] [PubMed]
143
Int. J. Mol. Sci. 2018, 19, 1602
43. Voskens, C.J.; Watanabe, R.; Rollins, S.; Campana, D.; Hasumi, K.; Mann, D.L. Ex-vivo expanded human
NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell
lines by direct recognition and antibody directed cellular cytotoxicity. J. Exp. Clin. Cancer Res. 2010, 29, 134.
[CrossRef] [PubMed]
44. Ishikawa, T.; Okayama, T.; Sakamoto, N.; Ideno, M.; Oka, K.; Enoki, T.; Mineno, J.; Yoshida, N.; Katada, K.;
Kamada, K.; et al. Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination
with IgG1 antibody in patients with gastric or colorectal cancer. Int. J. Cancer 2018, 142, 2599–2609. [CrossRef]
[PubMed]
45. Sakamoto, N.; Ishikawa, T.; Kokura, S.; Okayama, T.; Oka, K.; Ideno, M.; Sakai, F.; Kato, A.; Tanabe, M.;
Enoki, T.; et al. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients
with advanced digestive cancer. J. Transl. Med. 2015, 13, 277. [CrossRef] [PubMed]
46. Kloss, S.; Oberschmidt, O.; Morgan, M.; Dahlke, J.; Arseniev, L.; Huppert, V.; Granzin, M.; Gardlowski, T.;
Matthies, N.; Soltenborn, S.; et al. Optimization of human NK cell manufacturing: Fully automated
separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of
anti-CD123-CAR-expressing effector cells. Hum. Gene Ther. 2017, 28, 897–913. [CrossRef] [PubMed]
47. Uherek, C.; Tonn, T.; Uherek, B.; Becker, S.; Schnierle, B.; Klingemann, H.G.; Wels, W. Retargeting of
natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor
cell destruction. Blood 2002, 100, 1265–1273. [PubMed]
48. Schonfeld, K.; Sahm, C.; Zhang, C.; Naundorf, S.; Brendel, C.; Odendahl, M.; Nowakowska, P.; Bonig, H.;
Kohl, U.; Kloess, S.; et al. Selective inhibition of tumor growth by clonal NK cells expressing an
ErbB2/HER2-specific chimeric antigen receptor. Mol. Ther. 2015, 23, 330–338. [CrossRef] [PubMed]
49. Zhang, C.; Burger, M.C.; Jennewein, L.; Genssler, S.; Schonfeld, K.; Zeiner, P.; Hattingen, E.; Harter, P.N.;
Mittelbronn, M.; Tonn, T.; et al. ErbB2/HER2-specific NK cells for targeted therapy of glioblastoma. J. Natl.
Cancer Inst. 2015, 108, 375. [CrossRef] [PubMed]
50. Guo, Y.; Han, W. Cytokine-induced killer (CIK) cells: From basic research to clinical translation.
Chin. J. Cancer 2015, 34, 99–107. [CrossRef] [PubMed]
51. Pfirschke, C.; Engblom, C.; Rickelt, S.; Cortez-Retamozo, V.; Garris, C.; Pucci, F.; Yamazaki, T.;
Poirier-Colame, V.; Newton, A.; Redouane, Y.; et al. Immunogenic chemotherapy sensitizes tumors to
checkpoint blockade therapy. Immunity 2016, 44, 343–354. [CrossRef] [PubMed]
52. Liu, K.; Song, G.; Hu, X.; Zhou, Y.; Li, Y.; Chen, Q.; Feng, G. A positive role of cytokine-induced killer cell
therapy on gastric cancer therapy in a Chinese population: A systematic meta-analysis. Med. Sci. Monit.
2015, 21, 3363–3370. [CrossRef] [PubMed]
53. Mu, Y.; Zhou, C.H.; Chen, S.F.; Ding, J.; Zhang, Y.X.; Yang, Y.P.; Wang, W.H. Effectiveness and safety of
chemotherapy combined with cytokine-induced killer cell/dendritic cell-cytokine-induced killer cell therapy
for treatment of gastric cancer in China: A systematic review and meta-analysis. Cytotherapy 2016, 18,
1162–1177. [CrossRef] [PubMed]
54. Introna, M.; Correnti, F. Innovative clinical perspectives for CIK cells in cancer patients. Int. J. Mol. Sci. 2018,
19, 358. [CrossRef] [PubMed]
55. Zhang, L.; Zhao, G.; Hou, Y.; Zhang, J.; Hu, J.; Zhang, K. The experimental study on the treatment
of cytokine-induced killer cells combined with EGFR monoclonal antibody against gastric cancer.
Cancer Biother. Radiopharm. 2014, 29, 99–107. [CrossRef] [PubMed]
56. Del Zotto, G.; Marcenaro, E.; Vacca, P.; Sivori, S.; Pende, D.; Della, C.M.; Moretta, F.; Ingegnere, T.;
Mingari, M.C.; Moretta, A.; et al. Markers and function of human NK cells in normal and
pathological conditions. Cytometry B Clin. Cytom. 2017, 92, 100–114. [CrossRef] [PubMed]
57. Xu, X.; Xu, L.; Ding, S.; Wu, M.; Tang, Z.; Fu, W.; Ni, Q. Treatment of 23 patients with advanced gastric cancer
by intravenously transfer of autologous tumor-infiltrating lymphocytes combined with rIL-2. Chin. Med.
Sci. J. 1995, 10, 185–187. [PubMed]
58. Zhang, G.Q.; Zhao, H.; Wu, J.Y.; Li, J.Y.; Yan, X.; Wang, G.; Wu, L.L.; Zhang, X.G.; Shao, Y.; Wang, Y.; et al.
Prolonged overall survival in gastric cancer patients after adoptive immunotherapy. World J. Gastroenterol.
2015, 21, 2777–2785. [CrossRef] [PubMed]
59. Shi, L.; Zhou, Q.; Wu, J.; Ji, M.; Li, G.; Jiang, J.; Wu, C. Efficacy of adjuvant immunotherapy with
cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol. Immunother.
2012, 61, 2251–2259. [CrossRef] [PubMed]
144
Int. J. Mol. Sci. 2018, 19, 1602
60. Jiang, J.T.; Shen, Y.P.; Wu, C.P.; Zhu, Y.B.; Wei, W.X.; Chen, L.J.; Zheng, X.; Sun, J.; Lu, B.F.; Zhang, X.G.
Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric
cancer patients. World J. Gastroenterol. 2010, 16, 6155–6162. [CrossRef] [PubMed]
61. Chen, Y.; Guo, Z.Q.; Shi, C.M.; Zhou, Z.F.; Ye, Y.B.; Chen, Q. Efficacy of adjuvant chemotherapy combined
with immunotherapy with cytokine-induced killer cells for gastric cancer after d2 gastrectomy. Int. J. Clin.
Exp. Med. 2015, 8, 7728–7736. [PubMed]
62. Zhao, H.; Fan, Y.; Li, H.; Yu, J.; Liu, L.; Cao, S.; Ren, B.; Yan, F.; Ren, X. Immunotherapy with cytokine-induced
killer cells as an adjuvant treatment for advanced gastric carcinoma: A retrospective study of 165 patients.
Cancer Biother. Radiopharm. 2013, 28, 303–309. [CrossRef] [PubMed]
63. Liu, H.; Song, J.; Yang, Z.; Zhang, X. Effects of cytokine-induced killer cell treatment combined with FolFox4
on the recurrence and survival rates for gastric cancer following surgery. Exp. Ther. Med. 2013, 6, 953–956.
[CrossRef] [PubMed]
64. Mirzaei, H.R.; Rodriguez, A.; Shepphird, J.; Brown, C.E.; Badie, B. Chimeric antigen receptors T cell therapy
in solid tumor: Challenges and clinical APPLICATIONS. Front. Immunol. 2017, 8, 1850. [CrossRef] [PubMed]
65. Fesnak, A.D.; June, C.H.; Levine, B.L. Engineered T cells: The promise and challenges of
cancer immunotherapy. Nat. Rev. Cancer 2016, 16, 566–581. [CrossRef] [PubMed]
66. Feng, K.; Liu, Y.; Guo, Y.; Qiu, J.; Wu, Z.; Dai, H.; Yang, Q.; Wang, Y.; Han, W. Phase I study of chimeric antigen
receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.
Protein Cell 2017, 1–10. [CrossRef] [PubMed]
67. Han, Y.; Liu, C.; Li, G.; Li, J.; Lv, X.; Shi, H.; Liu, J.; Liu, S.; Yan, P.; Wang, S.; et al. Antitumor effects and
persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models. Am. J. Cancer Res.
2018, 8, 106–119. [PubMed]
68. Luo, F.; Qian, J.; Yang, J.; Deng, Y.; Zheng, X.; Liu, J.; Chu, Y. Bifunctional αHER2/CD3 RNA-engineered
CART-like human T cells specifically eliminate HER2+ gastric cancer. Cell Res. 2016, 26, 850–853. [CrossRef]
[PubMed]
69. Song, Y.; Tong, C.; Wang, Y.; Gao, Y.; Dai, H.; Guo, Y.; Zhao, X.; Wang, Y.; Wang, Z.; Han, W.; et al.
Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro
and xenotransplanted tumors in vivo. Protein Cell 2017, 1–12. [CrossRef] [PubMed]
70. Shibaguchi, H.; Luo, N.; Shirasu, N.; Kuroki, M.; Kuroki, M. Enhancement of antitumor activity by using
a fully human gene encoding a single-chain fragmented antibody specific for carcinoembryonic antigen.
Onco Targets Ther. 2017, 10, 3979–3990. [CrossRef] [PubMed]
71. Neelapu, S.S.; Tummala, S.; Kebriaei, P.; Wierda, W.; Gutierrez, C.; Locke, F.L.; Komanduri, K.V.; Lin, Y.;
Jain, N.; Daver, N.; et al. Chimeric antigen receptor T-cell therapy—Assessment and management of toxicities.
Nat. Rev. Clin. Oncol. 2018, 15, 47–62. [CrossRef] [PubMed]
72. Morgan, R.A.; Yang, J.C.; Kitano, M.; Dudley, M.E.; Laurencot, C.M.; Rosenberg, S.A. Case report of
a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor
recognizing ERBB2. Mol. Ther. 2010, 18, 843–851. [CrossRef] [PubMed]
73. Sharma, P.; Allison, J.P. Immune checkpoint targeting in cancer therapy: Toward combination strategies with
curative potential. Cell 2015, 161, 205–214. [CrossRef] [PubMed]
74. Tran, P.N.; Sarkissian, S.; Chao, J.; Klempner, S.J. PD-1 and PD-L1 as emerging therapeutic targets in gastric
cancer: Current evidence. Gastrointest. Cancer 2017, 7, 1–11. [CrossRef] [PubMed]
75. Boger, C.; Behrens, H.M.; Mathiak, M.; Kruger, S.; Kalthoff, H.; Rocken, C. PD-L1 is an independent
prognostic predictor in gastric cancer of Western patients. Oncotarget 2016, 7, 24269–24283. [CrossRef]
[PubMed]
76. Kim, J.W.; Nam, K.H.; Ahn, S.H.; Park, D.J.; Kim, H.H.; Kim, S.H.; Chang, H.; Lee, J.O.; Kim, Y.J.;
Lee, H.S.; et al. Prognostic implications of immunosuppressive protein expression in tumors as well
as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer 2016, 19,
42–52. [CrossRef] [PubMed]
77. Schlosser, H.A.; Drebber, U.; Kloth, M.; Thelen, M.; Rothschild, S.I.; Haase, S.; Garcia-Marquez, M.;
Wennhold, K.; Berlth, F.; Urbanski, A.; et al. Immune checkpoints programmed death 1 ligand 1 and
cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. Oncoimmunology 2015, 5, e1100789.
[CrossRef] [PubMed]
145
Int. J. Mol. Sci. 2018, 19, 1602
78. Gu, L.; Chen, M.; Guo, D.; Zhu, H.; Zhang, W.; Pan, J.; Zhong, X.; Li, X.; Qian, H.; Wang, X. PD-L1 and
gastric cancer prognosis: A systematic review and meta-analysis. PLoS ONE 2017, 12, e0182692. [CrossRef]
[PubMed]
79. Saito, R.; Abe, H.; Kunita, A.; Yamashita, H.; Seto, Y.; Fukayama, M. Overexpression and gene amplification
of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein–Barr virus-associated gastric cancer:
The prognostic implications. Mod. Pathol. 2017, 30, 427–439. [CrossRef] [PubMed]
80. Liu, Y.; Cheng, Y.; Xu, Y.; Wang, Z.; Du, X.; Li, C.; Peng, J.; Gao, L.; Liang, X.; Ma, C. Increased expression of
programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates
poor prognosis in digestive cancers. Oncogene 2017, 36, 6143–6153. [CrossRef] [PubMed]
81. Nowak, E.C.; Lines, J.L.; Varn, F.S.; Deng, J.; Sarde, A.; Mabaera, R.; Kuta, A.; Le, M.I.; Cheng, C.; Noelle, R.J.
Immunoregulatory functions of VISTA. Immunol. Rev. 2017, 276, 66–79. [CrossRef] [PubMed]
82. Boger, C.; Behrens, H.M.; Kruger, S.; Rocken, C. The novel negative checkpoint regulator VISTA is expressed
in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric
cancer therapy? Oncoimmunology 2017, 6, e1293215. [CrossRef] [PubMed]
83. Du, W.; Yang, M.; Turner, A.; Xu, C.; Ferris, R.L.; Huang, J.; Kane, L.P.; Lu, B. TIM-3 as a target for cancer
immunotherapy and mechanisms of action. Int. J. Mol. Sci. 2017, 18, 645. [CrossRef] [PubMed]
84. Takano, S.; Saito, H.; Ikeguchi, M an increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in
immune evasion in gastric cancer. Surg. Today 2016, 46, 1341–1347. [CrossRef] [PubMed]
85. Lu, X.; Yang, L.; Yao, D.; Wu, X.; Li, J.; Liu, X.; Deng, L.; Huang, C.; Wang, Y.; Li, D.; et al. Tumor
antigen-specific CD8+ T cells are negatively regulated by PD-1 and Tim-3 in human gastric cancer.
Cell. Immunol. 2017, 313, 43–51. [CrossRef] [PubMed]
86. Ralph, C.; Elkord, E.; Burt, D.J.; O’Dwyer, J.F.; Austin, E.B.; Stern, P.L.; Hawkins, R.E.; T histlethwaite, F.C.
Modulation of lymphocyte regulation for cancer therapy: A phase II trial of tremelimumab in advanced
gastric and esophageal adenocarcinoma. Clin. Cancer Res. 2010, 16, 1662–1672. [CrossRef] [PubMed]
87. Vanneman, M.; Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment.
Nat. Rev. Cancer 2012, 12, 237–251. [CrossRef] [PubMed]
88. Catenacci, D.V.; Kim, S.S.; Gold, P.J.; Philip, P.A.; Enzinger, P.C.; Coffie, J.; Schmidt, E.V.; Baldwin, M.;
Nordstrom, J.L.; Bonvini, E.; et al. A phase 1b/2, open label, dose-escalation study of margetuximab (M) in
combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal
(GEJ) junction or gastric (G) cancer. J. Clin. Oncol. 2018, 35, TPS219. [CrossRef]
89. Chen, D.S.; Mellman, I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013, 39, 1–10.
[CrossRef] [PubMed]
90. Ngwa, W.; Irabor, O.C.; Schoenfeld, J.D.; Hesser, J.; Demaria, S.; Formenti, S.C. Using immunotherapy to
boost the abscopal effect. Nat. Rev. Cancer 2018. [CrossRef] [PubMed]
91. Chao, J.; Chen, Y.; Frankel, P.H.; Chung, V.M.; Lim, D.; Li, D.; Fakih, M.; Lee, P.P. Combining pembrolizumab
and palliative radiotherapy in gastroesophageal cancer to enhance antitumor T-cell response and augment
the abscopal effect. J. Clin. Oncol. 2018, 35, TPS220. [CrossRef]
92. Bang, Y.J.; Cho, J.Y.; Kim, Y.H.; Kim, J.W.; Di, B.M.; Ajani, J.A.; Yamaguchi, K.; Balogh, A.; Sanchez, T.;
Moehler, M. Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable
locally advanced/metastatic gastric or gastroesophageal junction cancer. Clin. Cancer Res. 2017, 23, 5671–5678.
[CrossRef] [PubMed]
93. Muro, K.; Chung, H.C.; Shankaran, V.; Geva, R.; Catenacci, D.; Gupta, S.; Eder, J.P.; Golan, T.; Le, D.T.;
Burtness, B.; et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012):
A multicentre, open-label, phase 1b trial. Lancet Oncol. 2016, 17, 717–726. [CrossRef]
94. Doi, T.; Piha-Paul, S.A.; Jalal, S.I.; Saraf, S.; Lunceford, J.; Koshiji, M.; Bennouna, J. Safety and
antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced
esophageal carcinoma. J. Clin. Oncol. 2018, 36, 61–67. [CrossRef] [PubMed]
95. Wainberg, Z.A.; Jalal, S.; Muro, K.; Yoon, H.H.; Garrido, M.; Golan, T.; Doi, T.; Catenacci, D.V.; Geva, R.;
Ku, G.; et al. Oesophageal cancer gastric cancer cancer immunology and immunotherapy. In Proceedings
of the ESMO 2017 Congress, Annals of Oncology, Madrid, Spain, 8–12 September 2018; Volume 28,
pp. v605–v649.
146
Int. J. Mol. Sci. 2018, 19, 1602
96. Ohtsu, A.; Tabernero, J.; Bang, Y.; Fuchs, C.S.; Sun, L.; Wang, Z.; Csiki, I.; Koshiji, M.; Cutsem, E.V.
Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal
junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study. J. Clin. Oncol. 2018, 34, TPS183. [CrossRef]
97. Chau, I.; Bendell, J.C.; Calvo, E.; Santana-Davila, R.; Ahnert, J.R.; Penel, N.; Arkenau, H.; Yang, Y.;
Rege, J.; Mi, G.; et al. Interim safety and clinical activity in patients (pts) with advanced gastric or
gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R)
plus pembrolizumab (P). J. Clin. Oncol. 2018, 35, 102. [CrossRef]
98. Janjigian, Y.Y.; Ott, P.A.; Calvo, E.; Kim, J.W.; Ascierto, P.A.; Sharma, P.; Peltola, K.J.; Jaeger, D.;
Jeffry Evans, T.R.; De Braud, F.G.; et al. Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic
chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer:
CheckMate 032 study. J. Clin. Oncol. 2018, 35, 4014.
99. Kang, Y.K.; Boku, N.; Satoh, T.; Ryu, M.H.; Chao, Y.; Kato, K.; Chung, H.C.; Chen, J.S.; Muro, K.;
Kang, W.K.; et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer
refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2):
A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017, 390, 2461–2471. [CrossRef]
100. Heery, C.R.; O’Sullivan-Coyne, G.; Madan, R.A.; Cordes, L.; Rajan, A.; Rauckhorst, M.; Lamping, E.;
Oyelakin, I.; Marte, J.L.; Lepone, L.M.; et al. Avelumab for metastatic or locally advanced previously treated
solid tumours (JAVELIN Solid Tumor): A phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017, 18,
587–598. [CrossRef]
101. Bang, Y.Y.; Wyrwicz, L.; Park, Y.L.; Ryu, M.; Muntean, A.; Gomez-Martin, C.; Guimbaud, R.; Ciardiello, F.; Boku, N.;
Van Cutsem, E.; et al. Avelumab (MSB0010718C.; anti-PD-L1) + best supportive care (BSC) vs BSC ± chemotherapy
as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN
Gastric 300 trial. J. Clin. Oncol. 2018, 34, TPS4135.
102. Marcus, H.; Moehler, M.H.; Taïeb, J.; Gurtler, J.S.; Xiong, H.; Zhang, J.; Cuillerot, J.; Boku, N.
Maintenance therapy with avelumab (MSB0010718C.; anti-PD-L1) vs continuation of first-line chemotherapy
in patients with unresectable, locally advanced or metastatic gastric cancer: The phase 3 JAVELIN Gastric
100 trial. J. Clin. Oncol. 2018, 34, TPS4134.
103. Kelly, R.J.; Chung, K.; Gu, Y.; Steele, K.E.; Rebelatto, M.C.; Robbins, P.B.; Tavakkoli, F.; Karakunnel, J.J.;
Lai, D.W.; Almhanna, K. Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab
(MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic
gastric/gastroesophageal junction adenocarcinoma. J. Immunother. Cancer 2018, 3, P157. [CrossRef]
104. Bang, Y.J.; Golan, T.; Lin, C.; Kang, Y.; Wainberg, Z.A.; Wasserstrom, H.; Jin, J.; Mi, G.; McNeely, S.;
Laing, N.; et al. Interim safety and clinical activity in patients with locally advanced and unresectable or
metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study
of ramucirumab plus durvalumab. J. Clin. Oncol. 2018, 36, 92.
105. Linch, S.N.; McNamara, M.J.; Redmond, W.L. OX40 Agonists and combination immunotherapy: Putting the
pedal to the metal. Front. Oncol. 2015, 5, 34. [CrossRef] [PubMed]
106. Chester, C.; Sanmamed, M.F.; Wang, J.; Melero, I. Immunotherapy targeting 4-1BB: Mechanistic rationale,
clinical results, and future strategies. Blood 2018, 131, 49–57. [CrossRef] [PubMed]
107. Burugu, S.; Dancsok, A.R.; Nielsen, T.O. Emerging targets in cancer immunotherapy. Semin. Cancer Biol.
2017, 10–17. [CrossRef] [PubMed]
108. Curti, B.D.; Kovacsovics-Bankowski, M.; Morris, N.; Walker, E.; Chisholm, L.; Floyd, K.; Walker, J.;
Gonzalez, I.; Meeuwsen, T.; Fox, B.A.; et al. OX40 is a potent immune-stimulating target in late-stage
cancer patients. Cancer Res. 2013, 73, 7189–7198. [CrossRef] [PubMed]
109. Chester, C.; Ambulkar, S.; Kohrt, H.E. 4-1BB agonism: Adding the accelerator to cancer immunotherapy.
Cancer Immunol. Immunother. 2016, 65, 1243–1248. [CrossRef] [PubMed]
110. Takeda, K.; Kojima, Y.; Uno, T.; Hayakawa, Y.; Teng, M.W.; Yoshizawa, H.; Yagita, H.; Gejyo, F.; Okumura, K.;
Smyth, M.J. Combination therapy of established tumors by antibodies targeting immune activating and
suppressing molecules. J. Immunol. 2010, 184, 5493–5501. [CrossRef] [PubMed]
111. Sanmamed, M.F.; Pastor, F.; Rodriguez, A.; Perez-Gracia, J.L.; Rodriguez-Ruiz, M.E.; Jure-Kunkel, M.;
Melero, I. Agonists of co-stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27,
CD28, and ICOS. Semin. Oncol. 2015, 42, 640–655. [CrossRef] [PubMed]
147
Int. J. Mol. Sci. 2018, 19, 1602
112. Fan, X.; Quezada, S.A.; Sepulveda, M.A.; Sharma, P.; Allison, J.P. Engagement of the ICOS pathway markedly
enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J. Exp. Med. 2014, 211, 715–725. [CrossRef]
[PubMed]
113. Taieb, J.; Moehler, M.; Boku, N.; Ajani, J.A.; Yanez, R.E.; Ryu, M.H.; Guenther, S.; Chand, V.; Bang, Y.J.
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and
future perspectives. Cancer Treat. Rev. 2018, 66, 104–113. [CrossRef] [PubMed]
114. Kottschade, L.A. Incidence and management of immune-related adverse events in patients undergoing
treatment with immune checkpoint inhibitors. Curr. Oncol. Rep. 2018, 20, 24. [CrossRef] [PubMed]
115. Niccolai, E.; Taddei, A.; Prisco, D.; Amedei, A. Gastric cancer and the epoch of immunotherapy approaches.
World J. Gastroenterol. 2015, 21, 5778–5793. [CrossRef] [PubMed]
116. Kono, K.; Takahashi, A.; Sugai, H.; Fujii, H.; Choudhury, A.R.; Kiessling, R.; Matsumoto, Y. Dendritic cells
pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer.
Clin. Cancer Res. 2002, 8, 3394–3400. [PubMed]
117. Sadanaga, N.; Nagashima, H.; Mashino, K.; Tahara, K.; Yamaguchi, H.; Ohta, M.; Fujie, T.; Tanaka, F.;
Inoue, H.; Takesako, K.; et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach
for gastrointestinal carcinomas. Clin. Cancer Res. 2001, 7, 2277–2284. [PubMed]
118. Ajani, J.A.; Hecht, J.R.; Ho, L.; Baker, J.; Oortgiesen, M.; Eduljee, A.; Michaeli, D an open-label, multinational,
multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with
untreated, advanced gastric or gastroesophageal cancer: The GC4 study. Cancer 2006, 106, 1908–1916.
[CrossRef] [PubMed]
119. He, Q.; Gao, H.; Gao, M.; Qi, S.; Yang, K.; Zhang, Y.; Wang, J. Immunogenicity and safety of a novel tetanus
toxoid-conjugated anti-gastrin vaccine in BALB/c mice. Vaccine 2018, 36, 847–852. [CrossRef] [PubMed]
120. Higashihara, Y.; Kato, J.; Nagahara, A.; Izumi, K.; Konishi, M.; Kodani, T.; Serizawa, N.; Osada, T.;
Watanabe, S. Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides
in patients with advanced gastric cancer. Int. J. Oncol. 2014, 44, 662–668. [CrossRef] [PubMed]
121. Zhang, K.; Peng, Z.; Huang, X.; Qiao, Z.; Wang, X.; Wang, N.; Xi, H.; Cui, J.; Gao, Y.; Huang, X.; et al.
Phase II trial of adjuvant immunotherapy with autologous tumor-derived Gp96 vaccination in patients with
gastric CANCER. J. Cancer 2017, 8, 1826–1832. [CrossRef] [PubMed]
122. Popiela, T.; Kulig, J.; Czupryna, A.; Szczepanik, A.M.; Zembala, M. Efficiency of adjuvant
immunochemotherapy following curative resection in patients with locally advanced gastric cancer.
Gastric Cancer 2004, 7, 240–245. [CrossRef] [PubMed]
123. Sato, Y.; Shomura, H.; Maeda, Y.; Mine, T.; Une, Y.; Akasaka, Y.; Kondo, M.; Takahashi, S.; Shinohara, T.;
Katagiri, K.; et al. Immunological evaluation of peptide vaccination for patients with gastric cancer based on
pre-existing cellular response to peptide. Cancer Sci. 2003, 94, 802–808. [CrossRef] [PubMed]
124. Masuzawa, T.; Fujiwara, Y.; Okada, K.; Nakamura, A.; Takiguchi, S.; Nakajima, K.; Miyata, H.; Yamasaki, M.;
Kurokawa, Y.; Osawa, R.; et al. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines
for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.
Int. J. Oncol. 2012, 41, 1297–1304. [CrossRef] [PubMed]
125. Fujiwara, Y.; Sugimura, K.; Miyata, H.; Omori, T.; Nakano, H.; Mochizuki, C.; Shimizu, K.; Saito, H.;
Ashida, K.; Honjyo, S.; et al. A pilot study of post-operative adjuvant vaccine for advanced gastric cancer.
Yonago Acta Med. 2017, 60, 101–105. [PubMed]
126. Sundar, R.; Rha, S.Y.; Yamaue, H.; Katsuda, M.; Kono, K.; Kim, H.S.; Kim, C.; Mimura, K.; Kua, L.F.; Yong, W.P.
A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. BMC Cancer 2018,
18, 332. [CrossRef] [PubMed]
127. Koido, S. Dendritic-tumor fusion cell-based cancer vaccines. Int. J. Mol. Sci. 2016, 17, 828. [CrossRef]
[PubMed]
128. Takakura, K.; Kajihara, M.; Ito, Z.; Ohkusa, T.; Gong, J.; Koido, S. Dendritic-tumor fusion cells in
cancer immunotherapy. Discov. Med. 2015, 19, 169–174. [PubMed]
148
Int. J. Mol. Sci. 2018, 19, 1602
129. Lasek, W.; Zagozdzon, R.; Jakobisiak, M. Interleukin 12: Still a promising candidate for tumor immunotherapy?
Cancer Immunol. Immunother. 2014, 63, 419–435. [CrossRef] [PubMed]
130. Koido, S.; Homma, S.; Okamoto, M.; Namiki, Y.; Takakura, K.; Takahara, A.; Odahara, S.; Tsukinaga, S.;
Yukawa, T.; Mitobe, J.; et al. Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented
cytotoxic T lymphocytes. PLoS ONE 2013, 8, e59280. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
149
 International Journal of 
Molecular Sciences
Review
Inhibition of the CCL5/CCR5 Axis against the
Progression of Gastric Cancer
Donatella Aldinucci * and Naike Casagrande
Department of Molecular Oncology, CRO Aviano National Cancer Institute, via F. Gallini 2, I-33081 Aviano, Italy;
naike.casagrande@libero.it
* Correspondence: daldinucci@cro.it
Received: 26 April 2018; Accepted: 14 May 2018; Published: 16 May 2018
Abstract: Despite the progress made in molecular and clinical research, patients with advanced-stage
gastric cancer (GC) have a bad prognosis and very low survival rates. Furthermore, it is challenging
to find the complex molecular mechanisms that are involved in the development of GC, its
progression, and its resistance to therapy. The interactions of chemokines, also known as chemotactic
cytokines, with their receptors regulate immune and inflammatory responses. However, updated
research demonstrates that cancer cells subvert the normal chemokine role, transforming them into
fundamental constituents of the tumor microenvironment (TME) with tumor-promoting effects. C-C
chemokine ligand 5 (CCL5) is a chemotactic cytokine, and its expression and secretion are regulated in
T cells. C-C chemokine receptor type 5 (CCR5) is expressed in T cells, macrophages, other leukocytes,
and certain types of cancer cells. The interaction between CCL5 and CCR5 plays an active role in
recruiting leukocytes into target sites. This review summarizes recent information on the role of the
CCL5 chemokine and its receptor CCR5 in GC cell proliferation, metastasis formation, and in the
building of an immunosuppressive TME. Moreover, it highlights the development of new therapeutic
strategies to inhibit the CCL5/CCR5 axis in different ways and their possible clinical relevance in the
treatment of GC.
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1. Introduction
Several research findings suggest that unresolved pathogen infections and chronic inflammation
promote tumor development. Hence, inflammation has become another hallmark of cancer [1–3].
Indeed, inflammatory cellular effectors and cytokines within the tumor microenvironment (TME) can
promote an antitumor immune response or support tumor pathogenesis [3–5]. Thus, the new challenge
is to find drugs or drug combinations that are capable of counteracting the pro-tumorigenic effects of
the TME or its formation [6].
Tumor cells can promote the formation of an immunosuppressive/protective TME by recruiting
and then “educating” monocytes, myeloid cells, or T cells to become immunosuppressive
tumor-associated macrophages (M2-TAM) [7], myeloid-derived suppressor cells (MDSC), T-regulatory
cells (T-reg) [8], and mesenchymal stromal cells (MSCs) [9] capable of suppressing T and natural
killer cells (NK) responses [10]. Consistently, the presence of inflammatory cells and high amounts
of inflammatory mediators (e.g., cytokines, chemokines, enzymes) in the primary tumor is often
associated with a bad prognosis and an increased capability to form metastasis [4,11,12].
Tumor cells and the TME can communicate through direct contact and/or through paracrine
signals [6], including cytokines and chemokines, which are considered to be key orchestrators not only
in inflammation and immune surveillance, but also in cancer progression [13,14] since they can act
as survival/growth factors [15,16], improve angiogenesis [17], affect tumor immunity, and influence
therapeutic outcomes in patients [18].
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A variety of chemokines and chemokine receptors has been detected in neoplastic tissues [1,6].
We will focus our attention primarily on the C-C chemokine ligand 5 (CCL5), also known as
RANTES (Regulated upon Activation, Normal T cell Expressed, and Secreted), and its receptor,
C-C chemokine receptor type 5 (CCR5). CCL5 belongs to the C-C chemokine family whose
members also include CCL3(MIP-1α) and CCL4(MIP-1β) [19]. CCL5, a target gene of nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB) [20,21], is expressed by T lymphocytes,
macrophages, platelets, synovial fibroblasts, tubular epithelium, and certain types of tumor cells [19].
CCL5 induces the recruitment of different leukocyte types, including T cells,
monocytes/macrophages, eosinophils, and basophils to sites of injury and infection. In collaboration
with IL-2 and IFN-γ which are released by T cells, CCL5 induces the activation and proliferation of
particular NK cells to generate C-C chemokine-activated killer cells [19].
CCL5 activity is mediated mainly by binding to CCR5, but also to CCR1 and CCR3 [19].
CCR4 [20,22] and CD44 are auxiliary receptors for CCL5 [22,23]. CCR5 is a promiscuous receptor that
binds with high affinity CCL5, CCL3, and CCL4. CCR5 is the major co-receptor for HIV cell entry [24],
and this property has significantly boosted the research on CCR5 antagonists/inhibitors [25].
2. The CCL5/CCR5 Axis in Cancer: General Mechanisms
2.1. CCL5–CCR5 Interactions May Favor Tumor Development in Multiple Ways
2.1.1. Proliferation
CCL5 can increase cancer cell growth [15,18,26,27]. It stimulates cell proliferation by inducing
the mammalian target of rapamycin (mTOR) pathway followed by a rapid upregulation of cyclin
D1, c-Myc, and Dad-1 expression, or by enhancing glucose uptake with increased ATP production
and glycolysis [28]. CCL5 may act indirectly by recruiting the TME, monocytes/macrophages, or
fibroblasts that, in turn, may promote and sustain tumor cell survival/proliferation [14,29].
2.1.2. Immunosuppression
Tumor-associated macrophage (TAM)s are a heterogeneous population of myeloid cells that contribute
to immunosuppression, favoring the establishment and persistence of solid tumors as well as metastatic
dissemination. The immunosuppressive effect of TAMs stems from their enzymatic activities and their
production of anti-inflammatory cytokines, such as indoleamine 2,3-dioxygenase (IDO), interleukin-10
(IL-10), and transforming growth factorβ (TGF-β), which have inhibitory effects on tumoricidal lymphocytes
and expand T-reg populations [30]. Consistently, Halama et al. found that blocking the CCR5/CCL5 axis
with the CCR5 antagonist Maraviroc (MVC) in functional organoids derived from metastatic colorectal
cancer (CRC) patients, determined a macrophage repolarization with anti-tumoral effects. Myeloid-derived
suppressor cells (MDSCs) are a heterogeneous population of myeloid cells that can limit productive immune
responses against tumors [31]. Targeting the autocrine CCL5/CCR5 axis with MVC was found to reprogram
the MDSCs and reinvigorate the antitumor immunity [32].
2.1.3. Angiogenesis
Angiogenesis is a prerequisite for tumor growth and invasion [33]. CCL5 exerts proangiogenic
effects by promoting endothelial cell migration, spreading, neovessel formation, and vascular
endothelial growth factor (VEGF) secretion. Moreover, tumor cells, upon CCL5 stimulation, can
produce VEGF or, by secreting CCL5, may recruit CCR5-expressing TAMs [19,34]. In turn, by secreting
VEGF, TAMs can induce angiogenesis [18,30,35]. Thus, targeting tumor-promoting TAMs, which are
now considered to be the major players in the regulation of tumor angiogenesis, may represent an
attractive new therapeutic strategy.
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2.1.4. Migration (Metastasis Formation)
The binding of chemokines to their G-protein-coupled receptors (GPCRs) activates a series
of downstream effects that facilitate receptor internalization and signal transduction, leading to
integrin activation (adhesion) and polarization of the actin cytoskeleton [36]. The consequences
are directional sensing, cell polarization, accumulation of the small GTPases Rac and Cdc42 and
of PI3K at the leading edge, actin polymerization, and F-actin formation. These changes cause
actomyosin contraction, tail retraction, and, finally, cell migration [36]. More specifically, in lung
cancer, CCL5 contributes to the activation of the αvβ3 integrin and to cell migration through PI3K/Akt,
which in turn activates IKKalpha/beta and NF-κB [37]. In ovarian cancer, CCL5 can induce matrix
metalloproteinases-9 (MMP-9) secretion by monocytes, which, by degrading the matrix, allows
for tumor cell extravasation [38]. In prostate cancer, CCL5 promotes invasion by increasing the
secretion of both MMP-2 and -9 and by activating extracellular signal–regulated kinases (ERK) and
Rac signaling [39]. In osteosarcoma, CCL5/CCR5 interactions act via MEK, ERK, and then NF-κB,
resulting in the activation of αvβ3 integrin [40].
A schematic representation of the consequences of the CCL5/CCR5 interactions in cancer is
shown in Figure 1.
Figure 1. Effects of the C-C chemokine ligand 5 (CCL5) and C-C chemokine receptor type 5 (CCR5)
interactions on cancer. CCL5 secreted by tumor cells or by cancer-associated fibroblasts (CAFs)
recruits monocytes, T cells, eosinophils, and mast cells in the tumor microenvironment (TME). CCL5
induces tumor cell proliferation via the mammalian target of rapamycin (mTOR) pathway and
increases ATP production, enhances tumor cell migration/invasion through αvβ3 integrin activation
and matrix metalloproteinases-2/9 (MMP-2/9) upregulation, promotes angiogenesis by inducing
vascular endothelial growth factor (VEGF) secretion; targeting the CCR5/CCL5 axis reprograms the
immunosuppressive M2-tumor-associated macrophage (TAM) to anti-tumoral M1-TAM. Thin arrow,
up-regulation; bold arrow, repolarization; red cross, inhibition.
152
Int. J. Mol. Sci. 2018, 19, 1477
3. Possible Clinical Applications: CCL5 and CCR5 as Therapeutic Targets
One of the strategies in cancer therapy is to counteract the formation of a pro-tumorigenic and
immunosuppressive TME. There is evidence suggesting possible clinical applications of drugs that are
capable of inhibiting the CCR5/CCL5 axis or decreasing CCL5 production/secretion by tumor cells or
by the TME [18].
Moreover, CCL5 levels, as well as their changes in liquid biopsy samples, could potentially be
useful to monitor or predict disease progress and treatment outcomes. Clinical evidence has revealed
that elevated levels of tissue or plasma CCL5 are markers of an unfavorable outcome in patients with
breast [41–44], cervical [45], prostate [26], ovarian [46], gastric [47,48], colorectal [49], or pancreatic
cancer [50].
3.1. Inhibition of CCL5–CCR5 Interactions
Finding new therapies for cancer patients is necessary, however the discovery of safe and
efficacious drugs remains expensive and time-consuming [51,52]. Thus, several non-oncology
drugs have been successfully repurposed for cancer [52], including the CCR5 antagonists TAK-779,
Anibamine, and, especially, MVC [18,53].
MVC is a U.S. Food and Drug Administration (FDA)-approved CCR5 antagonist, which is highly
selective and well tolerated, originally developed for HIV patients as a viral entry blocking inhibitor.
Recently, it has demonstrated its potential to treat different types of cancer (Table 1).
Table 1. CCL5/CCR5 axis inhibitors used in preclinical studies and clinical trials (cancer and HIV).
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Table 1. Cont.
Compound Mechanism/Molecule Cancer-Related Studies References
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https://www.clinicaltrials.
gov/ct2/show/NCT01338883
In breast cancer, MVC decreased the migration of CCR5+ regulatory T cells, reduced metastatic
breast cancer growth in the lungs [55,67], and enhanced cell killing mediated by DNA-damaging
chemotherapeutic agents [54]. In human colon cancer, it reduced the accumulation of fibroblasts in the
tumor [68]. Recently, Halama et al. [53] demonstrated that T cells at the invasive margins of human
CRC liver metastases produced CCL5 which had tumor-promoting effects and was responsible for
the functional reprogramming/education of immunosuppressive TAMs toward a pro-tumorigenic
phenotype. In a phase I trial in patients with liver metastases of advanced refractory CRC, MVC
confirmed antitumoral potency [53], since treatment with the drug was associated with mitigation of
tumor-promoting inflammation within the tumor tissue and objective tumor responses [53].
TAK-779, a quaternary ammonium derivative, is a non-peptide CCR5 antagonist with a small
molecular weight, that binds exclusively to CCR5. It inhibited HIV infection and CCL5-induced
proliferation and invasion of prostate cancer cells (PCa) [18].
Anibamine is the first natural product reported as a CCR5 antagonist. It produced significant
inhibition of both PCa and ovarian (OVCAR-3) cancer cell line proliferation and suppressed adhesion,
invasion, and tumor growth in mice [62,63].
A detailed list of inhibitors of the CCL5/CCR5 axis used in preclinical studies and clinical trials
in cancer and HIV patients is shown in Table 1.
3.2. Inhibition of CCL5 Secretion
The inhibition of CCL5 secretion by cancer cells or by TME may represent an additional
system to affect tumor progression [18]. In classical Hodgkin lymphoma, the PI3Kδ-specific
inhibitors GS-1101 [17] and Auranofin [69] and the NF-κB inhibitor dehydroxymethylepoxyquinomicin
(DHMEQ) [70] not only were cytotoxic, but also decreased CCL5 secretion by cancer cells, leading to a
reduced capability to recruit peripheral blood mononuclear cells (PBMCs) [69].
Another therapeutic modality that deserves some consideration deals with the possibility to
counteract the cross talk mediated by the CCL5/CCR5 axis between cancer cells and MSCs.
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Breast cancer cells stimulated de novo secretion of the chemokine CCL5 from mesenchymal stem
cells, which then acted in a paracrine fashion on the cancer cells to enhance their motility, invasion,
and metastasis [71]. Zoledronic acid (ZA) [72], as well as PEGylated nanoparticles (NPs) encapsulating
ZA [73], decreased both CCL5 and IL-6 secretion by MSCs, suggesting that ZA may exert antitumor
activity by affecting the ability of MSCs to interact with breast cancer cells.
Along this line, we recently found that the epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor, gefitinib decreased the capability of supernatants from PCa cells to increase CCL5
secretion by MSCs [74].
Overall, decreasing cancer cells or TME secretion of CCL5 using anticancer drugs may affect both
tumor cell proliferation and/or the formation of a protective/immunosuppressive TME.
4. Gastric Cancer and Its TME
Gastric cancer (GC) is the fifth most common cancer worldwide [75]. The precise pathogenesis of
GC remains unclear. It has been correlated to many factors, such as eating habits, environmental factors,
hereditary predisposition, chronic gastritis, gastric polyps, gastric mucosa abnormal hyperplasia, and
Helicobacter pylori (H. pylori) infection. At diagnosis, over 50% of patients present locally advanced
or metastatic GC and consequently are ineligible for curative surgery. When surgery is not possible,
chemotherapy is often given to reduce tumors, but with low benefit to patients. Therefore, to
improve GC treatment, it is fundamental that we find the molecular events that are responsible
for the development and progression of this malignancy [76,77].
Inflammation plays a decisive role at different stages of tumor development, including initiation,
promotion, malignant conversion, invasion, and metastasis [1,2,77–80]. H. pylori, a microaerophilic
gram-negative bacterium that colonizes the gastric mucosa of 50% of the human population, plays
a predominant role in the etiology of GC [81]. Its carcinogenic potential is driven by the interplay
between bacterial virulence factors and the host’s immune responses that allow H. pylori to switch
between commensalism and pathogenicity. The result is chronic inflammation, with the production
of cytokines/chemokines and cell proliferation, which increases the risk of DNA damage and,
consequently, tumorigenesis [81]. According to the strong association between infections with H. pylori
and neoplastic transformation in the human stomach, H. pylori has been classified as a class I carcinogen
by the World Health Organisation in 1994, representing the strongest known risk factor for GC [81,82].
While many virulence factors of H. pylori have been described, the CagA (cytotoxin-associated gene A)
toxin, which is translocated into gastric epithelial cells via a bacterial secretion system, appears to be
the most specific for the development of a pathological phenotype. Infection with H. pylori, a potent
activator of NF-κB in gastric epithelial cells, increases CCL5 [47,81–83] and induces the expression of a
variety of genes, including IL-1, IL-6, IL-8, IL-10, TNF-α, VEGF, cyclooxygenase-2 (COX-2), inducible
nitric oxide synthase (iNOS), cell cycle regulators, the matrix metalloproteinases (MMP)-2, MMP-7,
MMP-9, and also adhesion molecules [82,84].
The chronic inflammatory state of the stomach, caused by H. pylori infection as well as the
production of inflammatory mediators, cytokines, and chemokines, such as CCL5 within gastric tissues,
plays an important role in the initiation and progression of GC. Furthermore, in GC, tumor cell survival,
growth, proliferation, and metastasis are promoted by the interaction with the TME [84]. The TME
of GC is composed of many different types of cells, including TAMs, lymphocytes, cancer-associated
fibroblasts (CAFs), and endothelial cells [84].
4.1. Macrophages (TAMs)
Monocytes from the peripheral blood are recruited in the TME and differentiate into TAMs
in response to chemokines, including CCL5, and growth factors produced by stromal and tumor
cells [30]. In GC, TAMs can improve genetic instability, promote cancer stem cells [85], increase
metastasis, and contribute to the formation of an immunosuppressive TME by inhibiting T cell
activation [86,87]. Thus, inhibition of monocytes/macrophage recruitment and/or survival in tumors
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or their immunosuppressive reprogramming may also represent a new therapeutic option for GC.
Indeed, TAM levels into GC tumor tissue directly correlate with tumor vascularity [84] and the strength
of tumor invasion, nodal status, and clinical stage [84,87].
4.2. Regulatory T Cells (T-Regs)
T-regs are functionally immunosuppressive subsets of T cells, and play an important role in
immunological self-tolerance [88]. T-reg (FOXp3+) cells have been identified as regulatory components
of the adaptive immune response and are associated with H. pylori-related inflammation and bacterial
persistence [89]. The frequency of T-regs among tumor infiltrating lymphocytes (TILs) derived from
tumor-draining regional lymph nodes or peripheral blood lymphocytes is higher in GC than in normal
gastric tissue [84,89]. Patients with a higher proportion of T-regs showed poorer survival rates than
those with a lower proportion. Interestingly, after patients underwent curative resection for GC,
the proportion of T-regs decreased and came back to levels comparable to those for normal, healthy
donors [89]. Thus, naturally occurring Foxp3+ T-regs may be induced to migrate from the peripheral
blood to the tumor sites by the chemokines CCL17, CCL22, and CCL5 and then increase in number by
tumor-related factors to create a favorable environment for tumor growth [89].
4.3. Cancer-Associated Fibroblasts (CAFs)
CAFs are important components of various types of tumors, including GC [90,91]. During
tumorigenesis and progression, CAFs play critical roles in tumor invasion and metastasis via
a series of functions, i.e., extracellular matrix deposition, metabolism reprogramming, and
chemoresistance [90,91]. CAFs may modulate several aspects of tumor biological behavior in GC,
including the ability to proliferate, metastasize, and invade. Additionally, CAFs increase the infiltration
of immune cells into GC stroma and increase the rate of angiogenesis by secreting VEGF [92].
4.4. Endothelial Cells (Angiogenesis)
Angiogenesis is the result of an imbalance between positive and negative angiogenic factors
released by tumor and host cells into the TME. In GC, angiogenesis is promoted by H. pylori [93],
high numbers of CAFs [77,92], and TAMs [94,95]. In addition, both GC tumor and stromal cells
produce various angiogenic factors, including VEGF, IL-8, and platelet-derived endothelial cell growth
factor (PD-ECGF). Tumor angiogenesis plays an essential role in growth, invasion, and metastatic
spread of GC [96], indicating that pharmacologic blockade of angiogenesis is a promising new therapy,
and that the real-time assessment of the vasculature status is a promising approach to predict the
efficacy of the treatments and improve the clinical management of patients with GC [97]. Indeed, high
levels of angiogenic factors in serum and tumors are associated with worse outcomes in GC patients.
VEGF-A, the most extensively studied angiogenic factor, appears to be a useful biomarker for disease
progression and remission, but not for diagnosis [96].
5. The CCL5/CCR5 Axis in GC Development and/or Progression
GC is a common gastrointestinal tumor characterized by rapid lesion development and poor
prognosis. Diagnosis of GC is difficult because most patients are asymptomatic in the early stages of
disease, which leads to a delay in treatment [81]. Therefore, early diagnosis of GC is essential, and
cytokines detection is now regarded as a potential diagnostic tool.
Existing literature highlights the fundamental role of CCL5 in GC progression. GC patients
have significantly higher serum CCL5 levels compared with control groups [47,98]. The overall
survival of patients with CCL5 levels higher than 71 pg/mL was found to be significantly lower
than that of patients with less CCL5 [47,99]. Higher CCL5 levels were associated with lower
histological differentiation, higher depth of tumor invasion, more frequent lymph nodes involvement,
and advanced tumor stage [99]. More recently, a retrospective analysis of 105 patients with GC
demonstrated that increased CCL5 serum levels correlated with more advanced T and N stages,
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poorly- or undifferentiated histological types, peritoneal metastasis, higher rates of residual tumor,
and shorter survival [100].
Patients in the high CCL5 group also had stronger CCL5 immunohistochemistry (IHC) staining in
tumor tissues [47,98] and in metastatic lymph nodes [101]. Thus, high CCL5 serum levels, along with
strong IHC (CCL5) staining and poorly- or undifferentiated cancer, may be used to predict peritoneal
dissemination and a poorer prognosis [100].
A novel prognostic gene expression risk score, including the expression of CCL5, CTNNB1,
EXOSC3, LZTR1, and clinical parameters, was recently established and validated for perioperative
chemotherapy treatment of GC [102]. CCL5 was also included among genomic markers that could be
useful predictors of chemotherapy efficacy for better prognosis and survival outcomes in GC [103].
High expression of the CCL5 and CXCL12 genes in Lauren’s diffuse type of GC and increased expression
of ADAMTS1, CXCL12, and CCL19 genes were found in peritoneal metastasis, suggesting their
involvement in tumor progression [103].
Human GC cell lines characterized by a high metastatic potential have increased CCL5 expression
levels [104]. In vitro studies demonstrated that supernatants from highly metastatic GC cell lines
increased CCL5 expression in PBMCs. In turn, GC cells cultured with PBMCs had higher invasion
properties, and this process was inhibited by neutralizing anti-CCL5 antibodies [105].
Sugasawa et al. [106] demonstrated that CCL5 is expressed by TILs (CD4+ rather than CD8+
cells) and CCR5 is expressed by GC cells. CD4+ cells, but not CD8+ cells, cocultured with GC
cells (MKN45 and KATO III cell lines) remarkably enhanced CCL5 production in a direct cell–cell
contact manner [106]. Treatment of GC cells with CCL5 increased the proliferation and cocultivation
of CCL5-treated GC cells, and PBMCs decreased the proportion of CD8+ cells but not CD4+ cells,
suggesting a Fas-FasL-mediated apoptosis in CD8+ cells. In immunodeficient mice coinjected with
KATO III and PBMCs, neutralization of CCL5 decreased tumor growth, suggesting that GC cells may
induce CD4+ T cells to secrete the tumor-promoting CCL5 and may inhibit the anticancer activity of
CD8+ cells [106].
CAFs represent the prominent stromal cellular components in the GC TME [92,107].
The Krüppel-like factor (KLF) KLF5 is a DNA-binding transcriptional regulator that is involved
in the tumor-initiating properties of cancer stem-like cells, migration, and drug resistance [108]. In GC
patients, high levels of KLF5 in CAFs were closely associated with clinical pathological features such
as tumor size, invasion depth, cell grade, and lymph node metastasis, as well as poor prognosis [109].
Yang T et al. demonstrated that the upregulation of KLF5 in CAFs promoted tumor growth, migration,
and invasion of GC cells in vitro and in vivo. The major factor contributing to these effects was the
increased secretion of CCL5 due to KFL5 in CAFs. Moreover, they found that CCR5 expression in
GC cells was activated by CCL5 produced by CAFs. Since the downregulation of KLF5 in CAFs
inhibited GC cell progression, KLF5 and/or the CCL5/CCR5 axis may represent promising targets for
the treatment of GC [109].
Monocytes/macrophages, which are crucial drivers of tumor progression, express the CCR5
receptor [30]. Consistently, a significant positive correlation was found between the expression of
CCL5 and CD68 (macrophage marker) in GC tissues [85]. High levels of CCL5 and CD68 are associated
with tumor size, degree of tumor invasion, lymphatic metastasis, pathological grading, and tumor
thrombus, but are unrelated to patient age and gender [85].
In addition, Ding et al. also [98] found that CCL5 and CD68 expression are positively correlated,
were highly expressed in GC tissues, and were associated with the depth of invasion, lymph node
metastasis, TNM staging, and tumor differentiation. In vitro experiments demonstrated that the
co-cultivation of GC cells with THP-1 used as a model for monocytes/macrophages, increased
CCL5, MMP2, and MMP9 in THP-1 cells [98] and increased proliferation, clone-forming ability,
and movement/migration in GC cells (also enhanced by exogenous CCL5) [98]. Thus, the authors
suggested that, by secreting CCL5, TAMs promote GC cell proliferation, invasion, and metastasis.
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In conclusion, CCL5 may represent a marker of GC staging, disease progression, and a new
therapeutic target [98].
6. Possible Clinical Applications of MVC in GC
The CCL5/CCR5 axis is a potential therapeutic target in different cancer types. Since several
studies have demonstrated its involvement in GC progression [48,101,106,110], counteracting the
pro-tumorigenic effects of the CCL5/CCR5 axis with CCR5-antagonists, such as MVC [53,111], or
alternatively, with drugs that are capable to of decreasing CCL5 secretion [69] may be a new therapeutic
options for GC treatment.
By using anti-CCL5 antibodies, Cao et al. [92] reverted chemotaxis of GC cells induced by protein
extracts from GC lymph nodes harboring metastasis, suggesting that CCL5 and CCR5 contribute to
the migration of GC cells from primary to metastatic sites.
In another study, Mencarelli et al. demonstrated that MKN45, MKN74, and KATOIII GC cell
lines at different stages of differentiation expressed both CCR5 and CCL5 and that MVC reduced
tumor cell migration induced by CCL5 and adhesion to the explanted murine peritoneum [110]. MVC
treatment decreased tumor xenograft growth of MKN45 GC cells and the extent of peritoneal disease
and increased mice survival. Thus, the CCR5/CCR5-ligand axis seems to be involved in GC cell
dissemination, suggesting anticancer potential of CCR5 antagonists [110].
Consistently, DT-13, a saponin of dwarf lilyturf tuber (Table 1), was found to inhibit BGC-823 and
HGC-27 GC cell lines migration through downregulation of both CCR5 and CCL5 expression [64].
More recently, using CCR5 antagonists, Wang et al. demonstrated the involvement of CCL5/CCR5
signaling in the cross-talk between GC cells and TAMs leading to tumor growth [112], providing an
additional link between inflammation and GC. Chronic inflammation can promote tumor progression
via aberrant DNA methylation, an epigenetic modification [113] in neoplastic cells. DNA methylation
is catalyzed by enzymes of the DNA methyltransferase (DNMT) family, including DNMT1, the major
DNMT in adult cells, highly expressed in GC [114]. Gelsolin (GSN) is an actin-binding protein
that controls actin filament assembly and disassembly. Its expression is downregulated in many
cancers, including GC tissues, which suggests that it has a potential role in tumor suppression [112].
GSN staining in gastric tumors revealed high GSN expression in early-stage GC compared with
advanced-stage tumors [112]. GSN decrease was mediated by DNMT1 promoter methylation and low
GSN levels, associated with high DNMT1, and predicted poor survival in GC.
Wang et al. [112] found that TAMs infiltration in GC tissues correlated with high DNMT1
expression. Consistently, co-culture experiments demonstrated that M2-like macrophages suppressed
GSN expression in GC cells by upregulating DNMT1. Using anti-CCL5 neutralizing antibodies
and the CCR5 antagonist MVC, Wang et al. [112] demonstrated that co-cultivation of GC cells
with macrophages increased the secretion of several cytokines, but only CCL5 (secreted by M2-like
macrophages) stimulated DNMT1 expression. Moreover, treatment with 5-AZA, a potent DNMT1
inhibitor, or with the CCR5-antagonist MVC slowed GC tumor xenograft growth, revealing the
antitumor effects of DNMT1 suppression by the inhibition of CCR5 engagement in GC. Thus, MVC,
which is capable of disrupting CCL5/CCR5 interactions, may represent a new potential therapeutic
option to counteract TAM-induced tumorigenesis [112].
A schematic view of the CCL5 functions in GC and possible clinical applications of MVC are
shown in Figure 2.
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Figure 2. A schematic representation of the proposed role of CCL5 in gastric cancer (GC). (1) By
activating nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), Helicobacter pylori
may induce CCL5 expression in GC cells. (2) By secreting CCL5, M2-TAMs may activate signal
transducer and activator of transcription 3 (STAT3) and DNA methyltransferase (DNMT) and inhibit
gelsolin (GSN) expression, leading to enhanced GC cancer cell proliferation and invasion/metastasis
formation. CCL5 up-regulation (3) Krüppel-like factors 5 (KLF5) overexpression in CAFs enhances
the secretion of CCL5, which induces GC cell invasion and proliferation. (4) By secreting CCL5, CD4+
tumor-associated lymphocytes (TILs) may enhance GC cell proliferation and invasion. (5) By secreting
CCL5, GC cells may recruit T-regulatory cells (T-regs), monocytes, and macrophages in the TME.
(6) Increased CCL5 in GC metastatic tissues and serum may enhance GC cell invasion. Thin up-arrow,
CCL5 up-regulation; red cross, inhibition; curved arrow, binding of CCL5 to CCR5 (3, 4); curved arrow,
cell migration to GC cells (5).
7. Conclusions
Collectively, several studies suggest that the CCL5/CCR5 axis is associated with GC progression
due to increased growth and metastasis formation, though we cannot rule out a role of CCL5 also in
the formation of an immunosuppressive TME [32,53]. Our current knowledge leads us to suggest the
CCL5/CCR5 axis as a potential therapeutic target in GC.
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Abstract: Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide
and the disease outcome commonly depends upon the tumour stage at the time of diagnosis.
However, this cancer can often be asymptomatic during the early stages and remain undetected
until the later stages of tumour development, having a significant impact on patient prognosis.
However, our comprehension of the mechanisms underlying the development of gastric malignancies
is still lacking. For these reasons, the search for new diagnostic and prognostic markers for gastric
cancer is an ongoing pursuit. Modern mass spectrometry imaging (MSI) techniques, in particular
matrix-assisted laser desorption/ionisation (MALDI), have emerged as a plausible tool in clinical
pathology as a whole. More specifically, MALDI-MSI is being increasingly employed in the study of
gastric cancer and has already elucidated some important disease checkpoints that may help us to
better understand the molecular mechanisms underpinning this aggressive cancer. Here we report
the state of the art of MALDI-MSI approaches, ranging from sample preparation to statistical analysis,
and provide a complete review of the key findings that have been reported in the literature thus far.
Keywords: gastric cancer; MALDI imaging; proteomics; metabolomics; lipidomics
1. Introduction
Gastric cancer (GC) develops from the lining of the stomach and is the fifth most common
malignancy worldwide [1]. The prognosis of patients with this cancer is related to tumour extent; often
early stages of the disease can be asymptomatic, and consequently late diagnosis in advanced stages
makes treatment less likely to succeed and reduces patients’ chances of survival. The general prognosis
is in fact rather grim for gastric cancer patients, with less than 25% of patients surviving at the five-year
time-point following diagnosis [2]. Given the high morbidity and mortality rate, the study of GC
represents a pressing area of clinical research and much work is ongoing. However, our comprehension
of the mechanisms underlying the development of gastric malignancies is still lacking. Given the
breadth of modern analytical instrumentation now at our disposal, the detection of early diagnostic
biomarkers of GC may not be a distant hope and such findings could be used to elucidate potential
pathways for tailored therapeutic treatment.
Mass spectrometry (MS)-based techniques have become some of the most prevalently employed
analytical strategies for the detection and identification of endogenous biomolecules in tissue.
The application of these techniques is now commonplace in clinical research [3–5] and the mass
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spectrometric detection of pathologically significant molecules has already shown promise in the study
of gastric cancer, providing greater insights into the molecular aspects of the disease and aiding in the
identification of candidate biomarkers [6]. Furthermore, the emergence of modern mass spectrometry
imaging (MSI) techniques has further revolutionised this area of research. Using MSI, the chemical
specificity of MS can be combined with the imaging capabilities offered by optical microscopy in order
to simultaneously detect the distribution of hundreds, if not thousands, of biomolecules directly in
situ, making it an ideal discovery method for new potential biomarkers for gastric cancer.
Matrix-assisted laser desorption/ionisation (MALDI) remains the most widely applied MSI
technique owing to its capability to analyse a wide range of analyte classes (xenobiotics, metabolites,
lipids, and proteins) [5]. In particular, the MS-imaging of proteins has been readily performed given
their significant role in a large number of pathways involved in defective cellular signalling cascades.
Therefore, the ability to spatially resolve the localisation of a number of proteins within the same
section of pathological tissue can enable the detection of pathological processes, and, ultimately, define
biomarker candidates. Additionally, it has also become increasingly common for the distribution of
lipids and metabolites to be recorded by MALDI-MSI, owing in particular to their ease of analysis.
Furthermore, there is an ever-increasing body of evidence to suggest that these small molecules play
a significant role in biological systems and, as such, are heavily involved in disease pathogenesis.
Finally, MALDI-MSI is now readily used to monitor the distribution of xenobiotics and their metabolites
within tissue, establishing itself as an invaluable tool in drug distribution studies [7].
In this review, we provide a concise overview of the methodological aspects of MALDI-MSI and
summarise how the technique has been used to advance gastric cancer research for the purpose of
biomarker detection and monitoring treatment response.
2. Matrix-Assisted Laser Desorption/Ionisation-Mass Spectrometry Imaging (MALDI-MSI) in
a Nutshell
MALDI-MSI applied to thin mammalian tissue sections was formally introduced in 1997 and
its use has increased exponentially in recent years [8]. The technique relies on the use of a MALDI
matrix, which consists of small organic molecules that are designed to absorb the energy of a pulsed
laser beam. These molecules commonly possess a suitable chromophore, usually in the form of
an aromatic core, and it is this property of the matrix that facilitates the absorption of the UV laser
energy. When this matrix is applied to the surface of a sample, it promotes the formation of a ubiquitous
layer of co-crystals, which incorporates both matrix and analyte molecules in its network. When the
laser beam is applied to the surface of the sample, the absorbed energy leads to rapid desorption of
both the matrix and analyte crystals and subsequent “soft” ionisation [3].
Typical MALDI-MSI analysis is most commonly performed on tissue sections that have been
sectioned and mounted onto electrically conductive glass slides, such as those coated with indium tin
oxide (ITO) [9]. For protein, lipid, xenobiotics and metabolite imaging, the analysis is most commonly
performed using fresh-frozen (FF) tissue [10,11].
Regarding the imaging of drugs and products of drug metabolism, MALDI-MSI has been readily
used within the pharmaceutical community for the purpose of drug discovery and development [12].
The monitoring of the spatial distribution of drugs and their metabolites in order to evaluate a drug’s
absorption properties, as well as the characterisation of a drug’s delivery and penetration in a target
organ, represent some examples of how MALDI-MSI tools have been successfully applied in this
field [13,14]. In addition to qualitative MALDI-MSI approaches, the ability to obtain absolute
quantitative information by MALDI-MSI for drug analysis, by applying internal standards, has recently
been further investigated [15,16].
In the case of protein imaging, formalin-fixed paraffin-embedded (FFPE) tissue is now also readily
employed [17]. FFPE tissue accounts for a large percentage of the patient samples collected and stored
in medical centres [18] and thus represents a potential gold mine of information for histopathological
studies involving MALDI-MSI. It also facilitates multi-centric studies using tissue specimens from
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numerous tissue banks [19,20]. However, the sample preparation for protein imaging of FFPE tissue is
more complex and requires an antigen retrieval step followed by tryptic digestion prior to MALDI-MSI
analysis. Metabolite imaging has also been conducted on FFPE tissue [21]; however, it has been less
extensively investigated with respect to proteins. Finally, a number of groups have focused on the
analysis of N-glycans in tissue [22,23], demonstrating that it is possible to monitor the distribution of
both N-glycans and proteins within the same tissue section [23]. The potential to monitor N-glycans,
one of the most common post-translational modifications, may significantly advance MALDI-MSI
investigations in gastric cancer given their fundamental role in many cellular processes and their
establishment as clinical biomarkers [23]. A general overview of the MALDI-MSI sample preparation
and analysis workflow is given in Figure 1.
Figure 1. Illustration of the workflow for the matrix-assisted laser desorption/ionisation-mass
spectrometry imaging (MALDI-MSI) analysis.
2.1. Sample Preparation
Particular attention to detail must be paid during the collection of FF tissue, as negligence
during the sample collection can lead to degradation and delocalisation of the analytes of interest.
The method most commonly employed during collection is snap-freezing using liquid nitrogen;
however, this procedure can damage tissue morphology if it cools at different rates. This can be
overcome to some degree by lightly wrapping the tissue in aluminium in order for it to cool at a more
uniform rate [24]. Alternatively, Goodwin et al. recommend the use of ethanol or isopropanol solutions
at temperatures of ≤−70 ◦C [25]. Once snap-frozen, FF tissue sections can be maintained at −80 ◦C
for up to a year without evidence of degradation [3,24,26]. Prior to matrix application, tissue washes
are also performed in order to remove any molecules that may interfere with the ionisation of the
target analytes, including any compounds used during the sectioning procedure. Standard protocols
for protein MS-imaging recommend washing the tissue sequentially in increasing concentrations of
ethanol, whilst, for example in tissue with a high lipidomic content, washing this tissue with chloroform
or xylene can improve protein detection [24,25,27]. Conversely, different washing protocols should
be used if the intended analytes are not proteins, e.g., ethanol (70%) with the addition of ammonium
acetate (NH4Ac) is recommended for the desalting of tissue prior to lipidomic analysis [28].
Regarding FFPE tissue, metabolite MS-imaging requires tissue immersion in xylene, or a similar
organic solvent, in order to remove any paraffin [21]. Protein MS-imaging, however, requires a more
complex procedure [4,29,30]. Following paraffin removal, tissue rehydration is then performed prior to
antigen retrieval. The antigen retrieval step is generally performed at 97 ◦C whilst immersed in a buffer
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solution that most commonly contains either Tris-HCl or citric acid [31–33], and is required in order
to break the methylene bridges that have formed between amino acids during the fixation process.
Whilst enzymatic digestion is conventionally performed in solution for proteomic investigations,
here the spatial integrity of the proteins is required, and thus the procedure is performed in situ.
However, the hydrophobic nature of certain proteins renders them proteolytically resistant to digestion
and ultimately limits the peptide yield when performed in this manner. The addition of detergents
to the trypsin solution can improve solubilisation by unfolding the proteins, increasing the number
of possible enzymatic cleavage sites. A number of detergents have been shown to be compatible
with MALDI-MSI analysis, such as N-Octanoyl-N-methylglucamin (MEGA-8) and RapiGest SF
(Waters Corporation, Manchester, UK) [34,35], and significantly improved peptide yield as well
as signal intensity, facilitating a greater number of peptide identifications whilst using a bottom-up
approach. Alternatively, enzymatic digestion can be performed using N-glycosidase F (PNGase F) in
order to visualise the distribution of N-glycans that are associated with different pathological states of
tissue [23].
Matrix deposition plays a crucial role in MALDI-MSI experiments and can limit the true spatial
resolution that can be achieved. The general aim of the co-crystallisation process is to maximise analyte
extraction whilst at the same time limiting the degree of lateral diffusion, which is equally important to
the choice of matrix [9]. Wet matrix deposition methods, involving the use of automated spotters [36]
and, in particular, sprayers [37], are particularly efficient for the extraction of proteins and peptides and
commonly lead to the formation of crystals of between 10 and 50 μm in diameter. On the other hand,
solvent-free matrix deposition involving sublimation has surged in popularity for the analysis of lipids
and metabolites due to its ability to deposit a uniform coating of fine matrix crystals that are only a few
microns in diameter [38]. Therefore, sublimation represents a highly cost-effective approach to matrix
deposition that is both reproducible and compatible with high spatial resolution MALDI-MSI [9].
In contrast to sublimation methods that deposit dry matrix onto the surface of the tissue section,
microscope glass slides can also be pre-coated with a MALDI matrix prior to tissue mounting [39].
This has also been shown to be a high-throughput approach that can be effective for the analysis of
both proteins [39] and low molecular weight compounds, such as lipids and metabolites [40].
Depending on the target analyte of choice, a number of different matrices can be used. For example,
DHB (2,5-Dihydroxybenzoic acid), sinapinic acid (SA; 3,5-dimethoxy-4-hydroxycinnamic acid) and
α-CHCA (α-cyano-4-hydroxycinnamic acid) are the most common matrices of choice for the extraction
of low molecular weight proteins, peptides, and lipids (1–20 kDa) [41]. However, the addition
of hexafluoroisopropanol (1,1,1,3,3,3-hexaluoro-2-propanol) and 2,2,2-trifluoroethanol to the matrix
solution [42], along with the use of detectors designed for the detection of higher molecular weight
analytes, has been shown to enhance the potential to detect higher molecular weight proteins whilst
using SA (up to 110 kDa) [43]. Alternatively, ferulic acid (3-(4-hydroxy-3-methoxy-phenyl)-prop-2-enoic
acid) may also be used for the extraction of high molecular weight proteins (up to 140 kDa) [44].
Additionally, ionic matrices such as CHCA/aniline (CHCA/ANI) and CHCA/N,N-dimethylaniline
(CHCA/DANI) have been employed to obtain a more ubiquitous matrix layer and enhance the detection
of protein signals [45]. For metabolite imaging, 9-aminoacridine (9AA) is often employed and the mass
spectrometer is set in negative-ion mode [46]. In view of the rapid evolution in mass spectrometric
instrumentation, the search for novel matrices and matrix deposition protocols has also come to the
fore. For example, Garate et al. demonstrated the use of MBT (2-mercaptobenzothiazole) and DAN
(2,5-diaminonapthalene) as MALDI matrices that produced very small crystals and were not a limiting
factor during the acquisition of MALDI-MS images with pixel sizes as low as 5 μm [47].
2.2. Instrumental Advancements
MALDI mass spectrometry instrumentation has rapidly evolved in recent years, offering ever
more mass resolution and increased sensitivity. In fact, state-of-the-art MALDI-MS instrumentation
enables the generation of individual spectra with intensities measured at 25,000–50,000 m/z-bins for
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ToF MS and even greater than 1,000,000 m/z-bins for Fourier-transform ion cyclotron resonance (FTICR)
MS measurements [48]. These advancements have enabled more comprehensive analysis and the better
resolution of species with similar m/z values. In fact, modern MALDI-FTICR-MS instrumentation,
as well as MALDI linear ion trap (Orbitrap), can enable the unequivocal identification of certain
analytes (particularly for small molecular weight compounds such as lipids, drugs and metabolites)
based on their accurate mass alone [49,50]. Furthermore, the addition of a separate dimension,
the drift time, to quadrupole-ToF and ion mobility instrumentation can overcome the inability of
MALDI-ToF instruments to differentiate isobaric ions, enabling the detection of a higher number of
peaks [51]. Notwithstanding this rapid evolution, several technical issues related to MALDI-MSI
still need to be improved, such as spatial resolution and sensitivity. However, next-generation
instruments are beginning to address these limiting factors [52], not only improving spatial resolution
and sensitivity, but also increasing the spectral acquisition rate as well as minimising pixel-to-pixel
variability, facilitating higher quality and more robust analysis. Continuing in this vein, MALDI-MSI
will be able to not only analyse single cells, but also potentially delve deeper and analyse at a subcellular
level, enabling the intra-cellular proteome to be investigated. Furthermore, it will also be possible
to routinely generate three-dimensional MALDI-MS images in order to obtain a snapshot of the
pathological state of an entire organ by combining MALDI-MS images of consecutive tissue sections
and reconstructing a three-dimensional representation using the appropriate (and currently available)
software [53–55].
2.3. Statistical Analysis and Data Elaboration
MALDI-MSI records the presence and relative abundance of a great variety of molecules on
tissue, allowing the localisation and spatial distribution of such molecules to be visualised. For each
pixel of the digitalised tissue image, a mass spectrum is acquired, generating a so-called “data cube”
(Figure 2A), a tensor in which the two spatial dimensions (x and y axes) of the digitalised tissue
section are combined with a third dimension consisting of the mass-to-charge ratio (m/z) of the
molecules present within the tissue section. Depending on the spatial resolution and the number
of data points (sampling rate) per spectrum, a MALDI-MSI dataset can be of several gigabytes,
even terabytes. Therefore, efficient statistical methods for data mining must be employed in order to
extract information from the spectral data [56].
Before proceeding with the statistical analysis, however, a series of pre-processing steps are
required in order to remove the analytical variability connected with the chemical impurities present
in the samples and the electronic nature of the mass spectrometric instrumentation [57,58]. These steps
adequately prepare the MS data for statistical analysis and enhance the biological information present
within the data (Figure 2B) [59]. Smoothing, performed by employing algorithms such as the
Savitzky–Golay filter and the moving average window, aims at discarding the fluctuations in the
spectrum mainly due to the electronic nature of the mass spectrometer: this process enhances and eases
the peak detection phase, since false positive peaks corresponding to electrical noise are discarded.
Baseline subtraction, performed by algorithms such as TopHat, iterative convolution and convex hull,
ensures that the spectra all lie on the x-axis and all the peak intensities are estimated from the x-axis
itself. Normalisation multiplies the intensity of the data points of the spectra by a scaling factor in
order to bring the intensity scale (merely related with the analogue-digital conversion of the signal)
within the same range and therefore make analyses more reproducible [60]: the total ion count (TIC)
method divides the spectrum intensities by the sum of all the intensity values for that spectrum;
the root mean square (RMS) method divides the spectrum intensities by the square root of the sum of
the intensity values for that spectrum squared; the median method divides the spectrum intensities
by the median intensity of that spectrum. Finally, peak picking extracts the information regarding
the peaks present within the mass spectrum, in the form of m/z and intensity pair values. After peak
maxima have been aligned to each other in order to account for fluctuations in the peak values among
the spectra of the dataset related with the peak picking process, the data can be submitted to statistical
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analysis. Mostly, machine learning algorithms are employed for statistical analysis of the data cube,
and, depending on the data provided and on the aim of the data mining process, unsupervised or
supervised approaches are carried out (Figure 2C,D) [61].
Unsupervised learning takes unlabelled data as input, i.e., data in which the outcome is not
known; by the exploitation of the intrinsic information present in the data, clustering operations are
performed in order to highlight hidden structures and/or patterns within the data and are achieved by
estimating the similarities among data observations [62]. However, these approaches can also be used
in a partially supervised manner, in such a way that the outcome of each observation is preserved
during the unsupervised analysis but not taken into account by the algorithm, which performs its
operations blind.
Examples of the unsupervised methods for statistical analysis that have been applied in the case
of MALDI-MSI gastric cancer datasets are hierarchical clustering analysis (HCA), principal component
analysis (PCA) and t-distributed stochastic neighbour embedding (t-SNE). Hierarchical clustering
analysis (HCA) estimates the pairwise distance among data observations and generates a dendrogram,
in which the observations are grouped under the same nodes based on their similarity to each other [62].
In mass spectrometry imaging, data observations correspond to individual spectra and pixels are
associated with spectra; therefore, pixels corresponding to spectra under the same node can be coloured
in the same way, generating an unsupervised segmentation tissue image, which can highlight areas
of interest on a molecular basis without a priori knowledge regarding the presence of such areas in
the tissue section [63]. Therefore, the MSI approach has the potential to aid the diagnostic process by
bringing areas of tissue to the attention of the pathologist and highlighting the molecular alterations,
even if they do not correlate with cyto-morphological features. Principal component analysis (PCA) is
a mathematical technique that aims at reducing data dimensionality whilst preserving the information
present within the data [64]. PCA provides an overview of the entire spectral dataset by generating
new variables (called principal components, PC) from the linear combination of the spectral features
(i.e., peaks): since the PCs are generated orthogonally to one another, no redundancy among the
new variables is present and PCs are sorted according to the amount of variance that is retained
from the original dataset. This is done in such a way that an overview of almost all the information
present within the data can be obtained by looking at the first principal components. The output
of a PCA consists of a score chart and a loadings plot: the former places data observations in a 2D
or 3D graph according to the score of the PCs, allowing the degree of similarity among the spectra
to be evaluated according to their distribution/clustering in the chart; the latter, by resembling the
distribution of the former, allows us to evaluate which feature contributes more significantly in driving
the distribution/clustering of data observations in the score chart. By combining the two plots,
not only is it possible to determine whether the data is capable of discriminating among different
classes, but also putative signals of interest can be highlighted for further investigation. t-SNE is
a non-linear dimensionality reduction technique that aims at reducing the number of dimensions to
two or three in such a way that a 2D or 3D visualisation is easily computed [65]: each n-dimensional
data point is mapped to a two- or three-dimensional point in such a way that similar observations
correspond to close points in the mapped space. While PCA generates new variables by computing
a linear combination of features, t-SNE retains all the features as they are in order to perform the
computations. In the case of spectral datasets, t-SNE can be applied by employing either all the
individual peaks or only the spectral data points.
On the other hand, supervised learning aims at employing algorithms, referred to as classifiers,
which learn from labelled data, i.e., data in which the outcome is known, in order to exploit known
features (which correspond to peaks in the mass spectrometry imaging dataset) to make predictions
about new, unknown data, resembling the classification problem [66]. The first phase, the training
phase, allows classifiers to build the mathematical formula by taking labelled data as input and
discriminate among the provided categories via different techniques: for example, support vector
machines (SVMs) fit a hyperplane, with the additional aid of kernel functions, to maximise the
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distance between the closest data observations belonging to different classes [67]; random forests
(RF) build a decision tree in which thresholds of feature values determine whether the observation
belongs to a class or to another [68]. The following phase is the validation phase, in which the
performances of the classifiers are evaluated by the predictions made in a partition of the same training
set (cross validation) or in an externally labelled dataset (external validation). The discrepancy between
the predicted class and the actual class yields the performance parameters of the model, such as
sensitivity (TPR), specificity (TNR), positive predictive value (PPV) and negative predictive value
(NPV). Finally, the classifier can be employed for making predictions regarding new data, which can
also be weighed according to the performance parameters evaluated in the previous phases. In MSI,
an on-tissue classification can be obtained, by generating a MS segmentation image resembling the
classification by colouring pixels according to the predicted class.
Figure 2. A schematic overview of the MSI data elaboration workflow. (A) Data cube; (B) the
series of spectra pre-processing steps; (C) unsupervised and (D) supervised statistical analysis
performed on a spectra dataset. MSI, mass spectrometry imaging; PCA, principal component analysis;
HCA, hierarchical clustering analysis; SVM, support vector machine.
3. Applications in Gastric Cancer
Gastric cancer is a complex, heterogeneous and aggressive disease that represents the third leading
cause of cancer-related deaths worldwide [1]. Unfortunately, patients are frequently diagnosed at
advanced stages, when the survival outcome is poor [69]. Thus, the discovery of novel drug targets
and treatment strategies for patients with advanced GC is the most challenging task in clinical practice.
Recent genomic studies have discovered mutations in the GTPase, Ras homolog family member
A (RHOA), that are associated with a poor clinical prognosis in patients with diffuse-type gastric
cancers [70,71]. The RHOA signalling pathway activates RHO-associated protein kinases 1 and 2
(ROCK 1/2), which regulate cell contractility, and thus migration and growth may play a role in
cancer development [72]. Hisenkamp et al. recently demonstrated that MALDI-MSI could be used to
determine the distribution of the drug fasudil to the tumour and surrounding tissues, and to evaluate
the pharmacological inhibition of ROCK 1/2 and its effectiveness against gastric cancer in mice [73].
In particular, this study revealed that the parent drug, fasudil, distributed into the stomach and
was converted to its active metabolite, hydroxyfasudil. Furthermore, the distribution of the drug in
172
Int. J. Mol. Sci. 2017, 18, 2588
tumorous and non-tumorous tissue was not homogeneous. Fasudil signal intensities were higher in
columnar epithelia of the gastric corpus and in parts in the squamous epithelia of the forestomach [73].
There was no obvious enrichment of fasudil or hydroxyfasudil in the tumour areas compared with
the non-malignant regions of the stomach. Nevertheless, a significant amount of the drug and its
metabolite was able to distribute to the gastrointestinal tumour, suggesting that the drug reached
the target organ of interest without being selective for tumour cells [73]. In this analysis, several
ion signals were elevated in the tumour region compared to stromal tissue. One signal in particular
was then identified as potassium-adducted phophatidylcholine [PC(34:1) + K]+ (m/z 798.541) using
FTICR-MS/MS [73]. Similarly, MALDI-MSI has been used to simultaneously map differences in
the lipid distribution between gastric cancer lesions and non-neoplastic mucosa whilst preserving
the morphological integrity of the analysed tissue. Interestingly, the lipid ion at m/z 798.5 has been
detected in another MALDI-imaging study by Uehara et al., revealing that it was overexpressed in
cancer tissue compared to the adjacent non neoplastic mucosa [74]. On the contrary, the intensity of
the lipid signal at m/z 496.3, identified as the proton-adducted lysophosphatidylcholine (LPC) (16:0),
was low in cancer lesions [74].
A recent study based on the integrated strategy of MALDI-MSI and immunohistochemical assays
investigated the association of cancer progression and the effects of de novo lipogenesis [75]. In fact,
it has been reported that high lipogenic activity is one hallmark of tumour cells [76]. In particular,
MALDI-FTICR-MSI has been used to analyse lipid localisation in six types of cancer tissue, including
19 samples of gastric cancer (adenocarcinoma), and the results highlighted that the levels of lipids
with monounsaturated acyl chains were increased in the cancer microenvironment compared with the
adjacent normal tissue, whereas polyunsaturated lipids were decreased in the cancerous area [75].
In addition, MALDI-MSI in negative ion mode has the ability to visualise small molecule
metabolites (typically < 500 Da), which are important cellular components closely linked with
tumour development and progression [77]. Guo et al. developed an electric field matrix-assisted
scanning spraying matrix coating system to deposit matrix on tissue with crystal sizes of <10 μm [78].
The method enabled the in situ detection of cancer-related small molecule metabolites and to visualise
their distribution by MALDI-FTICR mass spectrometry imaging on snap-frozen tissues from five gastric
cancer patients. It was found that the lipids octadecenoic acid and lysophosphatidylethanolamine
(18:1), as well as phosphorylated nucleosides, were significantly upregulated in cancerous areas
compared with the adjacent noncancerous areas [78]. On the other hand, nucleosides and
N-acetylneuraminic acid were significantly decreased in the cancerous area [78].
The poor prognosis of gastric cancer is due to a lack of reliable tumour markers that may improve
early-stage diagnosis of cancer. Recently, proteomic approaches using MALDI-MSI techniques have
been adopted in order to better understand the pathology and to search for novel diagnostic and
therapeutic targets through the characterisation of the proteome profile of a malignant lesion with
respect to the non-tumour area.
Deininger et al. employed hierarchical cluster analysis along with principal component analysis in
order to uncover proteomic differences in gastric cancer tissue and non-neoplastic stomach mucosa [79].
They demonstrated that histological differences could also be detected on the sole basis of different
protein and peptide profiles, thus confirming the reliability of the approach. Furthermore, it was
also proposed that MALDI-MSI may be capable of highlighting phenotypic tumour heterogeneity,
which cannot be uncovered by using traditional histology [79].
A recent MALDI-MSI study detected seven tumour-specific proteins that predicted unfavourable
disease outcome in a cohort of 63 patients with intestinal gastric cancer [80]. Three proteins were
identified and successfully validated by immunohistochemistry on an independent set of 118 samples.
A protein previously unknown to be implicated in gastric cancer, cysteine-rich intestinal protein 1
(CRIP1), which plays a key role in tumour behaviour, was confirmed to be an independent prognostic
factor for gastric cancer. Furthermore, human neutrophil peptide-1 (HNP-1) and S100 calcium binding
protein A6 (S100A6) were found to be able to further classify patients with gastric cancer disease at
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stage I from patients at more advanced stages [80]. Human neutrophil peptides (HNPs) are expressed
in neutrophil granules of the innate immune system and are found to be highly expressed in a variety
of cancers [81–83]. Interestingly, the protein detected at m/z 3445 (HNP-1) was overexpressed in
cancer tissue, confirming the observation of two other MALDI-MSI studies on gastric cancer [84,85],
and another that performed MALDI-MS profiling [86]. Besides HNP-1, Cheng et al. demonstrated that
HNPs α-defensin 2 and 3 were also overexpressed in gastric cancer tissues and the distribution
of HNPs 1–3 overlapped in cancerous tissues, with high abundance in the lamina propria [85].
Similarly, the calcium-binding protein S100A6 was highly expressed in gastric cancer lesions and
has also been identified by MALDI-MSI as a potential marker for tumour development of Barrett’s
adenocarcinoma [87], known to develop more rapidly than any other gastrointestinal malignancy.
Another protein signal, at m/z 4156, has been observed in the cancer area of intestinal-type gastric
cancer and oesophageal adenocarcinoma [84,87], and its role in carcinogenesis and drug resistance was
highlighted [88]. Moreover, MALDI-MSI of fresh-frozen Barrett’s adenocarcinoma samples revealed the
prognostic role of cytochrome c oxidase subunit 7A2 (COX7A2) and transgelin-2 (TAGLN2) concerning
the disease-free survival, whereas the expression of the protein ion at m/z 11,185, identified as S100
calcium binding protein A10 (S100A10), was an independent prognostic factor [87]. Morita et al.
introduced an easy-to-use method for the detection of histological type-specific proteins using
a MALDI-MSI approach and 12 FFPE tissue microarrays (TMA) from well, moderately, and poorly
differentiated gastric carcinoma samples [89]. Among the detected signals, 54 were classified as signals
specific to cancer, with statistically significant differences between adenocarcinoma and normal tissues
being observed. The tryptic peptide at m/z 1325.6 was specifically increased in the poorly differentiated
cancer tissue and was identified as histone H4 [89]. Recently, Munteanu et al. employed MALDI-MSI
for the in situ analysis of a histone deacetylase inhibitor, the hydroxamic acid panobinostat (LBH-589),
focusing on its pharmacodynamic effects in order to visualise the spatiotemporal distribution of
acetylated histones and the tumour-selective pharmacodynamic responses in a mouse model of
gastrointestinal cancer [90]. Following LBH-589 administration, the nonacetylated (0 Ac) histone H4
was decreased, whereas the acetylated (Ac) H4 states (2 to 4 Ac) were markedly increased in the
tumour regions [90].
The MALDI imaging approach in combination with two classification models (support vector
machine and random forest) has been promisingly used for gastric cancer tumour classification as well
as for the classification of the human epidermal growth factor receptor 2 (HER2/neu) status prediction
in gastric cancer [91,92]. Meding et al. were able to classify both the training set and the test set of gastric
cancer and Barrett’s adenocarcinoma primary tumour entities with high accuracy [91]. The training
set could be classified nearly perfectly, whereas the classification of the test set yielded an accuracy
above 94% for Barrett’s cancer and above 88% for gastric cancer with both classifiers [91]. Balluff et al.
demonstrated that the HER2/neu status of gastric cancer could be predicted by specific protein patterns
originating from breast cancer, with accuracies above 90% independent of the prediction method [92].
Thus far, intratumor heterogeneity is an unresolved factor that influences the evolution of cancer
and adversely affects patient outcome. Phenotypically distinct gastric cancer subpopulations have been
investigated by MALDI imaging in combination with advanced clustering methods and t-SNE [65,84].
In particular, extensive heterogeneity was noted within and between individual tumour samples.
Both studies highlighted two proteins, at m/z 3445 (HNP-1) and m/z 14021 (histone H2A), respectively,
which were found to be involved in the prognostic signature of the subpopulations [65,84].
Among the post-translational modifications, glycosylation is the most abundant and complex,
and alterations in the glycosylation of gastric cancer cells have an impact on gastric carcinogenesis and
cancer progression [93,94]. Kunzke et al. investigated in situ native-glycans (N-glycans) in 106 primary
resected FFPE human gastric cancer tissues by MALDI-MSI in order to understand the underlying
molecular mechanisms and discover the clinical implications of glycosylation in gastric cancer [95].
The study pointed out the presence of a glycosaminoglycan fragment (HexNAc-HexA-HexNAc) in
tumour stroma regions, an independent prognostic factor for gastric cancer patients [95].
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4. Concluding Remarks
In the context of gastric cancer, the application of MALDI-MSI is still in its relative infancy.
However, there is already sufficient evidence in the literature to suggest that MALDI-MSI can play
a crucial role in uncovering the molecular pathways implicated in the development of this particularly
deadly cancer.
This approach has already detected molecular alterations associated with gastric cancer at the
proteomic, lipidomic, and metabolomic level, and can also monitor the distribution and xenoboiotic
metabolism of prospective therapeutic agents such as fasudil. On the basis of these findings,
the potential of MALDI-MSI is evident and, by combining these findings using integrative omics
approaches, we can improve our understanding of gastric cancer at numerous molecular levels and
assist in the clinical management of patients. Whilst this final goal is not imminent, and cannot be
achieved using a single approach, MALDI-MSI can certainly make a significant contribution to this
pursuit. Nevertheless, the potential of MALDI-MSI for obtaining findings able to contribute to the
diagnosis, prognosis, and understanding of numerous diseases, most specifically cancer, is expected to
grow in the future as this technology advances.
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FTICR Fourier transform ion cyclotron resonance
GC Gastric cancer
HCA Hierarchical clustering analysis
HER2/neu Human epidermal growth factor receptor 2
HNP Human neutrophil peptide
MALDI Matrix-assisted laser desorption/ionisation
MSI Mass spectrometry imaging
PCA Principal component analysis
ROCK 1/2 RHO-associated protein kinase 1 and 2
ToF Time of flight
t-SNE t-Distributed stochastic neighbour embedding
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Abstract: The ability to analyze individual epithelial cells in the gastric mucosa would provide
important insight into gastric disease, including chronic gastritis and progression to gastric cancer.
However, the successful isolation of viable gastric epithelial cells (parietal cells, neck cells, chief
cells, and foveolar cells) from gastric glands has been limited due to difficulties in tissue processing.
Furthermore, analysis and interpretation of gastric epithelial cell flow cytometry data has been
difficult due to the varying sizes and light scatter properties of the different epithelial cells, high levels
of autofluorescence, and poor cell viability. These studies were designed to develop a reliable method
for isolating viable single cells from the corpus of stomachs and to optimize analyses examining
epithelial cells from healthy and diseased stomach tissue by flow cytometry. We performed a two
stage enzymatic digestion in which collagenase released individual gastric glands from the stromal
tissue of the corpus, followed by a Dispase II digestion that dispersed these glands into greater than 1
× 106 viable single cells per gastric corpus. Single cell suspensions were comprised of all major cell
lineages found in the normal gastric glands. A method describing light scatter, size exclusion, doublet
discrimination, viability staining, and fluorescently-conjugated antibodies and lectins was used to
analyze individual epithelial cells and immune cells. This technique was capable of identifying
parietal cells and revealed that gastric epithelial cells in the chronically inflamed mucosa significantly
upregulated major histocompatibility complexes (MHC) I and II but not CD80 or CD86, which are
costimulatory molecules involved in T cell activation. These studies describe a method for isolating
viable single cells and a detailed description of flow cytometric analysis of cells from healthy and
diseased stomachs. These studies begin to identify effects of chronic inflammation on individual
gastric epithelial cells, a critical consideration for the study of gastric cancer.
Keywords: flow cytometry; gastric epithelium; autoimmune gastritis; atrophic gastritis
1. Introduction
Chronic atrophic gastritis is a common complication after infection with Helicobacter pylori and
in individuals that develop autoimmune gastritis [1]. Chronic atrophic gastritis is a major risk
factor for developing gastric cancer, which is the third most common cause of cancer-related deaths
worldwide [2,3]. The pathophysiology of gastric cancer development has been well studied in several
mouse models using primarily histopathological microscopy techniques [4]. While these are the
standard techniques to analyze progression of pathologic changes in gastric epithelial tissue, there are
difficulties in obtaining organ-wide surveys of epithelial cells. Proper statistical analysis would require
the counting of numerous cells in many different areas of tissue [5]. With respect to these technical
difficulties, flow cytometric analysis is ideal for measuring protein expression on individual gastric
epithelial cells.
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Flow cytometry relies on the identification of proteins using antibodies conjugated to
fluorochromes that, when excited by incident light, emit fluorescence at distinct wavelengths.
This enables identification of cell populations based on the wavelength of fluorescence detected [6].
Flow cytometry provides an organ-wide survey of protein expression that can be used to differentiate
cell types, identify surface receptors, assess production of secreted protein products, determine
activation state of transcription factors, and many other applications [7–10]. Flow cytometry analysis
is used sparingly in the analysis of freshly isolated gastric epithelial cells partly due to the difficulties
in tissue processing and data interpretation of highly autofluorescent populations [5,11–13].
The goal of this study was to provide a comprehensive methodology for single cell analysis
of the complex gastric gland that is composed of parietal, chief, foveolar, and mucous neck cell
types. This necessitated isolating individual cells from gastric corpus glands, staining for surface
molecules, and gating that allows for analysis of gastric epithelial cells by flow cytometry. Generation of
single cell suspension from the stomachs of BALB/c mice was assessed morphologically using
cytospin preparations of gastric epithelial cells at various stages of digestion. Staining for antibodies
against epithelial cell adhesion molecule (EpCAM) and cluster of differentiation (CD)45 were used to
differentiate epithelial cells and hematopoietically derived immune cells, respectively. Analysis
of gastric epithelial cells from control mice and from mice that develop autoimmune chronic
atrophic gastritis (TxA23) allowed for a comparison of cells in the fundic mucosa under normal
conditions and conditions of inflammatory gastric preneoplasia [14,15]. After generating single cell
suspensions from cohorts of BALB/c and TxA23 mice, we used flow cytometry to: (1) Identify gastric
epithelial cells; (2) identify immune cells in the gastric mucosa of mice with chronic atrophic gastritis;
(3) identify parietal cells; and (4) demonstrate that inflammation causes a significant increase in major
histocompatibility complex (MHC) molecules on the surface of gastric epithelial cells. The ability to
isolate cells from the corpus mucosa, identify immune and epithelial cell populations using lineage
specific markers, and analyze inflammation-induced changes by flow cytometry significantly enhances
our ability to study the effects of chronic gastritis on the gastric epithelium in this model of gastric
preneoplasia and others.
2. Results
2.1. Enzymatic Digestion Results in a Single Cell Suspension Comprised of Major Gastric Epithelial
Cell Lineages
As flow cytometric analysis requires single cell suspensions, we sought to optimize a protocol that
yielded high numbers of gastric epithelial single cells. We isolated gastric glands using collagenase and
observed normal glandular structure by light microscopy following cytospin preparation (Figure 1A,
left). Glands were then further digested into single cells using Dispase II and Cytospin preparations,
confirming a majority of single cells present in solution (Figure 1A, right). We next isolated RNA
from these single cell suspensions and assessed the major gastric epithelial cell lineages present
using quantitative RT-PCR probes against parietal cells (Atp4a), chief cells (Gif ), surface mucous cells
(Muc5ac), and mucous neck cells (Muc6). This analysis determined that all of these major lineage
transcripts were present, particularly Atp4a and Gif, which had crossing threshold (CT) values lower
than that of the control target Gapdh (Figure 1B). Finally, we performed cell counting using Trypan
blue exclusion and observed that these isolation methods yield on average over 1 × 106 viable cells
(Figure 1C). Therefore, this epithelial cell isolation method generates single cell suspensions that
contain major cell populations present in the stomach.
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Figure 1. Isolating single cells from gastric corpus glands. (A) Representative cytospins of freshly
isolated glands (left) and single cell suspensions generated from glands isolated from the corpus
mucosa of stomach from mice (right). (B) qRT-PCR analysis of lineage markers for parietal cells (Atp4a),
chief cells (Gif ), surface mucous cells (Muc5ac), and mucous neck cells (Muc6). mRNA was isolated
from gastric glands as seen in (A). (C) Table showing average viable cell number determined using
Trypan blue exclusion from BALB/c and TxA23 mice. n = 3 mice per group.
2.2. Optimizing Flow Cytometric Analysis of Gastric Epithelial Cells
Gastric epithelial cells have proven to be difficult to analyze by flow cytometry, in part, due to
the degree of cell-intrinsic autofluorescence and the tendency of epithelial cells to re-aggregate after
isolation. To minimize autofluorescence and the improper analysis of cell doublets, we developed a
strategy to: (1) Filter cells immediately before analysis, (2) exclude highly autofluorescent cell fragments
according to size and internal complexity, (3) exclude aggregated cells according to the ratio of cell
height to cell area, and (4) differentiate dead cells according to cell viability dye. The forward-scatter
vs. side-scatter gate specifically excludes very small cell fragments and debris (Figure 2A, left).
The single cell gate compares the height of a given event to its area, and events that fall along the
central axis are single cells rather than aggregated multiplets (Figure 2A, center). Finally, dead cells
are excluded using a viability dye, 7-aminoactinomycin D (AAD), that preferentially stains dying
cells with porous membranes (Figure 2A, right). We then selected epithelial cells according to the
expression of epithelial cell adhesion molecule (EpCAM/CD206). In the case of cells isolated from
our mouse model of autoimmune gastritis, it is necessary to exclude infiltrating immune cells present
in the sample using CD45 staining, a cellular protein expressed on all hematopoietically-derived
cells (Figure 2B). These methods minimize autofluorescence and cell aggregation and provide a way
to specifically analyze the effect of chronic inflammation on individual gastric epithelial cells while
excluding hematopoietically derived immune cells. Finally, we wanted to use this methodology
to identify a gastric epithelial cell lineage. Dolichos biflorus agglutinin (DBA) has been previously
shown to be a parietal cell-specific staining reagent [16,17]. We performed immunocytochemistry on
glands from BALB/c mice and stained them with Hoechst, DBA-fluorescein isothiocyanate (FITC),
and anti-EpCAM antibodies and observed parietal cell specific staining (Figure 2C). We then adapted
DBA staining to our flow cytometry analysis and observed a subset of EpCAM+cells that were also
DBA+ (Figure 2D), demonstrating the ability to identify parietal cells using flow cytometry.
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Figure 2. Gating strategy for analyzing gastric epithelial cells by flow cytometry. (A) A gate based
of forward area and side scatter area is first established, these cells are then put through a forward
scatter area and forward scatter height gate to identify single cells, finally, 7-AAD is used to separate
live cells from dead/dying cells; (B) Representative flow plots of live single cells from healthy BALB/c
and TxA23 mice stained with an epithelial cell marker (EpCAM) and an immune cell marker (CD45).
Immune cells are undetectable in the gastric mucosa control mice, and present in TxA23 mice that have
autoimmune gastritis; (C) Representative immunocytochemistry of glands isolated from a 2 month old
BALB/c mouse and stained with hoechst (blue), parietal cell marker Dolichous bifluorous agglutinin
(DBA, green), and anti-EpCAM (red) with a high magnification inset in yellow showing an individual
gland; (D) A representative flow cytometry plot of live single cells from a BALB/c mouse stained with
anti-EpCAM and DBA demonstrating a subset of EpCAM + DBA + parietal cells.
2.3. Gastric Epithelial Cells Upregulate MHC-I and MHC-II in Response to Chronic Inflammation
Cell lines and immunofluorescent staining of gastric mucosal tissue sections have been used
to demonstrate that gastric epithelial cells respond to inflammatory stimuli such as interferon-γ by
expressing MHC-II [18,19]. Preparation of single cell suspensions involves the use of proteases that
could alter the detection of proteins expressed on the cell surface by flow cytometry. To determine if
our methodology was capable of detecting MHC-I and MHC-II upregulation directly ex vivo from
chronically inflamed mucosa we analyzed MHC-I and MHC-II on gastric epithelial cells (GECs)
isolated from normal BALB/c stomachs and chronically inflamed TxA23 stomachs. Analysis revealed
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that MHC-I proteins were upregulated >150-fold on TxA23 GECs compared to BALB/c (mean
fluorescence intensity: 260 ± 19.5 vs. 42,390 ± 1783). Furthermore, while MHC-II expression levels
were undetectable on BALB/c GECs, expression levels were >1500 fold higher on GECs isolated
from mice with autoimmune gastritis (mean fluorescence intensity: 12.6 ± 12.6 vs. 19,990 ± 1682)
(Figure 3A–D). Immunofluorescent staining of corpus sections from BALB/c and TxA23 confirmed
that MHC-II protein expression was much higher on epithelial cells in the chronically inflamed
stomach (Figure 3E). Overall these studies indicate that this method is both sensitive and specific to
inflammation-induced changes in the gastric epithelium and can be used for direct ex vivo analysis of
gastric epithelial samples.
Figure 3. Gastric epithelial cells upregulate MHC-I and MHC-II in response to inflammation. (A,B)
Representative flow plots of EpCAM+CD45-gated cells stained with antibodies to detect MHC-I or
MHC-II surface proteins. Identical gating strategies show that MHC-I and MHC-II molecules are
expressed at higher levels on gastric epithelial cells from mice with autoimmune gastritis (TxA23 mice).
(C,D) Histograms showing the relative expression of MHC I and MHC II in BALB/c (blue) and TxA23
(red) mice. Data are representative of 2 experiments, 5 mice per group. (E) Representative images of
gastric tissue sections from BALB/c and TxA23 mice stained with Hoechst (blue), VEGF-B (yellow),
GS-II (green), and MHC-II (red).
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3. Discussion
Microscopic analysis is standard in studies of the pathophysiology of gastric diseases. It allows
for the qualitative assessment of disease phenotype and epithelial cell changes and, when coupled
with techniques like immunofluorescence and immunohistochemistry, it also allows for comparisons
of protein expression. However, quantitation of these data is time-consuming and highly dependent
upon proper tissue preparation and sampling of many portions of the tissue in the case of focal disease
processes. To assess gastric epithelial cell changes in our model of inflammation-induced gastric
atrophy, TxA23, we have developed a reliable method for processing tissue and analyzing via flow
cytometry that yields repeatable results.
Our method of tissue processing involves a two-step enzymatic digestion: first with collagenase
to release the glands from the stromal tissue, followed by a digestion step with Dispase II that
further separates glands into single cells. While previous publications have noted that enzyme
digestion is harsh on cells and significantly effects viability, our use of this method generates
an average of 1 million viable single cells per stomach (Figure 1C) [5]. Moreover, this digestion
protocol requires no special equipment beyond a microtiter plate shaker placed at 37 degrees Celsius.
We have also observed that gastric epithelial cells are very sensitive to centrifugation, with speeds
above 50× gravity decreasing viability. This change in protocol could explain our improved cell
yields despite the use of enzyme digestion. While previous studies have used various forms of
enzymatic digestion, these publications reported additional steps involving mechanical disruption,
microdissection, DNase incubation, or frequent media changes during digestion. However, we did not
determine these additional steps to be necessary for successful isolation of viable single cells. [5,11,13]
(Table 1).
Table 1. Comparison of Methods for Generating Single Cell Suspensions.
Reference Disruption Enzymes Region FACs Gating Description
Zavros et al.; 2000 [5] Medimachine Collagenase Whole Stomach No
Moore et al.; 2015 [11] Medimachine Dispase II Corpus No
Hinkle et al.; 2003 [13] None Pronase Corpus No
Bockerstett et al.; 2018 None Collagenase + Dispase II Corpus Yes
Following single cell suspension, cells were stained with 7-AAD, a DNA-binding viability dye that
efficiently discriminates between live and dead cells during flow cytometric analysis. Attempts to use
fixable viability dyes that bind to free amines as a measure of cell viability proved difficult to interpret
due to high background staining. This is possibly due to nonspecific staining of mucins, as 7-AAD binds
to nucleic acid rather than protein substrates. Anti-EpCAM was also used to select only the epithelial
cells, which is critical for distinguishing between immune and epithelial cells in models with significant
inflammatory infiltrate. All staining was done in PBS supplemented with 0.5% bovine serum albumin
and 2 mM ethylenediamineteraacetic acid (EDTA) to prevent aggregation of cells during staining.
When analyzing, we first exclude cells by size and internal complexity using forward and side scatter
of incident light. As GECs are much larger and more complex than typical lymphocytes, voltage levels
for the forward-scatter and side-scatter detectors were adjusted accordingly. We then gated on viability
dye negative, EpCAM positive cells for the remainder of the analysis. To verify the ability of this
method to detect differential expression of surface markers, we stained epithelial cells with anti-major
histocompatibility complex class I (MHC-I), which is present on most nucleated cells and compared
it to the expression of MHC class II, which is a molecule typically limited to antigen presenting cells
of the immune system. In normal BALB/c mice, we see typical expression of MHC-I and little to
no expression of MHC-II on gastric epithelial cells. While antibodies against lineage markers of the
gastric epithelium have been published as effective in differentiating the different cell types using
flow cytometry [5,12,20], we found no staining conditions that were sufficiently specific to confidently
distinguish between lineages using the published antibodies. However, we were able to identify
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parietal cells using the fluorescently conjugated DBA lectin that has been published in tissue staining
as a parietal cell specific marker [16,17]. This is the first report of using flow cytometry to identify
parietal cells according to staining with DBA. It should also be noted that use of a hematopoietic
immune cell marker such as CD45 also allows for the analysis of infiltrating immune cells without
interference from the more problematic epithelial cell populations, which has also been a focus of
some groups [21]. We repeated these analyses using C57Bl6 mice, which are commonly used in mouse
models of gastric cancer, and observed no difference in the efficacy of these cell isolation and FACs
analysis methods.
It has been described that epithelial cells of the gastrointestinal tract, such as those of the small
intestine, react to inflammatory stimuli by upregulating MHC-I and MHC-II and are even capable of
presenting antigens to CD4+ T cells. It has also been shown that gastric epithelial cell lines exhibit
this phenomenon and that MHC-II plays a role in the adherence of Helicobacter pylori to the gastric
epithelium and induction of apoptosis by crosslinking of MHC-II molecules [18,19]. We wanted
to use our method to perform a direct ex vivo analysis of inflammation-induced changes in MHC
expression. To do this, we analyzed MHC-I and MHC-II expression on gastric epithelial cells of mice
with chronic atrophic gastritis (TxA23) compared to normal gastric epithelium (BALB/c). We observed
a significant upregulation in both MHC-I and MHC-II, which duplicates results seen by other groups
using immunofluorescent staining. While we did not observe the expression of costimulatory molecules
required for naïve T cell activation, MHC-II expression could implicate a role for gastric epithelial
cells in reactivating infiltrating CD4 T cells during chronic inflammatory states, furthering disease
progression by stimulating the production of more inflammatory cytokines. However, this requires
further experimentation to determine unequivocally.
From these experiments we conclude that enzymatic digestion to single cells followed by flow
cytometric analysis is an effective way to analyze large numbers of viable gastric epithelial cells,
and that this method is useful for studying inflammatory changes in surface markers on gastric
epithelial cells during chronic disease processes such as Helicobacter infection or autoimmune gastritis.
It is anticipated that this method will enable valuable future studies in the gastric cancer field
such as: analysis of immune activating or inhibitory receptors on gastric epithelial cells, changes
in the expression of these receptors during inflammation, fluorescence activated cell sorting of




TxA23 mice express a transgenic T cell receptor specific for a peptide from H+/K+ ATPase alpha
chain and spontaneously develop preneoplastic lesions such as parietal cell atrophy, mucous neck cell
hyperplasia, and spasmolytic polypeptide expressing metaplasia [14,15,22,23]. BALB/c mice were
purchased from Jackson Laboratories. All mice were maintained in our animal facility and cared for
in accordance with institutional guidelines (Protocol 2600, Approved 6-07-2016 by the Saint Louis
University Institutional Care and Use Committee).
4.2. Immunofluorescence/Immunohistochemistry
Stomachs were prepared, stained, and imaged using methods modified from Ramsey et al. [24].
The primary antibodies used for immunostaining were goat anti-VEGF-B (1:100 from Santa Cruz
Biotechnology, Santa Cruz, CA, USA, sc-13083) and rat anti-mouse MHC-II (1:100 from BD Biosciences,
San Jose, CA, USA, 556999). Secondary antibodies, nuclear labeling, and GS-II lectin labeling were
as described.
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4.3. Generation of Gastric Epithelial Single Cell Suspensions
Gastric glands were isolated from the corpus region of BALB/c and TxA23 mouse stomachs
using collagenase (10 mg/mL from Sigma-Aldrich, St. Louis, MO, USA, C9891) in a digestion
media comprised of advanced MEM (Gibco, Gaithersburg, MD, USA, 12492-013), 20 mM HEPES,
0.2% BSA (Millipore, Burlington, MA, USA, 810033), penicillin-streptomycin (Sigma-Aldrich, P7081),
and 50 μg/mL gentamycin (Sigma-Aldrich, G-1914). The whole gastric corpus was separated from
the forestomach, antrum, and esophagus and agitated at 600 rpm in collagenase for 30 min at
37 ◦C. Following digestion, remaining gastric serosa and connective tissue were removed from the
glands. Glands were pelleted by centrifugation at 50× g gravity for 10 min and washed twice
using DMEM/F12 (Sigma-Aldrich, D6421) supplemented with penicillin-streptomycin, gentamycin,
and 0.5 mM 1,4-Dithiothreitol (DTT) (Sigma-Aldrich, GE17-1318-01). Glands were then digested
into single cells by agitating at 600 rpm using Dispase II (Sigma-Aldrich, D4693) for 90 min at 37 ◦C.
Following Dispase digestion, single cells were washed twice using flow cytometry staining buffer
supplemented with 20 mM EDTA (Promega, Madison, WI, USA, V4231) and counted using Trypan blue
exclusion. For Cytospins, glands and cells were stained using the Hema 3 Stat Pack (Fisher Scientific,
Hampton, NH, USA, 123-869) and spun onto microscopy slides using the Cytospin 4 Cytocentrifuge
(ThermoFisher, Waltham, MA, USA, A78300003). For immunocytochemistry, Cytospin preparations
were fixed in 4% PFA for 10 min followed by permeabilization in 0.5% BSA/0.1% Triton X-100/ 2 mM
EDTA and then stained according to immunofluorescent protocols listed above.
4.4. Quantitative Real Time PCR
Total RNA was prepared using RNeasy Mini Kit (Qiagen, Hilden, Germany, 74104). The quantity
and quality of RNA was determined using a NanoDrop 2000 spectrophotometer (Thermo
Scientific). cDNA copy of RNA isolated from cells was done according to the manufacturer’s
instruction (High Capacity cDNA Reverse Transcription Kit, Applied Biosystems, Foster City,
CA, USA). Quantitative PCR was run on the 7500 Real-Time PCR System (Applied Biosystems).
The following primer/probe sets were used: Gapdh (Mm99999915_g1), Atp4a (Mm00444417_m1),
Gif (Mm00433596_m1), Muc5ac (Mm01276718_M1), Muc6 (Mm00725165_m1).
4.5. Flow Cytometry
Cell surface staining was performed on gastric epithelial cells in staining buffer (PBS + 2% BSA)
supplemented with 20 mM EDTA. Cells were kept on ice at all points during the staining procedure and
analysis to prevent cell aggregation. Staining against surface antigens was performed using antibodies
against Pan CD45 (BD Biosciences, San Jose, CA, USA 559864), EpCAM (eBioscience, San Diego, CA,
USA, 47-5791-80), CD45.1 (BD Pharmigen, San Jose, CA, USA, 553776), MHC-I (BioLegend, San Diego,
CA, USA, 125506), MHC-II (BD Biosciences, 557000). Following surface stain, cells were washed twice,
passed through a 40 μm filter, and resuspended in staining buffer with 1 μL/mL 7-AAD (eBioscience,
00-6993-42) for dead cell exclusion. For identification of parietal cells, single cell suspensions were
fixed in 4% PFA for 5 min at 37 degrees Celsius followed by permeabilization in 0.5% BSA/0.1% Triton
X-100/2 mM EDTA for 30 min in the dark at room temperature on a plate shaker. Dolichos biflorus
agglutinin conjugated to FITC (EYLabs, San Mateo, CA, USA, F-1201) was then added to cells at 1:500
and incubated for 1 h in the dark at room temperature. All flow cytometry was performed on a BD
LSRII and analyzed using FlowJo (FlowJo, LLC, Ashland, OH, USA).
4.6. Statistical Analysis
Data are expressed as means of individual determinations ± standard error. Statistical analysis
was performed by either the Mann-Whitney U Test, an unpaired Student’s t-test, or a two-way ANOVA
with Bonferroni post-tests (* p < 0.05; ** p < 0.01; *** p < 0.001) using GraphPad Prism 5 (GraphPad
Software, La Jolla, USA).
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Abstract: Helicobacter pylori is the most abundant bacterium in the gastric epithelium, and its presence
has been associated with the risk of developing gastric cancer. As of 15 years ago, no other bacteria
were associated with gastric epithelial colonization; but thanks to new methodologies, many other
non-H. pylori bacteria have been identified. It is possible that non-H. pylori may have a significant
role in the development of gastric cancer. Here, we discuss the specific role of H. pylori as a potential
trigger for events that may be conducive to gastric cancer, and consider whether or not the rest of the
gastric microbiota represent an additional risk in the development of this disease.
Keywords: H. pylori; gastric microbiota; gastric cancer; pro-inflammation
1. Introduction
Helicobacter pylori was the first bacterium whose presence was associated with increased risk
of developing any type of cancer, in this case gastric cancer [1,2]. This was an alarming finding in
1991, because H. pylori was, and continues to be, responsible for one of the most prevalent infections
in humans globally [3]. However, it was demonstrated that only a minority of the subjects infected
with H. pylori eventually developed gastric cancer [4]. H. pylori infected more than half of the world’s
population [3], but it is currently estimated that only between 1% and 3% of those infected individuals
develop distal gastric cancer [5,6]. Furthermore, this risk is decreasing gradually with the decrease of
H. pylori prevalence that has been occurring in the last 100 years [7,8]. This declining risk of developing
gastric cancer varies by regions of the world, in which underdeveloped countries possess the larger
number of cases for distal gastric cancer. Likewise, these same countries are where the prevalence of
H. pylori is at its peak [9].
H. pylori is responsible for a series of histopathological changes in the gastric mucosa that
are recognized as major factors in the development of gastric cancer. This particular series of
histopathological changes that lead to gastric cancer are collectively known as Correa’s model [10].
Correa’s model was proposed several years before the discovery and isolation of H. pylori, and almost
15 years before the recognition of this organism as a risk factor for gastric cancer [1]. The model was
developed exclusively based on histopathological observations related to the gradual progression
from a normal gastric epithelium to gastric cancer [11]. Surprisingly, each of the histological changes
proposed by Correa in his original paper were later confirmed with H. pylori findings, with the
progression from a normal gastric mucosa prior to infection followed by chronic superficial gastritis,
atrophic gastritis, intestinal metaplasia, dyspepsia and finally gastric carcinoma [12].
Recent progress in the identification of bacteria that colonize different body sites of the human host
since birth, collectively named microbiota, has provided detailed insights into the numerous organisms
present in the gut and a variety of other body sites, including the oral cavity, skin, lungs, etc. [13].
The human stomach is no exception, and we now know that in addition to H. pylori, many other
Int. J. Mol. Sci. 2018, 19, 1353; doi:10.3390/ijms19051353 www.mdpi.com/journal/ijms191
Int. J. Mol. Sci. 2018, 19, 1353
organisms can be present, colonizing the stomach [14]. The relative abundance of bacteria other
than H. pylori varies depending of the H. pylori status of the individual [14]. As a result of these
findings, there are now major concerns of the role of bacteria other than H. pylori in the development
of gastric cancer.
We discuss, in this review, the potential role of the human gastric microbiota in gastric
carcinogenesis in the presence or absence of H. pylori. We also discuss which H. pylori traits contribute
to increasing the risk of the development of gastric cancer and whether other members of the gastric
microbiota possess similar capabilities.
2. Is H. pylori a Risk Factor or a True Carcinogen?
The first solid evidence of the association between H. pylori infection and gastric cancer was
derived from three independent epidemiological studies published in 1991. All three studies reported
elevated odds ratios for the development of gastric cancer in subjects who had tested positive for
H. pylori more than 2 decades before the diagnosis of gastric cancer, when compared with subjects
without H. pylori infection [15–17]. These types of studies have been repeated, and have confirmed the
role of H. pylori as the most relevant risk factor in the development of gastric cancer [18].
The second type of evidence that implicates H. pylori as a risk factor in gastric pathology was
obtained from animal models, including piglets, dogs and monkeys. Their normal gastric mucosa
was challenged with H. pylori, and the development of active and chronic superficial gastritis, and in
some cases atrophic gastritis, was confirmed to be associated with H. pylori colonization, but not with
gastric cancer [19]. The first animal report of H. pylori inducing a progression from superficial gastritis
to intestinal metaplasia (pre-malignant lesion) was with the use of the Mongolian gerbil model [20].
Some years later, using the same animal model it was confirmed that colonization with H. pylori can
lead to the development of gastric cancer [21]. More recently, a report summarized the findings of
several investigators who had developed a mouse model of gastric cancer in which H. pylori challenges
were associated with the development of gastric cancer [22]. This model represents a major step
forward in the study of H. pylori and its role in gastric cancer.
Another approach to documenting the role of H. pylori in gastric carcinogenesis is the use of
in vitro models. Most of these studies have been dedicated to investigating the role of the major
virulence factors of H. pylori, including the cytotoxin-associated gene pathogenicity island (CagPAI).
It was discovered that H. pylori strains expressing the CagPAI are more virulent, and are more
frequently isolated from patients with severe clinical outcomes of the infection, including peptic
ulcer disease and gastric cancer. The CagPAI is a major chromosomal insertion, encoding around 34
genes, that can be acquired by horizontal transfer [23]. The demonstration that a subset of the CagPAI
genes comprises a type IV secretion system was followed by multiple studies confirming the intimate
interaction of the transferred CagA protein into the host cells [24]. As a result of these observations,
it has been suggested that CagA may be the oncogenic factor in H. pylori [25]. It is important to
mention that until now, there has not been a single study in vitro that has confirmed the mutagenic
ability of H. pylori CagA, vacuolating cytotoxin (VacA), or any of its other components. Assessment
of mutagenic activity of these factors using methods such as the Ames test is needed to confirm the
role of CagA as a true oncogenic protein. The Ames test is a biological assay to assess mutagenic
potential of individual compounds using bacteria to test its mutagenic activity. An in vivo experiment
in a transgenic mouse model demonstrated that expression of CagA predominantly in the stomach
was associated with epithelial hyperplasia, gastric polyps and adenocarcinoma. Systemic expression
of CagA was associated with leukocytosis, leukemia and B cell lymphomas [26]. It is important to
mention that such neoplastic effects mostly occur after 70 weeks of age, suggesting a chronic process.
If H. pylori and its components have no direct mutagenic effects in gastric epithelial cells, how does
H. pylori affect the gastric epithelium in order for it to be considered a major risk factor in gastric
cancer development?
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To answer this question, we need to revisit the Correa model. Colonization with H. pylori occurs
early in life, and is maintained for decades or perhaps for the whole life of the colonized individual.
The presence of H. pylori induces a superficial chronic gastritis influencing the balance between the
rate of cellular loss and regeneration [27]. The chronic inflammation induced by H. pylori maintains
a constant production of a cascade of cytokines, which attracts neutrophils that generate oxidative
radicals that have the potential to damage the host DNA. Infection with H. pylori has been associated
with a reduction in cell replication, and increase in apoptosis, autophagy induction, and endoplasmic
reticulum and oxidative/nitrosative stress [28]. These innate immune responses are important to
enhance cell survival and proliferation, but as a consequence of the chronic inflammation process due
to H. pylori, there is a greater chance of acquiring potentially malignant characteristics, which may
explain the relevance of this infection as a major risk factor in the development of gastric cancer [28].
This chronic, so-called pro-inflammatory, process appears to be a common denominator and initiator of
several chronic diseases [29]. The pro-inflammatory conditions, in concert with the immune response,
can lead to a necrotic state. In infections with hepatitis virus B and C, this has been linked to the
development of liver cancer. This identical pathophysiological mechanism might be related to H. pylori
infection and the development of gastric cancer.
Pro-inflammation is a key player in the chronic interaction between H. pylori and the host.
The original study of El-Omar et al. [30] reported a strong association between pro-inflammatory
cytokine polymorphisms and increase risk of developing H. pylori-associated gastric cancer. This study
provides strong evidence for the influence of host genetic factors and the possibility that the immune
necrotic state is relevant for the development of gastric cancer. In addition, these results indicate that
an increased inflammatory response, particularly linked with an over-production of pro-inflammatory
cytokines and mediators in the Th1 pathway, increase the odds ratio of H. pylori-positive individuals
developing gastric cancer [31]. Several studies have reported an even greater risk of developing
gastric cancer in individuals that are colonized with highly virulent H. pylori strains expressing CagA
and VacA, and simultaneously carrying cytokine polymorphisms associated with pro-inflammation.
Here, the odds ratio for developing gastric cancer increases more than 40-fold [32].
With the improvement of sequencing technology, it has been demonstrated that in addition to
H. pylori, other bacteria also colonize the gastric mucosa [14]. An important medical question to ask is:
What is the role of the non-H. pylori microbiota in the process of gastric carcinogenesis? Particularly,
what role do these microorganisms play once H. pylori has produced gastric atrophy and intestinal
metaplasia, and is no longer capable of colonizing the affected gastric mucosa?
3. Gastric Microbiota and its Influence on Gastric Carcinogenesis
The recent development of methods for the analysis of 16S rRNA data has provided a clear
picture of the bacterial communities present in the human host [33]. Of particular relevance to the
detected microbes for this review has been the characterization of the gastric microbiota in patients
with and without H. pylori infection [34]. One interesting observation was the presence of H. pylori
sequences in biopsy samples of subjects who had been identified as H. pylori negative by most
conventional methods [35]. These results show that we now have a powerful and highly sensitive
method for detecting bacteria present in very low numbers. However, Kim et al. have established
that a key indicator of the biological relevance of detected microbes is the relative abundances of their
sequences [35]. In the majority of studies in which subjects were reported negative for H. pylori by
conventional methods, the sequence data demonstrated the relative abundances of Helicobacter to be
<2.0%. The clinical relevance of these low-relative-abundance sequences of H. pylori remains unsolved.
To assess the role of the gastric microbiota as a potential player in H. pylori-associated gastric cancer,
and to determine the potential interactions between the gastric commensal bacteria and H. pylori, it is
important to consider the relative abundance of these players, and what type of effect they could
produce. In addition, we need to consider the presence of H. pylori and its impact on the gastric
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microbiota, as well as the selectivity that H. pylori has in colonizing the gastric epithelium, where any
changes affecting the gastric mucosa may affect the ability of H. pylori to colonize the stomach.
Another relevant point that needs to be considered is the occurrence of dysbiosis in the gastric
community. Most currently available studies report changes in the gastric microbiota in patients with
gastric cancer compared to those without [6]. Because of the series of histological changes leading
to gastric cancer, the assessment of variations in the gastric microbiota in cancer patients versus
non-gastric cancer patients can be clearly predictive. The Correa model describes the histological
changes that lead to the progression from a normal gastric mucosa to gastric cancer. The normal
acidic pH of the stomach is no longer a main feature of patients with gastric cancer, and they are
more likely to present achlorhydria, which is a condition that makes the stomach more permissible
for colonization [36,37]. Therefore, the number and type of bacteria colonizing the stomachs of cancer
patients will be different from those without cancer.
We need to remember that the chronic infection of H. pylori in the stomach induces several
histopathological changes in the gastric epithelium. In particular, the early pre-malignant changes
involving the presence of intestinal metaplasia may precipitate the elimination of H. pylori from the
human stomach (Figure 1). We believe that those histological changes are critical in the gradual loss of
H. pylori colonization and the replacement with other microbiota with the capabilities to colonize the
modified gastric tissue.
Figure 1. Opposite trends for H. pylori density and noncardia gastric cancer risk in relation to the
histopathological changes in the human gastric mucosa.
Another important point in the study of the gastric microbiota and its association with H. pylori
and gastric carcinogenesis is the nature of H. pylori colonization, which has a patchy distribution [11].
There are no systematic studies of the gastric microbiota that evaluate whether the presence and
composition of the microbiota in the gastric epithelium is homogeneous, or whether it is patchy, like
that of H. pylori. In order to evaluate this point, multiple gastric biopsies from the same individual
need to be studied to determine the true distribution of the gastric microbiota. Furthermore, location of
H. pylori colonization in the stomach may predict the clinical outcome [38]. It has been suggested that
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colonization of the antrum region of the stomach is linked with the development of duodenal ulcer.
In contrast, the colonization of the body or corpus of the stomach has been associated with a higher
risk of developing gastric ulcers and gastric cancer. This topographic distribution of the diseases
associated with H. pylori may be related to the fact that the enzyme gastric HK-ATPase is found in
the gastric parietal cells that are mostly located at the oxyntic gastric glands of the gastric body [39].
The distribution of the acid-producing cells mentioned above might explain why colonization with
H. pylori of this specific stomach region is a major risk factor for the development of gastric cancer.
Future studies aiming to evaluate the role of the gastric microbiota in the development of gastric cancer
should specify from which region of the stomach the gastric biopsies are taken.
The relevance of the gastric microbiota in the development of gastric cancer has been confirmed
using the transgenic insulin-gastrin mouse model. INS-GAS mice colonized with H. pylori alone have
a delayed onset of gastric cancer when compared with mice infected with H. pylori harboring a gastric
microbiota [40]. These results indicate that a gastric microbiota magnifies the effects of H. pylori in
gastric carcinogenesis but does not necessarily have a direct role in carcinogenesis. H. pylori is the major
trigger of the histopathological changes leading to gastric cancer and its presence influences the gastric
microbiota. In addition, most of the effects related to the development of gastric cancer in H. pylori
infection are exacerbated if the infected strain is CagA+. However, infection with H. pylori CagA+
strains has minor effects on the gastric microbiota, affecting alpha diversity, but not beta diversity or
its relative abundance [41].
Most studies of the gastric microbiota have shown that the most dominant phyla are
Proteobacteria, Firmicutes, Actinobacteria, Bacteroides, and Fusobacteria [39]. These same phyla
are dominant in all the other sites of the human host [33]. This constant prevalence of the same
microbes makes it difficult to identify major differences in the microbiota in patients with different
clinical outcomes. However, even as some of the studies reported differences in the gastric microbiota
between patients with gastritis and patients with gastric cancer [6], it is impossible to determine
whether those differences are the cause or the effect of the changes in the gastric epithelium.
Only a few studies have investigated the changes in the gastric microbiota in the pre-malignant
stages of gastric cancer (gastric atrophy and intestinal metaplasia) [6,42], or compared the composition
of the gastric microbiota in cancer tissue versus non-cancer tissue from the same patient [43]. In the
pre-malignant stages, the main finding is that H. pylori dominates the microbiota, making it difficult to
observe relevant taxa differences between cancer and non-cancer tissue in the same patient.
There are no well-designed studies that implicate the participation of non-H. pylori gastric
microbiota in the development of gastric cancer. However, in some regions of the world, despite
the decline of H. pylori infections, increased incidence of gastric cancer has been reported [44,45].
Interestingly, most of these cases have been observed in young adults (<40 years) [46–48]. This new
epidemiological data may suggest that changes in the gastric microbiota mainly associated with new
standards of living, and not infection with H. pylori, could be implicated in this age-specific increase in
gastric cancer [46]. There are some characteristics of these new cases of non-cardia cancer in young
individuals that are different from the traditional non-cardia cancer of all individuals. There is a
concordance in most of the reports that young subjects (<40 years) with non-cardia cancer had a more
diffuse type than older subjects (>40 years) [46–49]. Furthermore, contrary to previous statistics in
which gastric cancer affected males twice as frequently as females [48], non-cardia cancer in young
subjects (<40 years) had an occurrence in women that was higher than or equal to that in men [46–48].
A possible explanation for the recent increase in gastric cancer in the USA is perhaps the large
immigration of Hispanic populations that has occurred recently [49]. However, the incidence of gastric
cancer in Hispanics cannot explain the increased incidence of gastric cancer in young individuals in
all regions of the world. Another possibility is that changes in non-cardia cancer related to age and
sex might be associated with an increased risk of developing autoimmune gastritis [46]. Autoimmune
gastritis was associated with elderly women of Northern European ancestry, but has recently been
recognized as a disease in all populations and ethnic groups [50], with a predominance in women and
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early-age onset, similar to the incidence of gastric cancer in young individuals. This disease could be
an alternative explanation for the increased incidence of gastric cancer in young subjects (<40 years).
However, autoimmune gastritis occurs in all populations and ethnic groups [51], and does not explain
the specific increase of non-cardia cancer exclusively in the white non-Hispanic population in the
US [46].
A recent Japanese study suggested the assessment of aberrant DNA methylation in gastric tissue
as a means to determine risk of gastric cancer [52]. Hypermethylation of DNA sequences in specific
genes, such as tumor suppressor genes, has been observed in the gastric mucosa of infected H. pylori
subjects [28]. Therefore, identification of epigenetic markers for gastric cancer risk might be important
for assessing gastric cancer risk. It is imperative to monitor older subjects who are H. pylori negative
and living in high-prevalence areas of gastric cancer and H. pylori infection for potential development
of gastric cancer. Two independent studies have recently reported the benefits of antibiotic treatment in
reducing the development of gastric cancer particularly in older individuals [53,54]. Both studies found
that early treatment had a significant reduction in the risk of developing gastric cancer. In addition,
one of the studies found that the risk for gastric cancer gradually increases with increased number of
eradication treatments in patients [54].
In conclusion, the published studies support the idea that the presence of H. pylori has a major
effect on the composition and relative abundance of the gastric microbiota. In the absence of H. pylori
the gastric microbiota likely contributes to the perpetuation of the inflammatory stimuli. The role of
the microbiota as inflammation stimuli is particularly important in patients previously colonized by
H. pylori. The pre-malignant changes in the gastric epithelium may favor the conditions for bacteria
other than H. pylori to induce the inflammatory process related to cancer development. The term
“point of no return” in the cascade of events that lead to gastric cancer has been associated with
patients with intestinal metaplasia and dysplasia, independent of H. pylori status, who are at the
highest risk of developing gastric cancer [28]. This phenomenon could explain why patients who
become spontaneously negative for H. pylori continue on the pathway of gastric carcinogenesis.
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Abstract: Infections contribute to carcinogenesis through inflammation-related mechanisms.
H. pylori infection is a significant risk factor for gastric carcinogenesis. However, the molecular
mechanism by which H. pylori infection contributes to carcinogenesis has not been fully elucidated.
H. pylori-associated chronic inflammation is linked to genomic instability via reactive oxygen and
nitrogen species (RONS). In this article, we summarize the current knowledge of H. pylori-induced
double strand breaks (DSBs). Furthermore, we provide mechanistic insight into how processing of
oxidative DNA damage via base excision repair (BER) leads to DSBs. We review recent studies on
how H. pylori infection triggers NF-κB/inducible NO synthase (iNOS) versus NF-κB/nucleotide
excision repair (NER) axis-mediated DSBs to drive genomic instability. This review discusses current
research findings that are related to mechanisms of DSBs and repair during H. pylori infection.
Keywords: H. pylori; RONS; BER; DSBs; NF-κB; NER
1. Introduction
Infection contributes to 20% of cancer worldwide [1]. H. pylori infection is one of the most common
risk factors for gastric carcinogenesis [2]. More than 50% of the human population is infected with
H. pylori, but few develop gastric cancer [3]. Several studies have shown that H. pylori infection causes
chronic inflammation with different degrees of pathological severity, including chronic gastritis, peptic
ulcers that eventually cause gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue
(MALT) lymphoma [4–6]. Chronic gastritis that is associated with H. pylori infection is the first and
early stage of inflammation. When accompanied by gastric epithelial cell injury, it may contribute
to gastric cancer development [7–9]. H. pylori virulence factors that contribute to host-pathogen
interaction have been characterized, which increase the risk of gastric cancer pathogenesis [4,10]. These
virulence factors enhance the severity of the mucosal inflammatory response, which may largely be
responsible for the virulence factor-associated increased risk of gastric cancer [10].
H. pylori causes chronic gastritis and contributes to genotoxic activity [11,12]. However, the molecular
mechanisms by which H. pylori promotes genotoxic activity and the host response to genotoxic factors
to drive gastric carcinogenesis require more study. Based on the current knowledge, H. pylori infection
induces a genotoxic effect via two potential mechanisms. First, H. pylori infection enhances the infiltration
of immune cells, including neutrophils and macrophages, to produce reactive oxygen species and
nitrogen species (RONS) [13]. RONS can cause DNA base damage that leads to single strand breaks (SSBs)
and the enhanced expression of oncogenes [14–16]. Alternatively, RONS activate the oxidant-sensitive
transcription factor NF-κB, which induces the expression of oncogenes and cell-cycle regulators [17,18].
Activated NF-κB is translocated to the nucleus and it forms a protein complex with NER proteins (XPG
and XPF) to cleave the promoter regions of the genes and cause double strand breaks (DSBs) that impact
gene expression [11].
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2. H. pylori Induces Inflammation-Dependent DNA Damage
Chronic inflammation is estimated to contribute to approximately 25% of human cancers [19].
Gastric inflammation in H. pylori infection may be induced via two different mechanisms. The first
mechanism is initiated via physical contact between the pathogen and the host epithelial cells,
producing direct cell damage or enhancing the ability of epithelial cells to release pro-inflammatory
mediators (Figure 1). The second mechanism is likely promoted by H. pylori virulence factors
(e.g., CagA, VacA) that may target the potential cell signaling pathways to stimulate immune responses.
Interestingly, the H. pylori CagA positive strain enhances chemokine activation, such as IL-8, a potent
neutrophil-activating chemotactic cytokine or chemokine [20,21]. Furthermore, chemokines that are
released from infected gastric epithelial cells can stimulate neutrophil infiltration and T lymphocytes
to enhance RONS-mediated gastritis [22,23]. Overall, H. pylori-mediated gastric inflammation is
associated with humoral and cell-mediated immune cells.
 
Figure 1. Molecular mechanisms of H. pylori-induced double strand breaks (DSBs). Schematic
representation of how H. pylori induces DSBs. H. pylori infection causes DNA damage in gastric epithelial
cells [24]. H. pylori-host cell interaction is a prerequisite for DSBs [25] (top panel). Persistence of the
host-bacterium interaction leads to chronic inflammation and the release of inflammatory cytokines and
chemokines, which contribute to oxidative DNA damage that is processed via base excision repair (BER)
pathways (bottom panel). Processing oxidative DNA damage by DNA glycosylase (e.g., OGG1, NEIL1,
etc.) contributes to accumulation of apurinic/apyrimidinic (AP) sites that are eventually converted
to DSBs [26]. In addition, some cytokines (e.g., TNF-α) inhibit BER proteins to exacerbate genomic
instability. The second pathway associated with H. pylori-mediated NF-κB activation leads to formation
of a protein complex with nucleotide excision repair proteins (XPF and XPG), cleaves the promoter
regions, and alters gene expression [11] including HR DNA repair proteins (Rad51). Alternatively,
NF-κB/iNOS-mediated NO production leads to DNA damage and/or inhibits DNA repair proteins
(AAG) that likely impact BER and cause DSBs. Note that solid arrow and dot arrow shows activation
and alternative avenue for the down stream events respectively; T bar shows inhibition or suppression
of protein activity or gene expression.
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3. H. pylori Induces Base Excision Repair (BER) Intermediate-Dependent Double Strand
Breaks (DSBs)
Chronic inflammatory conditions induce immune and epithelial cells to release RONS, which are
capable of causing DNA damage and persistent cellular proliferation [27]. In addition, RONS accumulation
may result in proto-oncogene activation, chromosomal aberrations, and DNA mutations [28,29]. There
is considerable evidence that H. pylori itself induces genomic instability and epigenetic alteration in the
host genome. However, there is little experimental evidence to provide mechanistic insight into how
oxidative DNA damage leads to DSBs and how oxidative-damaged DNA processed via BER (Figure 1),
which is thought to be the primary repair pathway against oxidative DNA damage [30]. The mechanism
of H. pylori-induced host genomic instability remains poorly understood.
BER is crucial for maintaining genomic stability to prevent carcinogenesis [31–34]. BER is
a major DNA repair pathway that removes the majority of oxidative and alkylating DNA damage
without affecting the double helix DNA structure [30,35,36]. BER is the primary repair pathway of
RONS-induced DNA damage during inflammation that occurs during H. pylori infection [37] (Table 1).
Tight coordination of the different steps in BER is necessary to avoid genomic instability [38]. BER
is initiated by the recognition and excision of the damaged base by specific DNA glycosylases. For
example, the best characterized 8oxoG DNA lesions paired with cytosine are recognized and excised
by bifunctional OGG1 glycosylase [39–42]. Subsequently, OGG1 remains bound to its abasic site (AP)
and its turnover is stimulated by apurinic/apyrimidinic endonuclease1 (APE1) [43,44]. After AP site
processing and end-remodeling, the single-nucleotide gap is filled by Pol β, and the nick is sealed
by DNA ligase I to complete repair [45,46]. H. pylori can alter DNA repair gene expression and/or
interfere with DNA repair activity [26,47,48]. Ding et al. reported live H. pylori upregulated APE1
expression in cultured gastric adenocarcinoma cell lines (AGS) and gastric epithelial cells that were
isolated from uninfected human subjects [49]. Overexpressed APE1 likely interacts with other redox
proteins to suppress ROS production [50]. In addition, Taller et al. show that coculture of H. pylori
with gastric cancer cell lines induces DSBs in a contact-dependent manner [12]. DSBs in those cell lines
lead to the activation of the ATM-dependent DNA damage response. H. pylori-induced DSBs likely
cause chromosomal aberrations, such as deletions, insertions, and translocations, which are a major
cause of the loss of heterozygosity.
Repair of oxidative DNA damage is critical for suppression of inflammation-associated
carcinogenesis. However, host BER insufficiency caused by genetic polymorphism or loss of repair
capacity likely exacerbates RONS-mediated DNA damage and cancer development [51–53] (Table 1).
In addition, altered function of BER proteins causes aberrant function, including the processing of
H. pylori-induced oxidative DNA damage that leads to SSBs [54] and mutation [47,48]. In vivo studies
have shown that H. pylori infection in an OGG1 knockout mouse model enhances accumulation of
8oxoG DNA lesions and promotes resistance to inflammation [55–57]. In addition, loss of DNA
glycosylase, such as MYH and alkyladenine DNA glycosylase (AAG), causes the accumulation of
oxidative DNA damage lesions and promotes inflammation-associated tumor development [37,58,59].
H. pylori infection activates other BER proteins, such as PARP1 and enhances the inflammatory response,
suggesting that the bacterium modulates the host PARP1 status to drive inflammation-associated
gastric cancer [60]. However, cell culture experiments have shown that OGG1 downregulation in
gastric epithelial cells decreases the formation of AP sites and suppress DSBs formation [26]. However,
silencing of APE1 as part of the BER machinery failed to cause a significant level of H. pylori-induced
DSBs [11].
202
Int. J. Mol. Sci. 2018, 19, 2891
Table 1. Interplay between H. pylori and relevant DNA repair gene products.
Gene Role of Gene Products Interplay between H. pylori & Gene References
BER
OGG1 removes 8oxoG and FapyG DNAlesions
absence causes increased mutation
frequency, fewer DSBs and decreased
inflammation
[26,55,61]
NEIL1 removes 8oxoG and Tg lesions decreases mRNA in tumor; unknownrole during infection [34]
APE1 acts as a negative regulator of ROSand enhances chemokine release
enhances the expression of mRNA
and protein [49,62,63]
POLB removes 5
′-dRP group and adds
a single nucleotide base
infection does not affect gene
expression and protein level [26]
XRCC1 scaffold protein enhance ligation downregulated via promoterhypermethylation [64,65]
NER
XPG
cuts the 3′ of the DNA damage site;
forms complex with NF-κB and
promotes target gene expression
moderates change in gene expression [11,66,67]
XPF forms complex with NF-κB &promotes targeted gene expression moderates change in gene expression [11,66]
XPA recognition bulk DNA adduct increases IL-8 cytokine expression [11,66]
NHEJ
DNA-PK
increases cellular proliferation &
facilitates NHEJ (nonhomologous
DNA end-joining) repair
enhances activity and expression [68]
Ku70/80 protects DNA DSB ends and preventscell death decreases protein level [69]
DNA
ligase IV
completes NHEJ repair by sealing
DNA DSB regions knock-down enhances DSBs [11]
XRCC4 scaffold to hold DNA DSBs ends toenhance ligation knock-down promotes DNA DSBs [11]
HR
NBS1 DNA DSB end processing/DDR decreases expression and may impairDNA end processing and DDR [66]
Rad51 strand exchange and enhances DSBrepair
decreases gene expression; however,
infection does not increase DSBs [25]
RPA1 ssDNA binding and DDR downregulates mRNA [66]
Mre11 DSB end processing and DDR decreases expression and impairs endprocessing and DDR [66]
DSBs are the principle cytotoxic lesions generated by H. pylori infection. DSBs can be caused
by the accumulation of unrepaired BER intermediates in DNA replication independently and/or
arise when DNA replication forks encounter BER intermediates including DNA SSBs [70,71]. Few
studies have shown that accumulation of AP sites in H. pylori-infected human gastric epithelial cells
leads to DSBs [26]. Toller et al. [12] reported that a direct bacterium-host interaction is a prerequisite
to DSBs, rather than the release of DNA-damaging components. Overall, these results suggest that
DSB formation is mediated by BER intermediates that are generated from a direct response of the
host-bacterium interaction (Figure 1).
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4. NF-κB-iNOS Axis-Dependent DSB Formation
H. pylori infection induces DNA damage in gastric epithelial cells [24]. Contact-dependent
interactions between H. pylori bacteria and gastric epithelial cells activate intracellular signaling events
that have further downstream effects via activation of the transcription factor NF-κB [72]. NF-κB
activation is effected through a series of phosphorylation and transactivation events, triggering
a downstream signaling pathway that contributes to gastric inflammation in H. pylori-infected
individuals [73,74]. H. pylori-mediated NF-κB activation leads to the upregulated expression of
a variety of inflammatory mediators, including IL-8 [75], and regulates genes that govern the innate
and adaptive immune response [76,77]. However, aberrant NF-κB activation has been reported to
function as a tumor promoter in inflammation-associated cancer [78,79].
Moreover, the host response to H. pylori infection enhances NF-κB activation in immune and
epithelial cells, resulting in inducible nitric oxide synthase (iNOS) [80–84]. iNOS is an inflammatory
mediator that causes the production of nitric oxide (NO) by immune cells, such as macrophages, linking
chronic inflammation and tumorigenesis [85–87]. iNOS is expressed in response to bacterial endotoxins
and cytokines and leads to NO production that enhances carcinogenesis [88]. iNOS-mediated NO
induces oxidized DNA and leads to mutations associated with the infection [89,90] and DSBs [91].
Furthermore, NO has a biphasic effect on NF-κB to exert both pro- and anti-inflammatory actions.
Although the ability of NO to directly damage DNA has been studied to a limited degree [92], its role in
promoting potentially mutagenic changes in DNA has received far less attention. NO prevents NF-κB
transactivation via the stabilization of IκBα [93] and nitrosate, a specific cysteine residue on the p50
subunit of NF-κB that reduces its DNA-binding capacity [94,95]. Few studies have shown that NF-κB
plays a significant role in inhibition of pathogen-induced apoptosis in immune cells [96], suggesting
that NF-κB may play a pro-inflammatory role to induce persistent macrophage activation. Other
studies have shown that DNA repair proteins that are involved in BER and SSBs (PARP1) interact
with NF-κB to facilitate the interactions with DNA to promote the expression of pro-inflammatory
cytokines and enhance the activity of iNOS [97–99].
iNOS-mediated NO enhances inactivation of DNA repair enzymes that eventually contribute
to genomic instability, leading to cancer development [86]. NO can nitrosylate thiol and tyrosine
residues of the DNA repair proteins, causing loss of their function [100,101]. Thus, determining the
effect of iNOS-generated NO on DNA repair proteins is scientifically important to uncover the impact
of H. pylori-triggered iNOS-mediated DNA repair defects (Figure 1). Few studies have shown that
DNA repair proteins are vulnerable to oxidative damage from NO because of their active sites, such
as sulphydryl, tyrosine, and phenol side chains [102]. DNA repair enzymes, such as MGMT, FpyG,
and PARP may be inactivated by NO-mediated nitrosylation of the cysteine-rich residues of the active
site [103,104]. The integrity of the genome may be challenged during exposure to high concentrations
of NO by direct oxidative damage to DNA and by inhibiting the DNA repair capacity of the enzyme
(Table 1).
5. NF-κB-Nucleotide Excision Repair (NER) Axis-Dependent DSB Formation
H. pylori infection increases NF-κB activation to promote the inflammatory immune response [105].
NF-κB modulates many DNA repair genes to facilitate repair and generate DNA DSBs [106,107].
Endonucleases XPF and XPG are critical components of NER that are responsible for excising the
damaged DNA strand to remove the DNA lesion. The endonuclease XPG cuts the DNA strand
approximately 5–6 nucleotides downstream of 3′ of the DNA damage site. In addition, the ERCC1-XPF
protein complex performs an incision of the DNA strand 20–22 nucleotides upstream of the 5′ end of
the DNA [108,109]. Although these two endonucleases are recruited and form complexes with NF-κB
to make preincision complexes, proper assembly of all the factors seems to be required for dual incision
at the promoter region of a given gene. XPF/XPG-mediated DSBs amplify NF-κB target inflammatory
gene expression and promote host cell survival [11]. The NF-κB complex in XPG and XPF in the
formation of the active DSBs at the chromatin region of the genome likely promotes a hub that controls
204
Int. J. Mol. Sci. 2018, 19, 2891
gene expression (Figure 1). Furthermore, the expression level of XPG is significantly associated with
an H. pylori-positive sample [110] (Table 1). However, silencing XPG strongly reduced the DSBs upon
H. pylori infection, suggesting that NER-dependent DSBs contribute to genomic instability during
infection. H. pylori infection modulates NER and enhances the interaction with NF-κB, likely providing
a molecular basis for insights into how H. pylori infection induces transcription-associated DSBs
(Figure 1).
6. H. pylori Impairs DSBs Repair
DSBs can be repaired via two major repair pathways [111,112]. Homologous recombination
(HR) requires sequence homology of extensive DNA regions from an undamaged sister chromatid or
homologous chromosomes. In contrast, nonhomologous DNA end-joining (NHEJ) occurs throughout
the cell cycles and is processed without any sequence homology or few end homology sequences.
H. pylori-induced DSBs are likely recognized by the MRE11-RAD50-NBS1 (MRN) complex [113,114],
which is recognized and processed the DNA ends, resulting in the activation of ataxia telangiectasia
mutated kinase (ATM) [115,116]. ATM is a major DNA damage response sensor of DSBs. It directly
binds to the damaged DNA and phosphorylates target proteins, including H2AX protein at serine 139
of the histone (γH2AX) to mark DSBs sites [116–119]. Alternatively, ATM is involved in mediating the
NF-κB response to DSBs [120].
In the NHEJ pathway, DNA-dependent protein kinase (DNA-PK) and Ku proteins play key
roles in mediation of incompatible DNA ends. DNA-PK may function as a DNA damage sensor
or scaffolding to assemble repair proteins including Ku proteins to bind the two ends of the break
together. Then, ligase IV/XRCC4/XLF carries out the ligation reaction [121] to complete NHEJ
repair. However, H. pylori causes an increase in Ku70/80, which may indicate that NHEJ-mediated
repair contributes to genomic instability [69]. Recent evidence has shown that altered DNA-PK and
Ku70/80 are associated with pathological processes in different types of cancer [122]. Moreover,
Ku70 and DNA-PK are expressed in H. pylori-associated gastritis, intestinal metaplasia and gastric
adenoma tissues [68]. Furthermore, Lim et al. [123] showed that activated NF-κB-Cox2 axis plays
a significant role in enhancing the expression of KU70/80. In contrast, the loss of Ku proteins leads to
an accumulation of DNA damage that eventually causes cell death in gastric epithelial cells [124].
Our previous study shows that DSBs significantly increase in the G1 stage of the cell cycle after
H. pylori infection [26], suggesting that NHEJ repair might be involved in promotion of error-prone
repair. When DSBs are generated during the S phase at DNA replication forks or after replication in the
G2 phase of the cell cycle, HR may contribute to genome integrity (Figure 1). Few studies have shown
that NF-κB interacts with HR proteins (e.g., CtIP-BRCA1 complexes) to stabilize BRCA1 and stimulate
HR-mediated repair [125] Activation of multiple molecular targets by NF-κB enhances rapid activation
of HR and may permit the accelerated proliferation of cells. However, H. pylori infection-mediated
activation of the NF-κB/NER axis causes defects in HR that reduce the ability of DSB repair [11].
H. pylori infection modulates DSB repair efficiency to exacerbate genomic instability and facilitate
gastric carcinogenesis.
7. Summary
H. pylori infection is a contributing factor for gastric cancer. This review highlights how
H. pylori-associated DNA base damage in infected host cells is likely processed via BER to generate
DSBs. In addition, this review provides a comprehensive overview of how H. pylori-associated DSBs
are induced via the NF-κB/NER axis and NF-κB/iNOS axis, influencing DNA repair gene expression
and enhancing genomic instability and carcinogenesis (Figure 1). Several studies have shown that
H. pylori induces DSB and promotes gastric carcinogenesis. Host BER, NER, and NHEJ genetic variants
could modify the process of carcinogenesis in H. pylori infected hosts. Alteration of the activity of
enzymes that function in DNA repair as a result of genetic mutation could significantly impact gastric
cancer risk. Other studies are needed to uncover the associations of the BER, NER and NHEJ genetic
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variants with increased susceptibility to gastric cancer in H. pylori-infected hosts. In addition, many
questions remain regarding the mechanism of DSB formation and how breaks are processed via the
NHEJ or HR pathways. Does H. pylori infection decrease tumor latency for carriers of BER variant
genotypes? Future studies will likely explore how H. pylori manipulates host DNA repair genetics
and how NHEJ processes DSBs. Therefore, the relevant DNA repair of the host genetics and H. pylori
infection status of the host should be considered in studies of gastric cancer susceptibility in the future.
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Abstract: The reprimo (RPRM) gene family is a group of single exon genes present exclusively within
the vertebrate lineage. Two out of three members of this family are present in humans: RPRM
and RPRM-Like (RPRML). RPRM induces cell cycle arrest at G2/M in response to p53 expression.
Loss-of-expression of RPRM is related to increased cell proliferation and growth in gastric cancer.
This evidence suggests that RPRM has tumor suppressive properties. However, the molecular
mechanisms and signaling partners by which RPRM exerts its functions remain unknown. Moreover,
scarce studies have attempted to characterize RPRML, and its functionality is unclear. Herein,
we highlight the role of the RPRM gene family in gastric carcinogenesis, as well as its potential
applications in clinical settings. In addition, we summarize the current knowledge on the phylogeny
and expression patterns of this family of genes in embryonic zebrafish and adult humans. Strikingly,
in both species, RPRM is expressed primarily in the digestive tract, blood vessels and central nervous
system, supporting the use of zebrafish for further functional characterization of RPRM. Finally,
drawing on embryonic and adult expression patterns, we address the potential relevance of RPRM and
RPRML in cancer. Active investigation or analytical research in the coming years should contribute
to novel translational applications of this poorly understood gene family as potential biomarkers and
development of novel cancer therapies.
Keywords: gastric cancer; reprimo; tumor suppressive gene properties; development; evolution; biomarker
1. Introduction
The reprimo (RPRM) gene family is a novel and poorly understood single-exon intronless gene
family. RPRM genes are expressed across many species and are associated with developmental
patterning of the gastrointestinal tract, brain and blood vessels [1,2]. In humans, who have only RPRM
and RPRM-Like (RPRML), the RPRM gene appears to be involved in tumor suppression in tumors of
the gastrointestinal tract as well as in multiple other organs. Expression of RPRM is mainly induced
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by p53 after DNA damage, though expression of this gene has also been associated to expression of
p73, another member of the p53 gene family [3]. Upregulation of RPRM results in cell cycle arrest at
the G2/M checkpoint [4]. Epigenetic silencing of RPRM, mainly by DNA methylation of its promoter
region, occurs at early stages of human cancer. Assessment of this biochemical DNA modification in
body fluids has opened an interesting opportunity for translational applications of this family of genes,
as cancer biomarkers.
Here, we describe and discuss the structure, genomic location and homologies of these
poorly characterized genes. In addition, we explore the role in development as well as functional
diversification of the RPRM family. In gastric cancer as well as in other human neoplasms, this family
of single exon and intronless genes had led to the discovery of novel clinical applications such as
non-invasive biomarkers for early diagnosis and disease monitoring and the development of new
drugs for cancer therapies.
2. Structure and Genomic Location of the RPRM Gene Family
The RPRM gene family is composed of three members: RPRM, RPRML and RPRM3. While RPRM
and RPRML are expressed in most of the vertebrate lineages, RPRM3 is only found in cartilaginous fish
(e.g., sharks and rays), bony fish (e.g., zebrafish) and coelacanths [1]. In humans, RPRM and RPRML
are both single exon and intronless genes, which is an uncommon type of gene representing roughly
3% of the human genome [5]. RPRM and RPRML are located on the minus strand of chromosomes
2q23.3 and 17q21.32, respectively. RPRM spans 1.47 kb of genomic DNA and encodes a 109-amino acid
protein with an estimated molecular weight of 11,774 Da. Similarly, RPRML spans 1.09 kb of genomic
DNA encoding a 120-amino acid protein with an estimated molecular weight of 12,312 Da. RPRM3
is also a single exon gene and intronless gene, that is located on the minus strand of chromosome
23q32.2 in zebrafish, RPRM3 spans 1.794 kb of genomic DNA and encodes a 103-amino acid protein
with an estimated molecular weight of 11,323 Da.
RPRM is a highly glycosylated protein which has two N-glycosylation sites at amino acids 7 and
18, a potential serine-phosphorylation site at residue 98, a predicted sumoylation site at position 82
and a potential transmembrane domain covering amino acids 56 to 76 (Figure 1) [6]. Furthermore,
RPRML has predicted N-glycosylation sites at amino acids 2 and 27, a predicted sumoylation site at
position 93 and a transmembrane site covering amino acids 67 to 87 (Figure 1). As other intronless
gene families, such as JUN and FOX, the RPRM gene family is often implicated in cancer through their
overrepresentation in cell growth and proliferation [7]. Functional analyses have suggested that RPRM
is a transcriptional target for p53 and as a cell cycle arrest protein at the G2/M checkpoint, operating
through inhibition of the nuclear translocation of the Cdc2/cyclin B1 complex [4].
Figure 1. Cont.
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Figure 1. Domain structure and potential post-translational modification sites of human RPRM and
RPRML proteins. Schematic representation shows the RPRM and RPRML putative N-glycosylation
(green hexagons), serine-phosphorylation (blue circle) and sumoylation (purple triangle) sites.
The N-terminal, transmembrane and C-terminal domains are represented by colored boxes (turquoise,
yellow, and red, respectively). An * (asterisk) indicates positions which have a single, fully conserved
residue. A: (colon) indicates conservation between groups of strongly similar properties—scoring
>0.5 in the Gonnet PAM 250 matrix. A. (period) indicates conservation between groups of weakly
similar properties—scoring 0.5 in the Gonnet PAM 250 matrix. Post-translational modification
sites were predicted using *NetNGlyc (http://www.cbs.dtu.dk/services/NetNGlyc/), **NetPhos
(http://www.cbs.dtu.dk/services/NetPhos/) and ***SumoPlot (http://www.abgent.com/sumoplot).
3. Evolution of the RPRM Gene Family
Based on current sequenced genome data, the evolutionary history of the RPRM gene family
traces back to the last common ancestor of vertebrates, which lived between 676 and 615 million
of years ago [1]. At that time the ancestor of vertebrates presumably had only a single RPRM gene
in its genome, which likely performed many of the physiological functions that the current gene
family performs today. Through time, this ancestral gene diversified as a consequence of the two
rounds of whole genome duplications (WGDs), which occurred early in the evolutionary history of
vertebrates [8,9]. Thus, the single copy gene present in the genome of the vertebrate ancestor gave rise
to four RPRM genes [1], three of which were retained in actual vertebrates (Figure 2A). The presence of
co-duplicated genes that are found on the chromosomes where the RPRM genes are located in actual
species, and the fact that the genomic regions in which the RPRM genes are located derived from
a single linkage group in the chordate ancestor support this hypothesis [10].
During the diversification of vertebrates the RPRM gene family was differentially retained, as not
all RPRM genes are present in all main vertebrate groups (Figure 2A). Although it was previously
claimed that the RPRM gene was not retained in birds [1], searches in the most recent version of bird
genomes revealed the presence of the RPRM gene in this subgroup of amniotes. Thus, all groups of
jawed vertebrates (gnathostomes) have retained this gene (Figure 2A). The RPRML gene has also been
identified in all main groups of gnathostomes, whereas RPRM3 was only retained in four distantly
related vertebrate groups: cartilaginous fish (e.g., sharks, skates, and rays), holostean fish (e.g., bowfish,
gars), teleost fish (e.g., zebrafish) and coelacanths (Figure 2A). In cyclostomes, the group that includes
lampreys and hagfish, two RPRM genes has been identified (Figure 2A). However, phylogenetic
reconstructions have failed in defining orthology. RPRM sequences of this group are recovered sister
to each other, which might be due to features of their genomes (e.g., GC bias) that differ substantially
from all other vertebrate genomes [11–13], making it difficult to recover the true evolutionary history
using phylogenetic approaches.
More recently in vertebrate history, the RPRM gene family further expanded as a consequence of
the teleost-specific genome duplication (TSGD) that occurred in the ancestor of this group between 325
and 275 million of years ago [14,15] (Figure 2A). Although the TSGD potentially doubled the number
of all RPRM genes in the common ancestor of teleosts, only the rprm gene retained duplicated copies,
termed rprma and rprmb (Figure 2A).
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Figure 2. Evolution and diversification of RPRM genes in vertebrates. (A) During the diversification
of vertebrates RPRM genes were differentially retained, as not all RPRM genes are present in all
main groups of vertebrates. Thus, RPRM and RPRML genes were retained in all main groups of
jawed vertebrates (gnathostomes), whereas RPRM3 was only retained in four distantly related groups:
cartilaginous fish (e.g., sharks, skates, and rays), holostean fish (e.g., bowfish and gars), teleost fish
(e.g., zebrafish) and coelacanths. In the group that includes lampreys and hagfish, two RPRM genes
have been identified, however, phylogenetic and synteny analyses have failed in defining orthology.
(B) Schematic representation of the evolution of the RPRM gene family in teleost fish. On the left,
the RPRM gene family diversified as a product of the two rounds of whole-genome duplication
occurred in the vertebrate ancestor, as well as, a teleost-specific whole genome duplication. On the left,
the expression territories of the three RPRM gene lineages present in teleost fish.
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4. Developmental Expression Patterns of RPRM Gene Family
The use of animal models is the primary step to understand the process of human carcinogenesis
and the development of new drugs for cancer therapies [16]. In this scenario, Zebrafish combines the
complexity of a whole vertebrate animal with the easy-to-use and high-throughput characteristics of
in vitro models [17,18]. Despite differences with teleosts, most of the genetic pathways that regulate
development are similar between zebrafish and human [19]. In zebrafish embryos—both duplicated
copies of rprm (rprma and rprmb) are expressed in a tissue-specific manner in the gastrointestinal tract,
brain and blood vessels. Strikingly, expression of RPRM protein in adult human was also detected in
the same organs [2]. Expression of rprm3, a gene that is lost in all tetrapods, is restricted to the central
nervous system (CNS) in zebrafish embryos and larvae [2].
Our recent observations also indicate that the three rprm genes (rprma, rprmb and rprml) genes
are expressed in the developing digestive tract in embryonic fish [2]. Importantly, in humans,
RPRM is a gene which expression is lost in many human gastrointestinal malignancies and serves
as a potential biomarker for non-invasive detection of gastric cancer (reviewed in the following
section). The RPRM protein is located in epithelial cells lining the intestinal crypts and gastric
glands and smooth muscle cells (SMCs) from the Muscularis propria [2], As in humans, the digestive
tube of the zebrafish is organized in concentric layers of SMCs [20]. However, the role of RPRM
genes during the differentiation process of gastrointestinal epithelial cells, which occurs during the
migration of these cells from the base of gastric glands and intestinal crypts, remains to be determined.
In this scenario, the zebrafish model organism offers an interesting alternative to dissect this role in
developmental physiology.
Figueroa et al. [2] also show that, in zebrafish and humans, the RPRM and RPRML genes are
expressed in vascular tissues. In humans, RPRM is expressed in endothelial and vascular smooth
muscle cells (VSMCs). The expression of RPRM and RPRML in blood vessels suggests a potential
involvement of RPRM during angiogenesis or vasculogenesis. Future studies require molecular
manipulation of the RPRM gene family to unveil the role of RPRM genes in the formation and
dynamics of the blood vessels.
As we recently reported, in embryonic zebrafish larvae, rprma, rprmb and rprml are expressed
distinctly in the developing brain [21]. Some of the structures that express these genes include the
forebrain, telencephalon and the olfactory epithelium (OE), among other sensory organs. For example,
the expression of rprma is largely restricted to the peripheral nervous system at the OE, while rprmb
transcripts are located in most posterior neuronal territories such as the optic tectum and trigeminal
ganglia. In contrast to rprma and rprmb, expression of rprml is not detectable in the retina. In adult
zebrafish and humans, the RPRM messenger and protein are both located in brain tissues. The human
RPRM is expressed in grey and white matter neurons and glial cells from the brain cortex, a tissue that
displays low mitotic rates during adulthood [2,21,22]. These findings suggest that the RPRM genes
may play a key role in the regulation of cell proliferation in brain development and/or regeneration
during adulthood [21]. Models that compare brain-specific gene expression profiles between wild-type
animals and those with loss-of-function of rprm and rprml will help to define the expression and
function of the RPRM gene family in the processes that contribute to brain development.
5. Functional Diversification of the RPRM Gene Family
Due to the three WGDs, the diversification of the RPRM gene family opens new opportunities for
physiological innovation within this lineage. In the literature it has been difficult to probe the causal
link between the WGDs and biological innovation [23], although for some well-studied gene families,
this causal association has been demonstrated [24–26]. As mentioned above, expression profile analyses
of the RPRM genes demonstrate that they exhibit unique—although partially overlapping—expression
patterns during embryonic and larval vascular development [2]. On one hand, rprma, rprmb and
rprml are all expressed in the digestive tube, blood vessels and brain; whereas rprm3 possesses
a unique expression profile restricted only to the brain. Importantly, the expression patterns of
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rprma and rprmb transcripts in the zebrafish resembled expression profiles of the RPRM protein in
humans. This evidence suggests that the developmental expression pattern for the RPRM gene
family is the same in fish and mammals [1]. Furthermore, the compartmentalization in humans
of RPRM genes in partially overlapping territories seems to agree with the pattern described for
teleost fish (Figure 2B) [27]. Future studies should elucidate the functional role of the RPRM gene
family during the physiological processes such as gut, vascular and neuronal development across the
vertebrate subphylum.
6. Role of the RPRM Gene Family in Human Carcinogenesis
In order to uncover the RPRM and RPRML tissue expression patterns in human samples, we have
assessed in silico RNAseq data from the Genotype Tissue Expression (GTEx) database [28]. As shown
in Figure 3A, RPRM has a variable expression across different tissues, whereas RPRML is expressed at
very low levels in most tissues, except for brain compartments where expression levels are the highest.
However, low transcript levels are expected for intronless genes, which generally express at lower
levels than intron-containing genes despite having important biological roles [29]. Transcriptome
studies in several vertebrate species reveal that RPRM genes are mainly expressed in the central
nervous system. In accordance with this observation, our previous studies have shown that the
transcript and protein for RPRM are expressed in the zebrafish and human brain [2]. In the case of
cancer tissues, as shown in Figure 3B, both genes display down regulated expression in tumor tissues
in comparison with non-tumor adjacent mucosa, including gastric cancer [30].
At experimental and clinical levels, only the RPRM gene has been examined in terms of biological
functions and significance in human cancer. In gastric cancer cells, restoring the expression of RPRM
by transfecting exogenous cDNA results in reduced colony formation and anchorage-independent
growth [3,31]. Correspondingly, mouse xenografts models of gastric cancer cells deficient in RPRM
expression have demonstrated enhanced tumor formation and volume [31,32]. In other tumors, such as
breast cancer, pituitary tumors and renal cell carcinoma cell lines, overexpression of RPRM suppresses
cell proliferation, cell migration, clonogenic capacity and invasiveness [33–35]. Furthermore, the role
of RPRM in cell-cycle has also been explored. Ohki et al. [4] overexpressed RPRM through adenoviral
infection in cells with wild-type (HeLa, Lovo, MCF7) and mutated (DLD1 and Saos2) p53, observing
cell-cycle arrest in G2/M phase, independently of p53 mutational status. However, conflicting
results have been reported in gastric cancer and pituitary cell lines where RPRM overexpression
results in a significant increase in the sub-G1 population with minimal changes in S and G2/M
populations [31,34]. Ectopic expression of RPRM cDNA in gastric cancer cell lines after exposure to
DNA-damaging agents, such as 5-fluorouracil or cisplatin, results in an apoptotic phenotype 24 h after
treatment [31]. In other types of tumors, with both wild-type and mutated p53 gene, overexpression of
RPRM induces an apoptotic phenotype after 4 days of adenoviral infection, suggesting that RPRM
may also repress cell growth by induction of apoptosis [4]. Taken together, these results suggest that
RPRM has tumor suppressive properties not only in gastric cancer but also in other tumors.
Clinical studies have shown that the loss of RPRM expression is as common event in gastric
cancer [3,31,32,36] as in other tumors of the gastrointestinal tract including Barrett’s-associated
esophageal adenocarcinoma, pancreatic and colorectal carcinoma [37–41]. Loss of expression of RPRM
has been also reported in non-digestive tumors including breast, renal cell carcinoma, adrenocortical
and pituitary tumors [33–35,42,43]. Conversely, enhanced RPRM expression has been described in
metastatic brain tumors [44].
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Figure 3. RNA expression of RPRM and RPRML across different tissues. (A) Tissue-specific expression
profile from 570 human donors available in the Genotype-Tissue Expression (GTEx) database [28].
Data is expressed as log10 of Transcripts Per Kilobase Million (TPM). (B) Expression levels of human
tumor and matched normal tissue samples from Broad Institute TCGA Genome Data Analysis
Center [30]. Data is expressed as log2 of RSEM (RNA-Seq by Expectation Maximization).
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RPRM is located within a CpG-enriched region of the genome. In these regions, a significant
proportion of cytosines contain a methyl group in the fifth carbon when they are immediately
preceded by a guanine (CpG sites). Although unevenly distributed across the genome, CpG sites
generally cluster near gene promoters (CpG islands), thus controlling local chromatin structure
and transcription factor binding [45]. In normal cells, a few CpG islands are usually methylated
(DNA methylation), maintaining genomic stability and controlling expression of tissue-specific,
imprinted and housekeeping genes [46]. In contrast, an aberrant pattern of DNA methylation has
been observed in some cancers characterized by a genome wide low methylation state that promotes
transcriptional activation of oncogenes, genomic instability, and loss of imprinting, while some CpG
islands, particularly those located in the promoter regions of tumor suppressor genes, show a local
hypermethylated state that may result in gene silencing [47]. This is one of the most common epigenetic
alterations found in human cancers. In the case of RPRM, bisulfite sequence experiments to evaluate
the density of methylated CpG sites of the promoter region have correlated positively with the levels of
the transcriptional expression of the gene [3]. Consequently, restoring the expression of RPRM by the
use of demethylating agents, such as 5-aza-cytidine has confirmed that the expression of RPRM gene is
regulated by DNA methylation in gastric cancer cells [3,32,48]. In other neoplasm similar results have
been obtain confirming the role of DNA methylation as the main mechanisms of regulation of RPRM
gene expression [35,49]. In addition, DNA methylation of RPRM has been associated with a compact
chromatin structure and further increasing transcriptional silencing of the gene [49]. Interestingly, an in
agreement with the enhanced RPRM expression in metastatic brain tumors [44], bisulfite sequence
studies in pituitary tumors have shown that loss of RPRM is not due to hypermethylation of the
promoter region [34]. This observation raises the possibility that other mechanisms, genetic and/or
epigenetic (i.e., microRNAs), might contribute to RPRM gene regulation.
As previously mentioned, RPRM has been proposed as a transcriptional target for p53.
In gastric cancer cells expressing wild-type p53, a significant down-regulation of RPRM has been
described. Conversely, RPRM-induced changes were not seen in p53-deficient NCI-N87 cells. [50].
Analogous findings have been described by in silico analysis of the TCGA data, where a negative
correlation between Survivin and RPRM expression was identified exclusively in patients with
wild-type p53 protein status [50].
Based on a positive co-expression between RPRM and p73 proteins in a large cohort of tumor
samples, the possibility that other members of the p53 gene family participate in the regulation of
RPRM has been raised [3]. Since cytoplasmic overexpression of RPRM inhibit nuclear translocation of
the Cdc2-Cyclin/B1 complex inducing cell cycle arrest at the G2/M stage [4] further binding and or
co-immunoprecipation experiments should contribute to clarify the role of p73 in the regulation of the
expression of RPRM (Figure 4).
The clinical significance of the loss of RPRM expression in gastric cancer was first explored by
Luo et al. [36]. This study analyzed RPRM protein expression along with tumor suppressor S100A2
(S100 calcium binding protein A2) in a cohort of 100 consecutive gastric cancer cases identifying
loss of RPRM expression in up to 65% of cases. Interestingly, Luo et al. [36] found that there exists
a positive relationship between the expressions of both genes. Furthermore, loss of RPRM expression
was significantly associated with depth of tumor invasion, lymphatic vascular invasion and lymph
node metastasis. These clinical findings have been confirmed by Saavedra et al. [3] showing also that
loss of RPRM expression is particularly associated with the progression from stage I to stages III-IV
(Japanese classification of gastric carcinoma) [51] in a cohort of Hispanic/Amerindian cases from Latin
America, one of the highest regions in gastric cancer incidence worldwide [52]. Although none of the
earlier studies were able to show that loss of expression of RPRM could influence overall survival
in gastric cancer, our group has recently found that loss of RPRM expression does confer a worse
prognosis only when accompanied with overexpression of Survivin, a well establish oncogene in
gastric cancer [50,53]. Taken together, data suggest that RPRM requires a genetic background including
other cancer-related genes, such as S100A2 and/or Survivin to drive the gastric carcinogenesis process.
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Figure 4. Schematic model of RPRM-mediated cell cycle and G2 arrest mechanisms. RPRM has been
identified as a transcriptional target for: (1) p53 [4]; (2) histone deacetylase 7/FoxA1 (HDAC7/FoxA1)
in an estrogen mediated mechanism [49]; and (3) for epigenetic silencing by hypermethylation of its
promoter region [54]. A potential regulation by p73 it has also been proposed [3]. RPRM expression
results in inhibited dephosphorylation of Cdc2, suppressing the activation of the Cdc2-Cyclin B1
complex. Thus, inducing cell cycle arrest at G2 suggesting a potential role for RPRM as a tumor
suppressor gene [4]. The balance towards cell cycle arrest or proliferation can be shifted by multiple
antagonistic effectors, amongst them RPRM. Straight lines with arrowheads indicate activation. Lines
with no arrowhead indicate inhibition. Curved arrow on the bottom left indicates dephosphorylation
of Cdc2/Cyclin B1 complex. Curved thick arrow on the bottom right indicates nuclear translocation of
dephosphorylated Cdc2/Cyclin B1 at the G2/M checkpoint.
Interestingly, it has recently been shown that upregulation of endogenous RPRM expression by
the use of CRISPR/dCas9 (Clustered Regularly Interspaced Short Palindromic Repeats and associated
dead Cas9) system, a platform that utilizes a catalytically deactivated Cas9 (dCas9) linked to effector
domains for gene expression regulation (i.e., Synergistic Activation Mediator (SAM) complex) reduced
cell proliferation and increased apoptosis in gastric cancer cells [55]. This finding has been expanded to
other genes with tumor suppressor properties embedded in a CpG-enriched region of the genome such
as Maspin or METTL3 [55,56]. The use of this new tool will be useful not only for the understanding
of the epigenetic modifications in an endogenous biological context but also for the potential cancer
therapies based on these findings.
Studies have shown that across the gastric precancerous cascade, RPRM becomes increasingly
hypermethylated, in association with loss of protein expression. These findings are particularly related
with the transition from intestinal metaplasia to dysplasia and/or gastric cancer [57]. Consequently,
no differences in methylation levels have been found between paired tumor and non-tumor adjacent
cells [3]. Taken together, loss of expression and/or methylation of RPRM could be proposed as a late
event in the gastric precancerous cascade. Methylation of the RPRM promoter region is associated
with the infection of Helicobacter pylori particularly to cytotoxin-associated gene A (CagA) strains [58].
Accordingly, methylation of RPRM promoter region has been proposed as a tissue biomarker for the
evaluation of H. pylori eradication [59].
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Accordingly, with this line of evidence, follow-up studies examining DNA methylation levels of
RPRM on the longitudinal progression of the gastric precancerous lesions after H. pylori eradication,
have revealed an increasing level of the DNA methylation six-years prior the progression of gastric
lesions [60]. Interestingly, these changes were independent of the effect of the duration of H. pylori
infection and other clinical parameters [60].
Since RPRML is also located within a CpG-enriched region of the genome, as has been well
documented in the case of RPRM [3,35,48,49] and also correlates with transcriptional silencing [3,32],
the evaluation of RPRML methylation may yield similar findings to that of RPRM. To assess this issue,
an exploratory in silico analysis of RNAseq expression data from paired gastric adenocarcinomas
and non-tumor adjacent mucosa from The Cancer Genome Atlas (TCGA) database [0] is in progress.
In addition, in vitro gain/loss of function experiments focused on evaluation of tumorigenic or tumor
suppressive effects may provide insights on the role of RPRML in cancer.
7. Methylated RPRM Cell-Free DNA as a Potential Non-Invasive Biomarker in Gastric Cancer
The discovery of methylated cell-free DNA in body fluids has expanded the translational
applications of DNA methylation of cancer-related genes [61,62]. Due to its relatively stable nature and
availability, DNA methylation can be easily detected in serum, plasma and a variety of body fluids.
Thus, the assessment of DNA methylation through cell-free DNA or liquid biopsy approaches has
been proposed as a candidate for the diagnosis and management of cancer [63].
Our group was the first to propose the assessment of methylated cell-free DNA of the RPRM
promoter gene region for non-invasive detection of gastric cancer with a sensitivity of 95.35% [95% CI:
84.19–99.43%] and specificity of 90.32% [95% CI: 74.25–97.96%] [48]. These values achieved the
highest OR (OR = 191.33 [95% CI = 30.01, 1220.01]) in a comprehensive meta-analyses undertaken
by Sapari el al. [64] after consolidation of 132 case-controls studies for potential biomarkers based on
methylated DNA in gastric cancer. This approach has subsequently been extended to the detection of
precancerous lesions [32,57,65]. Therefore, clinical trials addressing the role of RPRM as a non-invasive
biomarker in gastric cancer should be performed.
8. Unanswered Questions and the RPRM Gene Family
There are many biological questions still to be answered regarding RPRM gene family.
Protein structure and the biological relevance of post-translational modifications such as glycosylation,
phosphorylation and sumoylation should be assessed (Figure 1). Furthermore, the regulation of
expression and the translational applications of the RPRM gene family in cancer medicine need to
be further elucidated, along with a potential role in other pathologies [4]. Originally described as
a p53-dependent cell cycle arrest mediator (Figure 4), yet the functions and mechanisms by which
RPRM acts still remain unknown. Evolutionary studies, developmental genetics and molecular biology
approaches will prove useful tools in determining the origin and function of this single exon and
intronless RPRM gene family [7,66]. The evaluation of different and complementary lines of evidence
such as (1) selective pressures; (2) phenotypical variations as a consequence of loss- or gain-of-function;
and (3) pre- and post-transcriptional and translational variations may deliver a better understanding
of this gene family. From an evolutionary perspective, comparative genomics and phylogenetic
analyses may provide evidence of co-evolution and potential relationships between RPRM and other
gene families, and thus uncover new signaling partners. Questions regarding a “de novo” origin or
retrotranscription of mRNA followed by insertion of the resulting DNA copy into the genome should
be addressed to clarify the origin and evolution of the RPRM single exon gene family. Using molecular
and genetic approaches, which rely on DNA sequence or RNA/protein expression alterations, it may
be possible to establish the pathophysiological role of the RPRM genes in the regulation of cellular
functions. Mutation of RPRM family genes will be useful to identify phenotypic defects generated by
RPRM loss-of-function as well as to dissect the role of RPRM in developmental processes.
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The function and role of the RPRM genes in gastric carcinogenesis should be expanded to
incorporate RPRML (Figure 5); as to date, only the human RPRM gene has been examined. Importantly,
the unique expression pattern of rprml suggests that this is a functional gene and will hopefully initiate
studies into its presence and function in human gastric physiology and cancer tissues.
Figure 5. Unanswered questions in RPRM gene family. RPRM is as a p53-induced protein which
induces cell cycle arrest at the G2/M checkpoint [4], through an unknown mechanism. Recently,
RPRM genes have been shown to be expressed during brain, gut and blood vessel development [2].
Additional functions for RPRM include its role as a potential tumor suppressor gene (TSG),
and a biomarker—through the assessment of the methylation status of its promoter region—for
non-invasive detection of gastric cancer and other tumors [48,62]. Much like RPRM, RPRML is
also expressed during embryonic development [2], but its role in physiological processes has never
been investigated.
Although the ectopic expression of RPRM induces cell cycle arrest and apoptosis in vitro [4,34,55],
unanswered questions still remain as to how transcriptional silencing of RPRM predisposes tissues to
gastric cancer development. In multiple tumors, DNA methylation is the most common epigenetic
mechanism of loss-of-expression of RPRM [62]. In fact, loss-of-expression by DNA methylation
of the RPRM promoter region it is an indicator of cancer progression and the continuous use of
demethylating agents such 5-aza -cytidine can restore RPRM gene function and dampen indicators
of tumor progression [3]. In this scenario, more specific approaches to re-activate RPRM expression,
for example through CRISPR/dCas9-based artificial transcription factors, may open the door to new
translational opportunities in cancer therapeutics.
9. Concluding Remarks
The role of the RPRM gene family in vertebrate physiology and disease is still a bourgeoning
field. A comprehensive characterization of the genetic interactions, signaling pathways, protein
modifications and regulatory mechanisms of the RPRM gene family may shed light on its role in both
physiological and oncological processes. RPRM is known to play a role in tumors of the stomach and
has translational applications in the monitoring and treatment of disease. Whether other members
of this gene family also have tumor suppressor properties or play relevant roles in other pathologies,
remains a key question in need of further research. In this scenario, this family of single exon genes
could lead to the discovery of novel biomarkers and therapeutic targets, together with the development
of new drugs and clinical applications. The coming years should bring forth active investigation to
help understand, define and utilize the RPRM gene family.
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Abstract: Gastric cancer is the third leading cause of cancer-related deaths and ranks as the fifth most
common cancer worldwide. Incidence and mortality differ depending on the geographical region
and gastric cancer ranks first in East Asian countries. Although genetic factors, gastric environment,
and Helicobacter pylori infection have been associated with the pathogenicity and development of
intestinal-type gastric cancer that follows the Correa’s cascade, the pathogenicity of diffuse-type
gastric cancer remains mostly unknown and undefined. However, genetic abnormalities in the cell
adherence factors, such as E-cadherin and cellular activities that cause impaired cell integrity and
physiology, have been documented as contributing factors. In recent years, H. pylori infection has
been also associated with the development of diffuse-type gastric cancer. Therefore, in this report,
we discuss the host factors as well as the bacterial factors that have been reported as associated factors
contributing to the development of diffuse-type gastric cancer.
Keywords: gastric cancer; diffuse gastric cancer; hereditary diffuse gastric cancer; contributing factors
1. Introduction
Gastric cancer (GC) was the most common cancer as of 1975 [1] and because of the lack of
sophisticated advancements, most of the GC cases were diagnosed at the advanced stages with
poor prognosis [2]. However, relying on the development of advanced endoscopic techniques and
national policy on Helicobacter pylori eradication, currently GC can be detected at earlier stages and
better interventions can be provided to prevent its advance in some countries, such as Japan and
Korea [3,4]. In fact, the declining trend in the global incidence and mortality of GC has been observed
over past decades; however, it still ranks as the fifth most common cancer and the third leading
cause of cancer-related mortality worldwide with an estimated number of 841,000 deaths, including
530,000 deaths and 11.7 million disability-adjusted life years (DALYs) for men in 2013 [5]. Hence, GC is
still a significant public health issue and is still an area of focus for many international organizations
in terms of both the prevention and control of the disease. The incidence and mortality of GC varies
according to geographical region and it remains the highest in East Asian countries in comparison
with other parts of the world [1].
GC is a multifactorial, morphologically heterogeneous disease where adenocarcinoma accounts
for almost 90% of cases and lymphoma up to 5% [6,7]. Histologically, the adenocarcinomas originate
from the glandular epithelium of gastric mucosa, whereas almost 90% of the primary gastrointestinal
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lymphomas are of B cell lineage with few T-cell or Hodgkin lymphomas [6,8]. In general, most GCs are
sporadic (90%) and a positive family history exists in approximately 10% of cases, of which 1–3% are
hereditary [9,10]. Based on differences in morphology, epidemiology, pathology, and genetic profiles,
adenocarcinoma is classified as the well-differentiated or intestinal type gastric cancer (IGC) accounting
for 60% of cases that typically show cohesive groups of tumor cells with a well-defined glandular
architecture leading to expanding growth pattern. Poorly-differentiated or diffuse type gastric
cancer (DGC) accounts for 30% of cases; DGC lacks the intercellular adhesion, often observed with
scattered signet-ring cell morphology predisposed to the diffuse invasion growth pattern throughout
the stroma [11,12]. IGC is found in older patients and is associated more with environmental
factors, such as high salty diet, smoking, obesity, and alcohol consumption [13–15], as well as
H. pylori infection [16]. DGC is more commonly observed in younger patients [17,18]. IGC is
the more common variant and its carcinogenic pathway is mainly caused by H. pylori infection,
which predisposes a person to chronic gastritis, followed by atrophic gastritis, intestinal metaplasia,
dysplasia, and finally carcinoma through the Correa’s cascade [19]. The latter three lesions—atrophic
gastritis, intestinal metaplasia, and dysplasia—are considered precancerous lesions. IGC accounts for
the vast majority of GC. Although the pathogenicity of IGC has been well-characterized and studied,
that of DGC mostly remains undefined and is considered to be primarily genetically determined
and less associated with environmental factors and the inflammatory cascade. Even though DGC
accounts for a lower proportion, an increasing incidence of DGC has been reported [20]. Moreover,
a minor proportion of DGC (1–3%) has been inherently linked and associated with germline alterations
in cellular physiology, which is known as hereditary-DGC (HDGC) [21–23]. Along with the worse
prognosis characterized by early age of onset, rapid disease progression, being highly metastatic,
inherited possibility within family in comparison associated with IGC, DGC has become a challenge
for researchers and physicians. In practice, due to the clinical importance, several guidelines about
diagnosis criteria, treatment, and monitoring of hereditary DGC (HDGC) were established and updated
by a multidisciplinary group including clinical geneticists, gastroenterologists, surgeons, oncologists,
pathologists, molecular biologists, and dieticians [24–26]. Nonetheless, the underlying molecular
pathways of the disease have not yet been well-studied and understood. Notably, a report summarizing
the molecular pathogenicity of GC in general has been published previously [27]. However, in this
report, we summarized the current understanding of published knowledge to create a possible outline
of the contributing factors involved in the molecular pathogenicity of DGC in order to gain deeper
awareness about its mechanism (Table 1).
Table 1. Contributing factors for pathogenicity of diffuse type gastric cancer (DGC).
Factor Mechanism Effects References
Host Factor





Post-translational modification Glycosylation modification ofE-cadherin [33]
Promoter hyper-methylation E-cadherin inactivation [34]
Promoter polymorphism Alterations in E-cadherin [35]
Ras homolog gene family A
(RHOA) Mutational alterations Loss of E-cadherin activity [36]
Sphingosine-1-phosphate
(S1P) Synthesis




Mutations leading to altered
expression of APC protein
Accumulation of β-catenin
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Table 1. Cont.




Inhibition in the cellular
activities [41,42]
Tumor protein 53 (TP53) Mutational alteration Loss of cell regulatingmechanism [43–46]
Helicobacter pylori














Disruption of normal cell
junctions [52–56]
2. Factors Associated with Molecular Pathogenicity of DGC
2.1. Role of E-Cadherin
For the normal maintenance of tissue morphogenesis and homeostasis, cell–cell adhesion
is a critical phenomenon, also important for other cellular processes such as cell differentiation,
cell survival, and cell migration, which are controlled by gene expression and signaling pathway
activation [57]. E-cadherin (calcium-dependent classical cadherin), a trans-membrane glycoprotein
consisting of three domains—extracellular, trans-membrane, and cytoplasmic—is involved in the
cell–cell adhesion and tight adherent junctions that define cell differentiation and proliferation
specificity of epithelial cells and invasion suppression [30,58–60]. The cytoplasmic domain of
E-cadherin forms a protein complex with β- or γ-, p120-, and α-catenins linking the domain with
the actin-myosin network that co-ordinates the specificity of cell shape, polarity, and function of the
epithelial cells [61,62]. The extra-cellular domain of E-cadherin from the adjacent cells is involved in
the cell adherence, providing a tight junction between the cells (Figure 1).
Figure 1. Cell–cell adhesion through E-cadherin. The extracellular domain of E-cadherin from adjacent
cells is involved in cell adhesion and tight junction. The cytoplasmic domain forming a protein complex
with catenins (α-, β-, and p120-) regulates the cytoskeleton protein and actin, which is an important
protein for normal cell integrity.
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The glycoprotein E-cadherin is encoded by the cadherin (CDH1) gene, which is located in
chromosome 16q22.1 and contains 16 exons with a 4.5-kb mRNA [63]. E-cadherin is one of the
major tumor suppressors in GC and the structural modifications in its encoding gene CDH1 or
alterations in its expression have been found as the common events that suppress the broad-ranging
functions of E-cadherin during cancer progression and contribute to the morphogenetic effects
in cancer [10,28,61]. The common mutations in CDH1 are the well-known mechanism for its
deregulation [29,64]. According to the human gene mutation database (HGMD), 121 variants have
been reported for CDH1 alterations to date [65,66]. In addition to the mutations, down regulation of
E-cadherin expression can also occur via other mechanisms, such as overexpression of transcription
repressor, alterations of microRNAs (miRNAs), protein trafficking deregulation, and post-translational
modification of the protein [30–32]. Recently, glycosylation of E-cadherin has been suggested as another
post-translational modification mechanism for its deregulation in many pathophysiological steps of
tumor development and progression [33]. The alterations mediated by promoter hyper-methylation
and epigenetic inactivation of CDH1 has been found most commonly in DGC, playing a vital role as
a second-hit mechanism in deregulation of the wild-type of CDH1 in HDGC patients [34,67]. In a recent
study, the substitution in CDH1 encoding for the extracellular domain, such as NM_004360.3: c.2076T
> C rs:1801552 in exon 13 together with c.348G > A as a new variant, were found to impair its cell
adhesion function and contributed to the development of DGC [64]. On the other hand, substitution
NM_004360.3: c.2253C > T rs:33964119 located in exon 14, encoding for the cytoplasmic domain of
E-cadherin, was also found in DGC [64]. The cytoplasmic domain of E-cadherin binding with β-catenin
plays a critical role in the inhibition of nuclear signaling pathways and tumor-suppression function [68].
In prior studies, the frequency of promoter polymorphism at the −160 position (C > A) of CDH1 was
found to be significantly greater in DGC than in the control groups. The three-marker haplotype
(−160C > A, 48 + 6T > C, 2076C > T) was found to significantly contribute to DGC, whereas ATC
and ACC haplotypes contributed to higher risk of the development of DGC [35,69,70]. Humar et al.
also confirmed that the three-marker haplotype (−160C > A, 48 + 6T > C, 2076C > T) was associated
with DGC [35]. In a recent study, impairment of E-cadherin expression was reported with a decreased
membranous expression in early lesions of DGC [71].
Park et al. performed a study of gastro-duodenal epithelium-specific knockout of one allele of
CDH1 and both alleles of tumor protein 53 (TP53) and SMAD4 (a homologous gene product to the
Caenorhabditis elegans gene (SMA) and the Drosophila gene ‘mothers against decapetaplegic’ (MAD)),
which are the most vulnerable to being inactivated in human GCs. The loss of E-cadherin function
together with SMAD4 was found, which underwent epithelium-mesenchymal transition (EMT) and
co-operated to promote the development of metastatic progression of TP53-null DGC [72]. This result
closely mimicked the human DGC and evaluated the possible role of E-cadherin and SMAD4 in the
development of DGC. In addition to its role in cell–cell adhesion, E-cadherin and the cadherin-catenin
complex have been demonstrated to modulate various signaling pathways in epithelial cells, such as
Wnt signaling, Rho GTPases (a Ras homolog that hydrolyzes the guanosine triphosphate), and nuclear
factor kappa-B (NF-κB) pathways [73]. Therefore, impairment of E-cadherin promotes dysfunctions of
these signaling pathways, thereby influencing cell polarity, cell survival, invasion and metastasis of
gastric cancer, and mainly promotes DGC through the EMT mechanism [74]. Therefore, the cellular
events and deregulation in E-cadherin results in the disruption of normal cellular functions (Figure 2).
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Figure 2. Pathogenicity and factors associated with the disruption of the normal cellular activity.
Hyper-methylation of the CDH1 gene and mutational alteration in TP53 protein causes the impaired
synthesis of E-cadherin. The truncated APC causes accumulation of β-catenin, which activates the
β-catenin-dependent genes and Wnt pathway, altering normal cellular functions. The Wnt pathway
after its activation causes the accumulation of β-catenins in cytoplasm and its translocation into the
nucleus where it transcriptionally activates the transcription factors belonging to the TCF family.
The recurrent mutation in RhoA is able to alter the RhoA pathway, which has a deleterious effect
on E-cadherin.
2.2. Alterations in Ras Homolog Gene Family A (RhoA)
Wang et al. conducted a study in 2014 utilizing primary mouse intestinal organoids and
determined that the recurrent mutations in RHOA (Y42C and L57V) inhibit the cell death induced
when anchorage-dependent cells detach from the surrounding extracellular matrix. This phenomenon
is known as anoikis and it plays a key role in the development of DGC [75]. It is well known
that the loss of E-cadherin leads to impairment of cellular adhesion, resulting in acute cell death
via anoikis. In other words, the alterations or impairment in RHOA function somehow impairs
E-cadherin function. Consequently, another study evaluated the role of RHOA mutations associated
with DGC [36]. These RHOA mutations in hotspot sites were Y42C, G17E, R5Q/W, and L57V with Y42C
being the most common mutation in the effector-binding region of RhoA. In 2014, The Cancer Genome
Atlas (TCGA) identified a rate of RHOA mutations in DGC [76]. The TCGA network also found
additional fusions in GTPase-activating proteins (GAPs), which are crucial in regulating RhoA activity.
More importantly, these mutations were generally found in DGC and not in IGC. Consequently,
Ushiku et al. also reported the RHOA mutations causing DGC in 2016 [77]. The impairment of
RhoA results in the loss of its expression and activity that may play a role in the development of
DGC [78]. RhoA, a member of the Rho family, is a small GTPase protein that plays a fundamental
role in regulating diverse cellular processes, such as cell growth, cell survival, polarity, adhesion,
cell migration, and differentiation [79–82]. The studies have shown that genetic alterations in the RhoA
pathway, including recurrent RHOA mutations and RhoGAP fusion along with the CDH1 mutations,
are quite common in DGC but not in other variants of gastric cancer [36,76]. These results suggest
a possible role of wild-type RhoA in the suppression of DGC development, whereas mutational
alterations in RhoA lead to its development, inhibiting the tumor suppression activity (Figure 2).
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2.3. Role of Sphingosine-1-Phosphate
Sphingosine-1-phosphate (S1P), a bioactive lipid mediator generated by sphingosine kinsase-1
(SphK1) inside the cancer cells, is a key regulatory molecule in cancer via cell proliferation, migration,
invasion, and angiogenesis [83–88]. S1P, after being generated by cancer cells, is exported to the tumor
microenvironment where binding to and signaling through specific G protein-coupled receptors,
known as S1PR1-5, regulates many functions [85–91]. The experimental models conducted by
Nagahashi et al. showed that S1P produced by SphK1 in cancer cells promotes lymph node metastasis
in tumor microenvironments and promotes lymphangiogenesis [37]. In a recent study, Hanyu et al.
reported the role of phosphorylated-SphK1 in the development of DGC and its lymphatic invasion [38].
2.4. Role of Adenomatous Polyposis Coli
The gene associated with human adenomatous polyposis coli (APC) is located on the long
arm of chromosome 5, which encodes a protein of 312 kDa with 2843 amino acids that acts as
a tumor-suppressive protein [92]. A Germline mutation of the APC gene and its inactivation
has been found responsible for familial adenomatous polyposis (FAP) [93,94]. Mutations in the
APC gene leading to the inactivation of this protein are involved in initiating the carcinogenesis
events [92]. The wild-type APC gene product has been found to interact with and degrade β-catenin,
whereas truncated APC promotes β-catenin accumulation, activating the members of Wnt signaling
pathway that stimulates cell division within intestinal crypts [95]. Therefore, maintenance of
low levels of cytosolic β-catenin by functioning APC proteins is essential to prevent excessive
cell proliferation [39]. In a recent study by Ghatak et al., the role of somatic mutations in APC
(g.127576C > A, g.127583C > T) in exon 14 altering the APC protein expression and cell cycle regulation
was shown to contribute to the development of DGC [40].
2.5. Role of Fibroblast Growth Factor Receptor (FGFR)
The overexpression of receptor tyrosine kinases (RTKs) has been correlated with the progression
and poor survival of GC, whereas the immuno-histochemical overexpression of RTKs variant
(i.e., human epidermal growth factor receptor 2—HER2) was found to be associated more frequently
in the development of IGC rather than DGC [96–98]. The role of genomic alterations in RTKs between
IDC and DGC has been revealed in comprehensive genomic analysis performed in TGCA [76].
The fibroblast growth factor receptor (FGFR) family comprises another type of RTKs that interacts with
fibroblast growth factors (FGFs) and regulates the essential developmental pathways participating in
several biological functions, such as angiogenesis and wound repair [41]. FGFRs also regulate essential
cell activities including cell proliferation, survival, migration and differentiation [41]. FGFR2 gene
amplification and protein overexpression was found in the GC cell line originating from DGC and
it has been recently reported in the development of GCs [99,100]. In a study, the significantly high
expression of the FGFR2 protein was commonly reported in DGC rather than IGC [42]. A similar
study also showed the significant association of FGFR2 protein overexpression with poor survival and
peritoneal dissemination of GC [97]. Moreover, a significant correlation of overexpression of FGFR1
and FGFR2 with tumor progression and survival was found only in DGC, which was also associated
with peritoneal dissemination [101]. Therefore, the findings of these studies suggest the possible role
of FGFR1 and FGFR2 in DGC development and their association with peritoneal dissemination.
2.6. Role of Growth/Differentiation Factor 15 (GDF15)
The results of another study reported the association of growth/differentiating factor 15 (GDF15)
with DGC; it was suggested that GDF15 may be the molecules involved in the progression of DGC [102].
Patients with DGC also showed significantly higher serum levels of GDF15, as analyzed by the
ELISA method [102]. The secreted growth factors, such as transforming growth factor-β (TGF-β),
platelet-derived growth factor (PDGF), and fibroblast growth factor-2 (FGF-2) released by cancer
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cells, play a key role in the activation of fibroblasts in DGC, and particularly in scirrhous GC [103].
The activated fibroblasts produce various growth factors that help in the progression of scirrhous GC
and the secreted proteins play a major role in the molecular pathology of DGC progression [103].
2.7. Li-Fraumeni Syndrome with Germline Mutations in Tumor Protein 53 (TP53)
Li-Fraumeni syndrome is genetically inherited in an autosomal dominant manner that is
characterized by an accumulation of brain tumors, sarcomas, and breast cancer. Li-Fraumeni syndrome
is caused by an alteration in TP53 (tumor protein 53 or p53), which is a tumor suppressive gene [104].
Upon activation under the cellular stress, the p53 protein performs several functions such as
induction of cell cycle arrest and apoptosis, inhibition of cell growth, and interaction with DNA
repair proteins [43]. The mutational alteration in TP53 is considered one of the most prevalent
genetic alterations in GC. However, the association of TP53 mutation with histological-type CG is
conflicting [105]. The truncating germline TP53 mutation was reported in a family characterized by
having both HDGC and Li-Fraumeni syndrome [106]. Several other studies highlighted a significant
association of the TP53 mutations with the development of DGC rather than IGC [44,45]. The frequent
mutations at TP53, CKLF-like MARVEL transmembrane domain-containing protein-2 (CMTM2),
CDH1, and RHOA were reported in DGC [46].
2.8. Role of Alteration in Other Genes
In addition to the alterations in the E-cadherin gene (CDH1), the mutations in the catenin
alpha-1 (CTNNA1), breast cancer gene (BRCA2), serine/threonine kinase-11 (STK11), succinate
dehydrogenase subunit-B (SDHB), serine protease-1 (PRSS1), ataxia-telangiectasia mutated gene
(ATM), macrophage scavenger receptor-1 (MSR1), and partner and localizer of BRCA2 (PALB2) genes
have been reported in the development of DGC [107]. In a recent study, the high frequency mutations
for DGC were also reported in lysine methyl-transferase-2D gene (KMT2D), AT-rich interactive
domain-containing protein 1A (ARID1A), APC, and phosphatidylinositol 3-kinase catalytic subunit
(PIK3CA), in addition to high frequency mutations in TP53, CDH1, and RHOA [108]. Alterations in new
candidates such as insulin receptor gene (INSR), F-box only protein 24 (FBXO24), and dot1-like histone
lysine methyltransferase (DOT1L) have also been reported for DGC susceptibility [109]. Choi et al.
found a novel mutation at CMTM2 in addition to the previously known mutations and they suggested
that it may play a crucial role in development of DGC [46]. CMTM2 is a chemokine-like factor
that regulates vesicular transport or membrane apposition events belonging to the CMTM family
(e.g., CMTM3, CMTM4, CMTM7, and CMTM8), which play a role in the tumor suppression [110–113].
3. Helicobacter pylori Infection and DGC
H. pylori colonizes the gastric epithelium and persists for several decades. Chronic infections have
been found to cause chronic gastritis and atrophic gastritis, a precancerous lesion of gastric cancer.
Based on the strong linking evidence of this bacterium with the development of peptic ulcers and
gastric cancer, the International Agency for Research on Cancer (IARC) categorized this bacterium as
a group I carcinogen (strong carcinogen) in 1994 [114,115]. H. pylori infection was initially believed
to be associated with the development of IGC, which arises from chronic gastritis, atrophic gastritis,
intestinal metaplasia, and dysplasia, whereas the sequence of events for DGC is poorly understood,
though it is thought that at least a subset of DGC is due to genetic abnormalities [19,116]. However,
unlike HDGC, H. pylori and/or Epstein-Barr virus (EBV) infections have been reported to play
an essential role in the development of sporadic DGC [117–119]. Several other studies have also
reported the association of H. pylori infection with the development of DGC [120–122]. A recent study
reported that patients with current infections were prone to developing DGC compared to patients
with past infections [123,124]. Similarly, the association of H. pylori was found in 85.36% of DGC [125].
There appears to be little difference in the sero-prevalence of H. pylori between the two types of
cancers, even after adjusting for age. Serological studies confirmed that H. pylori infection is associated
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with both histological types of GC. The studies suggested that patients with a low H. pylori-IgG titer
are more prone to developing IGC, whereas those with high H. pylori-IgG titer are at high risk for
developing DGC [18,122,126]. The progression of gastric mucosal atrophy associated with a decrease
in H. pylori titer may be attributable to the association between past infection or low H. pylori-IgG
titer and IGC [123]. Gong et al. also reported the association of high H. pylori-IgG titer with the
development of DGC [124].
H. pylori infection has been reported to inhibit several factors responsible for cell–cell adhesion
and DGC pathogenicity. Yang et al. demonstrated the cleavage of E-cadherin by H. pylori strains
SS1 and 26695, producing cytoplasmic fragments to induce apoptosis. Strain SS1 was found to
cleave E-cadherin more efficiently at 12 hour and 24 hour [127]. After translocation into the
gastric epithelium, the non-phosphorylated CagA binding with E-cadherin results in the separation
of E-cadherin and β-catenin complex, which causes accumulation of β-catenin in the cytoplasm
and nucleus, which ultimately trans-activates the β-catenin-dependent gene involved in cancer
progression [47]. The aberrant activation of β-catenin disrupts the normal apical-junctional complexes,
which lead to the loss of cellular polarity [128]. The binding of CagA with E-cadherin results in its
down-regulation, together with decreased expression of p120 and aberrant localization from membrane
to cytoplasm, which interacts with Rho GTPases and promotes motility and metastasis [129]. Moreover,
the unusual localization of p120 to the nucleus, preventing transcriptional repression of the matrix
metalloproteinase-7 (mmp7) gene, is involved in gastric carcinogenesis [130]. In a recent study, H. pylori
infection was found to degrade the membrane-bound β-catenin [131]. H. pylori infection has been also
shown to cause TP53 mutation and a decreased p27 protein expression [48,49]. Non-phosphorylated
CagA, in addition to E-cadherin, have been shown to target the phospholipase C-γ, the adaptor
protein Grb2, the hepatocyte growth factor receptor c-Met, and other components, leading to the
proinflammatory and mitogenic responses that disrupts cell–cell adhesion, cell polarity, and other
cellular physiology [132].
Impairment of myelocytomatosis oncogene (MYC) expression occurs in a broad range of human
cancers, indicating a crucial role in tumor progression [133,134]. The MYC gene, located on chromosome
8q24, encoding a transcriptional factor, plays a key role in the regulation of cell cycle progression, growth,
proliferation and apoptosis [135,136]. The results of a study indicated that the MYC protein plays a key
role in association with H. pylori for diffuse type gastric carcinogenesis, whereas it was concluded that the
MYC protein is not associated with the tumorigenic pathway of IGC [137].
Aberrant DNA hypermethylation and inactivation of the CDH1 gene have been found
in DGC [34,67]. H. pylori infection can induce aberrant hypermethylation of multiple genes,
including CDH1, leading to the reduction in E-cadherin expression in gastric mucosa, which increases
the risk for DGC [50,51]. H. pylori serine protease high temperature requirement A (HtrA) is a highly
active protein under extreme conditions and degrades the miss-folded protein in bacterial periplasm
that enhances the bacterial survival in adverse conditions [138]. In an in vitro infection experiment,
the HtrA protein was shown to cleave the extracellular domain of E-cadherin, which led to the opening
of the cell junctions in polarized cell monolayers [52]. The results of several other studies identified the
H. pylori HtrA protein as an E-cadherin targeting protease that directly cleaves-off the extracellular
domain of E-cadherin disrupting cell–cell adhesion, leading to cancer development [53–56]. Moreover,
a study conducted by Abdi et al. reported the H. pylori vacA d1 type as a potent bacterial virulence
factor significantly associated with the development of DGC [139]. Therefore, H. pylori proteins, such as
CagA, VacA, and HtrA, have regulatory effects on many cellular pathways, and in addition to their
role in IGC, they also contribute to the development and prognosis of DGC (Figure 3).
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Figure 3. H. pylori CagA has an inducible effect on the CDH1 methylation and TP53 mutational
alteration. CagA can directly degrade the β-catenin from the E-cadherin-catenins complex. CagA can
also degrade the E-cadherin directly. Bacterial HtrA protein can cleave the extracellular domain
of E-cadherin.
4. Hereditary Diffuse Gastric Cancer (HDGC) and Germline Mutations
Although the majority of the DGC cases are sporadic, approximately 1–3% of cases are
characterized by inherited syndrome, known as hereditary DGC (HDGC)—an autosomal-dominant
cancer susceptibility syndrome characterized by signet ring cell (diffuse) gastric cancer [21,22]. In DGC,
the somatic mutations of E-cadherin are described in up to 40–70% of cases, whereas the germline
mutations of E-cadherin (CDH1), causing loss of its function, are the only proven cause of HDGC,
found in approximately 40% of cases [23,140,141]. In 1994, Becker et al. first reported evidence of
an inherited form of DGC associated with E-cadherin mutations in specimens from sporadic DGC [113].
In 1998, Guilford et al. found multiple cases of early-onset DGC in Maori ethnic peoples of New
Zealand that were carriers of a three germline truncating mutation in the E-cadherin (CDH1) gene [23].
Several other publications emerged confirming the association of autosomal-dominant pattern of
inheritance with germline mutations of the CDH1 gene in the following years [26,71,90,107,140–145].
Sporadic DGC has shown germline mutations for CDH1 in a hot spot region between exons 7 and 9,
whereas genetic alterations scattered over the entire gene length have been observed for HDGC [146].
Individuals with germline CDH1 mutations have a single functional CDH1 allele, whereas the germline
CDH1 alterations in the entire coding region of the other allele may contain small frameshifts, splice-site,
nonsense, and missense mutations, as well as large rearrangements. The mutations causing the
truncating or pre-matured types are pathogenic, whereas several missense mutations cause impairment
of E-cadherin function [147]. Moreover, germline CDH1 mutations resulting in the complete loss of
E-cadherin expression is observed in about 80% of the cases due to the occurrence of premature stop
codons causing truncating or non-functional E-cadherin [148,149]. Also, missense-type mutations
substituting a single amino acid resulted in full-length E-cadherin in the remaining 20% of HDGC
cases [147,148,150,151].
The second hit molecular mechanism causing the inactivation of the remaining functional allele
by promoter hyper-methylation was demonstrated to be the most frequent cause of a second hit that
leads to the inactivation of both alleles of the E-cadherin (CDH1) gene, which is the trigger event for
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the development of DGC [31,152–154]. The second mutation or deletion is an apparently less frequent
cause of second hit molecular inactivation of E-cadherin [31,153].
The International Gastric Cancer Linkage Consortium has defined the well-characterized criteria
for ruling out HDGC: two GC cases in a family with one individual with confirmed DGC at any
age; or three confirmed cases in a family with GC in first- or second-degree relatives regardless
of age; or a single case of GC before 40 years of age; or a family history of GC and lobular breast
cancer, one diagnosed before 50 years of age [26]. In families meeting the consortium criteria for
HDGC carrying the germline mutations are predisposed to an extreme risk of developing DGC
from a relatively young age. Based on the familial trace-out of HDGC cases from around the world,
the estimated cumulative risk of developing DGC by the age of 80 years has been documented to be 70%
for men (95% confidence interval 59–80%) and 56% for women (95% confidence interval 44–69%) [155].
In addition to the risk for DGC, women carrying CDH1 mutations also possess a cumulative risk of
42% for developing breast cancer, typically the lobular type [155]. However, mutations in CDH1 are
not always associated with the development of GC. In another study, a CDH1 pathogenic mutation
was recorded in a patient but no history of DGC was found in three generations of that family [156].
Similarly, in another study, there was CDH1 germline missense mutation without any reported history
of DGC [157]. Moreover, approximately 60 to 70% of families that fulfill the current testing criteria for
HDGC do not possess the germline CDH1 mutations [152,155]. There has been a few, rare, and highly
penetrant familial GC genes; several other familial cancer syndromes also exist for which the GC has
a low penetrance feature [158]. Moreover, only about 40% of the probands meeting the 2010 consortium
criteria carry germline CDH1 alterations [159,160]; of the remaining 60%, a small percentage is due to
CDH1 deletions not detected by conventional DNA sequencing and others have shown mutations in
other genes such as CTNNA1 [161], MAP3K6 [162], INSR, FBXO24, and DOT1L [109]. Hansford et al.
showed results from targeted sequencing of 55 cancer-associated genes in 144 families with HDGC
who did not possess the detectable germline CDH1 mutations [155]. They identified two families
with germline mutations in CTNNA1 as well as germline mutations causing truncated type of BRCA2,
PRSS1, ATM, PALB2, SDHB, STK11, and MSR1 [155].
CTNNA1 encodes α-catenin, forming a complex with β-catenin to bind the cytoplasmic domain of
E-cadherin to the cytoskeleton, is involved in cell–cell adhesion [152]. In a recent study, the comparison
of caudal type homeobox-2 protein (CDX2) association with sporadic or HDGC showed that all HDGC
cases were negative for CDX2, whereas 19 out of 20 sporadic DGC cases showed CDX2 expression,
indicating that sporadic and HDGC may arise via different molecular carcinogenic pathways [163].
Other germline mutations described for familial DGC are in mitogene-activated protein kinase
kinase kinase 6 (MAP3K6) and myeloid differentiation primary response protein 88 (MYD88),
but their significance in causing DGC is not yet known [162,164]. In summary, germline CDH1
mutation—however not limited—is frequently associated with the development of HDGC, whereas the
mutations in TP53 and RHOA, in addition to the CDH1 mutations, are documented in sporadic-type
DGC. However, the detailed molecular mechanisms underlying the development of DGC have not yet
been clarified in detail [36,46,76].
5. Conclusions
Although the detailed pathogenicity of DGC is not well described, the combined information
presented in this report indicates that development of DGC involves multiple factors of cell signaling
pathways, cell–cell adhesion, and H. pylori infection. The E-cadherin and cell-signaling pathways play
a vital role in the maintenance of cell integrity and normal cell function. Deregulation and alterations in
these molecules disrupt the normal cellular functions that contribute to the initiation and progression
of gastric cancer. The alterations in E-cadherin have been known as a factor strongly associated factor
with DGC, with other less frequently associated and newly identified factors. Despite its role in IDC,
H. pylori has been found to influence the development of DGC. However, more details and further
investigations are needed.
237
Int. J. Mol. Sci. 2018, 19, 2424
Author Contributions: Conceptualization, Y.Y.; Literature Review, S.A., B.G. and V.P.T.; Manuscript Writing,
S.A.; Figure Preparation, S.A.; Final Manuscript Preparation, S.A., B.G. and V.P.T.; Manuscript Supervision, Y.Y.;
Funding Acquisition, Y.Y.
Funding: This work was funded by grants-in-aid for Scientific Research from the Ministry of Education,
Culture, Sports, Science, and Technology (MEXT) of Japan (221S0002, 16H06279, 15H02657 and
16H05191), by the Japan Society for the Promotion of Science (Core-to-Core Program), and by National
Institutes of Health (DK62813). Shamshul Ansari, Boldbaatar Gantuya and Vo Phuoc Tuan are PhD
students supported by the Japanese Government (MEXT) Scholarship Program for 2015 (S.A. and
V.P.T.) and 2014 (B.G.).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F.
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012.
Int. J. Cancer 2015, 136, 359–386. [CrossRef] [PubMed]
2. Hartgrink, H.H.; Jansen, E.P.; van Grieken, N.C.; van de Velde, C.J. Gastric cancer. Lancet 2009, 374, 477–490.
[CrossRef]
3. Hamashima, C.; Shibuya, D.; Yamazaki, H.; Inoue, K.; Fukao, A.; Saito, H.; Sobue, T. The Japanese guidelines
for gastric cancer screening. Jpn. J. Clin. Oncol. 2008, 38, 259–267. [CrossRef] [PubMed]
4. Choi, I.J. Endoscopic gastric cancer screening and surveillance in high-risk groups. Clin. Endosc. 2014, 47, 497–503.
[CrossRef] [PubMed]
5. Fitzmaurice, C.; Dicker, D.; Pain, A.; Hamavid, H.; Moradi-Lakeh, M.; Maclntyre, M.F.; Allen, C.; Hansen, G.;
Woodbrook, R.; Wolfe, C.; et al. The global burden of cancer 2013. JAMA Oncol. 2015, 1, 505–527. [CrossRef]
[PubMed]
6. Ajani, J.A.; Lee, J.; Sano, T.; Janjigian, Y.Y.; Fan, D.; Song, S. Gastric adenocarcinoma. Nat. Rev. Dis. Primer
2017, 3, 17036. [CrossRef] [PubMed]
7. Ferrucci, P.F.; Zucca, E. Primary gastric lymphoma pathogenesis and treatment: What has changed over the
past 10 years? Br. J. Haematol. 2007, 136, 521–538. [CrossRef] [PubMed]
8. Ghimire, P.; Wu, G.Y.; Zhu, L. Primary gastrointestinal lymphoma. World J. Gastroenterol. 2011, 17, 697–707.
[CrossRef] [PubMed]
9. Henson, D.E.; Dittus, C.; Younes, M.; Nguyen, H.; Albores-Saavedra, J. Differential trends in the intestinal
and diffuse types of gastric carcinoma in the United States, 1973–2000: Increase in the signet ring cell type.
Arch. Pathol. Lab. Med. 2004, 128, 765–770. [PubMed]
10. Paredes, J.; Figueiredo, J.; Albergaria, A.; Oliveira, P.; Carvalho, J.; Ribeiro, A.S.; Caldeira, J.; Costa, A.M.;
Simoes-Correia, J.; Oliveira, M.J.; et al. Epithelial E- and P-cadherins: Role and clinical significance in cancer.
Biochim. Biophys. Acta 2012, 1826, 297–311. [CrossRef] [PubMed]
11. Flejou, J. WHO Classification of digestive tumors: The fourth edition. Ann. Pathol. 2011, 31, 27–31.
12. Lauren, P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type
carcinoma. An attempt at a histo-clinical classification. Acta. Pathol. Microbiol. Scand. 1965, 64, 31–49.
[CrossRef] [PubMed]
13. Lee, S.; Lee, J.; Choi, I.J.; Kim, Y.W.; Ryu, K.W.; Kim, Y.I.; Oh, J.K.; Tran, B.T.; Kim, J. Dietary inflammatory
index and the risk of gastric cancer in a Korean population. Oncotarget 2017, 8, 85452–85462. [CrossRef]
[PubMed]
14. Peleteiro, B.; Lopes, C.; Figueiredo, C.; Lunet, N. Salt intake and gastric cancer risk according to
Helicobacter pylori infection, smoking, tumour site and histological type. Br. J. Cancer 2011, 104, 198–207.
[CrossRef] [PubMed]
15. Rota, M.; Pelucchi, C.; Bertuccio, P.; Matsuo, K.; Zhang, Z.F.; Ito, H.; Hu, J.; Johnson, K.C.; Palli, D.;
Ferraroni, M.; et al. Alcohol consumption and gastric cancer risk-A pooled analysis within the StoP project
consortium. Int. J. Cancer 2017, 141, 1950–1962. [CrossRef] [PubMed]
238
Int. J. Mol. Sci. 2018, 19, 2424
16. Binh, T.T.; Tuan, V.P.; Dung, H.D.Q.; Tung, P.H.; Tri, T.D.; Thuan, N.P.M.; Khien, V.V.; Hoan, P.Q.; Suzuki, R.;
Uchida, T.; et al. Advanced non-cardia gastric cancer and Helicobacter pylori infection in Vietnam. Gut Pathog.
2017, 9, 46. [CrossRef] [PubMed]
17. Ellison-Loschmann, L.; Sporle, A.; Corbin, M.; Cheng, S.; Harawira, P.; Gray, M.; Whaanga, T.; Guillford, P.;
Koea, J.; Pearce, N. Risk of stomach cancer in Aotearoa/New Zealand: A Māori population based case-control
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Abstract: The role of E-cadherin in Hereditary Diffuse Gastric Cancer (HDGC) is unequivocal.
Germline alterations in its encoding gene (CDH1) are causative of HDGC and occur in about 40% of
patients. Importantly, while in most cases CDH1 alterations result in the complete loss of E-cadherin
associated with a well-established clinical impact, in about 20% of cases the mutations are of the
missense type. The latter are of particular concern in terms of genetic counselling and clinical
management, as the effect of the sequence variants in E-cadherin function is not predictable. If a
deleterious variant is identified, prophylactic surgery could be recommended. Therefore, over
the last few years, intensive research has focused on evaluating the functional consequences of
CDH1 missense variants and in assessing E-cadherin pathogenicity. In that context, our group
has contributed to better characterize CDH1 germline missense variants and is now considered
a worldwide reference centre. In this review, we highlight the state of the art methodologies to
categorize CDH1 variants, as neutral or deleterious. This information is subsequently integrated with
clinical data for genetic counseling and management of CDH1 variant carriers.
Keywords: Hereditary Diffuse Gastric Cancer; E-cadherin; CDH1 missense variants; functional
characterization; diagnostic tools
1. Introduction
In this review article, a special focus is given to a particular type of gastric cancer, the Hereditary
Diffuse Gastric Cancer (HDGC). Herein, important aspects of HDGC are discussed, including the
molecular mechanisms involved, how E-cadherin deregulation affects the development of the disease,
and more importantly the translation of this knowledge into clinical practice.
An overview is given of the role of E-cadherin in normal epithelia and cancer, how distinct
missense mutations in the E-cadherin encoding gene, CDH1, differently disturb E-cadherin expression
and function, what are the recommendations and guidelines for the classification and management
of CDH1 mutation carriers, and what strategies are available, or being developed, to predict CDH1
variants pathogenicity. The latter includes in silico tools, in vitro assays for the analysis of E-cadherin
expression profiles, intracellular organization, cell-cell adhesion status and invasive and migratory
properties, and finally an in vivo approach taking advantage of the fly Drosophila melanogaster.
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We describe the technological developments and state of the art methodologies that have emerged,
and how bench results are used to help clinicians and genetic counselors in the management of HDGC
patients and families. In order to collect the available literature, related to germline E-cadherin missense
mutations in the HDGC context, the PubMed database was accessed and publications searched from
November 1982 to September 2017. Search terms included: CDH1, E-cadherin, E-cadherin in cancer,
gastric cancer, familial and Hereditary Diffuse Gastric Cancer, E-cadherin dysfunction, E-cadherin
germline mutation, CDH1/E-cadherin missense mutation, and in vitro and in vivo functional assays.
Overall, this review brings together issues that are of interest to researchers, clinicians, and genetic
counseling experts.
2. The Role of E-Cadherin in Normal Epithelia and Cancer
Cell-cell adhesion is critical for the maintenance of tissue morphogenesis and homeostasis,
but is also crucial for a plethora of other cellular processes, including cell differentiation, survival,
and migration through the control of gene expression and the activation of signaling pathways [1].
Particularly relevant in cell-cell adhesion are the classical cadherins, such as E-cadherin, that play
a key role in calcium-dependent cell-cell interactions, in establishing tight adherent junctions, and
in defining cell differentiation specificity [2]. In fact, the cytoplasmic tail of E-cadherin forms a
protein complex with β-, p120- and α-catenins that links this adhesion molecule with the actin-myosin
network, coordinating the shape, polarity, and function of the cells in an epithelium [3,4]. Given the
broad-ranging functions of E-cadherin on tissue organization, it is not surprising that alterations in its
expression or structural modifications in its encoding gene CDH1 are common events during cancer
progression and contribute to the aberrant morphogenetic effects in cancer [3,5,6]. Indeed, most human
carcinomas partially or completely lose E-cadherin as they progress towards malignancy, supporting
the role of E-cadherin and downstream targets in cancer development [3,7].
3. E-Cadherin Deregulation Mechanisms
Mutations in the CDH1 gene are a well-known mechanism of E-cadherin deregulation, as
thoroughly described in Section 4. In addition, downregulation of E-cadherin expression can occur
via other mechanisms including overexpression of transcription repressors, alterations of microRNAs
(miRNAs), deregulation of protein trafficking, and aberrant post-translational regulation of the
protein [7–9]. The transcriptional activity of E-cadherin can be negatively regulated by a multitude of
transcriptional repressors like SNAIL, with expression levels increased in ductal breast carcinomas [10],
but also Slug, zinc finger E-box-binding homeobox 1 (ZEB1), and ZEB2 [11,12]. Inhibition of members
of miR-200 family of miRNAs, which directly target the transcriptional repressors of E-cadherin (ZEB1
and ZEB2), was shown to induce the reduction of E-cadherin mRNA levels, and miR-9 and miR-101
have also been implicated in the complex network of E-cadherin regulation [13]. Further, deregulation
of exocytic and endocytic pathways is known to control the delivery and internalization of E-cadherin,
with consequences for protein turnover, recycling, sequestration, and degradation [14]. In particular,
the disruption of the binding of type Iγ phosphatidylinositol phosphate kinase (PIPKIγ) to E-cadherin
modulates the intracellular trafficking, inducing aberrant E-cadherin transport and blocking the
gathering of the adherent junctions [15]. Another key molecule in the endocytic pathway is the
ADP-ribosylation factor 6 (ARF6) [16,17], whose activation through epithelial growth factor receptor
(EGFR) signaling induces E-cadherin internalization into early endosomes [18]. In fact, abnormal
activation of proto-oncogenes such as EGFR, c-Met, and Src also results in increased phosphorylation
of tyrosine residues in the E-cadherin-catenin complex [7], which leads to internalization and
ubiquitination of the protein through the recruitment of E3-ubiquitin ligase Hakai [19]. More recently,
post-translational glycosylation of E-cadherin has also been suggested as a mechanism of deregulation
in many pathophysiological steps of tumour development and progression [20]. More specifically,
E-cadherin extracellular domain has four potential N-glycosylation sites essential for its correct folding
and transport to the cell membrane [20]. The abrogation of one of those specific residues (Asn633) was
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demonstrated to target E-cadherin for endoplasmic reticulum-associated degradation (ERAD) [21].
At the cytoplasmic region, E-cadherin undergoes O-glycosylation (O-GlcNAc) that blocks the transport
of newly synthesised molecules to the cell surface and prevents the process of intercellular adhesion
via p120-catenin [22].
4. The Hereditary Diffuse Gastric Cancer and Its Genetic Signature
The deregulation of E-cadherin is particularly well established in gastric cancer. More specifically,
in the diffuse type of gastric cancer, E-cadherin somatic mutations were described in up to 40–70%
of the cases. Moreover, germline loss-of-function mutations are the only proven cause of the cancer
syndrome HDGC, occurring in approximately 40% of cases [23–25]. In fact, the first evidence of an
inherited form of diffuse gastric cancer (DGC) associated with E-cadherin was observed in 1994, when
Becker and colleagues identified somatic E-cadherin mutations in specimens of sporadic DGC [26].
Later on, Guilford P. et al. presented a large kindred from New Zealand with multiple cases of early
onset DGC (EODGC) that were carriers of a causative germline mutation in the E-cadherin gene [23].
In the following years, several other publications emerged, confirming the autosomal-dominant pattern
of inheritance associated with germline mutations of the CDH1 gene [24,25,27–31]. Inactivation of
the remaining functional allele, by a second hit molecular mechanism, leads to biallelic inactivation
of the E-cadherin gene and is the trigger event for the development of diffuse type gastric cancer in
germline mutation carriers [8,32,33]. Interestingly, hypermethylation was demonstrated to be the most
frequent cause of a second-hit CDH1 inactivation in HDGC tumours, whereas a second mutation or
deletion is apparently less frequent [8,32]. In the sporadic forms of DGC, a hot spot region between
exons 7 and 9 is observed for CDH1 germline mutations, while in the hereditary forms of DGC, the
CDH1 genetic alterations are scattered over the entire gene length [34]. To date, 155 different mutations
were identified in members of these families, and no correlation has been reported between the clinical
phenotype and the location/type of the mutation presented [25,35]. Furthermore, in about 80% of the
cases, CDH1 germline mutations are of the truncating type, resulting in the complete loss of E-cadherin
expression due to the occurrence of premature stop codons [36,37]. However, in about 20% of the
HDGC patients, mutations are of the missense type, resulting in full-length E-cadherin molecules
with a single amino acid substitution [27,35,36,38]. In the latter, the impact on protein function is not
predictable and, for that reason, CDH1 germline missense mutations represent a serious problem in
terms of genetic counselling and clinical surveillance [27,35,36,38].
5. Management of CDH1 Germline Missense Mutation Carriers
The clinical and functional relevance of CDH1 missense mutations is still controversial, in part
because normal protein length and an apparent regular level of expression are observed. Therefore,
upon identification of a CDH1 missense variant, it is mandatory that additional studies are performed
to assess how this alteration could perturb the expression and function of E-cadherin, as well as related
signaling and cellular mechanisms [25,35,39]. Altogether, those features will determine E-cadherin
putative pathogenicity. In clinical terms, this information is extremely valuable, as once a germline
missense mutation is detected and classified as deleterious, CDH1 mutant carriers enter a surveillance
programme similar to that offered to carriers of truncating mutations, possibly involving prophylactic
surgery [25,35,39]. Thus, in the last decade, and due to the lack of comprehensive tools, Seruca’s group
established a multidisciplinary approach to evaluate the pathogenicity of germline CDH1 missense
variants and classify them as neutral or deleterious (pathogenic variants) (Figure 1) [27,38,40–42].
The pipeline is extensive and relies on familial data, in silico studies, expression analysis, and functional
characterization of CDH1 missense mutants in vitro and in vivo [27,40–42]. Based on the results of
these analyses, and upon clinical recommendations, a subset of patients with deleterious germline
missense mutations performed prophylactic gastrectomy and the histopathological examination of
the stomach revealed the presence of cancer foci in all the specimens, supporting the reliability and
the accuracy of this evaluation [33,43]. Regrettably, for about 17% of missense mutations, the current
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pipeline is not sufficient to ensure a confident result, and the functional relevance of the missense
variants remains undetermined. Therefore, carriers of unclassified missense variants should be closely
monitored and managed by clinicians, and an intensive endoscopic surveillance programme should
be carried out.
Figure 1. Timeline with the key findings and technological developments important to evaluate the
pathogenicity of CDH1 germline missense variants, in the context of Hereditary Diffuse Gastric Cancer
(HDGC) [27,33,40–42,44–50].
6. Clinical and Familial Data Collection for Classification of CDH1 Germline Missense
Mutation Carriers
In the last meeting of the International Gastric Cancer Linkage Consortium (IGCLC), the
clinical criteria and guidelines for HDGC family screening and surveillance were re-established [25].
In particular, the Consortium proposed that the analysis of genetic and familial data should be the first
approach in the evaluation of a CDH1 missense variant. Moreover, special attention should be given to
the presence of gastric and lobular breast cancer (LBC) within the family, as well as the occurrence of
cleft/lip congenital malformations [25]. The genealogy allows the analysis of co-segregation of the
mutation with the disease within pedigrees and, thus, the identification of inheritance patterns in the
family. Fitzgerald and Caldas [44] proposed that, in the case of CDH1 germline missense variants, at
least 4 affected family members need to be screened and present the same alteration. Unfortunately,
for most of the families, it is not possible to perform these studies, since geneticists are frequently
confronted with families of small size and/or with a low number of affected members within a family,
which prevents segregation analysis [42,44]. It is interesting that, and still not yet well understood why,
HDGC families with germline CDH1 missense mutations often display a low disease penetrance [35,42].
Besides the segregation analyses, it is mandatory to evaluate other genetic parameters, such as
mutation recurrence in unrelated HDGC families and mutation frequency in healthy controls [25,27,44].
Variant frequency in a control or a general population can be assessed by searching publicly available
population databases such as 1000 Genomes Project (http://browser.1000genomes.org), Exome Variant
Server (http://evs.gs.washington.edu/EVS), or dbSNP Database (http://www.ncbi.nlm.nih.gov/snp).
However, one should be aware that these databases can have limitations as low-quality data and may
lack details on the origin of the study or information regarding any possible associated phenotype [51].
7. In Silico Predictions of CDH1 Missense Mutation Pathogenicity
In silico tools are continuously being developed to improve the knowledge and interpretation
of DNA variants. Predictions can provide useful information regarding the effect of the variant
on the primary and alternative gene transcripts, as well as the potential impact of the variant
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on protein structure and function [41,42]. Most of the existing algorithms take into account the
degree of conservation of a particular nucleotide among species, the location and context within the
protein sequence, the biochemical properties of the amino acid substitution, the putative impact
of the variant in protein native-state, and the possible effect in splice sites [41,42]. The use of
multiple software programs for sequence variant interpretation is also recommended, as these
programs are based on distinct algorithms that result in different outputs [51]. To infer the impact of
CDH1 germline missense mutations using in silico analysis, SIFT and PolyPhen2 have become the
standard tools [30,41,42,52–56]. SIFT-Sorting Intolerant From Tolerant (http://sift.jcvi.org/) predicts
the impact of a particular amino acid replacement in protein function [57,58]. The method takes
into consideration the evolutionary conservation of amino acids within species. Highly conserved
residues are expected to be important for protein function, whereas those with a low degree of
conservation are likely to tolerate a number of substitutions without affecting the molecule and its
cellular function. SIFT workflow ends in a scaled probability, termed the SIFT score, that ranges
from 0 to 1 [57]. A substitution is classified as damaging if the score value is below 0.05 [41,42].
It is noteworthy that the software does not use protein structural information, lacking possible
compensatory effects of neighbouring positions [59]. In contrast, PolyPhen-2—Polymorphism
Phenotyping v2 (http://genetics.bwh.harvard.edu/pph2/) [60,61] employs a machine-learning
classification along with a multiple protein sequence alignment pipeline, which combines structural
and comparative evolutionary considerations to evaluate effects on protein stability and function [61].
Given that an amino acid replacement in a protein sequence can change many of its chemical and
physical properties, resulting in unfolding and decreased stability of polypeptides, structural modelling
has become a major tool. Indeed, FoldX (http://foldxsuite.crg.eu/) [62] has been extensively explored
to determine the structural impact of CDH1 missense mutations. Specifically, this theoretical tool
calculates how sequence variants, in comparison to the wild-type, affect the native-state stability of the
structures (ΔΔG = ΔGMut − ΔGWT), and if the stability change (ΔΔG) is higher than >0.8 kcal/mol,
the missense variant is considered destabilizing [62]. Such mutations are associated with high turnover
of the protein in the cell, protein premature degradation and, consequently, loss of E-cadherin
function [41]. This model covers most of E-cadherin, including the prodomain, the extracellular
domain, and the β-catenin binding domain [41]. However, the juxtamembrane region remains to be
structurally characterized.
An additional tool is the Netgene2 algorithm (http://www.cbs.dtu.dk/services/NetGene2/) that
investigates the potential of CDH1 variants to cause alternative splicing and processing of introns in
nuclear pre-mRNA [63,64]. Nevertheless, the identification of cryptic splice sites in CDH1 mutated
gene is limited due to the lack of transcript data available. Overall, in silico predictions can be very
useful for gathering information, but should be used with caution, as a complementary tool, and not
as the sole source of evidence to classify a missense variant [41,42].
8. Characterization of CDH1 Missense Mutations In Vitro
8.1. CDH1 Germline Missense Mutation Categorization According to Protein Expression
As previously mentioned, CDH1 germline variants can result in a normal length protein with
localization of the molecule at the membrane. However, missense mutations frequently lead to
abnormal E-cadherin levels and expression patterns through mechanisms of trafficking deregulation
and premature degradation of the molecule that are most often difficult to detect and interpret [17,49].
Therefore, our group developed a strategy to quantify and map E-cadherin expression for all CDH1
germline variants by combining Western-blotting, immunocytochemistry, and bioimaging techniques
(Figure 2). Briefly, our approach involves the use of an immortalized cell line in which CDH1 variants
are induced. Chinese Hamster Ovary (CHO) cells, which are negative for E-cadherin expression,
are transfected with vectors encoding the wild-type E-cadherin or the diverse variants identified at
the germline level [27,40–42,49,50,52–56,65–67]. Upon transfection, protein expression is assessed
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by Western blot (Figure 2A). Low E-cadherin levels strongly indicate structural destabilization and
degradation of the protein by mechanisms of Protein Quality Control (PQC) [41,49]. Occasionally,
a band mobility shift can also be detected, indicating that the mutation could affect glycosylation
sites [9,68].
 
Figure 2. Representative E-cadherin expression profiles in cells with CDH1 missense variants found
in the context of HDGC. (A) Chinese Hamster Ovary (CHO) cells transfected with different CDH1
missense variants were analysed for total E-cadherin expression levels by Western blot. Demonstrative
images of normal expression level (AI), low expression (AII) and abnormal glycosylation (AIII) of the
protein are shown. Small dots in (AIII) represent band mobility shift of total E-cadherin. Tubulin was
used as a loading control. (B) Immunofluorescence (IF) images (400×) of E-cadherin with a membrane
phenotype (BI), diffuse subcellular localization (BII), and cytoplasmic accumulation (BIII). E-cadherin
is labelled in green and nuclei are counterstained with DAPI (blue). (C) Average intensity of E-cadherin
internuclear profiles (IN) and the corresponding virtual illustration, obtained through IF images of cells
expressing CDH1 with distinct missense mutations. Examples for each type of protein accumulation are
illustrated. Protein at the membrane, diffused throughout the cytoplasm and perinuclear accumulation
of the protein are represented in (CI), (CII), and (CIII), respectively. (a.u.), arbitrary units. The data
are in accordance to previously described methods [40,48,49] and emphasize the diversity of CDH1
missense variants phenotypes.
Subsequently, immunostaining with monoclonal antibodies is used for E-cadherin analysis at
the cellular and intercellular level (Figure 2B). The qualitative evaluation of E-cadherin expression
and localization is performed by the classical approach, which involves visual inspection under a
fluorescence microscope. Still, this process is strongly operator-dependent and based on subjective
criteria. To overcome this limitation, we developed an objective and quantitative methodology that
extracts detailed information on E-cadherin distribution intracellularly and at boundaries of contiguous
cells (adherens junctions) [48,69]. This tool generates an inter- and intra-cellular expression profile
for the wild-type and mutated forms of E-cadherin, and deviations from the reference are used to
classify the level of E-cadherin dysfunction (Figure 2C) [48]. Typically, deleterious variants show
aberrant peaks of E-cadherin cytoplasmic accumulation, or low and diffuse expression throughout
the cell, as a result of trafficking anomalies [17,48,49,69]. For each E-cadherin variant, features such as
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mean fluorescence intensity at the membrane, position of the maximum fluorescence intensity, and
Maximum Mean Ratio (MMR) are computed and subject to analysis. The mean fluorescence intensity,
measured at the middle axis between two juxtaposed cells, reflects the number of molecules present
at the membrane and is significantly lower in dysfunctional mutants than in wild-type cells [48].
To quantify the variation of the fluorescence signals along the inter-nuclear space, the MMR parameter
is used. High MMR values are associated with a strong and well-defined pattern of expression at the
membrane, while a low MMR level indicates diffuse protein expression at the membrane and aberrant
expression patterns throughout the cell. Accordingly, deleterious variants show a lower MMR when
compared to the wild-type form [48].
In conclusion, quantification and characterization of E-cadherin expression patterns is crucial to
detect deregulated post-translational mechanisms induced by CDH1 pathogenic mutations.
8.2. CDH1 Germline Missense Mutation Classification According to Its Impact on Intercellular Organization
and Cell-Cell Adhesion Status
Cell adhesion is an essential mechanism in the formation and maintenance of cell architecture in
the epithelium [1]. Importantly, functional impairment of E-cadherin and eventual loss of the molecule
is typically associated with decreased cell-cell interaction and tissue remodelling [3,5,6]. Recently,
to characterize defects in the epithelial structure and morphology that can arise from E-cadherin
mutants, we developed a platform that identifies and quantifies cellular distribution patterns using
in situ microscopy images [46]. More specifically, we used DAPI-stained nuclei to create artificial
cellular networks, from which we could extract quantitative data regarding cell distribution and
organization (Figure 3A). The software creates digital meshes composed of triangles centred in triplets
of neighbouring nuclei, and explores their topological features, such as area, edges length, and
angles [46]. Pathogenic mutations with impact in cellular organization, present triangles with higher
areas and edges when compared with the wild-type cell counterparts. At the individual cell level,
the assessment of E-cadherin binding with its different cytoplasmic protein partners is important
as part of the missense mutation studies [40]. Notably, the cytoplasmic domain of E-cadherin has
a crucial role in its function, because it supports the assembly of a complex of cytosolic proteins,
including α-, β-, p120-, and γ-catenins, which provides anchorage to the actin cytoskeleton to form
stable cell-cell contact [2,3]. Nonetheless, this domain also has an essential role in protein trafficking
and regulation at the membrane [14,70]. The association of β-catenin and PIPKIγ to E-cadherin
cytoplasmic portion is necessary for newly synthesized E-cadherin molecules to be delivered to the
basolateral membrane [15,71]. For maintenance and stability of the molecules at the membrane,
p120-ctn binds to the juxtamembrane domain of E-cadherin and simultaneously blocks the interaction
with the endocytic machinery, such as with clathrin adaptor proteins and Hakai [19,72,73]. Importantly,
Hakai binds directly to E-cadherin and, being an E3 ubiquitin-ligase, it ubiquitinates and induces
E-cadherin endocytosis [19]. To verify the interaction of E-cadherin with its various interactors, we
use an indirect approach, the in situ Proximity ligation assay (PLA) [40]. This assay, which is a
PCR-based system, relies on the affinity between two proteins requiring their proximal binding to get
an amplification signal that can be detected at the cellular level [74,75]. Therefore, we have used in situ
PLA to determine which CDH1 missense variants, located at the cytoplasmic domain of the protein,
affect the correct interplay with the corresponding binding partners [40]. Using this strategy, we have
identified E-cadherin mutations that impair the association of E-cadherin/β-catenin, some located
outside of the E-cadherin β-catenin binding domain [40]. Further, we have also demonstrated that
E-cadherin mutations affecting the p120-binding domain are more available to be targeted by Hakai
and to be degraded, and in this way to behave functionally as a truncated mutation [40]. Interestingly,
the PLA results point out that each mutation behaviour is unique, as it interacts differently with its
binding partners, produces its own phenotype, and possibly plays different roles in signal transduction.
For these reasons, we believe that each E-cadherin missense mutation is likely to induce cell-specific
biological behaviour.
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Figure 3. Intercellular organization and cell adhesive properties induced by CDH1 germline missense
variants. (A) Patterns of cellular distribution elicited by E-cadherin variants. In the upper panel,
cell nuclei are overlapped with the corresponding network. In the lower panel, the final networks
are presented. (AI) Illustrates a more regular and cohesive cellular topology, while (AII) depicts
an intermediate cellular organization, and (AIII) represents a scatter and disorganized phenotype.
(B) Adhesiveness of cells expressing E-cadherin variants evaluated by slow-aggregation assays and
corresponding outlines of cellular aggregates. Variants preserving a functional adhesion complex
display compact cellular aggregates (BI), while dysfunctional E-cadherin forms present small cellular
aggregates (BII) or an isolated phenotype (BIII). The images illustrate different adhesiveness effects on
E-cadherin missense variants cells as firstly described in [40,46].
Furthermore, due to the pivotal role of E-cadherin in cell-cell adhesion, understanding how
E-cadherin impacts this cellular effect is of major relevance. Indeed, we have established a functional
in vitro cell model to determine the impact of CDH1 variants on cell compaction, a direct indicator of
cell-cell adhesion competence [27,42,65]. In this assay, a single-cell suspension is seeded on soft-agar,
and cells with a competent adhesion complex spontaneously aggregate (Figure 3B). Accordingly,
cells transfected with the wild-type protein form compact cellular aggregates, while cells expressing
dysfunctional E-cadherin form small cellular aggregates with different degrees of cohesion, or a
completely isolated phenotype. The areas and density of the aggregates are subsequently quantified
for a complete evaluation of cellular adhesiveness. Overall, using these different approaches,
we established a system for a thorough characterization of CDH1 variants with respect to their effect
on cellular topology, stability of the cadherin-catenin complex, and strength of cell-cell interactions.
8.3. Invasive and Migratory Properties of Cells with CDH1 Germline Missense Mutations
Gastric cancer of the diffuse type is a highly invasive and lethal cancer, as cells that lose E-cadherin
can evade apoptosis stimuli and acquire increased cell invasive potential, determining the fast and
silent progression of the disease [34,36,76]. Therefore, assessing the ability of directed migration and
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spread throughout the extracellular matrix is of major importance in the study of E-cadherin missense
variants [45,50,77–79].
A series of methodologies is used to evaluate the invasive and migratory properties of cells
with CDH1 germline missense mutations. Most frequently, the motile/migratory behaviour of the
cells, transfected with the wild-type protein or the missense variants, is evaluated using wound
reepithelialisation systems (Figure 4A). The method requires unilateral adhesion and transient
attachment to a substrate, usually fibronectin, and provides information regarding migration velocity,
persistence, and directionality during wound healing [80,81]. By exploiting this approach, we have
identified a subset of germline E-cadherin missense variants that are associated with particular
cellular phenotypes and biological behaviours [50]. Indeed, missense mutations clustering in the
extracellular region of E-cadherin lead to cytoskeleton rearrangements and fibroblastic morphology,
which provide cells with increased motility [50]. Cells expressing those variants migrate in an isolated
and random way, and faster than the wild-type cells or the cells with variants affecting the intracellular
portion of E-cadherin [50]. Further, we verified that E-cadherin-dependent migration is mediated
by reduced E-cadherin/EGFR interaction and, consequently, by aberrant activation of EGFR and
RhoA-GTP [45,79]. In contrast, intracellular mutants, such as V832M, display piled-up structures of
round cells and migrate collectively and in a directed manner across the wound due to a reduced
affinity between β-catenin and α-catenin [50]. Alternatively, the effects of the CDH1 deleterious
variants in cell motility can also be analysed independently of a wound stimulus by time-lapse
scanning microscopy. This assay, although corroborating the wound healing data, is only used as a
complementary tool [79]. To evaluate the invasive ability of E-cadherin mutant cells, matrigel invasion
chambers are the in vitro preferred system [27,40–42,49,53–56,65,66]. The matrigel matrix contains
structural proteins such as collagen, fibronectin, laminin, and proteoglycans, but also a panel of growth
factors, which reconstitute the basement membrane composition and provide proper conditions for
cell interaction with the surrounding microenvironment [82,83]. Upon seeding, invasive cells are able
to degrade the matrix and reach the lower side of the filter through the pores (Figure 4B,C). The total
number of invasive cells is then counted using a fluorescent microscope. In contrast, non-invasive
cells do not migrate through the membrane and remain in an epithelium-like structure on top of





Int. J. Mol. Sci. 2017, 18, 2687
 
Figure 4. Effect of CDH1 germline missense variants on the invasive and migratory properties of
cells. (A) Migratory behaviour of Chinese Hamster Ovary (CHO) cells transfected with CDH1 variants.
Panel (AI) illustrates cells with decreased motility, (AII) exhibits a compact front of migration with
unidirectional movement of cells, and (AIII) shows random colonization of the wound. Pictures were
captured in phase contrast microscopy (200×), 8 h after wound incision. (B) Illustrative scheme
of the non-invasive, invasive, and highly invasive phenotypes. (C) Invasive behaviour of cells
expressing CDH1 variants in matrigel-coated insert wells. The invasive cells on the lower part of
the insert membranes were stained with DAPI. (CI) Represents cells with a non-invasive phenotype,
(CII) represents cells with an invasive phenotype, and (CIII) shows cells with a high invasion rate.
(D) Structural organization (upper panel) and protrusion formation (lower panel) of cellular spheroids
embedded in collagen were monitored by time-lapse (400×). The area, as well as protrusion trajectories
over time, are marked by colored traces. Cells forming compact aggregates and short protrusions are
displayed in (DI). (DII) Shows a small multicellular structure with lower number of cells but more
extended protrusions. In (DIII), cells form a more extensive and disorganized structure with large
protrusions, indicating a highly invasive phenotype. The data in panels (A–C) are in accordance with
previously described methods [27,50,79]. Novel strategies and phenotypes to better evaluate CDH1
mutation variants are illustrated in panel (D).
As the process through which invasive cells leave the epithelium and cross the basement
membrane involves proteolytic degradation by the matrix metalloproteinase (MMPs) [84], additional
assays can be performed to evaluate whether cells harbouring deleterious variants of E-cadherin lead
to increased protease secretion. Although informative, this assay is not routinely used. Very recently,
and taking advantage of the morphological changes that cells undergo to escape the epithelium
and invade adjacent tissues, we have established an innovative approach using 3D culture systems.
In order to analyse structural organization, protrusion formation, and dissemination of cells with
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E-cadherin variants, spheroids of wild-type and mutant cells are embedded in collagen and monitored
by time-lapse. The aggregate area, the number of cells that disseminate, as well as the number and
extension of protrusive structures can be easily evaluated (Figure 4D). In line with this, our next step
is to track different cytoskeletal markers in these cells, and to develop new algorithms and software
applications to analyse their patterns and dynamics. We envision that our combined strategy will be
able to identify deleterious E-cadherin variants more efficiently and provide novel insights into the
clinical surveillance of CDH1 mutation carriers.
9. Assessment of CDH1 Germline Missense Mutation Aggressiveness through an In Vivo Strategy
In addition to in vitro studies, the use of animal models is of major relevance to better understand
the molecular mechanisms of cancer development. While mice models are frequently used in in vivo
studies, there are many limitations associated with this model in the context of gastric cancer [85–87].
Therefore, the use of alternative organisms has been suggested to study specific features of cancer
development. In particular, Drosophila melanogaster has received much attention as it is an inexpensive,
genetically tractable organism that can recapitulate key events of human carcinogenesis, allowing
investigation of cell morphology, invasion, and metastatic growth. Moreover, there is a high degree of
conservation in terms of the basic mechanisms and signaling pathways in flies and man. Junctional
complexes and overall epithelial organization are similar enough, in vertebrates and invertebrates,
to assume that most cellular and molecular mechanisms involved in epithelial maintenance and
reorganization are conserved [88]. Taking into account these similarities, the Drosophila’s potential
has been explored to unravel the cascade of events that follow E-cadherin loss of function due to
missense mutations and to understand how they contribute to cancer progression in the tissue, in
an in vivo context. Suriano G. and colleagues [47] generated transgenic fly lines carrying cDNAs
of wild-type human E-cadherin (hEcad) and two missense mutant forms obtained from HDGC
patients: hEcad-A634V, which affects the extracellular protein domain, and hEcad-V832M, affecting
the intracellular portion. Using a GAL4/UAS system, the different hE-cadherin forms were expressed
in the Drosophila-developing wing epithelium (the so-called wing imaginal disc) that forms a simple
monolayer epithelium and allows the inspection of an altered pattern of E-cadherin sub-cellular
localization [47]. Interestingly, it was observed that cells expressing the wild-type protein remain
confined to normal epithelial fold as a result of proper cell-cell interaction [47]. In contrast, the mutant
cells expressing A634V and V832M forms were found to infiltrate neighbouring regions of wing
epithelium [47]. Remarkably, the mutants exhibited unlike behaviours regarding its invasive pattern,
possibly due to distinctive abilities to support cell-cell adhesion. The A634V mutant still retains
homophilic adhesion, invading as a group of cells, whereas the hE-cadherin V832M has a stronger
effect on the adhesive capabilities and invades as smaller groups of cells or even individually [47].
Furthermore, it was shown that the fly β-catenin homolog, Armadillo (Arm), could mediate the distinct
migratory and invasive behaviours of the different E-cadherin forms. In accordance, overexpression of
hE-cadherin V832M in Drosophila imaginal disc exposed a weaker interaction with Arm at the plasma
membrane and, thus, the availability of Arm for the canonical Wtn-Notch signaling activation [47].
Those results recapitulated the in vitro findings for both mutations [50], validating the applicability
of the in vivo assays in the characterization of HDGC-associated germline missense mutations.
More recently, we are using the Drosophila ovary as a model to evaluate novel HDGC-associated
CDH1 variants and their impact on epithelial organization and cell migration (data not shown).
More specifically, we are able to easily analyse the influence of CDH1 variants on the monolayered
follicular epithelium (Figure 5) and also the effects of specific human cadherin transgenes on the
collective migration of epithelial cysts formed by border cells. To date, all the mutants studied affected
E-cadherin expression at the membrane and frequently disrupted epithelial organization, mimicking
what is observed in biological samples from HDGC patients [35,36]. Additionally, to investigate
migration dynamics of cells carrying E-cadherin variants in vivo, the fly dorsal closure model is also
being tested. Particularly, using live imaging and fluorescently tagged transgenes, we are able to
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monitor closure rates, zippering velocity, and epithelial cohesion, as well as leading edge morphology
and orientation in opposing migratory epidermis towards the dorsal midline of the embryos [89,90].
In conclusion, the use of the Drosophila model could have a huge impact in the current pipeline for
the characterization of CDH1 variants, as well as for research purposes in the context of targeting
interactors and signaling pathways mediated by E-cadherin dysfunction.
 
Figure 5. Expression of human CDH1 mutants in the Drosophila follicular epithelium and their effects
on tissue organization. (I) The expression of CDH1 mutants promotes the disruption of epithelial
organization, inducing epithelial invagination; (II) Cell extrusion from the monolayer occurs through
loss of contact with the apical surface of the tissue. Staining is as follows: DAPI labels the nuclei, aPKC
in red delineates the apical side, whereas integrins are labelled in green. Mosaic expression of CDH1
(labelled in white) enables direct comparison between wild-type and genetically manipulated clones.
The original data in Drosophila heighten the potential of novel strategies to evaluate CDH1 missense
variants in the context of HDGC.
10. Conclusions
Alterations in CDH1/E-cadherin are the proven cause for HDGC and LBC [34,36,76]. In these
cancers, loss of E-cadherin function alters cell morphology and epithelial architecture, disrupts cell-cell
adhesion, and increases cancer invasion, contributing to the high mortality rate of gastric cancer [3,4].
In case a germline pathogenic mutation is identified, the carrier is counselled to perform the ablation
of the target organ, since the disease is silent and has a very poor prognosis. The clinical guidelines for
truncating mutations are well established, but CDH1 missense sequence variants still pose a clinical
burden for geneticists and clinicians [27,35,36]. Therefore, and in the absence of appropriate clinical
and familial data, the characterization of these CDH1 variants and their classification, as neutral or
deleterious, is mandatory.
As a reference centre of the IGCLC, our group has established a series of functional assays and
developed novel approaches to assess the pathogenic role of all CDH1 germline sequence variants
detected worldwide (from New Zealand, Europe, and Asia to North and South America) and show their
added value in genetic counselling [27,40,42,46,48]. In close collaboration with experimental biologists,
bioinformaticians, and bioengineers, we show herein how these methods contribute to ameliorating
the classification of E-cadherin germline mutations. Based on our multidisciplinary approach, curative
prophylactic gastrectomy has already been performed in carriers of germline missense mutations and
histopathological examination of the gastrectomies revealed the presence of invasive cancer in all the
specimens, supporting the reliability of this working model [33,43]. We envisage that, in the near
future, the development of novel and user-friendly tools will further improve the identification and
management of deleterious variant carriers reported in genetic screening.
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Abstract: Alterations in the immune response of patients with autoimmune diseases may predispose
to malignancies, and a link between chronic autoimmune gastritis and gastric cancer has been
reported in many studies. Intestinal metaplasia with dysplasia of the gastric corpus-fundus mucosa
and hyperplasia of chromaffin cells, which are typical features of late-stage autoimmune gastritis,
are considered precursor lesions. Autoimmune gastritis has been associated with the development
of two types of gastric neoplasms: intestinal type and type I gastric carcinoid. Here, we review the
association of autoimmune gastritis with gastric cancer and other autoimmune features present in
gastric neoplasms.
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1. Introduction
Immune dysregulation is believed to play a pathogenic role in the development of both
autoimmunity and neoplasia, and autoimmune conditions have been described in patients with
neoplastic diseases. Antinuclear antibodies, the hallmark of many autoimmune rheumatic diseases,
have been reported in the sera of patients with malignant tumors [1–3]; anti-La antibodies which are
characteristically detected in sera of patients with Sjögren’s syndrome, and anti-CENP-B antibodies,
a marker of systemic sclerosis, were detected in patients with breast cancer [4,5]. Similarly, anti-dsDNA
antibodies which are of both diagnostic and prognostic value in systemic lupus erythematosus
(SLE), were also reported to be present in the sera of patients with various types of cancer [6,7];
the presence of rheumatoid factor was found to correlate with poor prognosis in different types of
neoplastic diseases including gastrointestinal cancer [8]. Also, organ-specific antibodies were reported
in malignancies; among these are anti-smooth muscle antibodies, anti-parietal cell antibodies and
anti-thyroid antibodies [9,10].
Conversely, an increased incidence of malignancies has been observed among patients with
autoimmune diseases [11]. According to the Bradford Hill postulates [12] that evaluate the degree in
which an autoimmune disease is conditioning a higher probability to develop a malignant neoplasm,
a link has been found for rheumatoid arthritis, SLE, Sjögren’s syndrome and celiac disease in association
with lymphoproliferative diseases [13,14]; idiopathic inflammatory myositis with solid tumors [15];
and systemic sclerosis in association with breast and gastrointestinal cancer [16]. In addition, recent
research has shown that neoplastic transformation of autoimmune gastritis is as high as 10% and that
autoimmune gastritis should be considered a pre-neoplastic disorder with an annual incidence of
gastric cancer of 0.3% [17].
Here, we review the association of autoimmune gastritis with gastric cancer and other
autoimmune features present in gastric neoplasms.
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1.1. Autoimmune Gastritis
Autoimmune gastritis (AIG) is an organ-specific disease characterized by a chronic inflammation
of the mucosa of the stomach that evolves in atrophic gastritis causing malabsorption of essential
elements and eventually microcytic iron-deficient anemia [18] or pernicious anemia due to vitamin B12
deficiency [19]. As the lesion progresses, the parietal and principal cells of the mucosa may be replaced
by cells containing mucus, similar to the intestinal ones. Two types of metaplasia are considered
to be associated with gastric carcinogenesis in humans: intestinal metaplasia, and spasmolytic
polypeptide-expressing metaplasia (SPEM). Goblet cells in intestinal metaplasia express appropriate
intestinal markers, including Muc2 and Trefoil factor 3 (TFF3), while the mucous metaplastic lineages in
SPEM display morphological characteristics more typical of deep antral gland cells or Brunner’s glands,
with expression of Muc6 and Trefoil factor 2 (TFF2). Importantly, recent investigations support the
origin of SPEM through transdifferentiation from mature principal cells following parietal cell loss [20].
Both intestinal metaplasia and SPEM have been associated with the progression to intestinal-type
gastric cancer [21].
Similar to other autoimmune conditions, AIG is more common in females than in males (3:1 ratio).
AIG is generally asymptomatic up to an advanced stage of atrophy and/or dysplasia of the mucosa [22].
For this reason, AIG is a frequently underdiagnosed disease, with an estimated prevalence of nearly
2% in the third decade to 12% in the eighth decade [17,23,24]. The prevalence is even higher in patients
affected by other autoimmune diseases, especially autoimmune thyroid diseases (AITD) and type 1
diabetes (T1DM) [25,26]. These associations define the multiple autoimmune diseases (MAS) type 3B
and 4 [27].
Chronic autoimmune gastritis (type A) is etiologically and histologically distinct from type B
gastritis associated with Helicobacter pylori (H. pylori) infection [28]. Different from H. pylori gastritis
which is mainly localized in the antrum, AIG is restricted to the gastric body and fundus because
inflammatory aggression affects the cells of the oxytocin glands [29]. However, there is a peculiar
form of AIG that may develop in genetically predisposed subjects during H. pylori infection [30].
The finding of anti-parietal cell antibodies in 20–30% of patients with H. pylori infection and of
anti-H. pylori antibodies in patients with AIG, suggests that there is a link between H. pylori and gastric
autoimmunity [31–33].
H. pylori infection could induce AIG through mechanisms of molecular mimicry and/or epitope
spreading; a high homology has been demonstrated between the β subunit of Hp urease and the
subunit β of gastric ATPase [34]. The activation of gastric Th1 cells reactive to different peptides
of H. pylori wall that cross-react with gastric H+K+-ATPase, results in an inflammatory process in
which T-cell-derived IFN-γ enables parietal cells to act as APCs and to become targets of cross-reactive
epitope recognition resulting in killing or apoptotic suicide. Apoptotic parietal cells would thus allow
cross-priming of T cells that are specific to private gastric ATPase epitopes [35,36].
Although histological healing of the mucosa of the body has been reported in patients in whom
H. pylori had been eradicated [37,38], a direct correlation between H. pylori infection and AIG remains
controversial [39–41]. To this end, it has to be noted that while the bacterium is present in the initial
stages of gastritis, in the atrophic stage the bacterium is no longer recognizable because hypocloridry
and mucosal destruction result in environmental conditions unsuitable for H. pylori survival.
1.2. Cell-Mediated Autoimmunity
In AIG, cell-mediated autoimmunity plays a primary role sustained by CD4+CD25− Th1 resting
lymphocyte effectors [42]. Most of these self-reactive cells produce IFN-γ and TNF-α and possess
cytolytic capacities, with perforin and Fas/Fas ligand-mediated mechanisms, which they express
in well-defined gene restriction conditions dictated by the MHC system [43]. They induce gastric
parietal cell death by apoptosis and perforin/granzyme B pathway, in particular through IFN-γ, which
increases the expression of Fas and MHC class II molecules on gastric parietal cells.
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The evidence that in the guinea pigs a single injection of an IFN-γ neutralizing antibody prevents
the development of gastritis makes it clear that this cytokine is active in the genesis of the disease [44].
Moreover, the role of CD4+CD25− Th1 lymphocytes in the pathogenesis of AIG has been
demonstrated by their isolation in the paragastric lymph nodes in experimental murine models
and the development of atrophic gastritis with appearance of parietal cell antibodies in association
with a decrease in CD4+CD25+ T-cell tolerance [45].
The main target of immunological injury is the gastric H+/K+-adenosine-triphosphate enzyme
(ATPase), a protein of the membrane that coats the secretory canaliculi of the parietal cells and is
responsible for the secretion of hydrogen ions in exchange for potassium ions (proton pump) [46,47].
The gastric H+/K+-ATPase is formed by a catalytic 100 kDa α subunit and a 60–90 kDa β subunit;
CD4+ T cells react to H+/K+-ATPase α chain and marginally to the β chain. Induced by a triggering
factor not yet entirely identified, the CD4+CD25− T-cells, together with macrophages and B
lymphocytes, infiltrate the submucosa, the lamina propria and the gastric glands causing the loss
of parietal, principal and P/D1 ghrelin-producing cells [48,49], the principal and P/D1 cells being
destroyed as bystanders of the parietal cells.
1.3. Humoral Autoimmunity
Patients with AIG have been shown to have two types of antibodies, one to parietal cells (PCAs)
and the other to intrinsic factor (IFA) or its binding site in the small bowel.
PCAs are present at a high frequency in AIG (80–90%), especially in early stages of the
disease [50,51] and bind to both α and β subunits of gastric H+/K+-ATPase. Antibody reactivity
to the α catalytic subunit includes epitopes on the cytosolic side of the secretory membrane. Antibody
reactivity to the β subunit requires that the antigen is linked in a disulfide-bond and glycosylated,
thus, suggesting that autoepitopes are located in the luminal domain of the glycoprotein [47,52].
In the later stages of the disease, the incidence of PCA decreases due to the progression of
atrophy and the loss of gastric parietal cells and, thus, the decrease in antigenic rate [53,54]. It is
currently unknown if these autoantibodies play a pathogenic role in AIG but their finding in serum in
the subclinical stage, especially in patients with autoimmune endocrine disease, is predictive of the
presence of AIG [55].
Human intrinsic factor (IF) is a 60-kDa glycoprotein secreted by gastric parietal cells. Its action is
high affinity binding and transport of vitamin B12. The complex IF-vitamin B12 reaches terminal ileum
where it is absorbed after binding to specific receptors in the membranes of cells of ileal lumen [56].
IFAs are considered specific markers for AIG and are present both in blood serum and in the gastric
juice of 30–50% of AIG patients [57]. In serum, two specific types of IFA, both of the IgG class, have been
described: type 1 (blocking antibodies) that react with the binding site for vitamin B12 and are found
in 70% of IFA-positive patients, and type 2 (binding or precipitating antibody) that recognizes a site
away from B12 binding sites and impedes binding of IF-vitamin B12 to the receptors in the ileal mucosa.
Type 2 IFAs are found in about 30% of AIG patients, and are rarely present in the absence of type I
autoantibodies [58].
2. Autoimmune Gastritis and Gastric Cancer
The incidence of gastric neoplasms is higher in patients with AIG compared to the general
population [59,60]. Prospective studies have shown that 4–9% of patients with AIG, or its more severe
form pernicious anemia, have gastric carcinoid tumors, whose frequency is 13-times higher than that
of control subjects [44]. In addition, AIG progression to atrophic gastritis, associated with intestinal
metaplasia, may predispose to gastric adenocarcinoma in more than 10% of patients [44].
Two recent studies, one with over 4.5 million adult male veterans admitted to US Veterans Affairs
hospitals in the United States [61] and the other including nine million individuals from Sweden [62],
reported that individuals with AIG/pernicious anemia had a three-fold increased risk of developing
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not only stomach carcinoid and adenocarcinomas, but also small intestinal adenocarcinomas and
esophageal squamous cell carcinomas.
Nguyen and coworkers [63], using a transgenic mouse model of AIG, investigated the potential
link between AIG and gastric cancer using CD4+ T cells expressing a T-cell receptor specific for
a peptide from the gastric H+/K+ ATPase proton pump. By 2–4 months of age, all mice developed
chronic gastritis that resulted from large numbers of CD4+ T cells that infiltrated the gastric mucosa
and produced large amounts of IFNγ and smaller amounts of IL-17. At this stage of the disease,
mice also developed several molecular features similar to those that precede gastric cancer in humans,
including SPEM.
For these reasons, autoimmune gastritis should be considered a precancerous lesion, and the
European MAPS (Management of Precancerous Conditions and Lesions in the Stomach) guidelines [64]
recommend a three-yearly endoscopic and bioptic follow-up for all patients with extensive atrophy
(stage III and IV of the OLGA classification [65]) (Table 1 and Figure 1).
Table 1. Clinical presentation, serology, pathology and neoplastic risk of autoimmune gastritis.
Clinical
Presentation
No symptoms or dyspepsia
Anemia (iron deficiency, vitamin B12 deficiency)
Coexisting autoimmune diseases:
Autoimmune thyroid diseases (Hashimoto and Graves)
Type 1 diabetes
Addison disease
Polyglandular autoimmune syndromes type III
Serology
Gastrin 17 >10 pmol/L
Pepsinogen I <30 μg/L
Pepsinogen II normal (3–15 μg/L)
Parietal cell autoantibodies pos 90–95%
Intrinsic factor autoantibodies pos 30–50%
Pathology Corpus/fundus restricted gastritis
Neoplastic Risk Gastric carcinoid: increased according to gastric (oxyntic) atrophy score to the corpus and fundus of the stomach
Gastric adenocarcinoma: increased according to pangastric atrophy score
Figure 1. OLGA (operative link for gastritis assessment) staging system for gastritis. Modified from
Rugge M. et al. [65].
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Gastric atrophy is a key step towards gastric neoplasms, as studies of resected stomachs from
patients with intestinal-type gastric cancer have shown gastric atrophy in every case [66]. Atrophy and
metaplasia (including SPEM), occur in a setting of inflammation and a complex milieu of cytokines [67].
Studies in humans and mouse models of gastritis and gastric cancer identified important roles for
cytokines in regulating oxyntic atrophy, hyperplasia, metaplasia, and progression to gastric cancer.
Several reports showed that IL-17A promotes tumorigenesis. In particular: (a) level of IL-17 mRNA
in gastric tumors was associated with the depth of tumor, lymph-vascular invasion and lymph node
involvement [68]; (b) gastric cancer patients have higher levels of IL-17 in serum and in cancer tissues
than the general population [69]; (c) genetic data show that IL-17A and IL-17F polymorphisms increase
gastric cancer risk [70]; (d) there are increased Th17 cells infiltrating tumors on patients with advanced
gastric cancer [71].
Kuai and coworkers have demonstrated that tumor cells produce IL-8, a cytokine of the CXC
chemokine family, as an autocrine growth factor, which promotes tumor growth, tissue invasion,
metastatic spread and chemoresistance of gastric cancer cells [72]. Genotypes of TNF, IL10, IL1B,
and the interleukin-1 receptor antagonist (IL-1RA) are also reported to confer greater risk of gastric
cancer [73]. IL-1β was able to directly induce DNA methylation, which may link inflammation-induced
epigenetic changes and the development of gastric diseases [74]. Several additional cytokines (IL-22,
IL-23, IL-32, IL-33) have been also implicated in gastric cancer progression [75–77]. Taken together,
these findings show that diverse cytokines and different combinations of cytokines might promote
gastric oncogenesis and/or metastasis. The risk may depend on the types of cytokines made by
different subsets of differentiated CD4+ helper T cells responding to H. pylori or self-antigens such as
H+/K+ adenosine triphosphatase (ATPase) in the case of autoimmune gastritis [73].
However, more information on cytokines that influence gastric cancer development is needed,
in particular in light of the development of new biological entities for targeting specific cytokines.
In fact, a better understanding of the cytokine pathway promoting gastric cancer development and
progression may be used to obtain additional therapeutic options for patients with chronic atrophic
gastritis and gastric cancer.
Overall, AIG has been associated with the development of two types of gastric neoplasms:
intestinal type and type I gastric carcinoid [78].
2.1. Intestinal-Type Gastric Cancer
As previously mentioned, the two known factors predisposing gastric cancer in patients with
AIG are intestinal metaplasia and concurrent H. pylori infection, which is the most common cause
of intestinal metaplasia of the gastric mucosa [79]. It should be noted that H. pylori eradication in
patients with precancerous lesions (gastric atrophy, intestinal metaplasia or gastric dysplasia) does
not significantly reduce the incidence of gastric cancer [80]. However, not all patients with H. pylori
gastritis develop gastric cancer. Chances are higher when there are some virulence factors. For example,
H. pylori cagA-positive strains have been shown to pose a significantly greater risk of developing
peptic ulcers and gastric cancer than cagA-negative strains [81,82]. Another well-known virulence
factor is the vacuolating cytotoxin A (vacA) protein [83].
The pathway of gastric cancer development, mainly of the intestinal histological type,
was described by Correa [84]: chronic inflammation leads to tissue atrophy, which is further followed
by intestinal metaplasia. Unknown genetic, metabolic or environmental triggers eventually lead to
the development of adenocarcinoma. In a recent systematic review, an annual incidence of gastric
adenocarcinoma of 0.27% per person-year was demonstrated, with an overall relative risk of 6.8 [60].
In another study, in which 877 Danish patients with gastric cancer were examined, 12 (1.3%) had
a previous diagnosis of AIG [85]. According to the typical distribution of lesions in AIG, these tumors
were localized to the body and to the fundus of the stomach, while they were mainly affecting the
antral and pyloric region in patients without AIG (H. pylori infection was not investigated).
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2.2. Type I Gastric Carcinoid
Hypergastrinemia resulting from the loss of HCl secretion by gastric parietal cells leads to the
development of hyperplasia of the enterochromaffin cells with possible evolution into a carcinoid
tumor. Carcinoid tumor in patients with AIG represents about 10% of all carcinoid tumors and about
1% of gastric neoplasms [86,87].
There are three types of gastric carcinoid characterized by different levels of gastrin: (a) type I
associated with a very high gastrinemia resulting from AIG; (b) type II which is present in patients
with multiple endocrine neoplasia (MEN) and show elevated levels of gastrin; (c) type III presenting
as Zollinger–Ellison syndrome which is the most aggressive variant and showing a normal gastrin
level [88]. In type I carcinoid, lesions are characterized by the secretion of gastrin in response to
the loss of the negative feedback due to the loss of parietal cells, which produce hydrochloric acid.
Hypergastrinemia, in turn, has trophic effects on enterochromaffin cells. Hyperplasia and subsequent
dysplasia of enterochromaffin cells may progress toward the gastric carcinoid type I over time [89].
In addition, chronic achlorhydria increases the production of gastrin by the G cells in the antrum,
which then stimulates enterochromaffin cells that lead to their hyperplasia. Patients with type I gastric
carcinoid are generally asymptomatic, although dyspeptic symptoms may be present. For this reason,
diagnosis is usually performed during endoscopic examination [90].
2.3. Cancer Stem Cells
Recently, a cancer stem/initiating cell concept was proposed to explain cancer development.
According to Visvader [91], either stem or progenitor cells can act as targets for tumor initiation.
Several diverse cancers are hierarchically organized and sustained by a subpopulation of self-renewing
cells that can generate the full repertoire of tumor cells (both tumorigenic and non-tumorigenic cells).
Stem cells have been favored candidates for targets of transformation because of their inherent capacity
for self-renewal and their longevity, which would allow the sequential accumulation of genetic or
epigenetic mutations required for oncogenesis.
Indeed, it has been demonstrated that, as one of the possible mechanisms of gastric carcinogenesis,
chronic inflammation induced by Helicobacter pylori infection can increase the number of tissue
stem/progenitor cells, promote their proliferation, and alter the properties of stem cells toward
intestinal metaplasia to cancer [92]. Thus, an intestinal phenotype in the stomach would be not just
a differentiated metaplasia in the stomach, but a phenotype of stem cell abnormality with precancerous
lesion susceptible to gastric carcinogenesis after chronic inflammation [92].
3. Autoantibodies as Markers of Gastric Cancer
Cancer cells can induce an immunological response resulting in the production of autoantibodies
against tumor antigens which can be used as biomarkers to detect cancer at an early stage. Indeed,
the immune system is capable of sensing at least some tumor-associated antigens before many standard
clinical tests for cancer diagnosis [93], so that detection of tumor-associated autoantibodies could
have both diagnostic and prognostic relevance [94,95]. Availability of early and specific markers
would be an important advance in cancer management because currently a significant proportion of
individuals are diagnosed late, presenting with advanced disease at which time the opportunities for
successful treatment are drastically reduced and treatment costs significantly increased [95]. The use
of autoantibodies as biomarkers in cancer immunodiagnosis is further justified by the fact that these
antibodies are generally absent or present in very low concentration in normal individuals and
in non-cancer conditions [96]. Importantly, although no evidence of correlation between antibody
concentration and cancer stage emerged from most studies [94], usually a marked decrease in antibody
levels is seen after surgical removal of solid tumors, indicating that they can be used in monitoring the
efficacy of surgical treatment and in patient follow up.
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Most tumor-associated autoantigens are cellular proteins and belong to three main classes: (a)
antigens resulting from genetic mutations or rearrangements; (b) viral antigens; and (c) antigens
that are ectopically expressed. Somatic mutations can increase immunogenicity by producing new
antigenic epitopes via point mutations, frame shifts, or coding sequence extensions or truncations [95].
Several techniques are used for their detection, including serological analysis of tumor antigens by
recombinant cDNA expression cloning (SEREX), phage display, serological proteome analysis (SERPA),
multiple affinity protein profiling (MAPPing), and protein microarrays [97].
Currently, there are some candidate autoantibodies as clinically useful biomarkers for gastric
cancer; namely, anti-p53, anti-carcinoembryonic antigen (CEA), anti-mucin, anti-survivin, and
anti-livin autoantibodies.
p53 is a tumor suppressor gene that plays a critical role in oncology. Its protein participates
in the regulation of the cell-cycle, acts as a transcriptional transactivator/repressor, helps in DNA
repair, suppresses cell growth, induces apoptosis and has many other functions [98]. The production
of anti-p53 autoantibodies is strongly related to p53 protein overexpression in the tumor tissue [99].
Autoantibodies against the p53 protein were detected for the first time in sera of patients with breast
cancer [100] and then in many other solid tumors. In gastric cancer, 20% of all patients and 46% of
patients with p53-positive tumors have high levels of anti-p53 antibodies [101]. Regardless of the
moderate sensitivity, there is consensus on the very high specificity (around 96%) of p53 antibodies
for malignancy [102,103]. Several studies have also demonstrated that anti-p53 antibodies are more
prevalent in advanced gastric cancers with a prevalence of regional lymph node involvement [95,101,
104,105] recognizing the poor prognostic value of p53 autoantibody markers in gastric carcinoma.
Antibodies to CEA, an oncofetal glycoprotein commonly measured as a tumor marker, may
be found in 46–56% of gastrointestinal tumors, especially in cancer at an early stage, even with
undetectable circulating CEA [7,106]. However, they are also found in 10% of healthy individuals
suggesting they could be part of the natural autoantibody repertoire. Anti-CEA antibodies are
associated with the host immune response against the tumor and show a good prognostic value
for survival [99,107]. Antibodies to mucin [108], surviving, and livin [109] have also been detected
in patients with gastric cancer, with a prevalence of 75%, 40%, and 50%, respectively. They could
represent new tumor markers not only for diagnosis but also for postoperative monitoring of gastric
cancer patients, particularly in those lacking anti-p53 antibodies [95].
Autoantibodies to the extracellular protein kinase A (ECPKA), a cAMP-dependent intracellular
enzyme, are markedly up-regulated in the sera of cancer patients, have been found in many malignant
tumors, including gastric cancer. Although these antibodies measure malignant transformation in all
cells and are not specific to one type of cancer, they have a sensitivity of 90% with a specificity of 87%
and could be used as a universal screening method to detect serum tumor markers [110].
However, notwithstanding their high diagnostic specificity, in clinical practice, autoantibody
response has been seen to be highly variable from patient to patient, probably due to diverse immune
responses resulting from the highly heterogeneous nature of cancer and inherent genotypic (and
epigenetic) variations within a population [95]. In addition, contrary to what occurs in autoimmune
diseases, assays that measure a single tumor-associated autoantibody appear to have little diagnostic
use for cancer due to their low frequency, rarely exceeding 30%. A possible strategy for overcoming
this limitation due to individual variability and poor diagnostic sensitivity could be combining
known autoantibody markers with other biomarkers for gastric cancer, such as tumor markers like
carcinoembryonic antigen (CEA) [111], CA19-9 [112], and CA72-4 [113] markers related to chronic
atrophic gastritis (e.g., parietal cell antibodies, H. pylori antibodies and serum pepsinogens I and II,
gastrin [114]), microRNAs [115] or glycosylation signatures [116].
Another strategy to increase diagnostic sensitivity is to associate multiple antibody markers.
To this end, Werner et al. studied 329 gastric cancer patients, 321 healthy controls and 124
participants with other diseases of the upper digestive tract by multiplex serology using a fluorescent
bead-based glutathione S-transferase (GST) capture immunosorbent assay [117]. Among 64 candidate
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autoantibodies directed against gastric tumor-associated antigens, they identified five antibodies:
MAGEA4, CTAG1, TP53, ERBB2_C, and SDCCAG8. At 98% specificity, sensitivity for gastric cancer
detection for single antibodies was not higher than 12%, while a combination of the five antibodies
enabled recognition of 32% of early-stage gastric cancer with a specificity of 87% [117].
Using an ELISA assay to detect autoantibodies towards an antigenic panel containing
a seven-marker combination (p53, Koc, p62, c-myc, IMP1, survivin and p16), in a cohort of 383 patients
(88 with gastric adenocarcinoma, 79 with gastric dysplasia, 76 with chronic atrophic gastritis,
and 140 individuals with normal gastric mucosa), Zhou et al. reported a sensitivity of 64% for
adenocarcinoma with a specificity of 87%. The area under the receiver operating characteristic (ROC)
curve was 0.730. Sensitivity for gastric cancer did not increase with the addition of other autoantibodies
to tumor-associated antigens [118].
In a similar study by Wang and coworkers, autoantibodies against eight tumor-associated
recombinant antigens (IMP1, p62, Koc, p53, c-myc, cyclin B1, survivin and p16) determined by
ELISA and Western blot, showed 56.1% sensitivity for gastric cancer detection, at 86.2% specificity.
The highest frequency (27%) was found for cyclin B1 [119].
Thus, a substantial number of autoantibodies present in patients with gastric cancer have been
identified. Although some of the autoantibodies are highly specific, their low diagnostic sensitivity
has limited their application in clinical practice and assays that measure a single tumor-associated
autoantibody appear to have little diagnostic utility for cancer detection. In the future, availability of
new multiplex technology for the simultaneous detection of many autoantibodies might prove to be
able to overcome these limitations by providing cancer-specific autoantibody profiles to be used for
population screening for the early detection of gastric cancer.
4. Conclusions
There is evidence that the incidence of gastric neoplasms is higher in patients with autoimmune
gastritis compared to the general population. Many studies in humans and in mouse models of
gastritis indicate that chronic inflammation stimulates gastric cells to produce inflammatory cytokines
which play a relevant role in regulating oxyntic atrophy, hyperplasia, metaplasia, and progression to
gastric cancer by up-regulating expression of progenitor cells. Recent data on gastric cancer stem cell
involvement may provide insights into the molecular pathway of carcinogenesis, eventually leading to
development of new therapeutic approaches to target early-stage gastric cancer.
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Abstract: Common variable immunodeficiency (CVID) is an immunodeficiency disorder with a high
incidence of gastrointestinal manifestations and an increased risk of gastric carcinoma and lymphoma.
This review discusses the latest advancements into the immunological, clinical and diagnostic
aspects of gastric malignancies in patients with CVID. The exact molecular pathways underlying
the relationships between CVID and gastric malignancies remain poorly understood. These include
genetics, immune dysregulation and chronic infections by Helicobacter pylori. Further studies are
needed to better stratify the risk for cancer in these patients, to elaborate surveillance programs aimed
at preventing these complications, and to develop new and more effective therapeutic approaches.
Keywords: common variable immunodeficiency; gastric cancer; human immunoglobulins;
lymphoproliferative disorders
1. Introduction
Common variable immunodeficiency (CVID) comprises a heterogeneous group of relatively
rare disorders characterized by remarkable decrease of two or three major immunoglobulin isotypes
(IgG, IgA, and IgM), often associated to defects in cell-mediated immunity [1]. Several immunological
studies of large cohorts of CVID patients have demonstrated phenotypic and functional abnormalities
of B cells [2,3], T cells [4–6], and antigen-presenting cells [7,8]. These abnormalities include mutations
that occur in genes essential for the co-operation between B and T cells in the germinal center, as well
as for intrinsic signaling pathways of such cells. A flow cytometry-based analysis of CVID patients
revealed a marked reduction of mature class-switched CD27+IgD−IgM− memory B cells and/or an
increased number of CD19+CD21− immature B cells [3]. In addition, a decreased number of CD4+
naïve T cells and regulatory T cells has been detected in the patients’ peripheral blood, possibly
ascribable to defective generation of T cell precursors in the bone marrow [4]. Bone marrow biopsies
have in fact shown the absence or a significant decrease of plasma cells and, conversely, an increase of
diffuse and nodular T cell infiltrates [9].
The diagnosis of CVID obviously requires the exclusion of other causes of
hypogammaglobulinemia [10]. The mean age at diagnosis is 29 years for males and 33 years
for females, although the condition can be diagnosed at any age without gender predominance [11].
The prevalence varies widely worldwide, ranging from 1:100,000 to 1:10,000 of the general
population [12]. Although CVID is clinically highly variable and heterogeneous, severe, recurrent,
and chronic bacterial infections of the respiratory and gastrointestinal tracts are the major
characterizing features. In addition, approximately half of the patients suffer from non-infectious
complications, including autoimmune, lung and gastrointestinal disease, benign lymphoproliferation,
and malignancies [11]. In particular, the gastrointestinal tract [13] and the lymphoid tissue are among
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the most affected systems [14–16], as shown by the fact that CVID patients have an almost 47-fold
increased risk for gastric cancer and a 30-fold increased risk for lymphoma [17].
In this paper, we will provide an overview of the main clinical, diagnostic and immunological
features of gastric malignancies in patients with CVID, with special emphasis for gastric carcinoma
and lymphoproliferative disorders.
2. Genetic Abnormalities
CVID is a polygenic disease which is the result of numerous genetic immune defects, summarized
in Table 1. The mode of inheritance is mostly autosomal dominant, and autosomal recessive in
about 20% of the cases. The most frequently identified mutations have been discovered in the
tumor necrosis factor (TNF) receptor superfamily member 13B (TNFRSF13B) gene encoding TACI
(transmembrane activator and calcium-modulating cyclophilin ligand interactor), a B cell-specific
TNF receptor superfamily member. Both homozygous and heterozygous coding variants have been
identified in patients with CVID [18,19]. TACI is preferentially expressed on marginal zone B cells,
CD27+ memory B cells, and plasma cells. Its ligands are the B cell-activating factor (BAFF) and the
proliferation-inducing ligand (APRIL) involved in cell survival, apoptosis, and isotype switching [20].
Defects of TACI impair BAFF and APRIL signaling, and consequently plasma cell survival,
maturation and class switch recombination, Ig production [21,22], and the removal of autoreactive
B cells at the central B cell tolerance checkpoint, thus increasing the susceptibility of CVID patients to
autoimmune diseases [23]. A181E and C104R are the two most frequent TNFRSF13B variants in these
patients [18,19,24], although the mentioned mutations are neither necessary nor sufficient to cause
CVID. While healthy individuals with a single pathogenic TNFRSF13B allele have a normal B cell
phenotype, this is not the case for CVID patients with the same TNFRSF13B status, suggesting that the
disease expression depends on the loss of compensating forces. Further studies are needed to elucidate
the additional genetic and environmental factors that act in concert to generate the disease.
Homozygous and heterozygous mutations in the BAFF receptor (BAFF-R) gene, and single
nucleotide polymorphisms resulting in BAFF-R missense mutations have been reported in CVID
patients [25]. BAFF-R is required for B cell maturation and survival [26], and its mutations are
associated to impairment in the proliferation, differentiation, and maturation of B lymphocytes [27].
Animal studies, carried out with both knockout and transgenic models, demonstrated that disruption
of BAFF-R results in an immunological phenotype similar to that observed in CVID, suggesting that
BAFF-R may be involved in the pathogenesis of CVID [28].
Biallelic deleterious mutations in members of the CD19 B-cell receptor complex (CD19, CD21, and
CD81) and CD20 could also be involved in the onset of CVID [29–31]. Homozygous deletion in the
inducible co-stimulator (ICOS) gene has been associated with adult-onset CVID [32]. ICOS belongs to
the family of co-stimulatory T cell molecules and is expressed by antigen-activated T cells. Its unique
ligand is ICOS-L expressed constitutively on B cells [33]. ICOS:ICOS-L interaction plays an important
role in mediating T-B cell cooperation and promoting the terminal differentiation of B cells into memory
cells and plasma cells. Patients with ICOS deletion displayed a reduced number of naïve, switched and
memory B cells as well as low serum Ig levels [32]. This is further supported by the results achieved in
ICOS and ICOS-L knockout mice, both showing a defect in germinal center formation and in humoral
immune responses, due to the lack of T cell-mediated help to the B cells [34].
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Table 1. Genetic immune defects in common variable immunodeficiency.
Gene Defect References
TNFRSF13B Homozygous and heterozygous mutations [18,19,24]
BAFF-R Homozygous and heterozygous mutations [25]
CD20 Homozygous mutations [29]
CD19-B-cell receptor complex Homozygous mutations [30,31]
ICOS Homozygous deletions [32]
Genes implicated in DNA repair
(MSH5, MSH2, MLH1, RAD50 and NBS1) Heterozygous non-synonymous mutations [35]
CARD11 Heterozygous single nucleotidepolymorphisms [36]
Bob1 Heterozygous single nucleotidepolymorphisms [36]
MHC region Single nucleotide polymorphisms [37]






PIK3CD Heterozygous splice site mutationsGain-of-function mutations [39]
NFκB2 Heterozygous frameshift mutationHeterozygous nonsense mutation [40]
PLCG2 Deletions [41]
LRBA Homozygous mutations [42]
CD27 Homozygous mutations [43]
TNFRSF13B, tumor necrosis factor receptor superfamily member 13B; BAFF-R, B cell-activating
factor receptor; ICOS, inducible costimulatory; CARD, caspase activation and recruitment domain;
Bob1, B cell-specific transcriptional co-activator; ADAM, disintegrin and metalloproteinas genes;
CTLA4, cytotoxic T lymphocyte antigen-4; PIK3CD, phosphatidylinositol-4,5-bisphosphate 3-kinase
catalytic subunit delta; NFκB2, nuclear factor kappa B2; PLCG2, phospholipase C gamma 2; LRBA,
lipopolysaccharide-responsive beige-like anchor.
The described mutations, however, account for less than 15% of CVID cases. The remaining
85% of the patients do not have a known genetic defect and it is likely that other genes besides those
already identified may be involved in the pathogenesis of the CVID. For example, single nucleotide
polymorphisms in genes implicated in deoxyribonucleic acid (DNA) repair (MSH5, MSH2, MLH1,
RAD50, and NBS1) and in genes involved in B cell development, encoding the caspase activation
and recruitment domain (CARD)11 and the B cell-specific transcriptional co-activator Bob1, could be
associated with CVID [35,36]. Furthermore, a genome-wide association study, using single nucleotide
polymorphism arrays and copy number variation, revealed a strong relationship between CVID and
the MHC region as well as between CVID and a disintegrin and metalloproteinase genes (ADAM) [37].
In addition, a CVID-like syndrome, characterized by hypogammaglobulinemia, progressive
loss of circulating B cells, immune dysregulation, and lymphocytic infiltration of target organs was
demonstrated to be caused by heterozygous mutations in: (a) cytotoxic T lymphocyte antigen-4
(CTLA4) involved in T and B lymphocyte homeostasis [38]; (b) phosphatidylinositol-4,5-bisphosphate
3-kinase catalytic subunit delta (PIK3CD) gene, resulting in hyperactivation of the PI3K signaling
pathway important for B and T cell development, differentiation, and function [39]; (c) nuclear factor
kappa B2 (NFκB2) required for B cell development and antibody production [40]; (d) phospholipase
C gamma 2 (PLCG2) causing gain of PLCγ(2) function, a signaling molecule expressed in
B cells [41]; (e) lipopolysaccharide-responsive beige-like anchor (LRBA) causing severe defects in
B cell development and activation [42]; and (f) CD27, a lymphocyte costimulatory molecule implicated
in B cell and plasma cell function, survival, and differentiation [43].
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3. Common Variable Immunodeficiency and Gastric Cancer
Many studies reported an increased risk of gastric cancer in CVID patients [15–17,44,45]. The first
evidence was described in 1985 when a prospective study of 220 patients with CVID followed for
11 years showed a 47-fold increased risk of stomach cancer [17]. A multicenter study which examined
176 Danish and Swedish patients with CVID and their relatives reported a risk of stomach cancer
10-fold higher for CVID subjects, whereas no increased risk was found for this or any other type of
cancer among 626 relatives of CVID patients. This suggests that the increased risk of gastric cancer is
related to the immunodeficiency per se, rather than to specific genetic alterations shared with their
relatives [45]. In an analysis of the Australasian Society of Clinical Immunology and Allergy primary
immunodeficiency disease registry of 1132 subjects from 79 centers, it was shown that only subjects
with CVID and ataxia telangiectasia had an increased risk of cancer. A high relative risk in relation to
an age-matched general population was observed for non-Hodgkin’s lymphoma (NHL), leukemia,
and gastric cancer [16].
In a recent study, the incidence of cancer in patients with primary immunodeficiency diseases
enrolled in the United States Immune Deficiency Network registry was assessed compared with
age-adjusted cancer incidence in the Surveillance, Epidemiology and End Results Program database.
An increased risk of NHL, gastric cancer, and skin cancer was observed in 1285 patients with CVID.
Gastric cancer, in particular, was more common than expected (n = 2 in men and n = 3 in women vs.
expected rates of n = 0.4 in men (p = 0.011) and n = 0.7 in women (p = 0.005)) [44].
The exact mechanisms underlying an enhanced frequency of gastric cancer in patients with CVID
are unknown, but a possible sequence of events is schematized in Figure 1. The weakened immunity
to potentially carcinogenic pathogens, such as Helicobacter pylori (HP), and the impaired tumor cell
surveillance should obviously be considered predisposing factors to gastric cancer. Several studies
have in fact ascribed the higher incidence of gastric cancer to HP infection (reviewed in [46]) and
achlorhydria [17]. Eradication of HP in patients with non-atrophic gastritis has been demonstrated to
prevent the subsequent development of gastric cancer [47]. Data from prospective studies revealed
a two to nine fold increased risk of gastric cancer in the general population with HP infection [48,49].
More recently, however, gastric cancer appears rarer in CVID, possibly due to the more common use of
antibiotics that would eradicate HP. Probably, the gastrointestinal defects associated with CVID, such as
the decreased production of gastric IgA (with bactericidal activity against HP) and hydrochloric acid,
may result in enhanced HP colonization and gastric inflammation, thus promoting carcinogenesis [50].
Figure 1. Hypothetical mechanisms of gastric cancer in patients with CVID.
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HP causes chronic gastritis by stimulating the release of pro-inflammatory cytokines and favoring
achlorhydria; in addition, certain strains produce virulence factors with oncogenic effects on the gastric
epithelium. It induces upregulation of oncogenes and silencing of tumor suppressor genes, triggering
a stepwise cascade of events ranging from intestinal metaplasia to dysplasia to neoplasia, the so called
Correa’s cascade (Figure 1) [51]. Moreover, an inflammatory response is generated, in that replicating
cells are invaded by neutrophils and monocytes, which release reactive oxygen species (ROS) and
reactive nitrogen species (RNS), thus inducing DNA breaks and point mutations in genes critical for
cell replication and death [52]. It should also be emphasized that hypochlorhydria and achlorhydria
may result in impaired defense against HP infection and enhanced bacterial overgrowth, including
nitrate reducing strains, with consequent increased levels of N-nitroso compounds in the gastric juice.
This endogenous nitrosation can promote the progression from gastric atrophy to intestinal metaplasia,
dysplasia, and eventually carcinoma [46,53,54].
4. Features of CVID-Associated Gastric Cancer
CVID-associated gastric cancer typically displays peculiar features. First, it is diagnosed in
patients younger than the overall gastric cancer population. Second, it is moderately to poorly
differentiated intestinal-type adenocarcinoma, containing a high number of intra-tumoral lymphocytes.
Third, it arises in a background of gastritis characterized by severe atrophy, pan-gastric distribution,
intestinal metaplasia, plasma cell paucity, lymphoid nodular aggregates, and apoptotic activity [55].
This latter feature, which is reminiscent of gastritis from HP, may also underlie autoimmune gastritis
given that autoimmunity is a well-known complication of CVID and pernicious anemia affects
approximately 10% of patients [46]. Pernicious anemia is readily suspected by a low serum vitamin B12
and macrocytic red blood cells, although a precise diagnosis in CVID patients is more difficult because
of the lack of typical anti-parietal cell and anti-intrinsic factor autoantibodies. Tissue damage in
autoimmune gastritis is indeed mediated not only by autoantibodies targeting the parietal cell proton
pump and intrinsic factor, but also by sensitized T cells. When fully developed, autoimmune gastritis
displays dense and diffuse lymphoplasmacytic inflammation with the oxyntic epithelia replaced by
atrophic (and metaplastic) mucosa, creating the phenotypic background in which gastric intestinal-type
adenocarcinomas may arise [56,57]. Several studies have also addressed the role of HP infection in
the pathogenesis of autoimmune gastritis, and there is evidence to support a mechanism of molecular
mimicry between HP antigens and the proton pump [58]. Epidemiological studies suggest that
a significant number of patients with autoimmune gastritis suffered from, or still have, HP infection
and anti-proton pump autoantibodies have consistently been demonstrated in HP-infected patients.
An additional, potential abnormality that can be identified in patients with CVID-associated
gastric cancer is granuloma resembling sarcoidosis [59]. Whether the granuloma reflects a primary
T-cell defect, or an abnormal response to infectious agents is presently unknown. In any case, fungal
and mycobacterial special stains are always appropriate when granulomas are identified, given that
tuberculosis has been described in the setting of CVID [60].
5. Gastric Cancer Screening and Prevention in CVID Patients
Gastric cancer is the fourth most common cancer and the second leading cause of cancer death
worldwide [61]. There is no ideal protocol for gastric cancer screening in high-risk CVID individuals,
and prerequisites of screening programs differ from country to country because of the variable
cancer incidence and mortality in each country, ethnic differences, and socio-economic conditions [62].
Consensus exists, however, over the usefulness of a risk assessment primarily based on the diagnosis
of HP infection and/or pernicious anemia.
Rather than on HP antibody test, the diagnosis of HP infection is usually based on urea breath
test (UBT), stool antigen immunoassay and/or endoscopic biopsy. UBT is largely preferred being
widely available, accurate, and noninvasive, with a sensitivity and specificity of roughly 90% [63].
An additional noninvasive method is the stool test, characterized by sensitivity in the range of 69–92%
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and specificity of approximately 75–89% [64]. HP infection is often asymptomatic, thus accounting for
its uncommon detection and eradication at an early stage. Following its eradication, HP rarely recurs
in the general population [65]. Whether this rare recurrence is also common to patients with CVID,
given their lack of secretory IgA on the gastric mucosa, has not been established.
The diagnosis of pernicious anemia can be made by showing the presence of megaloblastic or
macrocytic anemia, and measuring serum vitamin B12 and iron levels. Therefore, a screening protocol
to target patients with CVID who are at the highest risk of gastric cancer should include three easy,
non-invasive tests such as UBT, serum B12, and serum iron [65].
Regardless of the presence of pernicious anemia or HP infection, patients with CVID should be
considered at increased risk for gastric cancer [15–17,44,45]. We propose a step-by-step evaluation of all
patients with CVID, with invasiveness increasing stepwise according to the risk (Figure 2). The initial
screening should focus on noninvasive tests, such as UBT to detect HP infection and the measurement
of serum vitamin B12 and iron to detect the presence of pernicious anemia. If patients are positive for
HP infection, HP eradication should follow standard practice, repeating the UBT after one month to
demonstrate that treatment was effective. Because HP infection is the major cause of gastric cancer,
eradication of infection should be the most effective method to prevent its occurrence [47]. However,
only few studies have reported the effects of screening and treating this pathogen at the population
levels [66], given the lack of infrastructures for delivery of systematic screening services, the lack
of standardization to ensure that each subject receives the correct diagnostic testing and antibiotic
treatment, and limitation of resources.
 
Figure 2. Protocol of screening and surveillance for gastric cancer in patients with CVID.
If patients have low serum vitamin B12 and iron concentrations, their replacement should
obviously be effected. In addition, in patients negative for pernicious anemia it is advisable to
repeat the screening tests yearly, in that pernicious anemia or gastritis may appear later on.
During regular follow-up for CVID, patients with low serum levels of vitamin B12, patients with
positive UBT and those with dyspeptic symptoms or unexplained weight loss should undergo upper
gastrointestinal endoscopy, including biopsies of the antrum and fundus. Patients with premalignant
lesions should receive endoscopic surveillance.
In the absence of established guidelines, it seems reasonable to adopt the following
procedure: (a) no follow-up endoscopy in patients with normal histopathology and (b) repeat
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endoscopy after a time interval ranging from a few months to 5 years, depending on the
histopathological diagnosis [67,68] (Figure 2). The time intervals for follow-up of gastric precancerous
lesions are based upon data on estimated rates of progression to gastric cancer. Progression rates to
cancer vary from: 0 to 1.8% per year for atrophic gastritis, 0 to 10% per year for intestinal metaplasia,
and 0 to 73% per year for dysplasia [69]. Obviously, the time intervals of follow-up should be
personalized in each individual patient depending on location, severity and extent of gastric pathology
and the occurrence of other risk factors for gastric cancer.
6. CVID and Gastric Lymphoma
Lymphoproliferative disorders are common in CVID. Gastrointestinal lymphoid hyperplasia
and/or splenomegaly are found in at least 20% of the patients with CVID [70]. Splenomegaly has in
fact been reported in 26% of a cohort of 2212 European patients [15]. The cause of CVID-associated
gastrointestinal lymphoproliferation is not known, but the potential role of bacterial, protozoal (mainly
Giardia lamblia), and viral gastrointestinal infections should be kept in mind. Their eradication may be
difficult for some patients.
Biopsies of lymph nodes usually show atypical or reactive lymphoid hyperplasia,
but granulomatous inflammation may also be found. Typical features are the lack of plasma cells
and the presence of ill-defined germinal centers in lymph nodes and other lymphoid tissues [71].
These same tissues should be examined for B- and T-cell clonality, using fluorescence markers,
cytogenetics, and/or molecular analysis to rule out lymphoid malignancy. In lymph nodes with
B-cell infiltrates, examination for EBV-encoded RNAs by in situ hybridization should be performed,
often showing an expansion of transitional CD19+CD38++IgMhigh B cells or CD19+CD38lowCD21low
B cells [72]. Given that patients with CVID may have unusual lymphoid structures with loss of
characteristic boundaries, it is important that the biopsies be examined by an experienced pathologist,
in that the presence of clonal lymphocytes is not in itself diagnostic of lymphoma because these cells
can be found in CVID lymphoid tissue showing reactive hyperplasia [70].
The risk for lymphoma in CVID is estimated to lie between 1.4% and 7% [16,44,45,73]. About 2–8%
of subjects with CVID are diagnosed with NHL, in step with the longer survival of these patients [70].
In a study carried out on 248 consecutive CVID patients, who have been followed-up for 1–25 years,
23 patients were diagnosed with lymphoid malignancies. Specifically, 19 patients had NHL,
three Hodgkin’s disease, and one Waldenström’s macroglobulinemia [74]. In this context, it is worth
emphasizing that: (a) NHL occurs rarely in the pediatric population [75] and (b) in most cases it is
usually B cell in type, extranodal, EBV-negative and more frequent in females than males [76]. A study
of 98 CVID patients who have been followed-up for periods of 1–13 years showed an eight- to 13-fold
increase in cancer in general and a 438-fold increase in lymphoma for females [76]. An earlier report
based on a European cohort of 176 patients found three of the four NHL in women [45].
Extranodal marginal zone NHL arising in mucosal sites, named also mucosa-associated lymphoid
tissue (MALT) lymphomas or “maltomas”, can also affect CVID patients. In the earlier literature,
10 cases of extranodal marginal zone lymphoma complicating CVID have been reported [73],
but probably many more cases are clinically hidden. Extranodal marginal zone lymphomas are
low-grade B cell lymphomas that occur in organs with lymphoid infiltration, due to long-term
infectious or autoimmune stimulation [14]. A causal relationship is likely to exist between HP infection
and extranodal marginal zone lymphoma with gastric location, in that HP infection is present in more
than 90% of the patients with this type of lymphoma [77].
Finally, a subset of CVID patients with T cell lymphoma should be mentioned. Gottesman et al.
described the occurrence of a peripheral extranodal T cell lymphoma arising in the bone marrow,
liver and central nervous system of a patient with CVID. Immunohistochemical phenotyping and
gene rearrangement studies revealed a T cell origin of this lymphoma. It was not associated with
EBV infection of the lymphoma cells [78]. Recently, Jesus et al. illustrated a case of CVID associated
with hepato-splenic T-cell lymphoma mimicking juvenile systemic lupus erythematosus. The autopsy
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showed a diffuse involvement of bone marrow, spleen, liver, and lungs. The lymphoma cells were
positive for CD3 and negative for CD20 and lysozyme expression [79]. CD8+ granulomatous cutaneous
T-cell lymphoma is a rarely encountered entity that appears to be associated with immunodeficiency,
as reported by Gammon et al. in a retrospective review of four cases. Patients were characterized by
an asymptomatic papulo-nodular eruption occurring in association with immunodeficiency [80].
Usually, patients with splenomegaly alone may not need treatment. Likewise, persistent
hypertrophy of lymph nodes should suggest to review the diagnosis in order to exclude lymphoma
but, again, this does not imply that treatment should be given. The administration of corticosteroids
is commonly associated to regression of these phenomena, but they may recur when steroids are
tapered. A rapid increase in adenopathy or splenomegaly should prompt evaluation for possible
malignant transformation. Lymphoma may be difficult to distinguish from polyclonal lymphoid
proliferation. Clonal analysis can be misleading because oligoclonal lymphocyte subpopulations have
been found in biopsies, irrespective of histology [70]. Treatment follows the current protocols for
immunocompetent patients.
7. Conclusions
CVID seems to be a predisposing factor to gastric malignancies. The reasons for this increased
susceptibility are still unclear and additional animal models of CVID are needed to establish
mechanisms of its relationship to cancer. The impaired immunity to potentially carcinogenic pathogens,
the weakened tumor cell surveillance, and T and B cell defects are no doubt predisposing factors.
Due to the great heterogeneity of CVID patients, there are no set rules regarding their therapy
and follow-up. Although treatment obviously requires the infusion of human immunoglobulins,
an unsettled point is whether an adequate immunoglobulin replacement is sufficient to prevent the
increased risk of malignancy. Bacterial and viral infections must be treated. Low-dose corticosteroids
can be administered to ameliorate gastrointestinal lymphoproliferative disorders, but higher doses
should be avoided to prevent the risk of opportunistic infections [12]. Treatment of gastric cancer
and lymphoma must follow the current protocols for immunocompetent patients. Further studies are
recommended to better identify patients at high risk of gastric neoplasias and to better treat them.
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Abstract: Lynch syndrome (LS) and familial adenomatous polyposis (FAP) are autosomal dominant
hereditary diseases caused by germline mutations leading to the development of colorectal cancer.
Moreover, these mutations result in the development of a spectrum of different tumors, including
gastric cancers (GCs). Since the clinical characteristics of GCs associated with LS and FAP are not well
known, we investigated clinical and molecular features of GCs occurring in patients with LS and FAP
attending our Institution. The Hereditary Tumor Registry was established in 1994 at the Department
of Oncologic Gastroenterology, CRO Aviano National Cancer Institute, Italy. It includes 139 patients
with LS and 86 patients with FAP. Patients were recruited locally for prospective surveillance. Out of
139 LS patients, 4 developed GC—3 in the presence of helicobacter pylori infection and 1 on the
background of autoimmune diseases. All GCs displayed a high microsatellite instability (MSI-H)
and loss of related mismatch repair (MMR) protein. One of the FAP patients developed a flat
adenoma, displaying low-grade dysplasia at the gastric body, and another poorly differentiated
adenocarcinoma with signet ring cells like Krukenberg without HP infection. LS carriers displayed
a risk of GC. The recognition of HP infection and autoimmune diseases would indicate those at
higher risk for an endoscopic surveillance. Regarding FAP, the data suggested the need of suitable
endoscopic surveillance in long survivals with diffuse fundic gland polyps.
Keywords: gastric cancer; lynch syndrome; familial adenomatous polyposis (FAP), helicobacter
pylori infection; autoimmune gastritis; fundic gland polyps (FGPs)
1. Introduction
Lynch syndrome (LS) and familial adenomatous polyposis (FAP) are the most frequent syndromes
in hereditary colorectal cancer (CRC), causing, respectively, 6% and 1% of all CRC. Extracolonic
neoplasms are often observed in these syndromes and upper gastrointestinal (GI) malignancies are an
important cause of death.
LS is an autosomal dominant disorder caused by germline mutations in one of the mismatch
repair (MMR) genes (MSH2, MLH1, MSH6, PMS2) or the EpCAM gene that mainly determines CRC
risk. However, these mutations evolve into a spectrum of different extracolonic tumors. Endometrial
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cancer is the most frequent extracolonic cancer followed by urothelial, small bowel, and gastric cancers
(GCs) [1,2]. MSH2, MLH1, and EpCAM carriers display a 46% risk of developing CRC and a 57% risk
of endometrial cancer by the age of 75 years. Much lower is the risk for GCs (13%), but it is still higher
compared to the 1% risk in the general population. MSH6 carriers instead have a lower risk for CRC
(15%), endometrial cancer (46%), and also for GCs (<3%). Tumor tissue of CRC and extracolonic cancers
in an LS setting show two peculiar molecular features: microsatellite instability (MSI) that is characterized
by length alteration within simple, repeated DNA sequences called microsatellites, and loss of MMR
protein expression at immunohistochemical analyses. These two molecular features are useful screening
markers to identify patients with LS [3]. Guidelines are mainly focused on CRC prevention, suggesting
colonoscopy starting at the age of 20–22 years with a two-year interval for recognition and removal
of the precancerous lesions, i.e., adenomatous polyps. There is no consensus for extracolonic cancer
prevention and for GCs surveillance [3–5]. GCs in this setting are usually of intestinal type, showing
high microsatellite instability (MSI-H) and a loss of relative MMR protein expression. The natural history
and pathological transformation pathway are unknown. However, helicobacter pylori (HP) infection
represents a predisposing clinical condition to GCs, and its eradication is recommended. Gastric adenomas
are rarely observed in LS; however, a recent study reported PGA in 3 patients out of 15 cases of LS GC [6].
FAP is an autosomal dominant hereditary disease caused by germline mutations in the
adenomatous polyposis coli (APC) gene with 80–100% penetrance, leading to the development of
hundreds to thousands colorectal adenomatous polyps starting in teenage years and CRC at an average
age of 39 years. The correlation between genotype and phenotype has been highlighted. The APC gene
encodes 2844 aminoacids in 15 exons. The mutation cluster region, located between 1250–1464 codon,
is associated with florid and more aggressive colonic polyposis, whereas mutations in 5′ and 3′ regions
are related to an attenuated FAP (AFAP) with a lower number of colonic adenomas. Mutations between
140–1309 are linked to papillary thyroid carcinoma and between 1399–1580 to desmoids tumors [7,8].
CRC has been considered an inevitable consequence in the natural history of FAP. Guidelines suggest
colonic surveillance starting before teenage and prophylactic colectomy is the recommended treatment
for preventing cancer when adenomatous polyposis is not endoscopically manageable or in the
presence of adenomas with high-grade dysplasia [5]. Beside CRC, duodenal adenomas and carcinomas
and desmoids tumors are the most frequent cause of morbidity and mortality in FAP. Presently, upper
gastrointestinal (GI) endoscopy has been included in the surveillance starting at 25 years of age for
staging duodenal polyposis, and the intervals are based on the Spigelman score determined by the
number and grade of dysplasia of duodenal adenomas. However, GCs have also been reported [9].
Differences in frequency were seen between Western and Eastern countries [10]. A recent paper has
described GCs in 0.5% of FAP patients from a US registry [11], while among Japanese FAP patients,
the prevalence of GC has been reported to be from 2.8% to 15.5% [12]. The types of gastric lesions
associated with GCs in FAP are: fundic gland polyps (FGPs), gastric foveolar-type gastric adenoma,
gastric adenoma, and pyloric gland adenoma (PGA) [13]. FGPs are present in more than 60% of FAP
patients and they usually display biallelic inactivation of the APC gene often with foci of dysplasia
or microadenomatous polyps of the foveolar epithelium [14]. However, malignant progression in
FGPs is uncommon and the lifetime risk of GC is reported to be in the range of 0.5–1%. Intestinal-type
adenomas are rare (1–2% of gastric polyps) in Western countries compared to Asia (40–50% of gastric
polyps) [15]. A strong correlation between gastric adenomas and atrophic gastritis secondary to HP
infection has been showed in Japanese FAP patients [12,16]. PGAs have been recently recognized as a
new polyp subtype, developing on the mucosa with pyloric metaplasia [17]. They have been found in
6% of FAP patients and high grade dysplasia is seen in 10% of cases. Out of the FAP setting, PGAs
have been found in association with autoimmune metaplastic atrophic gastritis [18].
Since the clinical characteristics of GCs associated with LS and FAP are still not well understood,
in our study we investigated clinical and molecular features of GCs occurring in these patients
attending our Institution.
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2. Results
In LS, CRC was the most frequently diagnosed primary cancer (82 patients, 59%), followed by
endometrial cancer (55% out of 83 women). Out of 82 patients with CRC, 24 had multiple synchronous
lesions with a total of 131 CRCs diagnosed. Mucinous histotype was present in 55.7% (72) of CRCs,
and the remaining ones were well or poorly differentiated adenocarcinomas. GC was the fourth most
frequently diagnosed extracolonic cancer. Out of 139 patients, 18 (13%) showed HP infection and
4 patients (2.9%) (2 male, 2 female) developed a GC. All GCs displayed MSI-H and the loss of related
MMR protein. The four patients with GCs are described as follows. Patient 1 was a 53-year-old man
carrying the MLH1 mutation (Table 1, Figure 1) who developed an HP infection negative diffuse-type
adenocarcinoma (T2N0) at the fundus (Figure 2a). The tumor displayed the reduction of cytoplasmic
expression of E-cadherin (Figure 2b). Four years before diagnosis, he had two PGAs removed at
the body with high-grade dysplasia. On that setting, an autoimmune gastritis was diagnosed with
already atrophic gastritis and a deficit of acid secretion. Since the reduction of E-cadherin expression
in tumor tissue and mutations in the CDH1 gene (codifying for E-cadherin) are strongly associated
with diffuse-type adenocarcinoma, we also performed the sequence analysis of germline CDH1 gene.
The patient showed common polymorphisms and nonpathogenetic variants (Figure 3). This patient
has not developed CRC yet, but he underwent removal of four adenomas with low-grade dysplasia
during his colonoscopic surveillance.
Table 1. Molecular and pathological features of gastric cancer and adenoma in Lynch syndrome
and FAP.
Mutated Gene Mutation Age at Onset Gender Histology Stage
MLH1 c.688G>T p.(Glu230*) 53 M Diffuse T2N0
MSH2 c.(?_-68)_(*272_?)del p.(?) 73 F Intestinal HP+ T2N1
MSH2 c.2334C>A p.(Cys778*) 62 M Intestinal HP+ T2N0
MSH2 c.(?_-68)_1276+?del p.(?) 40 F Intestinal HP+ T2N1
APC c.1863-1866del p. (Thr621fs*8) 54 M adenoma
APC c.1495C>T p.(Arg499*) 72 F Krukenberg T3N3
Figure 1. Representative mismatch repair gene mutations. Top panels: MLPA electropherogram (left)
and analysis of MLPA data with the Software Coffalyser v.140721.1958 (MRC-Holland, Amsterdam,
Holland). (NET (right) showing the MSH2 c.(?_-68)_1276+?del variant, corresponding to a large
deletion encompassing exons 1–7. Bottom panel: Sanger sequencing showing the MLH1 c.688G>T
variant producing the truncated p.(G1u230*) protein. The mutated codon (GAA > TAA) is circled
in red.
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Figure 2. Patient 1: (a) Neoplastic cells showing diffuse solid growth and focal vague glandular
appearances. H&E staining, original magnification 10×; (b) Reduction of E-cadherin expression by
immunohistochemical staining, original magnification 20×.
Figure 3. Four germline mutations, one of uncertain significance and three presumably benign were
found in the CDH1 gene. Sequence chromatograms. (1) mutation of uncertain significance located in
the promoter region of the E-cadherin CDH1 gene (rs16260 C/A); (2) mutation located in the intron 1
(rs3743674 T/T); (3) insertion located in the intron 1 (rs74406246 ins); (4) mutation located in the codon
13 (rs2076 T/T).
Patient 2 (Table 1, Figure 1) was a 73-year-old female carrying an MSH2 mutation with
adenocarcinoma moderately differentiated intestinal type at antrum (T2N1) (Figure 4a). She had
previous diagnoses of multiple primary cancers (CRC at ascending colon at age 27 years, endometrial
cancer at 45 years, CRC at descending colon at 56 years, and urothelial cancer at 65 years). Patient 3
was a 62-year-old male carrying an MSH2 mutation with an adenocarcinoma poorly differentiated
intestinal type (T2N0) at corpus (Table 1 and Figure 4b) associated with HP infection. He had already
developed multiple CRCs at the ascending colon at age 34 years and at the sigmoid colon at 53 years.
Patient 4 was a 40-year-old female carrying an MSH2 mutation with adenocarcinoma intestinal type
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poorly differentiated at corpus (T2 N1) and HP infection (Table 1 and Figure 4c). A previous CRC at
the ascending colon was diagnosed at age 32 years.
Figure 4. (a) Patient 2: moderately differentiated intestinal-type adenocarcinoma; (b) Patient 3:
moderately differentiated intestinal-type adenocarcinoma; (c) Patient 4: moderately and poorly
differentiated intestinal-type adenocarcinoma; H&H staining, original magnification 400×.
Out of the 74 FAP patients under surveillance, 64 (94%) were diagnosed with FGPs and 11 (16%)
with a diffuse carpeting at fundus and body (Figure 5). After 15 years of prophylactic colectomy,
a 54-year-old male developed a flat adenoma displaying low-grade dysplasia at the gastric body about
25 mm in diameter in the presence of diffuse FGPs (Table 1, Figure 6). An adenocarcinoma poorly
differentiated with signet ring cells like Krukenberg (T3N+) without HP infection was diagnosed in a
72-year-old female with a previous prophylactic colectomy at age 43 years. She had few FGPs without
gastric adenomas and she developed ovary metastasis two years after gastrectomy (Table 1).
Figure 5. Diffuse fundic gland polyps.
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Figure 6. Flat adenoma in fundic gland polyposis.
3. Discussion
This study reports the clinical and molecular features of a small cohort of patients with FAP,
LS, and GC who were recorded in the Hereditary Tumor Registry of the Department of Oncologic
Gastroenterology at CRO Aviano. The small sample size necessarily implies a limitation of the
effectiveness of our report. However, a substantial interesting point comes from our cases since
all patients have been genetically characterized, come from the same geographical area, and the
surveillance procedures have been performed at our Institution.
Regarding LS, MSI-H and the absence of MMR proteins corresponding to the germline mutation
are the molecular features of GCs when they are related to this genetic disease [1,19]. GC has been
reported to be one of the most frequent extracolonic malignancies in MSH2 and MLH1 mutation
carriers with an estimated lifetime risk up to 13% and a frequency ranging from 1.6% in a Dutch
registry to 3.1% in Korea and 10.9% in Finland, with a mean age of 56 years in Western countries and
46 years in Eastern countries [1,2,6]. A correlation with familial GC history had been shown only in
Korea. Our regional cancer registry, Friuli Venezia Giulia Cancer Registry, has reported a cumulative
lifetime risk of GC of 2.6% for males and 1.2% for women in the general population, which is lower
than that estimated for LS patients. The frequency of GC in our cohort was 2.9% in the range of
previous reports.
GCs displayed features of LS, such as MSI-H and the lack of MMR protein expression. Our cases
had mutations in MLH1 and MSH2, the two genes mainly involved in GC risk [1,20]. The mean age
of patients with GC was 57 years, and they did not have a GC family history. Three cases were of
the intestinal type and one of the diffuse type. Intestinal GCs are often preceded by chronic atrophic
gastritis with intestinal metaplasia and are related to environmental exposures such as diet, smoking,
alcohol, and HP infection. In our series, HP infection was observed in all intestinal-type GCs and the
diagnosis of cancer was made by upper GI endoscopy in a work up for symptoms. HP infection has
been reported in about 20% of GCs in LS [2,6,21]. No differences in the frequency of HP infection were
observed between LS carriers and the general population [21]. Diffuse-type GC was already reported
in LS, with the highest frequency of 17% [2]. Our case of diffuse-type GC was diagnosed during a
follow-up for atrophic gastritis associated with diffuse intestinal metaplasia caused by autoimmune
diseases. The patient was positive at antiparietal cell antibodies. Atrophic gastritis was histologically
ascertained as was an acid-secretion deficit by pepsinogen I and a low dose of vitamin B12. Two PGAs
with high-grade dysplasia were endoscopically removed at the body and diffuse-type cancer was
diagnosed four years later. PGAs are a distinct entity, they can derive from deep gastric mucous
glands and they are likely accompanied by a background of intestinal metaplasia and autoimmune
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gastritis. They can evolve into invasive adenocarcinoma displaying pyloric gland differentiation [22].
PGAs were described in 3 out of 15 cases of GCs by Lee [6]. Two cases were diagnosed at the edge
of the tumor, and in one case, PGA was removed two years before the GC diagnosis. However,
we do not have any information on the association with autoimmune diseases. In autoimmune
gastritis inflammatory aggression affects oxytocin glands at the gastric body and fundus leading to
atrophia, and parietal cells may be replaced by cells containing mucus, similar to the intestinal ones,
i.e., intestinal metaplasia. Atrophic gastritis with intestinal metaplasia is a recognized precancerous
condition, usually predisposed to intestinal type adenocarcinoma or to carcinoid tumors in the setting
of autoimmune gastritis [23]. GC was diagnosed, although there was a close surveillance of yearly
endoscopy since our patient had already developed precancerous lesions as PGAs and he was an LS
carrier. Thus, we hypothesized a role of CDH1 in the pathogenesis of GC because the diffuse type is
uncommon in autoimmune gastritis; although CDH1 is involved in hereditary diffuse GC, pathogenetic
mutations were not found in the molecular analysis. GCs were mainly diagnosed after previous CRCs,
and one patient only developed GC as a primary cancer, but we must take into account that he was
under colonic surveillance and multiple adenomas were removed. GC guidelines suggest surveillance
in countries at higher risk of GC, such as Asian countries, or treatment of HP infection [3–5]. Our GC
developed in the two clinical conditions leading to atrophic gastritis: autoimmune gastritis and HP
infection. Our results confirmed current guidelines to search for and treat HP infection. Regarding the
role of autoimmune gastritis in LS patients, our findings must be confirmed by further research, as it
was identified only in one patient in a small cohort.
FAP is a genetic disease with an approximately 100% risk of CRC. Since mortality of CRC has
considerably shrunk after the introduction of genetic testing and prophylactic colectomy, surveillance
for extracolonic cancer has been suggested [5]. In our cases, metastatic CRCs were diagnosed in
12 patients because they were not aware of their genetic disease; no CRC was diagnosed in the other
patients. They started surveillance at the appropriate age and they were treated with prophylactic
colectomy or they were still under colonoscopic surveillance. Upper GI endoscopy is recommended
for staging duodenal polyposis and the intervals are based on the Spigelman score determined by the
number and grade of dysplasia of duodenal adenomas, regardless of gastric polyposis. However, recent
data has emerged on GCs developed on the background of FGPs [11]. Unlike Far East populations,
GC was uncommon in FAP [10] and our data are in line with previous reports. Actually, our case
of GC was not related to FAP; it was a Krukenberg tumor, which is a rare metastatic signet ring
cell tumor in the ovary. The stomach is the primary site in the majority of Krukenberg tumor cases,
followed by carcinomas of the colon, appendix, and breast. The tumor must display mucin-secreting
signet ring cell carcinoma in the dense fibroblastic stroma of the ovary to be defined as a Krukenberg
tumor. Instead, another patient developed a large gastric adenoma that was located at the gastric
body among diffuse FGPs. This adenoma probably could represent the precancerous lesions on a
dysplasia foci or small adenoma on FGP background as reported in [11]. Our cases displayed APC
mutations in the same region (between 685–2040 codon) as described by Walton [11]; this finding
is, however, controversial because the same correlation was not found with adenomas. Comparing
others features reported in GC cases, our patients did not have desmoid tumors or diffuse duodenal
adenomas. GC diagnoses in the Japanese FAP cohort differed from British ones as well as our case
for multicentric adenocarcinoma foci associated with HP infection and early onset. So far, guidelines
on FAP have not accomplished gastric surveillance in patients with diffuse FGPs. Different intervals
and new tools such as high-definition and narrow-binding light endoscopes must be considered for
detection of small adenomas among diffuse hyperplastic polyposis.
In conclusion, our results confirm the risk of GC in LS carriers and indicate that surveillance
programs should include investigation of HP infection. In addition, further studies are still needed the
shed light on the role of autoimmune diseases. Regarding FAP, our limited data did not allow us to
draw definitive conclusions, but previous reports suggest a suitable endoscopic surveillance for long
survivals with diffuse gastric FGPs in Western countries.
298
Int. J. Mol. Sci. 2018, 19, 1682
4. Materials and Methods
4.1. Patients
One hundred thirty-nine patients with LS and 86 patients with FAP were recorded in the
Hereditary Tumor Registry, that was established and approved on the 21th September 1994 by the
Institutional Board of CRO-IRCCS, National Cancer Institute of Aviano (PN), Italy. All registered
patients or their legal guardian, provided informed written consent. Ethical guidelines for research
involving human subjects were respected.
4.1.1. LS Patients
Out of 139 LS patients (83 females, 56 males; mean age 53 years), 33 had mutation in MLH1, 10 in
MSH6, and 96 in MSH2. Fifty-seven patients entered surveillance because of asymptomatic mutation
carriers and 82 patients were in follow-up after a previous CRC (Figure 7). The average follow-up time
was 10.5 years (2–26 years). The surveillance program consisted of colonoscopy starting at age 20 years,
repeated every 2 years until the age of 40 years, and annually thereafter. Gynecological surveillance
for women started at age 30 years with abdominal ultrasound, with urinary cytology beginning at age
35 years and repeated every 2 years. Upper GI endoscopy was performed according to guidelines only
in patients with a family history of GC or because of symptoms until 2005, then the procedure was
extended to all carriers staring at age 35, repeated every 3 years. Nowadays, European and American
guidelines still give different suggestions [3–5]. Figure 7 describes patient number and types of cancers
recorded during the follow-up.
Figure 7. Lynch syndrome patients and cancer registered.
4.1.2. FAP or AFAP Patients
FAP patients (42 female, 44 male; mean age 46.7 years) had mutations identified in the APC gene.
Sixty-two patients (32 female, 36 male; mean age 45.6) had mutations between 1250–1464 codon related
to more aggressive polyposis and 18 in regions associated with the attenuated form (AFAP) (Figure 8).
Upper GI endoscopy was performed according to guidelines starting at age 25 years or at the time of
prophylactic colectomy. Twelve patients had a metastatic CRC at FAP diagnosis. Seventy-four patients
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are still under surveillance (57 with classical FAP and 17 with AFAP) (Figure 2). The average follow-up
time was 11.6 years (1–36 years). Forty patients were under surveillance after their prophylactic
colectomy and 34 were still in colonoscopic follow-up. FGPs were diagnosed in 64 patients out of
74, with 11 showing a diffuse carpeting of polyps at the fundus and body and 63 displaying a small
number of polyps. The endoscopic intervals were determined by the burden and grade of dysplasia
of duodenal adenomas classified according to the Spigelman score, varying from every 4 years if
no polyps were found to every 3–6 months for diffuse duodenal adenomas or adenomas with high
grade dysplasia.
Figure 8. Familial adenomatous polyposis (FAP) patients.
4.2. Histology and HP Infection Status
GCs were classified according to Laurén into intestinal, diffuse, mixed, and indeterminate types,
whereas WHO classification identifies five main types, i.e., tubular, papillary, mucinous, signet
ring, and mixed carcinomas and a two- or three-tiered differentiation grading. Chronic gastritis,
atrophy, intestinal metaplasia, and HP infection were evaluated and graded according to the Sydney
classification. HP status was verified by conventional stainings (including H&E and special stains
like Giemsa).
4.3. Mutational Analysis
Screening for constitutional point mutations of the three main DNA MMR genes (MSH2, MLH1,
and MSH6) and APC gene was carried out on blood DNA by standard procedures of exon-by-exon
amplification of the whole genomic region and flanking intron borders, followed by single-strand
conformation polymorphism and/or direct bidirectional Sanger sequencing on an AB3130 xl Sequencer
(Applied Biosystems/Thermofisher, Foster City, CA, USA) or by next generation sequencing targeting a
custom gene panel on a MiSeq platform (Illumina, San Diego, CA, USA). Multiplex-Ligation Dependent
Probe Amplification analyses (MLPA, MRC-Holland, Amsterdam, The Netherlands) were also used to
detect large gene deletions/duplications.
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Screening for mutations of the CDH1 exons and neighboring intronic sequences was performed
using polymerase chain reaction (PCR) with previously described primers and reaction conditions [20].
In short, 15 PCR reactions were performed for a full mutational screening of all 15 exons and splice
junctions of the CDH1 gene. Amplified PCR products were sequenced on the Applied Biosystems 3130
automated sequencer (Applied Biosystems, Foster City, CA, USA) using the Big Dye v3.1 Terminator
Cycle Sequencing Kit (Life Technologies, Monza, Italy) and sequence data were aligned and analyzed
using CodonCode Aligner software [24].
4.4. Microsatellite analysis
Genomic DNA was obtained from blood and from paraffin-embedded or frozen tissues.
Standard MSI analysis was performed on paired tumor–normal tissue DNA samples using the
original Bethesda panel of microsatellite markers (BAT26, BAT25, D2S123, D5S346, D17S250) or
the mononucleotide panel (MSI Analysis System, Promega, WI, USA) including BAT26, BAT25, NR21,
NR23, and MONO27. Fluorescent-labeled PCR products were separated by capillary electrophoresis
using an ABI3130xl sequencer and evaluated with the GeneMapper software (version number 5,
Applied Biosystems/Thermofisher, Foster City, CA). Criteria for definition of MSS and MSI were
according to the Bethesda guidelines [25].
4.5. Immunohistochemistry (IHC)
MMR protein: formalin-fixed and paraffin-embedded sections from tumor blocks were stained
by an automated method on the Ventana BenchMark Ultra. MLH-1 (M1), MSH2 (G219-1129), MSH6
(44) mouse monoclonal primary antibodies (Roche/Ventana), and PMS2 (EPR3947) rabbit monoclonal
antibody (Roche/Ventana) were used to qualitatively identify human DNA MMR proteins. Lesions
were considered positive for protein inactivation when a complete absence of nuclear staining was
evident in tumor cells with concomitant nuclear staining of adjacent normal epithelial and stromal cells.
E-cadherin: the formalin-fixed, paraffin-embedded tumor block was cut into 4-μm-thick sections
for H&E and immunostaining. Immunohistochemistry was performed by using the mouse monoclonal
antibody against human E-cadherin (clone 36, Ventana Medical System, Tucson, Arizona). Lesions
were considered positive for E-cadherin in the presence of membrane staining.
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Abstract: A positive family history is a strong and consistently reported risk factor for gastric cancer
(GC). So far, it has been demonstrated that serum pepsinogens (PGs), and gastrin 17 (G17) are
useful for screening individuals at elevated risk to develop atrophic gastritis but they are suboptimal
biomarkers to screen individuals for GC. The main purpose of this study was to investigate serum
metabolomic profiles to find additional biomarkers that could be integrated with serum PGs and
G17 to improve the diagnosis of GC and the selection of first-degree relatives (FDR) at higher
risk of GC development. Serum metabolomic profiles included 188 serum metabolites, covering
amino acids, biogenic amines, acylcarnitines, phosphatidylcholines, sphingomyelins and hexoses.
Serum metabolomic profiles were performed with tandem mass spectrometry using the Biocrates
AbsoluteIDQ p180 kit. The initial cohort (training set) consisted of n = 49 GC patients and n = 37
FDR. Differential metabolomic signatures among the two groups were investigated by univariate and
multivariate partial least square differential analysis. The most significant metabolites were further
selected and validated in an independent group of n = 22 GC patients and n = 17 FDR (validation
set). Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic power
and the optimal cut-off for each of the discriminant markers. Multivariate analysis was applied
to associate the selected serum metabolites, PGs, G17 and risk factors such as age, gender and
Helicobacter pylori (H. pylori) infection with the GC and FDR has been performed and an integrative
risk prediction algorithm was developed. In the training set, 40 metabolites mainly belonging to
phospholipids and acylcarnitines classes were differentially expressed between GC and FDR. Out of
these 40 metabolites, 9 were further confirmed in the validation set. Compared with FDR, GC patients
were characterized by lower levels of hydroxylated sphingomyelins (SM(OH)22:1, SM(OH)22:2,
SM(OH)24:1) and phosphatidylcholines (PC ae 40:1, PC ae 42:2, PC ae 42:3) and by higher levels
of acylcarnitines derivatives (C2, C16, C18:1). The specificity and sensitivity of the integrative risk
prediction analysis of metabolites for GC was 73.47% and 83.78% respectively with an area under the
curve of the ROC curve of 0.811 that improves to 0.90 when metabolites were integrated with the
serum PGs. The predictive risk algorithm composed of the C16, SM(OH)22:1 and PG-II serum levels
according to the age of individuals, could be used to stratify FDR at high risk of GC development,
and then this can be addressed with diagnostic gastroscopy.
Keywords: gastric cancer; metabolomics; first degree relatives; biomarkers; early diagnosis; pepsinogen
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1. Introduction
The GC is the fourth most common cancer and the second leading cause of cancer-related death
worldwide [1]. Despite its decline in the last century, GC remains a major public health issue, with
approximately 950,000 new cases diagnosed every year worldwide, of whom about 723,000 die from
the disease [2]. GC is a genetically and phenotypically heterogeneous disease usually detected at an
advanced stage with a median survival below one year.
The marked geographic variation, time trends and the migratory effect on GC incidence suggest
that both genetic and environmental factors are implicated in the etiology. Besides the immutable
inherent risk factors such as age, gender, race, the presence of Helicobacter pylori (H. pylori) infection,
tobacco and diet are considered the major causes of GC [3]. However, other factors may also influence
GC susceptibility. Different studies have reported a GC aggregation within FDR with a risk of two
to 10 times higher than that of the general population. With the exclusion of the rare (<1% of GC)
hereditary diffuse gastric cancer (HDGC) condition harboring a CDH1 gene mutation [4], the observed
familial clustering of GC cannot, to date, be explain only on genetic bases. The widespread use of
upper endoscopy, an invasive but sensitive test for GC diagnosis, is limited by cost, risk complication
and discomfort to patients and its use is indicated only for very high risk or symptomatic individuals.
The five-year survival rate continues to be poor (about 25% of cases) for GC, but where early
diagnosis of cancer was confined to the inner lining of the stomach wall, a five-year survival rate of
95% can be reached. The problem of late diagnostics is due to a substantial proportion of patients with
an asymptomatic or unspecified GC disease. Ideally, the GC disease should be diagnosed at an early
stage by surveillance and management of individuals at high risk for GC. So far, extensive screening
programs for GC have been introduced with success in high-risk countries such as Japan and South
Korea. In Japan, eradication of H. pylori has been used as a first prevention strategy [5]; a secondary
prevention strategy focuses on the diagnosis of GC in an early stage by using endoscopy. In some cases,
the combination of serum pepsinogens (PGs) concentration and the presence of H. pylori antibody
(ABC method) has been recommended based on the knowledge that PG concentration reflects the
grade of gastric atrophy, a precursor condition for GC development [6]. The ABC method has been
used for GC mass screening since 2011 in Japan (Nishitokyo Medical Association). However, this
method is still debated because of the lack of satisfactory evidence in decreasing the mortality rates of
GC [7]. Therefore, the finding of an efficacious non-invasive triage of FDR at increased risk for GC,
that should undergo endoscopic examination remains a challenge for GC surveillance, particularly in
low GC incidence geographic areas.
Metabolomics has emerged as a fast and efficient method to identify novel cancer biomarkers
that gradually become a complementary technique to genomics and proteomics [8,9]. Metabolomics
specifically addresses the simultaneous monitoring of hundreds to thousands of small molecules
(metabolites < 1 kDa) from bio-fluids and tissue samples. The metabolomic profile is retained to give
a biochemical snapshot of the physiopathological conditions of the cells/tissues resulting from the
complex interplay between host genetic and environmental factors.
In this study, specific deficiency of serum sphingomyelins, phospholipids and an excess of
acylcarnitines lipids were detected in GC as potential risk biomarkers. The integration of serum
metabolomic biomarkers with other risk factors such as age and serum PG-II levels enhanced the
diagnostic power of the pepsinogen test allowing a risk stratification of FDR for endoscopic GC
examination. These results underline the role of the use of the individual's metabolomic trait to
complement the FDR screening for precancerous conditions.
2. Results
2.1. Individual Characteristics
Demographic and pathological characteristics of GC patients and FDR in the training and
validation sets are reported in Table 1, respectively. The training set comprised 49 GC patients
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and 37 FDR while the validation set included 22 GC patients and 17 FDR. In both these two sets,
age and PG-II level differed significantly (p < 0.05) in GC patients and FDR while the other clinical
and pathological conditions were superimposable. The odds ratio was 1.12 (95% CI 1.05–1.18) for
age, and 1.25 (95% CI 1.10–1.42) for PG-II. The loss of data for histological H. pylori infection and GC
classification is due to the difficulty of accessing tissue samples collected from the external hospital
during routine biopsies for GC diagnosis.
Table 1. GC patients and FDR characteristics in the training set (a) and in the validation set (b).
(a)
GC FDR p a
N 49 37 NS
M/F b 27/22 10/27 NS
Age c 61 (19–85) 53 (30–69) 0.00009
H. pylori (−) d,# 32 25 NS
H. pylori (+) e,# 14 10 NS
PG-I (ng/mL) f 118.2 (2.7–706.4) 97.2 (3.1–658.4) NS
PG-II (ng/mL) g 17.2 (1.1–104.0) 9.8 (0.2–35.5) 0.0075
G17 (pmol/L) h 15.7 (0.9–983.0) 3.7 (0.4–109.8) NS





GC FDR p a
N 22 17
M/F b 12/10 9/8 NS
Age c 67 (34–79) 45 (23–78) 0.001
H. pylori (−) d,# 12 12 NS
H. pylori (+) e,# 4 4 NS
PG-I (ng/mL) f 107.5 (3.9–341.2) 87.9 (59.3–112.0) NS
PG-II (ng/mL) g 12.6 (2.8–45.9) 9.0 (4.5–13.8) 0.033
G17 (pmol/L) h 3.8 (1.5–500.0) 4.0 (0.5–14.6) NS




a Statistical significance of the differences between GC (gastric cancer) and FDR (First-Degree Relatives) evaluated
by t-test, b M: male, F: female, c age expressed as median and (range), d non infected H. pylori patients, e infected
H. pylori patients, f,g serum pepsinogen I and II concentration, h gastrin 17 serum concentration. # data loss is due to
no access to tissue samples from the external hospital. NS: not significant.
2.2. Comparison of Serum Metabolomic Profiles of GC and FDR
The serum targeted metabolomic profiles were investigated by tandem mass spectrometry (MS).
The MS-targeted approach for serum metabolomic profile analysis adopted in this investigation has
the advantage of being highly robust in term of intra- and inter-day precision and accuracy and overall,
its application provides absolute quantification of serum metabolites. All these features contribute
to making the targeted approach particularly reliable for clinical metabolomic investigations and
guarantees a high standard quality among different clinical laboratories. The list of metabolites
analyzed by the targeted metabolomics method used in this study is shown in Supplemental Table
S1. Metabolomic profile data were analyzed using supervisor partial least squares discrimination
analysis (PLS-DA), which explains maximum separation between GC and FDR samples. The result of
this multi-parametric approach was summarized in the PLS-DA graph (Figure 1) where each point
corresponds to a metabolomic patient profile. The PLS-DA discriminated GC patients and FDR with
a classification accuracy of 72% (R2 = 0.40, Q2 = 0.20). Statistical validation of the obtained PLS-DA
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model was also confirmed with permutation testing (p < 0.004). Variable importance in the projection
(VIP) of the PLS-DA model indicated that SM(OH)22:1 and SM(OH)22:2 had the higher VIP score
(>2.1) (Supplemental Figure S1).
Figure 1. Multivariate partial least squares discrimination analysis (PLS-DA) of serum metabolomic
profiles from FDR (red color) and GC patients (green color) in the training set.
2.3. Identification and Selection of the Most Significant Metabolites
From the training data set we selected the most significant metabolites that discriminate GC
patients and FDR by both univariate (t-test, p < 0.05) and multivariate analysis (VIP > 1). Forty
metabolites met these criteria and are summarized in Table S2. They include carnitine/acylcarnitines
(n = 7), aminoacid derivatives (n = 5), phosphatidylcholines (n = 23) and sphingomyelins (n = 5)
lipids derivatives. Of these 40 metabolites identified in the training set, nine were further
confirmed as differentially expressed in the validation set (p < 0.05). They were three hydroxylated
sphingomyelins: SM(OH)22:1, SM(OH)22:2, SM(OH)24:1, three acylcarnitines: C2, C16 and C18:1 and
three phosphatidylcholine lipids PC ae 40:1, PC ae 42:2 and PC ae 42:3. Figure 2 shows the heat map
plot of the concentrations of the validated metabolites that show the main significant change between
GC patients and FDR in the training set. Hydroxylated sphingomyelins and phosphatidylcholines
lipids showed the highest abundance score in FDR, while acylcarnitine’s derivatives presented the
lowest abundance score in GC patients. Absolute mean concentration, expressed as serum micromolar
concentration, of each validated metabolite in GC patients and FDR are reported in Figure 3. In order to
assess the GC’s specificity of these nine validated metabolites, every single level of them was compared
with those obtained from patients with non-epithelial cancer (i.e., non-Hodgkin lymphoma (NHL),
n = 47) and with epithelial cancer (i.e., breast cancer, n = 34). When compared with FDR, the levels
of the acylcarnitine: C2, C16 and, C18:1 were found to be higher in GC as well as in NHL and breast
cancer groups. Conversely, the PC derivatives: PC ae 40:1, PC ae 42:2 and PC ae 42:3 as well as the SM
derivatives SM(OH)22:1 and SM(OH)22:2 were found to be lower only in the GC patients (Figure S2,
Supplemental Data).
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Figure 2. Heat map plot of the differential validated serum metabolites between FDR and GC patients.
Data refers to the relative serum concentration level observed in the training set.
Figure 3. Box plots of the selected and validated differential metabolites (mean ±SD) between FDR
and GC patients (training set). For each metabolite the serum concentration mean value is reported
inside the box and expressed as μmoles/L. * p < 0.05, ** p < 0.001, *** p < 0.0001.
2.4. Model Performance for Metabolites
In the multifactor logistic regression model containing the nine established metabolites, high C16
and low SM(OH)22:1 metabolites were found to be independent risk factors for GC patients; in the
training set the odds ratio (95% CI) were 2.83 (1.66–4.82) and 1.39 (1.19–1.62) for C16 and SM(OH)22:1,
respectively. The equation for logistic regression fit was logit(p) = 0.0778 + 44.76 × C16 − 0.26 ×
SM(OH)22:1. For the training set, the predictive accuracy of the logistic equation measured by ROC
curve analysis gave an area under curve (AUC )of 0.81 (95% CI: 0.75–0.89) with a sensitivity of 73.5%
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and a specificity of 83.8% (Figure 4a) and an AUC of 0.82 (95% CI: 0.66–0.92) with a sensitivity of 90.9%
and a specificity of 59.0% when the same equation was applied to the validation set (Figure 4b).
Figure 4. The receiver operating characteristic (ROC) curve plots for the metabolomic model based on
C16 and SM(OH)22:1 biomarkers in the training (a) and validation set (b).
2.5. Effect of H. pylori Infection on Levels of Sphingomyelins and Acylcarnitines
To investigate the effect of H. pylori infection on the observed metabolic differences among GC and
FDR, all samples were categorized according to the H. pylori-infection status and their sphingomyelins
or acylcarnitines serum levels. The mean values of the significative sphingomyelins and acylcarnitines
metabolites according to H. pylori infection status are shown in Figure 5. The main trend in metabolite
profile consists in a decrease of SM(OH)22:1 and SM(OH)22:2 levels and an increase of C16 acylcarnitine
in both infected and not infected individuals. In addition, a significant decrease of SM(OH)14:1,
SM(OH)16:1 and SM(OH)24:1 and an increase in C18:1 acylcarnitine in H. pylori-positive GC was
observed, while the C2 and C5 acylcarnitines were increased limitedly in negative H. pylori-GC.
Figure 5. Serum concentrations of significative sphingomyelins phospholipids (a) and acylcarnitines
derivatives (b) in FDR and GC patients according to H. pylori infection. Blue and dark-blue columns
refer to FDR (n = 37) and GC patients (n = 44) with negative H. pylori infection, respectively. Orange and
dark-orange columns refer to FDR (n = 14) and GC patients (n = 18) with positive H. pylori infection,
respectively. Statistical comparison performed for FDR vs. GC for both negative and positive H. pylori
groups by t-test: * p < 0.05, ** p < 0.001, *** p < 0.0001.
2.6. Age Effect on the Serum Levels of the SM(OH)22:1 and C16 Metabolites
Since there was a significant difference in the age between FDR and GC patients (median age
of 53 vs. 61 for the FDR and GC groups, respectively, p < 0.001, Table 1), we further investigated
the relationship between the level of metabolites SM(OH)22:1 and C16 and the age of individuals.
Considering all the FDR and GC data from both the training and validation sets a significant positive
correlation (Spearman’s rank test, p = 0.0076) was found between the level of C16 metabolite and
age (Figure 6a). Conversely, no significant relationship between the SM(OH)22:1 metabolite and age
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(Figure 6b) was reported. However, within the single FDR and GC groups, any significant correlation
(p = 0.4609 and p = 0.3081 respectively) was established between the levels of C16 and age.
Figure 6. Correlation between C16 (a) and SM(OH)22.1 (b) serum concentrations and age for
FDR (orange) and GC patients (gray). Correlation is performed considering all FDR and GC data.
Spearman’s rank test < 0.05 is considered significant.
2.7. Integrated Metabolomics Model
Data integration of metabolomics GC signatures with PGs, G17, H. pylori infection and individual’s
clinical data was our ultimate goal. Association of (a) SM(OH)22:1 and (b) C16 metabolites, and (c)
serum PG-II level on GC diagnosis was retained in the multivariate model. Although C16 was found
related to age when either FDR and GC group were considered separately, it was found independent
by age. Therefore, we included both age and C16 as independent covariates in the logistic classification
algorithm. The estimated regression coefficients for markers were as follows: 0.0898 for age, 0.0843 for
PG-II, 0.283 for SM(OH)22:1 and 0.604 for C16. Thus, the final equation that stratifies FDR at high risk
for GC development is computed as follow:
Y = −4.97 + 0.0898 × Age + 0.0843 × PG-II + 0.283 × SM(OH)22:1 + 0.604 × C16
In our series, the equation including the metabolites provided a significantly higher capability of
detecting GC than that provided by PG-I/PG-II ratio model. The model achieved good discriminatory
power (i.e., AUC = 0.857, 95% CI: 0.78–0.91) (Figure 7). Conversely, the analysis performed with the
current screening test for GC based on PG-I/PG-II ratio showed a ROC curve with a lower AUC value
of 0.765 (95% CI: 0.67–0.84) (p = 0.0278) in our series (Figure 7). The prognostic ability of the model
was further evaluated by using the optimal cut-off of Y > 0.063, as the score from ROC curve analysis
was able to better discriminate FDR from GC patients. By using this cut-off, we correctly identified
52 out of the 71 GC patients (73%). Instead, by using a PG-I/PG-II ratio of ≤3, which is a commonly
used cut-off for GC diagnosis, we correctly identified only nine out of the 71 GC patients (12.7%)
(Figure 8). The percentage of false-positive cases by using the Y > 0.063 cut-off was nine individuals
among the 54 FDR with a high-risk profile, while using the Y ≤ 3 cut-off for PG-I/PG-II ratio was zero.
Individuals identified by the integrated metabolomics/pepsinogen equation have been reported to the
310
Int. J. Mol. Sci. 2018, 19, 750
gastroenterologist for special attention in the follow-up and, as of now (median follow up of 4 years),
they have not developed a GC as confirmed by histological examination of the biopsies. The limited
number of FDR (9/54) at higher risk for GC development allows for effective prospective monitoring
of these individuals.
Figure 7. Comparison of ROC curves to test the difference among the areas under 3 dependent ROC
curves: patient age (blue), PG-II biomarker (green) and the integrated model including age, PG-II and
metabolites (orange).
Figure 8. Clinical application of the developed algorithm proposed to identify high risk FDR (Y= −4.97
+ 0.0898 age + 0.0843 PG-II + 0.283 SM(OH)22:1 + 0.604 C16) compared with the PG-I/PG-II basal
model currently in use.
3. Discussion
The prognosis of GC remains poor and its early detection is the key factor to improving survival.
Screening and prevention programs offer an opportunity to reduce GC mortality, but only a minority
of individuals (<1%) shows an identified germline gene defect (i.e., CDH1 gene mutation), for
which intense surveillance or prophylactic gastrectomy are provided. The identification of high
risk individuals without CDH1 mutations for further endoscopic examination to recognize GC at an
early stage remains a key point. Only in Japan, where GC incidence is very high, PG-I/PG-II ratio ≤ 3
was used as a screening of GC risk.
In this study, we explored the potential of a noninvasive screening test for detecting early stage
GC in FDR population using a metabolomics tool combined with clinical and pepsinogen tests.
Metabolomics is a useful new omic tool to identify specific metabolic dysregulation occurring in GC
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patients compared with FDR. In our series, the most significant metabolic alterations of GC involve
the acylcarnitines, sphingomyelins and phosphatidylcholines pathway. The present study highlighted
an integrated model that included sphingomyelin SM(OH)22:1 and acylcarnitine C16 as important risk
markers able to identify the large majority of GC (73%). Moreover, among FDR population, a feasible
number of high risk individuals (<15%) were identified. These latter FDR have been reported to the
gastroenterologist for further endoscopic examination and for special attention follow-up and as of
now (median follow-up of 4 years) they have not developed a GC. However, to reach a valid conclusion
more time to follow-up is necessary. The integrated model showed a better predictive performance
than the PG-I/PG-II ratio test (AUC 0.857 vs. 0.765, respectively). Thus, our data suggested that
the herein developed model represents an effective non-invasive test to screen FDR at risk of GC
development. The interpretation of findings from this study presents some limitations due to the
relatively small sample size and the short time of FDR follow-up as well as potential bias common in
retrospective studies.
Despite these limitations, results provided new molecular insights into the metabolism GC’s
hallmarks. The serum metabolites that were found significantly differentiated between GC and
FDR appear specific to GC disease. When the FDR levels were compared with those of patients
with non-epithelial cancer such non-Hodgkin lymphoma or epithelial breast cancer (Figure S2,
Supplementary Data), the acylcarnitines: C2, C16 and C18:1 and were found increased in all patients
with cancer, while, the PC ae 40.1, PC ae 42:2 and PC ae 42:3 as well as the SM(OH)22:1 and SM(OH)22.2
decreased in only the GC group, suggesting that these latter phospholipids derivatives are specific to
the GC disease.
Acylcarnitines are the obligate cofactors of mitochondrial fatty acid β-oxidation. The Acyls-CoA
derived from fatty acids are unable to penetrate the mitochondrial outer membrane, but by using
carnitine palmitoyltransferase activity, the Acyls-CoA are transformed to acylcarnitines, which are then
shuttled into the mitochondrial matrix by carnitine-acylcarnitine translocase. Finally, acylcarnitines are
converted back to Acyls-CoA by carnitine palmitoyltransferase 2 localized on the inner mitochondrial
membrane. Acyls-CoA then enter into the cycle of citric acid to generate NADH and FADH2 to
produce ATP along the electron transport chain [10]. An imbalance between the fatty acid uptake and
the oxidation due to defects or alterations in mitochondrial respiratory complex activities arises in
intracellular concentration of acylcarnitines that may be reflected at the serum level [11]. In our series,
C18:1, C18:1(OH) and C16 acylcarnitine levels increased in GC patients according to H. pylori infection
(Figure 6a), suggesting a positive correlation between these acylcarnitines and the bacterium presence.
The oxidative stress is one of the major factors in the development of gastric diseases, while the
inflammatory state associated with chronic H. pylori infection may increase the risk of GC development
due to the continuous exposure to oxidative species. Thus, H. pylori infection may partially explain
the higher serum level of specific acylcarnitine metabolites shown in our patients. On the other hand,
increased acylcarnitines in GC patients may be the consequence of the oxidative stress associated to
GC itself or to the higher age of patients since oxidative stress has been reported to increase with
aging [12]. Interestingly, we found a positive correlation between C16 acylcarnitine and patient’s age
(Figure 6). Thus, it is possible that the higher level of C16 carnitine observed in GC patients may be
related to both H. pylori infection and the age of the patient.
Conversely to acylcarnitines, some phosphatidylcholine derivatives such as PC ae 40.1, PC ae
42:2 and PC ae 42:3 were significantly lower in the serum of GC patients. The lower level of specific
serum phospholipids in GC serum could reflect alterations at tumor tissue. A previous metabolomics
investigation, performed by a mass spectrometry imaging technique, revealed that GC tissue as
compared with normal gastic mucosa may present specific shortages of phosphatidylcholine lipids
derivatives i.e., PC 36:4 and PC 34:2 [13,14]. Interestingly, the authors of this study were able to
demonstrate that the supplementation of such phosphatidylcholines in the culture medium suppressed
the NIH-3T3 transformation by K-Ras as well as the in vitro growth of 4 out of 8 GC cell lines.
Moreover, their oral administration was found to also reduce the in vivo growth of GC cells in nude
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mice without any side effects [13,14]. Overall, these preliminary results underline the importance of
the specific serum phospholipids shortage with the GC growth. The lower serum concentrations of
other specific phospholipids belonging to the sphingomyelins class observed in this study further
reinforce such suggestions.
Sphingomyelins are structural constituents of all cell membranes particularly abundant in
the myelin membrane sheaths surrounding axons. Sphingomyelins interact with cholesterol and
glycerophospholipids participating in the formation and maintenance of lipid microdomains in the
plasma membrane known as lipid rafts. Sphingolipids in lipid rafts modulate many cell processes,
such as membrane sorting and trafficking, cell polarization and signal transduction [15]. Through the
action of the sphingomyelinase (SMse), the sphingomyelins play a relevant role also in determining
the cell fate by hydrolyzing back to ceramide which is an important metabolic intermediate able
to induce cellular apoptosis [16]. Thus, sphingolipids have emerged as key effectors in different
tumors such as colon cancer, breast cancer, leukemia, esophagus cancer, and brain cancer [17], by
controlling various aspects of tumor cell growth and proliferation through ceramide molecules [15].
The specific metabolic signature observed in GC involved a lower serum level of several 2-hydroxylated
sphingomyelins (SM(OH)s): SM(OH)22:1, SM(OH)22:2 and SM(OH)24:1 (Figure 3). Collectively, these
specific hydroxylated sphingolipids require the action of the cellular fatty acid hydroxylase (FA2H)
for their synthesis [18] and like the other sphingomyelins, they can be hydrolyzed to generate 2
hydroxy-ceramide derivatives, which analogously to ceramides have a pro-apoptotic activity [19].
Thus, a shortage of SM(OH)s sphingolipids may contribute to a reduction in cellular ceramide load
promoting cell proliferation and tumor survival. Of interest, many cancers, including stomach,
pancreas, and colon, show increased nerve density in relation to tumor growth [20]. Nerves infiltrating
the GC microenvironment were found to release neurotransmitters to promote tumor growth and
reciprocally, tumors secrete neurotrophic factors, that stimulate both nerve outgrowth and cancer cell
growth [21]. The lower levels of circulatory sphingomyelins may reflect the increase tumor nerves
growth observed in GC. Taken together, these findings suggest further investigations on whether
nerve–cancer cell cross-talk involves sphingolipids in GC.
4. Experimental Section
4.1. Participants
Participants were excluded from clinically significant medications, surgery, radiotherapy or
chemotherapy for metabolic, liver, kidney diseases or any other cancers. From January 2009 to March
2014, 71 GC patients and 54 FDR were consecutively enrolled at the Oncological Gastroenterology,
Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano, Italy to characterize
their serum metabolomic profiles. For all the GC patients diagnosis was confirmed histologically
based on tissue specimens. For all FDR individuals, the GC lesion was excluded after gastroscopy and
histological examination of the biopsies. Two additional cohorts of patients unrelated to GC patients
with a representative non-epithelial (i.e., non-Hodgkin lymphoma; n = 47) and epithelial cancer (breast
cancer; n = 34) were included in the metabolomics investigation as unrelated independent cancer
groups. None of GC patients and FDR were treated with proton pump inhibitors. H. pylori infection was
detected in tissue sections using hematoxylin and eosin and Giemsa stains as previously reported [22].
Serum PG-I, PG-II and G-17 levels were measured as previously reported [22]. Clinical data from
GC patients and FDR were collected in a dedicated database in the oncological gastroenterology
center. Before enrolling each participant gave informed written consent. The study was approved on
December 2008 by the Institutional Review Board (ref no. IRB2008-14).
4.2. Sample Collection
All the study participants were in an overnight fasting state and 5 mL of peripheral venous
blood was taken in the morning. The blood was then allowed to clot for 30 min at 37 ◦C water bath
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and followed by centrifugation at 3000 rpm for 15 min. Then, the serum supernatant was taken and
transferred to a clean tube and stored at −80 ◦C until further analysis.
4.3. Design of the Study
Based on the diagnosis, participants were randomly divided into 2 sets; the training set included
49 GC patients and 37 FDR and a validation set of 22 GC and 17 FDR. Detailed characteristics of
patients are listed in Table 1.
The main steps of the study were: (1) characterization of metabolomic profiles associated with
FDR and GC patients, (2) identification and validation of the most important metabolomics GC
signatures by using the independent validation sample set, (3) apply multivariate statistical analysis of
selected serum metabolites, clinical data and pepsinogen biomarkers to develop an integrated risk
model for early stage GC detection, and (4) performance comparison between the model including the
metabolites and the model based on PG-I/PG-II risk score.
4.4. Metabolomics Investigation
A high-throughput liquid chromatography-tandem mass spectrometry (LC-MS/MS) platform
has been applied to evaluate serum metabolomics profiles. We used the commercial AbsoluteIDQ
p180 Kit (Biocrates Life Sciences, Innsbruck, Austria) according to the manufacturer’s instructions
for the quantification of 188 targeted metabolites covering the following compound classes: amino
acids, biogenic amines and polyamines (n = 40), acylcarnitines (n = 40), di-acyl-phosphatidyl lipids
(n = 92), sphingolipids (n = 15) and hexose (n = 1). The complete list of all metabolites investigated
is reported in supplemental Table S1. The analytical system consisted of a liquid chromatography
Agilent (Agilent, Santa Clara, CA, USA) coupled with an ABI4000 triple quadrupole mass spectrometer
(ABsciex, Framingham, MA, USA).
Briefly, 10 μL of serum was loaded onto an inserted filter in a 96-well sandwich plate, which
already contained appropriate internal standards, structurally identical but labeled with stable isotopes
such as deuterium, 13C, or 15N. The filters were dried under a nitrogen stream, derivatization of
amino acids was performed with 5% phenylisothiocyanate (PTC), and filters were dried again. After
extraction of metabolites with 500 μL of 5 mM ammonium acetate in methanol, the solution was passed
through a filter membrane and diluted with MS running solvent. Final extracts were then analyzed
by LC-MS/MS using amino acids and bioactive amines PTC-derivatives the Zorbax SB 100 × 2.1 mm
column (Agilent, Santa Clara, CA, USA), and a direct flow injection analysis (FIA-MS/MS) for the
analysis of acylcarnitines and phospholipids. Quantification of metabolites was achieved by multiple
reaction monitoring, neutral loss and precursor ion scan in positive and negative ion mode. The MS/MS
signals were integrated, by using Analyst 1.6.1 (ABsciex, Framingham, MA, USA) and quantified
using a calibration curve according to the AS-180 to the manufacturer’s instructions. Concentration
and validation data were then further processed using the MetIQ software by comparing the results of
triplicate analysis of low, medium and high-quality serum controls as an integral part of the analytical.
4.5. Data Processing and Statistical Analysis
Prior to statistical analysis, the serum concentration values of metabolites investigated were set to
a log scale and auto-scaled (mean-centered and divided by the standard deviation of each variable).
A supervisor multivariate partial least squares discrimination analysis (PLS-DA) was then applied to
identify the relevant metabolites that contributed the most significance in differentiating between the
GC and FDR groups in the training set. The PLS-DA model was further cross-validated by comparison
of the resulting goodness of fit (R2), predictive ability (Q2) values, and by internal validation using
1000 permutation tests. A variable importance in projection (VIP) score was applied to rank the
patients’ metabolites that best distinguished between the GC vs. FDR groups. The relevant metabolites
that distinguished the two groups in the training set were selected on the basis of VIP > 1 and by
p < 0.05 as resulted from the application of univariate t-test analysis. The more significant metabolites
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differentially expressed were further validated by the confirmation of significant variable (p < 0.05)
in the validation set. The ROC curves were constructed to test the diagnostic performance of the
more significant metabolomics biomarkers. In a ROC curve, the true positive rate (sensitivity) was
plotted against the false positive rate (1-specificity) for different cut-off points of a given parameter.
The ROC curve was validated by internal cross-validation and permutation testing. The optimal
cut-off was assessed by jointly maximizing sensitivity and specificity. Sensitivity and specificity,
computed at the optimal cut-off, were then used for further investigation. All above data processing
and the statistical analysis that included ROC analysis were performed using the Metabolanalyst web
portals [23]. Correlation between metabolite biomarkers and clinical features was analyzed by the
Spearman’s rank-order correlation test. Multivariate analysis was used to determine the coefficient
value for each of the independent variables and to make the integrated model equation including
metabolites, patient age and PG-II biomarker.
5. Conclusions
This exploratory study describes for the first-time serum metabolomic profiles that discriminate
GC patients from FDR sharing the same environment and a similar genetic background. As compared
with FDR, the GC patients showed specific serum metabolomic signatures characterized by an increase
in specific acylcarnitines and a decrease in a distinctive subclass of sphingolipids. The inclusion of
such serum metabolomic signatures with patient age and pepsinogen PG-II demonstrated they are
a key factor for the development of a model to distinguish FDR from GC patients. Compared with
the current PG-I/PG-II screening approach used in Japan, the model proposed showed an improved
discrimination between GC patients and the FDR. The current results demonstrate the potential
usefulness of the serum metabolomics as a noninvasive tool for the triage of individuals at higher
risk of GC development for further endoscopic examination. The feasibility of this approach, as well
as the biochemical mechanisms implicated in GC development, remain to be validated and warrant
further investigation.
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